<SEC-DOCUMENT>0001493152-23-030254.txt : 20230825
<SEC-HEADER>0001493152-23-030254.hdr.sgml : 20230825
<ACCEPTANCE-DATETIME>20230825170029
ACCESSION NUMBER:		0001493152-23-030254
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20230531
FILED AS OF DATE:		20230825
DATE AS OF CHANGE:		20230825

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		231209134

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9493792875

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:BMRA="http://biomerica.com/20230531">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_BMRA_biomerica.com_20230531 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20220601_20230531 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000073290 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_06A_Sqft_8_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityCentralIndexKey">0000073290</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0044" name="dei:AuditorFirmId">200</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-05-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-05-31" id="xdx2ixbrl0119" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0124" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-05-31" id="xdx2ixbrl0143" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-05-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-05-31" id="xdx2ixbrl0162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-05-31" id="xdx2ixbrl0163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2021-06-012022-05-31" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMRA:IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMRA:IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0982" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" id="xdx2ixbrl0983" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0994" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" id="xdx2ixbrl0995" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0997" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" id="xdx2ixbrl0998" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl1000" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" id="xdx2ixbrl1001" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl1021" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMRA:DeferredTaxAssetsCapitalizedCosts" contextRef="AsOf2022-05-31" id="xdx2ixbrl1060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMRA:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" contextRef="AsOf2023-05-31" id="xdx2ixbrl1062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-05-31" id="xdx2ixbrl1074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-05-31" id="xdx2ixbrl1075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMRA:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2023-05-31" id="xdx2ixbrl1150" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bmra-20230531.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-06-01to2023-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_srt_MinimumMember_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_srt_MaximumMember_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_srt_MinimumMember_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_srt_MaximumMember_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-072023-03-07_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-07</xbrli:startDate>
        <xbrli:endDate>2023-03-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-07_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:DistributorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:DistributorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorsInAsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:DistributorsInAsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_OneVendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneVendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_country_MX">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_country_MX">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_custom_MarketingAndDistributionRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BMRA:MarketingAndDistributionRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_custom_PurchasedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BMRA:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_custom_PolishDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BMRA:PolishDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_custom_ClinicalLabMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ClinicalLabMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_custom_ClinicalLabMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ClinicalLabMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_custom_OverTheCounteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:OverTheCounteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_custom_OverTheCounteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:OverTheCounteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_custom_ContractManufacturingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ContractManufacturingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_custom_ContractManufacturingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ContractManufacturingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_custom_PhysiciansOfficeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:PhysiciansOfficeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_custom_PhysiciansOfficeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:PhysiciansOfficeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BMRA:FurnitureAndFixturesLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BMRA:FurnitureAndFixturesLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneVendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoVendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:TwoVendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandFourteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BMRA:TwoThousandFourteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BMRA:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-29_us-gaap_EmployeeStockOptionMember_custom_TwoThousandTwentyPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BMRA:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember58847203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-222021-01-22_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-22</xbrli:startDate>
        <xbrli:endDate>2021-01-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-21_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BMRA:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-072023-03-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-07</xbrli:startDate>
        <xbrli:endDate>2023-03-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-072023-03-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-07</xbrli:startDate>
        <xbrli:endDate>2023-03-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BMRA:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-242020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BMRA:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-24</xbrli:startDate>
        <xbrli:endDate>2020-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-042020-03-24_us-gaap_ConvertiblePreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-04</xbrli:startDate>
        <xbrli:endDate>2020-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-042020-03-24_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-04</xbrli:startDate>
        <xbrli:endDate>2020-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-21_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-21_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_srt_NorthAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_srt_NorthAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_MiddleEastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_MiddleEastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_srt_SouthAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_srt_SouthAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-312023-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-31</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_BuildingInIrvineCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">BMRA:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012023-05-31_us-gaap_RoyaltyAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012022-05-31_us-gaap_RoyaltyAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_UniversityOFSouthernCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BMRA:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_UniversityOFSouthernCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BMRA:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_BiomericaInFoodsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BMRA:BiomericaInFoodsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-032023-08-03_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-03</xbrli:startDate>
        <xbrli:endDate>2023-08-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>BMRA:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20220601__20230531_zrFeZVx2Pn06"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span id="xdx_909_edei--DocumentAnnualReport_c20220601__20230531_zegEU4vk8Eib"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Fiscal Year Ended <span id="xdx_904_edei--DocumentPeriodEndDate_c20220601__20230531_zCK1IF2M9Er4"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_90C_edei--CurrentFiscalYearEndDate_c20220601__20230531_zu6qSgiVVJZ3"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">May 31</ix:nonNumeric></span>, <span id="xdx_90C_edei--DocumentFiscalYearFocus_c20220601__20230531_zeoGe4fTkVle"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span> </b>or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span id="xdx_902_edei--DocumentTransitionReport_c20220601__20230531_zOxJEcXzuyj5"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
 Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
The Transition Period From ______ To ______</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_901_edei--EntityFileNumber_c20220601__20230531_zzE5RnpMye7b"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityFileNumber">001-37863</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20220601__20230531_zNtbbssAQJ1i"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityRegistrantName">BIOMERICA,
INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220601__20230531_zu7VIZWZAaW7"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of<br />
</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation
    of organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20220601__20230531_zuIDAnQIVEBg"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityTaxIdentificationNumber">95-2645573</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer <br />
Identification No.)</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20220601__20230531_zSurjgld5Hsd"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityAddressAddressLine1">17571
Von Karman Avenue</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20220601__20230531_z3SgMTISsvQf"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityAddressCityOrTown">Irvine</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20220601__20230531_ztDBWF5kUNX6"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span><br />
</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20220601__20230531_zDOm9lAJghLg"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityAddressPostalZipCode">92614</ix:nonNumeric></span><br />
</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<b><span id="xdx_90D_edei--CityAreaCode_c20220601__20230531_z52QO6jFuutl"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:CityAreaCode">949</ix:nonNumeric></span>)
<span id="xdx_90A_edei--LocalPhoneNumber_c20220601__20230531_zoFuGLQGLcr2"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:LocalPhoneNumber">645-2111</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered under Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbols</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20220601__20230531_zYL5qw8AdRTb"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:Security12bTitle">Common
    Stock, par value $0.08</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20220601__20230531_zUkXCsWF4pai"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:TradingSymbol">BMRA</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20220601__20230531_zlnvWOSCi6B8"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_903_edei--EntityWellKnownSeasonedIssuer_c20220601__20230531_zsBK6urJO7yc"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_903_edei--EntityVoluntaryFilers_c20220601__20230531_z3MaXWGUs174"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityCurrentReportingStatus_c20220601__20230531_zzcCH6pss5B4"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityInteractiveDataCurrent_c20220601__20230531_zCBRWDSwtpSk"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
 &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Accelerated Filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 53%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    Filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20220601__20230531_zZF8ELOZ8oig"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-Accelerated
    Filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    Reporting Company <span id="xdx_90D_edei--EntitySmallBusiness_c20220601__20230531_ze2JTNkJfBK1"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20220601__20230531_zqr3rklhQzS2"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333333">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant
to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333333">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) <span style="color: #333333">by the registered public accounting firm that prepared
or issued its audit report. <span id="xdx_902_edei--IcfrAuditorAttestationFlag_c20220601__20230531_zE6pEr0CIxwi"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_908_edei--EntityShellCompany_c20220601__20230531_zlrEfz3GRzch"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s
most recently completed second fiscal quarter (based upon 12,281,164 shares held by non-affiliates and the closing price of $3.48 per
share for Common Stock as of November 30, 2022): $<span id="xdx_902_edei--EntityPublicFloat_iI_c20221130_zQQfSu2lYFCg"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-11-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,738,451</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding number of shares of common stock, par value $0.08, as of August 25, 2023 was <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_pid_c20230825_zJzQ6BRxZKqd"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-08-25" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,821,646</ix:nonFraction></span>. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOCUMENTS
INCORPORATED BY REFERENCE: <span id="xdx_90A_edei--DocumentsIncorporatedByReferenceTextBlock_c20220601__20230531_zBuwSdpOX4Vb"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions of the registrant&#8217;s definitive Proxy Statement on Schedule 14A relating to the registrant&#8217;s
2023 annual meeting of stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal
year covered by this Annual Report on Form 10-K, are incorporated by reference in Part III, Items 10 through 14 of this Annual Report
on Form 10-K. Except for the portions of the Proxy Statement specifically incorporated by reference in this Form 10-K, the Proxy Statement
and related proxy solicitation materials shall not be deemed to be filed as part hereof.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Except
for historical financial information contained herein, the matters discussed in this Form 10-K may be considered forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, and subject to the safe harbor created by the Securities Litigation Reform Act of 1995. Such statements include declarations
regarding our intent, belief, or current expectations, and those of our management. </i></span><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
&#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology.
<span style="background-color: white">Investors are cautioned that any such forward-looking statements are not guarantees of future performance
and involve a number of risks, uncertainties and other factors, some of which are beyond our control. Actual results could differ materially
from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from
those indicated by such forward-looking statements include, but are not limited to, those risks and uncertainties identified under &#8220;Risk
Factors,&#8221; in this Form 10-K and the other risks detailed from time-to-time in our reports and registration statements filed with
the Securities and Exchange Commission, or SEC. Except as required by law, we undertake no obligation to revise or update publicly any
forward-looking statements, whether as a result of new information, future events or otherwise.</span></span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BUSINESS
OVERVIEW</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc. (&#8220;Biomerica,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) was incorporated
in Delaware in September 1971 as Nuclear Medical Systems, Inc., and later changed its name to Biomerica, Inc. The Company has two wholly
owned subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing, and BioEurope GmbH, which acts as a distributor of
Biomerica products in certain markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products
used at the point-of-care (in home and in physicians&#8217; offices) and in hospital/clinical laboratories for detection and/or treatment
of medical conditions and diseases. Our products are designed to enhance the health and well-being of people, while reducing total healthcare
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided
therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other
inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address
very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that,
when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Instead of broad and difficult
to manage dietary restrictions, the InFoods&#174; IBS product works by identifying specific foods that may be an abnormally high immune
response &#160;&#160;in the patient. A food identified as positive, which is causing the abnormal immune response in the patient, can
be simply removed from the diet to help alleviate IBS symptoms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2022, we completed an endpoint determination clinical trial on our InFoods&#174; IBS product. This trial was conducted
at Mayo Clinics in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University
of Texas Health Science Center at Houston, Houston Methodist, the University of Michigan and other institutions. This trial monitored
IBS patients over an 8-week treatment period to determine the efficacy of our InFoods&#174; IBS product to improve the patients&#8217;
IBS symptoms or endpoints. The top-line trial results were reported in February 2022. Multiple endpoints demonstrated statistically significant
improvements, indicating that the elimination of specific foods may meaningfully reduce the symptoms of IBS in each patient subtype (including
patients with IBS-Constipation, IBS-Diarrhea &amp; IBS-Mixed). The greatest clinical improvements, including but not limited to abdominal
pain and bloating, were seen in patients diagnosed with IBS-Mixed and IBS-Constipation, in the top line data. The purpose of the endpoint
study was to validate the efficacy of the product, and to determine the primary symptom endpoint, or endpoints to be used in a final
pivotal trial that will be conducted to attain the validation data needed to apply for U.S. Food and Drug Administration (&#8220;FDA&#8221;)
clearance for the product. &#160;&#160;We are continuing to review and refine the complete dataset and have selected the final endpoint
that we would intend to use in a final pivotal trial. We are starting to develop the protocol for submission to the FDA, and once
approved the trial will be run thereafter. The trial is expected to include the large medical institution participants that conducted
the endpoint clinical trial, in addition to other new institutions and a Clinical Research Organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the successful completion and positive results from the Company&#8217;s InFoods<sup>&#174;</sup> IBS clinical trial, we saw
significant interest from Gastroenterology (&#8220;GI&#8221;) physicians who would like to provide the InFoods<sup>&#174;</sup> IBS product
to their patients. Therefore, while we continue the work of advancing this product toward FDA clearance, during our fourth quarter of
fiscal 2023, we launched the InFoods<sup>&#174;</sup> IBS product through a CAP-Certified high-complexity Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) laboratory facility and
began offering the product as a laboratory developed test (&#8220;LDT&#8221;) to GI physicians. The first physician group to offer InFoods<sup>&#174;
</sup>IBS to their IBS patients is Gastro Health at their flagship location in Miami, Florida. Gastro Health is a leading GI physician
group with over 390 physicians operating in over 150 offices in seven states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InFoods<sup>&#174;
</sup>IBS product is currently offered on a &#8220;cash-pay&#8221; basis (without insurance reimbursement) to IBS patients. However,
we have begun the process of speaking to reimbursement consultants who can help us seek and attain reimbursement through government pay
(i.e., Medicare and Medicaid), and from private insurers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also beginning the work of validating one new disease (such as ulcerative colitis or migraines), where there is evidence that
certain foods can trigger or contribute to the symptoms found in patients suffering from those illnesses. Each InFoods<sup>&#174; </sup>test
is developed specifically for patients suffering from the disease being targeted. For instance, the panel of foods that would be
tested for patients with migraines will be different from the known problematic foods that we test for in IBS. We have already
performed much of the initial research and development work necessary to determine what foods are commonly problematic for each of
eight different diseases. We have found that some diseases show approximately 20 foods that are commonly problematic for patients,
while other diseases show over 70 foods for which patients commonly show an abnormal immune response. Once the panel of problematic
foods is identified for a specific disease, the panel must then be tested to confirm which of the problematic food are
causing an abnormal and harmful immune response. We expect
any new disease we target will follow a similar development pathway as InFoods<sup>&#174;</sup> IBS in simultaneously seeking FDA
clearance of the product while also launching the product as an LDT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also continuing to evaluate partnership/licensing opportunities, as they arise, with U.S. and multinational companies that could
help us commercialize, or accelerate revenue growth of, the InFoods<sup>&#174;</sup> products in the United States and overseas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians&#8217;
offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal
or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring
or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in
a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2022, we finalized development of our H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria.
H. Pylori infection is extremely common, and if left untreated, can lead to ulcers and possibly stomach cancers. During our fourth quarter
of fiscal 2022, we applied for FDA clearance of this product though a 510(k) premarket submission. We have been in communication with
the FDA answering certain follow-up questions and providing additional data as requested. We are working with the FDA to perform one
additional set of in-lab tests that the FDA has requested prior to making their final determination on clearance of the product. Provided we receive FDA clearance, we will begin marketing the product in the U.S. market. We have already begun discussions with international distributors for
this product and expect to see revenues through these international channels during 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have recently added new employees in our sales and marketing department in order to increase sales of existing products. In fiscal 2023,
we also hired a Chief Commercial Officer (&#8220;CCO&#8221;) with broad experience launching new products at large diagnostic companies.
Our CCO is focused on the commercial launch of the InFoods<sup>&#174;</sup> IBS product to the GI physician groups in the U.S. market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the global 2019 SARS-CoV-2 novel coronavirus (&#8220;COVID-19&#8221;) pandemic, in March 2020, we began developing, marketing, and
selling COVID-19 diagnostic tests. In fiscal 2022, we generated revenues from the international sale of our COVID-19 antigen tests. Due
to falling demand for such tests, the Company generated 4% of our sales during fiscal year 2023, as compared to 75% of our revenue during
fiscal year 2022. Due to the dramatic increase in fiscal 2022 revenues, and subsequent decrease in fiscal 2023 revenues from this COVID-related
product, we saw significant volatility in our revenues and our earnings during those two fiscal years. By the end of fiscal year 2023,
and during our fourth quarter, none of our revenues came from the sale of COVID-related tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
non-COVID-19 products that accounted for approximately 96% and 25% of our revenues during the fiscal years ended May 31, 2023, and 2022,
respectively, are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test
products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered
by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technological
advances in medical diagnostics have made it possible to perform diagnostic tests within the home and the physician&#8217;s office (the
point-of-care), rather than in the clinical laboratory. One of our objectives also has been to develop and market rapid diagnostic tests
that are accurate, utilize easily obtained patient specimens, and are simple to perform without instrumentation. Our over-the-counter
(home use) and professional use (doctor&#8217;s office, clinics, etc.) rapid diagnostic test products help to manage existing medical
conditions and may save lives through early detection and diagnosis of specific diseases. Typically, tests of this kind require the services
of medical technologists and sophisticated instrumentation. Further, results are often not available until at least the following day.
We believe rapid point-of-care tests can be as accurate as laboratory tests when developed and used properly, may require limited to
no instrumentation, can give reliable results in minutes, and can be performed with confidence in the home or the physician&#8217;s office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expend considerable funds in research and development of certain new products that diagnose and, in certain cases, are designed to be
used as a therapy for several major medical diseases. These products are both internally developed and licensed from others. We employ
experienced and highly trained technical personnel (including Ph.D.&#8217;s and other scientists) to develop new products and evaluate
and implement technology technical transfer activities. Our technical staff, many of whom have been previously employed at large diagnostic
manufacturing companies, has extensive industry experience. We also rely on our Scientific Advisory Board of leading medical doctors
and clinicians to assist in guiding our clinical studies and product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica
maintains its headquarters in Irvine, California, where it houses administration, finance, regulatory compliance, product development,
sales and marketing, customer services and its primary manufacturing operations. Biomerica maintains manufacturing and assembly operations
in Mexicali, Mexico, in order to reduce the cost of manufacturing and compete more effectively worldwide. Biomerica also has a legal
entity in Europe, BioEurope GmbH, for the purpose of selling certain products internationally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information about Biomerica is available on our website at www.biomerica.com. The content on any website referred to in this Form 10-K
is not a part of or incorporated by reference in this Form 10-K unless expressly noted. Our Annual Report on Form 10-K, Quarterly Reports
on Forms 10-Q, Current Reports on Forms 8-K, Proxy Statements and all other filings we make with the Securities and Exchange Commission
(&#8220;SEC&#8221;) are available on our website, free of charge, as soon as reasonably practical after we file them with or furnish
them to the SEC and are also available online at the SEC&#8217;s website at <span style="text-decoration: underline">www.sec.gov</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRODUCTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of our diagnostic test kits are manufactured and/or assembled at our facilities in Irvine, California and in Mexicali, Mexico. We established
our manufacturing facility in Mexicali, Mexico in fiscal 2003 and moved a significant portion of our diagnostic packaging and assembly
to that facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production
of diagnostic tests can involve formulating component antibodies and antigens in specified concentrations, attaching a tracer to the
antigen, filling components into vials, packaging and labeling. We continually engage in quality control procedures to assure the consistency
and quality of our products and to comply with applicable FDA and international regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing operations and facilities are regulated by the FDA Good Manufacturing Practices for medical devices. We have an internal
quality department that monitors and evaluates product quality and output. We also have an internal Quality Systems department whose
goal is to ensure that our operating procedures are in compliance with current FDA, CE Mark and International Organization for Standardization
(&#8220;ISO&#8221;) regulations. We either produce our own antibodies and antigens or purchase these materials from qualified vendors.
We have alternate, approved sources for most critical raw materials and are working to procure alternate sources for the few that we
do not have.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESEARCH
AND DEVELOPMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our focus on development of our InFoods<sup>&#174;</sup> IBS product, we also focused a portion of our Research and Development (&#8220;R&amp;D&#8221;)
resources on continued validation of our H. Pylori diagnostic test. Our research and development spending driven by our focus on these
tests and outside clinical studies intended to demonstrate the feasibility of FDA clearance for such tests. We also utilize technical
personnel, with Ph.D. and other degrees and extensive experience in development and production of health diagnostic
tests, to conduct other development activities and improve existing products, as well as explore potential new technologies that we may
wish to develop and commercialize. Research and development expenses include the costs of materials, supplies, personnel, consultants,
facilities, outside clinical trial sites and equipment as well as outside contract services. Consolidated research and development expenses
incurred by Biomerica for the years ended May 31, 2023 and 2022, aggregated to approximately $1,584,000, and $1,812,000, respectively.
As Biomerica moves forward with development, validation and commercialization of additional key products that address diseases with large
market opportunities, research and development expenses are expected to be consistent during upcoming quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fourth quarter of fiscal 2022, we also submitted our proprietary H. Pylori test to the FDA for clearance through a 510(k) submission.
The clinical studies for our H. Pylori were conducted at the University of Southern California, a European University, and several other
U.S. locations. Biomerica&#8217;s test is designed to provide highly accurate sensitivity and specificity for H. Pylori testing and for
monitoring of treatment. We are in the process of finalizing one additional set of in-house validation tests that the FDA has requested
us to complete before they review the submission and decide on the allowance on this product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed a unique diagnostic-guided therapy which we call the InFoods<sup>&#174;</sup> technology, that is designed to allow physicians
to identify patient-specific foods (e.g. pork, milk, onions, sugar, chickpeas, etc.), that when removed from the patient&#8217;s diet,
may alleviate or improve their symptoms of IBS and other diseases. We have filed patents throughout the world pertaining to the use of
our InFoods<sup>&#174;</sup> diagnostic technology to detect abnormal immune responses in patients suffering from various diseases. Many
of these patents have recently been issued with many more in the review and prosecution phase. The United States Patent and Trademark
Office (&#8220;USPTO&#8221;) has issued the Company two patents with broad claims that protect this InFoods<sup>&#174;</sup> IBS product.
Patents have also been issued in the countries of Australia, Japan, Korea, Mexico, and Singapore. Additional patent applications pertaining
to the InFoods<sup>&#174;</sup> IBS product have been filed in the United States and in other countries. We are also developing and have
filed patents for products that target other diseases utilizing the InFoods<sup>&#174;</sup> technology platform which include: Functional
Dyspepsia, Crohn&#8217;s disease, Ulcerative Colitis, Gastroesophageal Reflux disease (&#8220;GERD&#8221;), Migraine Headaches, Depression,
and Osteoarthritis. Our first patent to be allowed for a disease/illness other than IBS was allowed in Japan in August 2021. This patent
covers the use of our InFoods<sup>&#174;</sup> technology to diagnose and treat persons suffering from depression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MARKETS
AND METHODS OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica
has approximately 80 current customers for its diagnostic business, of which approximately 40 are foreign distributors, 10 are domestic
distributors and the balance are primarily domestic hospital and clinical laboratories, medical research institutions, medical schools,
pharmaceutical companies, chain drugstores, wholesalers, physicians&#8217; offices, and e-commerce customers.&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
employ a director of sales and marketing for Europe and South America who is headquartered in Germany. She has over 20 years of experience
selling and marketing diagnostic and life science products across multiple diagnostics technologies and disciplines. She possesses broad
international business experience, with communication skills in German, English, Spanish, French, and Portuguese, and scientific and technical
understanding of gastrointestinal diagnostic products. She also has strong relationships with key strategic entities in Europe, Eastern
Europe, Latin America, Canada, and the United States and we expect that she will continue to help Biomerica add new distributors for existing
products and add new product-lines for future distribution by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on affiliated and unaffiliated distributors, advertising in medical and trade journals, exhibitions at trade shows, direct mailings,
and an internal sales staff to market our diagnostic products. We target two main markets: (a) clinical laboratories and (b) point-of-care
testing (physicians&#8217; offices and over-the-counter drug stores).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 68.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to global and economic disruptions caused by the global COVID-19 pandemic, the ongoing war in Ukraine, and tensions between the
country of China and the United States, the Company&#8217;s operations have been negatively impacted. The Company has faced
disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, cost inflation, loss
of contracts and/or customers, closure of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping
and logistical disruptions, government responses of all types, international business risks in countries where the Company makes
and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of
production, customer credit risk, and general economic calamities. The pandemic, war, and geopolitical related disruptions have
materially negatively impacted the Company&#8217;s operations and financial performance and may continue to have significant
material negative impacts on the Company </span>depending on possible disruptions from future outbreaks or issues. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net sales were approximately $5,339,000 for fiscal 2023 compared to $18,871,000 for fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal years ended May 31, 2023 and 2022, the Company had one distributor and two distributors, respectively, which accounted for
a total of 35% and 65% of total net sales, respectively. Of this, for the fiscal years ended May 31, 2023 and 2022, the largest of the
distributors mentioned above accounted for 35% and 55%, respectively, of net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
gross receivables on May 31, 2023 and 2022 were approximately $751,000 and $927,000, respectively. As of May 31, 2023 and 2022, the Company
had one distributor which accounted for 36% and 50%, respectively, of gross accounts receivable. Of the 36% as of May 31, 2023, 100%
was owed by a distributor in Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BACKLOG</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2023 and 2022, Biomerica had a backlog of unshipped orders of approximately $655,000 and $754,000, respectively. On May 31, 2023,
this consisted primarily of orders to a distributor in Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RAW
MATERIALS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal raw materials utilized by Biomerica consist of various chemicals, serums, reagents, and packaging supplies. Almost all of our
raw materials are available from several sources, and we are not dependent upon any single source of supply or a few suppliers. However,
due to the limited number of suppliers of some materials, especially those such as antibodies, there is always the possibility that we
may encounter difficulty in the future obtaining key raw materials for its manufacturing processes or that such materials may be exceedingly
costly. For the fiscal year ended May 31, 2023, the Company did not have any significant concentration of vendor spend for raw materials.
For the fiscal year ended May 31, 2022, the Company had one vendor, which accounted for 84% of our purchases of raw materials largely
related to COVID-19 products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inventory consists of various types of materials including antibodies, antigens, bottles, boxes, various chemicals, and reagents utilized
in the manufacture of our test kits as well as products in various stages of completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sourcing and receiving of raw materials were negatively impacted during the global COVID-19 pandemic. While most of these disruptions
have since been resolved, it is unclear to what extent raw material availability will be impacted in the foreseeable future, and how
that will impact our production and sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFLATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the global and domestic supply chain disruptions, and overall inflationary pressures in the economy, we have experienced material
increases in the cost of our raw materials and in our operating and labor costs. While we have attempted to respond by increasing the
selling price of our own products, the gross margins on our products sold have been negatively impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPETITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have certain proprietary products, such as our EZ Detect colon disease home test, the Aware Breast Self Exam product and our InFoods<sup>&#174;
</sup>IBS product. These products have certain and significant competitive advantages compared to tests offered by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors vary greatly in size. Many are divisions or subsidiaries of well-established medical and pharmaceutical companies which are
much larger than Biomerica and expend substantially greater amounts than we do for research and development, manufacturing, advertising,
and marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary competitive factors affecting the sale of diagnostic products are uniqueness, technology, quality of product, performance, price,
service, and marketing. We believe we compete primarily on the basis of the uniqueness of our products, the quality of our products,
the speed of our test results, our patent position, our pricing and our prompt shipment of orders. We offer a broad range of products
but have had limited marketing capability. However, recently we have expanded our sales and marketing capability, through
marketing and strategic cooperation with larger companies and distributors and by hiring new employees with marketing and sales expertise.
We have also hired a social media manager who focuses on social media campaigns that are directed at increasing awareness of our products
and driving sales of these products. In addition, during fiscal 2023, we hired an experienced Chief Commercial Officer, who is focused
on growing sales of our InFoods<sup>&#174;</sup> IBS product that is now being offered as an LDT through a certified CLIA lab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GOVERNMENT
REGULATION OF OUR DIAGNOSTIC BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary business consists of selling products that are generally legally defined as medical devices and in vitro diagnostic medical devices.
As a result, we are considered to be a medical devices and in vitro diagnostic medical devices manufacturer, and as such, we are subject
to the regulations issued and enforced by of numerous governmental entities. These agencies include the FDA, Environmental Protection
Agency, Federal Trade Commission, Occupational Safety and Health Administration, U.S. Department of Agriculture (&#8220;USDA&#8221;),
and Consumer Product Safety Commission, as well as European Government agencies. Our activities are also regulated by various agencies
of the states and localities in which our products are sold. These regulations govern the introduction of new in vitro diagnostic medical
devices and medical devices, the observance of certain standards with respect to the manufacture and labeling of medical devices, the
maintenance of certain records, the reporting of potential product problems, and other matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Food, Drug &amp; Cosmetic Act of 1938 (the &#8220;FDCA&#8221;) regulates medical devices in the United States by classifying them into
one of three classes based on the extent of regulation believed necessary to ensure safety and effectiveness. Class I devices are those
devices for which safety and effectiveness can reasonably be assured through general controls, such as device listing, adequate labeling,
and adherence to the Quality System Regulation (&#8220;QSR&#8221;) as well as Medical Device Reporting (&#8220;MDR&#8221;), labeling
and other regulatory requirements. Some Class I medical devices are exempt from the requirement of Pre-Market Notification or clearance.
Class II devices are those devices for which safety and effectiveness can reasonably be ensured through the use of special controls,
such as performance standards, post-market surveillance and patient registries, as well as adherence to the general controls&#8217; provisions
applicable to Class I devices. Class III devices are devices that generally must receive clearance prior to marketing by the FDA pursuant
to a pre-market approval to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting,
or implantable devices. However, this classification can also apply to novel technology or new intended uses or applications for existing
devices. Our products are primarily either Class I or Class II medical devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to FDA requirements, we have registered our manufacturing facility with the FDA as a medical device manufacturer and listed the medical
devices we manufacture. We are also subject to inspection on a routine basis for compliance with FDA regulations. This includes the QSR,
which requires that we manufacture our products and maintain our documents in a prescribed manner with respect to issues such as design
controls, manufacturing, testing, and validation activities. Further, we are required to comply with other FDA requirements with respect
to labeling and MDR regulations which requires that we provide information to the FDA on deaths or serious injuries alleged to have been
associated with the use of our products, as well as any product malfunctions that are likely to cause or contribute to death or serious
injury if the malfunction were to recur. We believe that we are currently in material compliance with all relevant QSR and MDR requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our facility is required to have a California Medical Device Manufacturing License. The license is not transferable and must
be renewed biannually. Our current license is valid until November 19, 2024. Through compliance with FDA and California regulations,
we can market some of our medical devices throughout the United States. International sales of medical devices are also subject to the
regulatory requirements of each country where the product is sold. In Europe, the directives of the European Union (&#8220;EU&#8217;)
require that a device have a CE Mark in order to be sold in EU countries. We comply with In Vitro Diagnostic Medical Devices Directive
(&#8220;IVDD&#8221;) 98/79/EC and Medical Devices Regulation 2017/745 (&#8220;MDR&#8221;). We also comply with ISO 13485:2016 Medical
Devices Quality Management Systems - Requirements for Regulatory Purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, outside of the EU, the international regulatory review process varies from country to country. We work with our distributors
and sales representatives in the foreign countries in which we market our products to ensure that we comply with the regulatory laws
of those countries. We believe that our international sales to date have been in compliance with the laws of all foreign countries in
which we have made sales. Exports of most medical devices are also subject to certain FDA regulatory controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
designing, development, manufacturing, marketing, post-market surveillance, distribution, advertising, and labeling of Biomerica&#8217;s
immunoassay in vitro diagnostic (&#8220;IVD&#8221;) medical device products are subject to regulation in the United States by the Center
for Devices and Radiological Health of the FDA and state agencies. FDA regulations require that some new products have pre-marketing
clearance or approval by the FDA and require these products to be manufactured in accordance with the FDA&#8217;s current Good Manufacturing
Practice (cGMP) regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and
limitations. After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including,
for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA&#8217;s medical device reporting
regulations and reporting of corrections and removals. The FDA enforces these requirements by inspection and post-market surveillance.
The last FDA announced inspection was in November 2019 and no observations were noted. We believe that all Biomerica products sold in
the United States comply with the FDA and state regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an FDA regulated and ISO 13485:2016 certified In Vitro Diagnostic Medical Devices company. Our goal is to provide high quality medical
diagnostic products that generally meet or exceed customer requirements and comply with all applicable regulatory requirements: FDA 21
CFR Part 820 Quality Management System, ISO 13485:2016, Medical Devices Quality Management Systems - Requirements for Regulatory Purposes,
In Vitro Diagnostic Medical Devices Directive 98/79/EC &amp; and Medical Device Regulation 2017/745, Guidelines related to Medical Devices
Directive/Regulation Guidance on CE Marking, among others. Biomerica involves its employees in a continuous improvement process to increase
productivity, improve quality and maintain the suitability, adequacy, and effectiveness of our quality management system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU In Vitro Diagnostic Medical Device Regulation (&#8220;IVDR&#8221;) 2017/746 was effective on May 26, 2022. Manufacturers need to update
their technical documentation and processes to meet the more stringent regulatory requirements of the European Union. Notified Bodies
can begin certifying devices to the new IVDR requirements once they have been designated under IVDR by their Competent Authority. Our
Notified Body is officially designated under the IVDR and listed in the European Commission NANDO database since August 19, 2021. We
are working closely with our Notified Body to update our technical documentation to comply with these more stringent IVDR requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
IVDR 2017/746 Amendment 2021/0323 (COD), devices with a CE certificate that was issued in accordance with IVDD may be placed on the market
or put into service until May 26, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exceptional
Renewal of CE Certificate for IVDD Quality System was granted to Biomerica. Biomerica received an extended CE Certificate on May 24,
2022, which remains effective until May 26, 2025. We have until May 26, 2025, to update the technical documentation and processes to
meet these regulatory requirements of IVDR 2017/746.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
IVDR 2017/746 Amendment 2021/0323 (COD), devices without a CE certificate that was issued in accordance with IVDD, for which a declaration
of conformity was drawn up prior to May 26, 2022, per IVDD and for which the conformity assessment procedure pursuant to IVDR requires
the involvement of a Notified Body, may be placed on the market, or put into service until the following dates. Biomerica also has until
the following dates to update the technical documentation and processes to meet these regulatory requirements of IVDR 2017/746:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2025, for class D devices.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2026, for class C devices.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2027, for class B devices; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2027, for class A devices placed on the market
    in sterile condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEASONALITY
OF BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business has not been subject to significant seasonal fluctuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTERNATIONAL
BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the dollar volume of revenue attributable to sales to domestic customers and foreign customers during our
last two fiscal years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="12" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asia</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,021,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,375,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,798,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,339,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">North America</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">997,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Middle East</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    America</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,339,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,871,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that our foreign sales could be subject to some special or unusual risks, which are not present in the ordinary course of business
in the United States. Changes in economic factors, government regulations, terrorism, tariffs, embargos, trade wars, import/export restrictions,
disruptions in shipping and distribution channels, drops in demand for our products due to regional or national shut-downs from the
COVID-19 pandemic, other disease outbreaks that cause patients&#8217; fear or refusal to visit hospitals and healthcare providers
due to the pandemic where our products are sold and used, the erosion of economic conditions in those countries, and many other factors
all could impact sales within certain foreign countries. In addition, these factors could also impact our ability to collect foreign
accounts receivable. Foreign countries have licensing requirements applicable to the sale of diagnostic products, which vary substantially
from domestic requirements; depending upon the product and the foreign country, these may be more or less restrictive than requirements
within the United States and may change without notice. Foreign sales of our diagnostic products are made primarily through a network
of approximately 40 independent distributors in approximately 30 countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTELLECTUAL
PROPERTY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regard the protection of our methodologies, designs, product formulations, manufacturing processes, diagnostic procedures,
copyrights, service marks, trademarks, and trade secrets as important to our future success. We rely on a combination of copyright,
trademark, patent, service mark and trade secret laws, and contractual restrictions to establish and protect our proprietary rights
in products and services. We have entered into confidentiality and invention assignment agreements with our employees and
contractors, and nondisclosure agreements with most of our fulfillment partners and strategic partners to limit access to and
disclosure of proprietary information. We cannot be certain that these contractual arrangements or the other steps taken by us to
protect our intellectual property (&#8220;IP&#8221;) will prevent misappropriation of our technology. We have licensed in the past,
and expect that we may license in the future, certain of our proprietary rights, such as trademarks, patents, trade secrets, or
copyrighted material, to third parties. While we attempt to ensure that the quality of our product brands is maintained by such
licensees, we cannot be certain that such licensees will not take actions that might hurt the value of our proprietary rights or
reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LICENSE
OF THIRD-PARTY INTELLECTUAL PROPERTY</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
occasion, we in-licensed both exclusive and non-exclusive rights to intellectual property and patents owned by third parties. These license
agreements typically require royalties and other payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a royalty agreement in which we obtained rights to manufacture and market an ACTH test (used to detect chronic metabolic conditions).
Royalty expenses of approximately $13,000 and $19,000, respectively, are included in cost of sales for this agreement for the fiscal
years ended May 31, 2023 and 2022. Sales of products manufactured under this agreement are not material to total sales for the fiscal
years ended May 31, 2023 and 2022, respectively. We may license other products or technology in the future as it is deemed necessary
or opportunistic for conducting business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the products that we manufacture, sell, or use may be covered by claims in issued patents held by other persons or entities, and as
such, upon notice from such persons or entity we may be required to pay a license fee or may be required to cease all manufacture, sale
or use of such products, which could negatively impact us. While we have not been notified of any such claims by third parties, we cannot
guarantee that such claims will not be made in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRANDS
AND TRADEMARKS</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
occasionally register our tradenames with the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;). Of note, we registered the tradename
&#8220;InFoods&#8221; on December 24, 2016. Our unregistered tradenames are &#8220;EZ Detect,&#8221; &#8220;EZ-H.P.,&#8221; and &#8220;EZ-PSA&#8221;.
A trademark for &#8220;Aware&#8221; was issued and assigned in 2001, renewed in 2011 and 2021. On January 11, 2020, the USPTO renewed
our &#8220;FORTEL&#8221; trademark for another ten years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some foreign countries do not protect our proprietary rights to the same extent as do the laws of the United States. Effective
copyright, trademark, and trade secret protection may not be available in such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PATENTS
AND INFOODS TECHNOLOGY</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed over 100 international and Patent Corporation Treaty patents (&#8220;PCT&#8221;) and have over multiple provisional and non-provisional
patents currently filed with the USPTO. Substantially all of our patents that are pending or registered pertain to the InFoods&#174; technology
platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most important family of patent applications pertains to our InFoods<sup>&#174;</sup> technology platform, which is a method of diagnosing
and treating symptoms of many different inflammatory diseases. Our first product launch using this technology is the InFoods<sup>&#174;
</sup>IBS product which is designed to diagnose and treat IBS. Using a patient blood sample, a physician or lab can run our test to identify
specific foods (e.g., pork, milk, shrimp, broccoli, eggs) that, if eliminated from an IBS patient&#8217;s diet, can alleviate or reduce
the individual&#8217;s IBS symptoms, including, but not limited to, constipation, diarrhea, bloating, cramping, severe pain, and indigestion.
We have filed many patent applications with the USPTO and with other such similar agencies in other countries outside of the United States
pertaining to this InFoods<sup>&#174;</sup> technology. These patent applications include claims that address the diagnosis and treatment
of several disease states including IBS, functional dyspepsia, Crohn&#8217;s disease, ulcerative colitis, gastroesophageal reflux disease,
osteoarthritis, psoriasis, migraine headaches, and depression. These applications include the use of this technology in both humans and
animals. The first InFoods<sup>&#174;</sup> patents filed by us pertained to IBS. Several of these patents pertaining to the InFoods<sup>&#174;
</sup>IBS technology have been issued and many more are in active review and prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, we received our first patent pertaining to the InFoods<sup>&#174;</sup> technology platform from the Korean Intellectual
Property Office, covering IBS. Since then, we have been granted a total of 19 patents; The United States Patent and Trademark
Office (&#8220;USPTO&#8221;) has issued the Company two patents with broad claims that protect our InFoods<sup>&#174;</sup> technology
in testing and treating patients with IBS. Patents have also been issued in the countries of Australia (two patents), Canada, Japan (two
patents), Korea (two patents), Mexico, Panama, Peru, and Singapore, covering our InFoods<sup>&#174;</sup> IBS technology. Additional patent
applications pertaining to the InFoods<sup>&#174;</sup> IBS product are in prosecution and review at the USPTO and with the patent issuance
authorities in other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing and have filed patents with claims that cover products that target other diseases utilizing the InFoods<sup>&#174;
</sup>technology platform. We have dozens of patents in prosecution or review pertaining to these other diseases, including: Functional
Dyspepsia, Crohn&#8217;s disease, Ulcerative Colitis, Gastroesophageal Reflux disease (&#8220;GERD&#8221;), Migraine Headaches, Depression,
and Osteoarthritis. In addition, we have a family of patents that cover the use of certain information technology (&#8220;IT&#8221;)
platforms and artificial intelligence/machine learning (&#8220;AI/ML&#8221;) tools that could assist patients in identifying and avoiding
packaged or processed food that contain specific foods that they are trying to eliminate from their diet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our IBS related issued patents, we have also been issued InFoods<sup>&#174;</sup> technology patents in the following countries
pertaining to the following diseases: Australia &#8211; Attention Deficit Disorder (&#8220;ADD&#8221;) and Attention Deficit Hyperactivity
Disorder (&#8220;ADHD&#8221;); Australia &#8211; GERD; Japan - psychological depression, IT based food monitoring and elimination technology;
China &#8211; IT based food monitoring and elimination technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the claims in these issued InFoods&#174; IBS patents and claims in our pending patents that protect the use of the InFoods&#174;
technology to diagnose and treat various other diseases, provide us with broad protections from other companies making or selling competing
products in this highly disruptive new field of medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the use of our own patents, we have acquired from third parties the rights to manufacture and sell certain products that
are protected by patents or intellectual property owned by these third parties. In some cases, royalties are paid on the sales of these
products. We anticipate that we will license or purchase the rights to other products or technologies in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also engage in contract research and development and contract manufacturing for third party companies. The technologies that relate to
this contract R&amp;D and manufacturing are protected by patents and other intellectual property. In these situations, this intellectual
property is typically licensed to us under a limited license agreement enabling us to perform the services being contracted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recently completed an endpoint determination clinical trial on our InFoods&#174; IBS product. Our business model for this product includes
the possible out-licensing of this product and the related patents to a large international life sciences or technology company that
would commercialize the product or assist us with the commercialization. We may also out-license the patents or other intellectual property
pertaining to one or more of our other products including but not limited to our H. Pylori product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, we employed a total of 62 and 64 employees, respectively, in the United States, Mexico, and Germany, of which
62 and 64 were full-time employees, respectively. Various employees listed in the production department also perform research and development
duties as a routine function of their job. We occasionally employ temporary employees when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a breakdown of employees by departments:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research &amp; Development</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales &amp; Marketing</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production
    &amp; Operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also engage the services of many outside Ph.D.&#8217;s, M.D.&#8217;s, and other types of industry expert consultants and organizations
as well as medical institutions for technical support, regulatory advisors, marketing and public relations advisors, financial advisors,
contract product development and manufacturing organization, and other advisors on a regular basis. We try to protect the Company with
the use of confidentiality, intellectual property ownership, and indemnifications agreements. However, we cannot guarantee that the use
of such experts will fully protect the Company from third-party claims or from theft of our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risks described below are not the only ones we face. Additional risks and uncertainties we are not presently aware of or that we currently
believe are immaterial may also impair our business operations. Our business could be harmed by any of these risks and uncertainties.
The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing
these risks, you should also refer to the other information contained or incorporated by reference into this annual report on Form 10-K,
including our consolidated financial statements and related notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISKS
RELATED TO OUR BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business could be adversely affected by the effects of widespread public health epidemics or other broad government-imposed restrictions
on societies<i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: #222222"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: #222222"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
recent years, certain aspects of our business were negatively impacted by the COVID-19 pandemic. We may be materially impacted by ongoing
outbreaks of illness or other health issues, such as the COVID-19 outbreak. The outbreak of the COVID-19 virus caused various governments,
including the United States, to implement quarantines, various restrictions on transportation, and shelter in place orders and other
broad restrictions. Governments have also implemented sweeping work restrictions that prohibit most employees from going to work. The
Company faces significant future risks from such government imposed restrictions, laws and regulations pertaining to health epidemics
or various other government declared crisis&#8217;, that include but are not limited to: a) supply chain disruptions making it difficult
for the Company to receive materials needed for production of its products, and needed to ship finished products to our customers, b)
loss of contracts and customers from the financial strains or other disruptions they are experiencing as a result of the government restrictions,
c) financial risks pertaining to receivables due from customers that may fall into insolvency or otherwise be unable to pay their bills,
d) government orders that make it difficult to remain open for business, restrict imports of raw materials or exports of finished goods,
refusal to allow the Company&#8217;s product to be licensed for sale in their countries, and other seen and unforeseen actions taken
by government agencies, e) absenteeism or loss of employees at the Company, or at our partner&#8217;s companies, due to health reasons
or government restrictions, that are needed to develop, validate, manufacture, and perform other necessary functions for our operations,
f) equipment failures, loss of utilities, and other disruptions that could impact our operations or render them inoperable, g) litigation
or government actions against the Company pertaining to existing products and new products sold by the Company that are directed at limiting
or treating the spread of the pandemic outbreak, h) a local or global recession or depression that could harm the international banking,
economic and financial systems, i) a drop in demand for our products, that are all medical related, due to patients&#8217; reluctance
or refusal to visit hospitals, labs, and doctors&#8217; offices where our products are used, due to their fear of contracting a disease,
and j) many other seen and unforeseen events and circumstances, all of which could negatively impact the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: #222222"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #222222"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: #222222"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have a history of operating losses.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have historically incurred net losses. There can be no assurance that we will generate net profits in future periods. Further, there
can be no assurance that we will be cash flow positive in future periods. In the event that we fail to achieve profitability in future
periods, the value of our common stock may decline. In addition, if we are unable to achieve or maintain positive cash flows, we would
be required to seek additional funding, which may not be available on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
operating results may fluctuate adversely as a result of many factors that are outside our control, which may negatively impact our stock
price.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating results are dependent upon many factors that are substantially outside of our control that could materially and adversely affect
our business, results of operations, and financial condition. Factors that are beyond our control and that could affect our operating
results in the future include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    clearance of our products in the U.S. and in other markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    compliance in the U.S., Europe and other territories;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the level of competition, such as would occur if one of our competitors introduced a new, better performing or lower priced product
    to compete with one or more of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the reimbursement systems or reimbursement amounts that end-users may rely upon in choosing to use our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in economic conditions in our domestic and international markets, such as economic downturns, decreased healthcare spending, reduced
    consumer demand, inflation and currency fluctuations; changes in government laws and regulations affecting our business; reluctance
    for consumers to visit healthcare providers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lower
    than anticipated market penetration of our new or more recently introduced products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    quantities of our product or that of our competitors in our distributors&#8217; inventories or distribution channels;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in distributor buying patterns;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
    mandated shelter-in-place, lock downs or other crisis related orders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential resurgence of the COVID-19 virus or mutations of the virus; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the healthcare market including consolidation in our customer base.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fluctuations
in our operating results, for any reason, could cause operating losses as a result of significant fixed expenses.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base the scope of our operations and related expenses on our estimates of future revenues. A significant portion of our operating expenses
are fixed, and we may not be able to rapidly adjust our expenses if our revenues fall short of our expectations. Our revenue estimates
for future periods are based, among other factors, on estimated end-user demand for our products. If end-user consumption is less than
estimated, revenues from our distribution partners and other distribution channels would be expected to fall short of expectations, and
because such a significant portion of our costs are fixed, could result in operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
remain competitive, we must continue to develop, obtain, and protect our proprietary technology rights; otherwise, we may lose market
share or need to reduce prices as a result of competitors selling technologically superior products that compete with our products, or
selling products at lower prices.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete successfully in the diagnostic market depends on continued development and introduction of new products, technology,
and the improvement of existing technology. If we cannot continue to improve upon or develop, obtain, and protect our technology, our
operating results could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitive position is heavily dependent on obtaining and protecting our own proprietary technology or obtaining licenses from others.
Our ability to obtain patents and licenses, and their benefits, is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there
is no assurance our efforts to develop new technologies, products, or markets will be successful or such technologies, products, or markets
will be commercially viable.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
devote a significant amount of financial and other resources to researching and developing new technologies, new products, and new markets.
The development, manufacture and sale of diagnostic products require a significant investment of resources. The development of new products
and markets also requires a substantial investment of resources, such as new employees, offices and manufacturing facilities, consultants,
and clinical trials. No assurances can be given that our efforts to develop new technologies or products will be successful, that such
technologies and products will be commercially viable, or our expansion into new markets will be profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also no guarantee that our new products, including our InFoods&#174; IBS products, will get approval and be well accepted into the
marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations will be adversely affected if our operating results do not correspondingly increase with our increased expenditures or if
our technology, product, and market development efforts are unsuccessful or delayed. Furthermore, our failure to successfully introduce
new technologies or products and develop new markets could have a material adverse effect on our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Company is required to obtain government or regulatory certification in many countries and the European community to sell its products
in those countries or regions. There is no assurance that the Company will be able to retain its certification in the future. This includes
the possibility and risk that the Company&#8217;s products do not meet the new EU IVDR testing and documentation requirements in the
future as described in the above &#8220;Research and Development&#8221; section of this document.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
government regulation exists in countries in which we conduct business. A large part of the Company&#8217;s sales is to distributors
in Europe, China, and other countries, which require us to maintain certain certifications to sell our products. Failure to comply with
current governmental regulations and quality assurance guidelines could cause the loss of these certifications, which could materially
adversely affect the results of the Company. Loss of certifications could lead to temporary manufacturing shutdowns, product recalls,
product shortages, or delays in product manufacturing and a decline in sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Company maintains a manufacturing plant in Mexico which presents risks to the Company including risks associated with doing business
outside the United States.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant investment in its manufacturing facility in Mexico through its subsidiary, Biomerica de Mexico. In addition,
the Company warehouses a significant amount of its inventory at the Mexico facility. There are a number of risks associated with doing
business in Mexico, including, exposure to local economic and political conditions, social unrest, including risks of terrorism or other
hostilities, export and import restrictions, the potential for shortages of trained labor, and the possible effects of currency exchange
rate fluctuations. These risks could lead to additional costs that we cannot foresee at this time and may materially adversely impact
our business, results of operations, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
use hazardous materials in our research and production that may result in unexpected and substantial claims against us relating to handling,
storage, or disposal.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use hazardous materials in our research and production. The risk of accidental contamination or injury from these materials cannot be
completely eliminated. In the event of such an accident, the Company could be held liable for any harm or damages that result and any
such liability could exceed the resources of the Company. The Company may incur substantial costs to comply with environmental regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any governmental authorities were to impose new environmental regulations requiring compliance in addition to that required by existing
regulations or alter their interpretation of the requirements of such existing regulations, such environmental and safety regulations
could impair our research, development, or production efforts by imposing additional, and possibly substantial, costs, restrictions,
or compliance procedures on our business. In addition, because of the nature of the penalties provided for in some of these environmental
and safety regulations, we could be required to pay sizable fines, penalties, or damages in the event of noncompliance with regulations
and environmental laws. Any environmental or safety violation or remediation requirement could also partially or completely shut down
our research and manufacturing facilities and operations, which would have a material adverse effect on our business. The risk of accidental
contamination or injury from these hazardous materials cannot be completely eliminated and exposure of individuals to these materials
could result in substantial fines, penalties, or damages that may not be covered by insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
rely on a limited number of key distributors that account for a substantial majority of our total revenue. The loss of any key distributor
or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net sales were approximately $5,339,000 for fiscal 2023 compared to $18,871,000 for fiscal 2022. For the fiscal years ended May 31, 2023
and 2022, the Company had one distributor and two distributors, respectively, which accounted for a total of 35% and 65% of our net sales,
respectively. Of this, for the fiscal years ended May 31, 2023 and 2022, the largest of the distributors mentioned above accounted for
35% and 55%, respectively, of net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
gross receivables on May 31, 2023 and 2022 were approximately $751,000 and $927,000, respectively. As of May 31, 2023 and 2022, the Company
had one distributor which accounted for a total of 36% and 50%, respectively, of gross accounts receivable. Of the 36% as of May 31,
2023, 100% was owed by a distributor in Asia. Adverse changes in our relationships with these distributors and other partners, or adverse
developments in their financial condition, performance, or purchasing patterns, could adversely affect our business and consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
sell to countries in Asia including China where trade policies and political issues could impact our revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenues could be negatively impacted by complex relationships between the United States and other Asian countries including China. While
trade between the countries remains extremely strong, there are no assurances that these trade relations continue to be strong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
extend credit to customers outside the United States which can be difficult to collect.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
extend credit to many of our customers including those outside of the United States. It is often difficult to obtain adequate credit
information on these customers. Further, our ability to collect receivables from these customers through the court systems in those countries
can be more difficult than here in the United States. Our inability to collect on receivables from customers, in particular those outside
of the United States, could negatively impact the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are not able to manage our growth strategy our operating results may be adversely affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy contemplates further growth, which would likely result in expanding into larger facilities, expanding the scope of
operating and financial systems and the geographical area of our operations, including further expansion outside the United States, as
new products and technologies are developed and commercialized or new geographical markets are entered. Because we have a small executive
staff, acquisitions, and other future growth may divert management&#8217;s attention from core aspects of our business and place a strain
on existing management and our operational, financial, and management information systems. Furthermore, we may expand into markets in
which we have less experience or incur higher costs. Any and all of these potential growth and expansion strategies and events could
impose material risks and cause the Company to incur adverse operating and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
property risks and third-party claims of infringement, misappropriation of proprietary rights, or other claims against us could adversely
affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, result
in significant costs, and materially adversely affect our operating results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
in or related to our industry often aggressively protect and pursue their intellectual property rights. There are often intellectual
property risks associated with developing and producing new products and entering new markets, and we may not be able to obtain, at reasonable
cost or upon commercially reasonable terms, if at all, licenses to intellectual property of others that is alleged to be part of such
new or existing products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on IP for the current products we sell and for the new products in research, development, and in clinical trials. While the Company
tries to protect its IP with confidentiality agreements and internal policies, we still face risks that our IP will be stolen or otherwise
misappropriated, by parties inside or outside of the United States. Further, we have filed many patents around the world on much of the
research and development done by the Company, and the proposed products to come from this research. The majority of these filed patents
are still under review and have not yet been allowed or issued. We may not be able to attain patent claims that adequately protect the
company from competitors developing similar products or copying our products. Finally, there is a great number of issued patents owned
by others that pertain to the product categories in which we operate. While we do not know of any patents with claims that we are violating
by manufacturing or selling our current products, there is a risk that certain third-party patents will come to our attention that prohibit
us from selling our products or that require us to pay royalty payments. Such third-party claims could have a material negative impact
on the Company. Any of these IP-related risks could cause material damage to future revenues and to the long-term enterprise values of
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have hired and will continue to hire individuals or contractors who have experience in medical diagnostics and these individuals or contractors
may have confidential trade secret or proprietary information of third parties. We cannot assure that these individuals or contractors
will not use this third-party information in connection with performing services for us or otherwise reveal this third-party information
to us. Thus, we could be sued for misappropriation of proprietary information and trade secrets. Such claims are expensive to defend
and could divert our attention and result in substantial damage awards and injunctions that could have a material adverse effect on our
business, financial condition, or results of operations. In addition, to the extent that individuals or contractors apply technical or
scientific information independently developed by them to our projects, disputes may arise as to the proprietary rights to such data
and may result in litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
defense and prosecution of patent and trade secret claims are both costly and time consuming. We or our customers may be sued by other
parties that claim that our products have infringed their patents or misappropriated their proprietary rights or that may seek to invalidate
one or more of our patents. An adverse determination in any of these types of disputes could prevent us from manufacturing or selling
some of our products, limit or restrict the type of work that employees involved with such products may perform for us, increase our
costs, and expose us to significant liability. In addition, the defense of such claims could result in significant costs and divert the
attention of our management and other key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the foregoing, we may also be required to indemnify some
customers, distributors, and strategic partners under our agreements with such parties if a third party alleges or if a court finds that
our products or activities have infringed upon, misappropriated, or misused another person&#8217;s proprietary rights. Further, our products
may contain technology provided to us by other parties such as contractors, suppliers, or customers. We may have little or no ability
to determine in advance whether such technology infringes the intellectual property rights of a third party. Our contractors, suppliers,
and licensors may not be required or financially able to indemnify us in the event that a claim of infringement is asserted against us,
or they may be required to indemnify us only up to a maximum amount, above which we would be responsible for any further costs or damages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the products that we manufacture, sell, or use may be covered by claims in issued patents held by other persons or entities, and as
such, upon notice from such persons or entity, we may be required to pay a license fee or may be required to cease all manufacture, sale
or use of such products, which could negatively impact our financial results or operations. We cannot guarantee that such claims will
not be made in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
need to continue to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on
our operations and the interests of our stockholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company focused on research and development of new products that do not yet generate revenues, we need to continue to raise funds through
public or private debt or sale of equity to achieve our business strategy. When we raise funds or acquire other technologies or businesses
through issuance of equity, this dilutes the interests of our stockholders. Moreover, the availability of additional capital, whether
debt or equity from private capital sources (including banks) or the public capital markets, fluctuates as our financial condition and
industry or market conditions in general change. There may be times when the private capital markets and the public debt or equity markets
lack sufficient liquidity or when our securities cannot be sold at attractive prices, in which case we would not be able to access capital
from these sources on favorable terms, if at all. We can give no assurance as to the terms or availability of additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to raise additional funds to finance our future capital or operating needs could force us to delay, reduce, or eliminate our
development programs or commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
related to development projects and approvals are hard to estimate due to factors that are unknown to us at this time. These future costs
could be much higher than anticipated and current operations are unlikely to be able to cover these costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
trials involve a lengthy and expensive process with an uncertain outcome, and results of studies and trials may not be predictive of
future trial results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are expensive, time consuming, and difficult to design and implement. Regulatory agencies may analyze or interpret the results
differently than we do. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates
may take a significant amount of time to complete. Regulatory authorities, including state and local authorities, may suspend, delay
or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular clinical trial to
continue for a longer duration than originally planned, or require a change to our development plans such that we conduct clinical trials
for a product candidate in a different order. There is no assurance that the results of the clinical trials will be positive. A negative
clinical trial could affect our ability to obtain regulatory clearances and/or potential licensing partners. There is also no assurance
that our clinical trials will not be delayed or will be completed. Any of the foregoing could have a material adverse effect on our business,
results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
results of operations and financial conditions may be adversely affected by the financial soundness of our customers, distributors, and
suppliers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our customers&#8217; or suppliers&#8217; operating and financial performance deteriorates, or if they are unable to make scheduled payments
or obtain credit, our customers may not be able to pay, or may delay payment of, accounts receivable owed to us, and our suppliers may
restrict credit or impose different payment terms or reduce or terminate production of products they supply to us, or may cease all operations.
Any inability of customers to pay us for our products and services, or any demands by suppliers for different payment terms, or inability
for such suppliers to continue operations may adversely affect our operating results and financial condition. Additionally, both state
and federal government sponsored and private payers, as a result of budget deficits or reductions, may seek to reduce their healthcare
expenditures by cutting or eliminating reimbursements for, or cutting purchase of our products. Any reduction in payments by such government
sponsored or private payers may adversely affect our earnings and cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may not achieve market acceptance of our new products among healthcare providers and physicians, and this would have a negative effect
on future sales.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our ability to introduce new products that gain acceptance among consumers, healthcare providers, and physicians is an important
part of our ability to grow our revenue in future periods. However, any new products we introduce may not gain market acceptance to the
extent we anticipate or project. The acceptance in the medical community for any of our new products is unpredictable at this time. In
addition, the Company will need to spend considerable funds in order to introduce new products into the marketplace. Sales, if any, of
these products in the future are uncertain. In addition, our competitors may offer different products and product formats at suggested
prices that are lower than our products or whose products are more accurate than our products. We can provide no assurances that consumers
and the medical community will purchase our products or that they will not prefer to purchase a competitive product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
industry and market segments in which we operate are highly competitive, and intense competition with other providers of diagnostic products
may reduce our sales and margins.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diagnostic tests compete with similar products made by our competitors. There are a large number of multinational and regional competitors
making investments in competing technologies and products. We also face competition from our distributors as some have created, and others
may decide to create their own products to compete with ours. A number of our competitors have a potential competitive advantage because
they have substantially greater financial, technical, research and other resources, larger, more established marketing, sales, distribution
and service organizations; more established relationships with healthcare professionals; and <span style="background-color: white">greater
experience in conducting research and development, manufacturing, clinical trials, and obtaining regulatory approval for products</span>.
Moreover, some competitors offer broader product lines and have greater name recognition than we have. If our competitors&#8217; products
are more effective than ours or take market share from our products through more effective marketing or competitive pricing, our operating
results could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been a trend toward industry consolidation in our markets over the last few years. We may not be able to compete
successfully in an increasingly consolidated industry. We expect this trend toward industry consolidation may continue as companies attempt
to strengthen or hold their market positions in an evolving industry and as companies are acquired or are unable to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by
failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals, or other changes to
the existing laws and regulations that adversely impact our ability to manufacture and market our products.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing, manufacturing, and sale of our products are subject to regulation
by numerous governmental authorities in the United States, principally the FDA, and corresponding state and foreign regulatory agencies.
Our future performance depends on, among other matters, if, when, and at what cost we will receive regulatory approval for new products,
and if we can continue to comply with the many regulatory requirements that enable us to manufacture and sell medical related products
and tests. Regulatory review can be a lengthy, expensive, and uncertain process, making the timing and costs of clearances and approvals
difficult to predict. Meeting all regulatory requirements, laws and mandates, and maintaining compliance with such in order to manufacture
and sell medical products can be difficult and expensive. Our results of operations would be negatively affected by failures or delays
in the receipt of regulatory approvals or clearances, the loss of previously received approvals or clearances, the placement of limits
on the marketing and use of our products, and restrictions on our ability to manufacture our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in government policy could adversely affect our business and potential profitability.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in government policy could have a significant impact on our business
by increasing the cost of doing business, affecting our ability to sell our products and negatively impacting our profitability. Such
changes could include tariffs, embargos, trade wars, modifications to existing legislation, such as U.S. tax policy, or entirely new legislation,
such as the Affordable Healthcare Act in the United States. We cannot predict the many ways that healthcare reform in the United States
and internationally, and changing trade legislation and policies could adversely affect our business. It is unclear whether and to what
extent, if at all, other anticipated developments, including changes due to new presidential administration priorities, or changes resulting
from healthcare reform, such as a change in the number of people with health insurance, may impact us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are subject to numerous government regulations in addition to FDA regulations, and compliance with laws, including changed or new laws,
could increase our costs and adversely affect our operations. There is also the risk that our facilities could fail to get the proper
licensing at our next inspection or renewal.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to FDA and other regulations referred to above, numerous laws relating to such matters as safe working conditions, manufacturing
practices, data privacy, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances
impact our business operations. If these laws or their interpretation change or new laws regulating any of our businesses are adopted,
the costs of compliance with these laws could substantially increase our overall costs. Failure to comply with any laws, including laws
regulating the manufacture and marketing of our products, could result in substantial costs and loss of sales or customers. Because of
the number and extent of the laws and regulations affecting our industry, and the number of governmental agencies whose actions could
affect our operations, it is impossible to reliably predict the full nature and impact of future legislation or regulatory developments
relating to our industry and our products. To the extent the costs and procedures associated with meeting new or changing requirements
are substantial, our business, results of operations and financial condition could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
total revenue could be affected by third-party reimbursement policies and potential cost constraints.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
end-users of our products are primarily physicians, labs, and other healthcare providers. In the United States, healthcare providers
such as hospitals and physicians who purchase diagnostic products generally rely on third-party payers, principally private health insurance
plans, federal Medicare, and state Medicaid, to reimburse all or part of the cost of the procedure. Use of our products would be adversely
impacted if physicians and other healthcare providers do not receive adequate reimbursement for the cost of our products by their patients&#8217;
third-party payers both in the United States and in foreign markets. Our total revenue could also be adversely affected by changes or
trends in reimbursement policies of governmental or private healthcare payers. We believe that the overall escalating cost of medical
products and services has led to, and will continue to lead to, increased pressures on the healthcare industry, both foreign and domestic,
to reduce the cost of products and services. Given the efforts to control and reduce healthcare costs in recent years, currently available
levels of reimbursement may not continue to be available in the future for our existing products or products under development. Third-party
reimbursement and coverage may not be available or adequate in either the United States or foreign markets, current reimbursement amounts
may be decreased in the future and future legislation, regulation, or reimbursement policies of third-party payers may reduce the demand
for our products or adversely impact our ability to sell our products on a profitable basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unexpected
increases in, or inability to meet, demand for our products could require us to spend considerable resources to meet the demand or harm
our reputation and customer relationships if we are unable to meet demand.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to meet customer demand for our products, whether as a result of manufacturing problems or supply shortfalls, could harm our
customer relationships and impair our reputation within the industry. In addition, our product manufacturing of certain product lines
is concentrated in our two manufacturing sites. Weather, natural disasters (including pandemics), fires, terrorism, political change,
governmental restrictions or stay-at-home orders in response to natural disasters (including pandemics), failure to follow specific internal
protocols and procedures, equipment malfunction, environmental factors, or damage to one or more of our facilities could adversely affect
our ability to manufacture our products. This, in turn, could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience unexpected increases in the demand for our products, we may be required to expend additional capital resources or engage
third-party manufacturers to meet these demands. These capital resources could involve the cost of new machinery or even the cost of
new manufacturing facilities. In addition, engaging third-party manufacturers would increase manufacturing costs and reduce margins.
This would increase our capital costs or third-party expenses, which could adversely affect our earnings and cash resources. If we are
unable to develop or obtain necessary manufacturing capabilities in a timely manner or to engage third-party manufacturers to meet demand,
our total revenue could be adversely affected. Failure to cost-effectively increase production volumes, if required, or lower than anticipated
yields or production problems, including those encountered as a result of changes that we may make in our manufacturing processes to
meet increased demand or changes in applicable laws and regulations, could result in shipment delays as well as increased manufacturing
costs, which could also have a material adverse effect on our business, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unexpected
increases in demand for our products could also require us to obtain additional raw materials in order to manufacture products to meet
the demand. Some raw materials require significant ordering lead time and we may not be able to timely access sufficient raw materials
in the event of an unexpected increase in demand, particularly those obtained from a sole supplier or a limited group of suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
one or more of our products is claimed to be defective or does not meet the performance criteria we claim in our marketing materials,
we could be subject to product recalls, claims of liability, harm to patients or users of our products, or harm to our reputation
that could adversely affect our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
claim of a defect in the design or manufacture of our products could have a material adverse effect on our reputation in the industry
and subject us to claims of liability for injuries and otherwise. Further, a claim that one of our products is defective or does not
actually meet the performance criteria we claim in our marketing materials, could require a product recall or otherwise have a substantial
impact on our revenues and financial performance. Any substantial underinsured loss resulting from such a claim or defect would have
a material adverse effect on our operating results and financial conditions and the damage to our reputation or product lines in the
industry could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are exposed to business risks which, if not covered by insurance, could have an adverse effect on our results of operations. We face
potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face a number of business risks, including exposure to product liability claims, employment law claims, claims that the Company or its
officers, directors or employees have engaged in illegal or wrongful acts, claims of violation of environmental laws, and many other possible
claims. Although we maintain insurance for a number of these risks, we may face claims for types of damages, or for amounts of damages,
that are not covered by our insurance. For example, although we currently carry product liability insurance for liability losses, there
is a risk that product liability or other claims may exceed the amount of our insurance coverage or may be excluded from coverage under
the terms of our policy. Also, our existing insurance may not be renewed at the same cost and level of coverage as currently in effect
or may not be renewed at all. Further, we do not currently have insurance against many environmental risks we confront in our business.
If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether
arising out of product liability matters, cybersecurity matters, or from some other matter, that claim could have a material adverse
effect on our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may rely on third parties to conduct or be part of our clinical trials. If these third parties do not successfully carry out their contractual
duties or meet expected deadlines, we may not be able to seek or obtain regulatory approval for or commercialize our product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third-party contract research organizations (&#8220;CROs&#8221;),
universities or/clinical sites (&#8220;Vendors&#8221;), to coordinate, monitor and conduct of our clinical trials and to manage, analyze,
and interpret data for our clinical programs. We, our Vendors, and our clinical sites are required to comply with current Good Clinical
Practices (&#8220;GCPs&#8221;), regulations, and guidelines issued by the FDA and by similar governmental authorities in other countries
where we are conducting clinical trials. We have an ongoing obligation to monitor the activities conducted by our Vendors and at our clinical
sites to confirm compliance with these requirements. In the future, if we, our Vendors or our clinical sites fail to comply with applicable
GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical
trials before approving our marketing applications. If our Vendors do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised
due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended,
delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.
As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase,
and our ability to generate revenue could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Failures
in our information technology and storage systems could significantly disrupt our business or force us to expend excessive costs.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We utilize complex information technology systems to support our business
and store information. We cannot be sure that our systems will meet our future business needs or that necessary upgrades will operate
as designed, which could result in excessive costs or disruptions in portions of our business. In particular, any disruptions, delays,
or deficiencies caused by our enterprise resource planning system could adversely affect our ability to process orders, ship products,
provide services and customer support, send invoices and track payments, fulfill contractual obligations, or otherwise operate our business.
In addition, despite the implementation of security measures, information technology systems are vulnerable to damage from a variety of
sources, including computer viruses, unauthorized access, telecommunications or network failures, malicious human acts, terrorism, and
natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical
or electronic break-ins, computer viruses and similar disruptive problems. Cyber security is a great and growing risk to operating companies.
Cyber-attacks may result in loss of vital Company documentation and data, or confidential third-party documents held by the Company, that
are necessary for the Company to operate. Despite the precautionary measures we have taken to prevent unanticipated problems that could
affect our systems, sustained or repeated system failures that interrupt our ability to generate and maintain data, could result in a
material disruption in our operations and material adverse financial costs to the Company. Furthermore, to the extent that any disruption
or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could face a variety of negative consequences, including regulatory actions or litigation, fines or penalties, adverse
publicity, increased cybersecurity protection costs, and lost revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that our measures to protect our systems from cyber-attack are not sufficient to avoid attacks by new sources and methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business could be negatively affected by the loss of or the inability to hire key personnel.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success depends in part on our ability to retain our key technical, sales, marketing, and executive personnel and our ability to
identify and hire additional qualified personnel. Competition for these personnel is intense, both in the industry in which we operate
and where our operations are located. Further, we expect to grow our operations, and our needs for additional management and other key
personnel are expected to increase. If we are not able to retain existing key personnel, or timely identify and hire replacement or additional
qualified personnel to meet expected growth, our business could be adversely impacted. In addition, the loss of any of our key personnel,
particularly key research and development personnel, could harm our business and prospects and could impede the achievement of our research
and development, operation or strategic objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
face risks relating to our international sales, including inherent economic, political, and regulatory risks, which could impact our
financial performance, cause interruptions in our current business operations and impede our growth strategy.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are primarily sold internationally, with the majority of our international sales to our distributors in Asia and Europe. We
currently sell and market our products through distributor organizations and sales agents which creates foreign risks include, among
others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with multiple different registration requirements and new and changing registration requirements, our inability to benefit from registration
    for our products inasmuch as registrations may be controlled by a distributor, and the difficulty in transitioning our product registrations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with complex foreign and U.S. laws and regulations that apply to our international operations, including U.S. laws such as import/export
    limitations, the Foreign Corrupt Practices Act, and local laws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tariffs
    or other barriers as we continue to expand into new countries and geographic regions, especially related to China as tariffs are
    changing constantly;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
    to currency exchange fluctuations against the U.S. dollar;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer
    payment cycles, generally lower average selling prices and greater difficulty in accounts receivable collection;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of ability to enforce receivables collections contracts in foreign legal courts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced,
    or lack of protection for, and enforcement of, intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    and economic instability in some of the regions where we currently sell our products or that we may expand into in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complex
    and potentially adverse tax consequences; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    to the United States of our products sold into international markets at lower prices.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
most of our international sales are negotiated for and paid in U.S. dollars. Nonetheless, these sales are subject to currency risks,
since changes in the values of foreign currencies relative to the value of the U.S. dollar can render our products comparatively more
expensive. These exchange rate fluctuations could negatively impact international sales of our products, as could changes in the general
economic conditions in those markets. In order to maintain a competitive price for our products internationally, we may have to continue
to provide discounts or otherwise effectively reduce our prices, resulting in a lower margin on products sold internationally. Continued
change in the values of the Euro, the Mexican peso and other foreign currencies could have a negative impact on our business, financial
condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have certain supply agreements with foreign vendors whereby we share the foreign currency exchange fluctuation risk. We
may, in the future, enter into similar arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material portion of our revenues come specifically from sales to our distribution partner located in China, who sells into the Chinese
market. Future political tensions between the U.S. and China governments could cause a disruption or reduction in our sales into that
market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
of our common stock in the public market could lower the market price for our common stock and adversely impact the trading price of
our securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales by the Company of a substantial number of shares of our common stock in the public market, or the perception that such sales may
occur, could adversely affect the then prevailing market price of our common stock and could make it more difficult for us to raise funds
in the future through a public offering of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2020, we filed with the SEC a &#8220;shelf&#8221; registration statement on Form S-3. The registration statement registers common
shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000. Shares of our common stock may be sold from
time to time under this registration statement for up to three years from the filing date. On January 22, 2021, we filed a prospectus
supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market (&#8220;ATM&#8221;) offering under the
shelf registration statement, of which approximately $5,290,000 were sold under the ATM. In March 2023, we terminated the ATM offering
and sold 3,333,333 shares of our common stock in a firm commitment public offering under the shelf registration statement. Shares sold
in the underwritten public offering were sold at a gross sales price of $2.40 per share, resulting in net proceeds from the offering,
after deducting issuance fees and expenses, of approximately $7,300,000. At fiscal year-end 2023, the Company did not have an open ATM
offering in place. However, the Company may in the future commence a new ATM offering or otherwise sell securities under a registration
statement or in private placements, which sales would be dilutive to existing shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of additional shares of our common stock, or issuances of additional securities, could dilute the ownership interest of our
common stockholders and could depress the market price of shares of our common stock and impair our ability to raise capital through
the sale of additional equity securities. We cannot predict the size of future issuances or the effect, if any, that they may have on
the market price for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have a number of stockholders who own large blocks of our common stock. If one or more of these stockholders were to sell large
portions of their holdings in a relatively short time, for liquidity or other reasons, the prevailing market price of shares of our common
stock could be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock market periodically experiences significant price and volume fluctuations that are unrelated to the operating performance of particular
companies. These broad market fluctuations may cause the market price of our common stock to drop. In particular, the market price of
our common stock has been very volatile and unpredictable and may vary substantially in the future in response to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors concerning technological innovations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introductions
    of new products by us or by our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA,
    SEC, Financial Industry Regulation Authority, and foreign regulatory actions against the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes relating to patents or proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet the expectations of stock market analysts and investors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company reporting material weakness in our internal control;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in stock market analyst recommendations regarding our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in healthcare policy in the United States or other countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lawsuits
    or liability claims from shareholders or other parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
    disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent
    protection for our product candidates, and the results of any proceedings or lawsuits, including patent or shareholder litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possible
    recalls of our products or false positive/false negative results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock or other securities by us or our stockholders in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in quarterly operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
    of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities
    analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effects
    of natural or man-made catastrophic events, including widespread public health epidemics like the pandemic related to COVID-19;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    stock market conditions and other factors unrelated to our operating performance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and disruptions in the capital and credit markets due to rising inflation and interest rates</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">wars
    or expansion of wars or other related actions and events that impact the markets in which we operate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    or societal unrest in the markets in which we operate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
of our common stock is not significant, therefore sales of a larger volume of the stock could adversely affect the stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 26, 2016, our Company&#8217;s stock has been traded on the Nasdaq Capital Market. Trading of our stock is limited and liquidation
of the Company&#8217;s stock may be difficult as there is a limited market for our stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
ability to use our net operating loss carry forwards in the future may be subject to limitation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have Federal income tax net operating loss carryforwards of approximately $21,778,000 and California state income tax net operating
loss carryforwards of approximately $17,090,000, use of these loss carryforwards will depend on future income in relationship to expirations
dates of these carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its facilities. On May 31, 2023, the Company had approximately 22,000 square feet of floor space at its corporate headquarters
at 17571 Von Karman Avenue in Irvine, California, 92614 which it has been leasing since 2009. This lease was scheduled to expire on August
31, 2016, but the Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015,
the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease
wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for
an additional five years. When the Company extended its lease in April 2021, it was also granted an additional five- year lease extension
option. The current rent is approximately $26,000 per month and will increase on September 1, 2023, to $27,000 per month. The security
deposit is approximately $22,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square
feet of manufacturing space located in Mexicali, Mexico. The Company has one 10-year option to renew at the end of the initial lease
period. The current rent is approximately $3,100 per month. Biomerica de Mexico also leases a smaller unit on a month-to-month basis
for use in one manufacturing process. In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as
headquarters for BioEurope GmbH, its Germany subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our space is adequate for our current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business that have
a negative impact on the financial results of the Company. While the amounts claimed may be substantial, the ultimate liability cannot
be estimated because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims,
and litigation could have a material negative effect on quarterly or annual operating results or cash flows when resolved in a future
period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the
Company&#8217;s consolidated financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no legal proceedings pending as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock is listed for trading on the Nasdaq Capital Market stock exchange under the symbol BMRA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 25, 2023, the number of holders of record of Biomerica&#8217;s common stock was approximately 800, excluding stock held in
street name. The number of record holders does not bear any relationship to the number of beneficial owners of the common stock as most
of the Company&#8217;s common stock is held in street name at securities brokerage firms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any cash dividends on its common stock in the past and does not plan to pay any cash dividends on its common stock
in the foreseeable future. The Company intends, for the foreseeable future, to retain any earnings to finance the continued operation
and expansion of the Company&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not purchase any of our shares of common stock or other securities during our fiscal year ended May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information relating to our equity compensation plans as of May 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Plan Category</span></td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Securities to be Issued Upon Exercise of Outstanding Options</span></td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    Plans Weighted-Average Exercise Price of Outstanding Options</span></td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Remaining Available for Future Issuance Under Compensation Plans (Excluding those Reflected in Second Column)</span></td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation
    Plans approved by Securities holders</span></td><td style="text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: middle; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,342,616</span></td><td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: middle; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="vertical-align: middle; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.52</span></td><td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: middle; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,301</span></td><td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
6. RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis in conjunction with our consolidated financial statements and the accompanying notes
thereto included in Part II, Item 8 of this Report. This discussion and analysis contains forward-looking statements that are based on
our management&#8217;s current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual
results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including
those discussed in &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OVERVIEW</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH), is a biomedical technology
company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians&#8217;
offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. Our diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis
of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens,
or other substances, which may exist in the human body in extremely small concentrations. The Company&#8217;s products are designed to
enhance the health and well-being of people, while reducing total healthcare costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided
therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other
inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address
very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that,
when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, and constipation. Instead of broad and difficult
to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to
specific foods. A food identified as positive, and causing an abnormal immune response in the patient is simply removed from the diet
to help alleviate IBS symptoms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2022, we completed an endpoint determination clinical trial on our InFoods&#174; IBS product. This trial was conducted at Mayo
Clinics in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University of
Texas Health Science Center at Houston, Houston Methodist, the University of Michigan, and other institutions. This trial monitored
IBS patients over an 8-week treatment period to determine the efficacy of our InFoods&#174; IBS product to improve the
patients&#8217; IBS symptoms or endpoints. The top-line trial results were reported in February 2022. Multiple endpoints
demonstrated statistically significant improvements, indicating that the elimination of specific foods may meaningfully reduce the
symptoms of IBS in each patient subtype (including patients with IBS-Constipation, IBS-Diarrhea &amp; IBS-Mixed). The greatest
clinical improvements, including but not limited to abdominal pain and bloating, were seen in patients diagnosed with IBS-Mixed and
IBS-Constipation, in the top line data. The purpose of the endpoint study was to validate the efficacy of the product, and to
determine the primary symptom endpoint, or endpoints to be used in a final pivotal trial that will be conducted to attain the
validation data needed to apply for U.S. Food and Drug Administration (&#8220;FDA&#8221;) clearance for the product. We are
continuing to review and refine the complete dataset and have selected the final endpoint that we would intend to use in a final
pivotal trial. We are starting to develop the protocol for submission to the FDA, and once approved the trial will be run thereafter. The trial is expected to include
the large medical institution participants that conducted the endpoint clinical trial, in addition to other new institutions and a
Clinical Research Organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the successful completion and positive statistical results from the Company&#8217;s InFoods&#174; IBS clinical trial (run at several prominent
centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. &#8211; a Harvard Medical School Teaching Hospital, Houston Methodist
Hospital, and the University of Michigan) which was completed in early calendar 2022, Biomerica received interest from Gastroenterology
(&#8220;GI&#8221;) physicians who would like to order the InFoods&#174; IBS test for their patients. As such, we are currently working with
key GI physician groups who are interested in offering this product to their patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2023, we worked to set up the InFoods&#174; IBS test to be performed in a CLIA
certified, and College of American Pathologists (&#8220;CAP&#8221;) accredited high-complexity laboratory facility and offered as a laboratory
developed test (&#8220;LDT&#8221;). During the quarter ended February 28, 2023, the CLIA lab completed all validation testing necessary
for the InFoods&#174; IBS product to be offered as an LDT and, as of quarter end, is now accepting patient samples. We also worked to
optimize the process for GI physicians to order the InFoods&#174; IBS test, send patient blood samples to the CLIA lab, and receive the test
results for their patients. We believe ease of order and workflow for physicians, with easy to understand and actionable results for
patients, is critical to our success. During the fiscal third quarter, we also set up customer service and payment systems, along with
a dedicated website for patients to receive answers to questions they may have about the test and attain information about how to eliminate
a specific food from their diet. This is especially important for foods that are ingredients in common processed foods like milk, eggs,
and wheat. As of the end of the fiscal third quarter, the product is now available to physicians and their patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also beginning the work of selecting and validating one new disease (such as ulcerative colitis or migraines), where there
is evidence that certain foods can trigger or contribute to the symptoms found in these indications. We expect any new disease we target
will follow a similar development pathway as InFoods&#174; IBS in simultaneously seeking FDA clearance of the product while also launching
the product as an LDT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also continue to evaluate partnership/licensing opportunities, as they arise, with U.S and multinational companies that could help
us commercialize, or accelerate revenue growth of, the InFoods&#174; products in the United States and overseas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our existing medical diagnostic products are sold worldwide primarily in
two markets: 1) clinical laboratories and 2) point-of-care (physicians&#8217; offices and OTC at Walmart, CVS Pharmacy, Amazon, etc.).
The diagnostic test kits are used to analyze blood, urine, nasal, or fecal specimens from patients in the diagnosis of various diseases,
food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones,
antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the global COVID-19 pandemic, in March 2020, we began developing
COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. In fiscal 2022, we generated revenues
from the international sale of our COVID-19 antigen tests. However, in fiscal 2023, due to the decline in severity of COVID-19 and the
corresponding lower sales volumes we no longer sell these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2022, we finalized development of our H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria.
H. Pylori infection is extremely common, and if left untreated, can lead to ulcers and possibly stomach cancers. During our fourth quarter
of fiscal 2022, we applied for FDA clearance of this product though a 510(k) premarket submission. We have been in communication with
the FDA answering certain follow-up questions and providing additional data as requested. We are working with the FDA to perform one
additional set of in-lab tests that the FDA has requested prior to making their final determination on clearance of the product. Once cleared, we will begin marketing the product in the U.S. market. We have already begun discussions with international distributors for
this product and expect to see revenues through these international channels during 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of our research and development efforts are focused on development and commercialization of non-COVID related products such
as our H. Pylori product, and our InFoods&#174; IBS product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing products that contributed to our fiscal 2023 revenues are primarily focused on gastrointestinal diseases, food intolerances,
and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or
sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for
sale in the United States by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESULTS
OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Sales and Cost of Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following is a breakdown of revenues according to markets to which the products are sold:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Year Ended May 31,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Increase (Decrease)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Clinical lab</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,310,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,064,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">246,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">8%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Over-the-counter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,169,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,089,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contract manufacturing</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">610,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">459,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">151,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Physician&#8217;s office</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,259,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,009,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-98%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,339,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">18,871,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(13,532,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-72%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net sales were approximately $5,339,000 for fiscal 2023 compared to $18,871,000 for fiscal 2022, a decrease of $13,532,000, or 72%. This
decrease in annual sales is primarily attributable to the decrease of $13,950,000 in sales of COVID-19 tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of sales were approximately $4,893,000 for fiscal 2023 compared to $15,894,000 for fiscal 2022, a decrease of $11,001,000, or 69%.
This decrease was driven by the significant decrease in the demand for our COVID-19 tests. The percentage of cost of sales compared to
revenue in fiscal 2023 was 92%, versus 84% in fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of operating expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended May 31,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    (Decrease)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Expense</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a % of Total Revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Expense</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a % of Total Revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling, General
    and Administrative Expenses</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,085,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,699,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">386,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,584,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,812,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(228,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-13%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling,
General and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
selling, general and administrative expenses were approximately $6,085,000 for fiscal 2023 compared to $5,699,000 for fiscal 2022, an
increase of $386,000, or 7%. The increase was primarily due to $350,000 in legal expenses and a $290,000 non-recurring write-off of bad
debt expense related to COVID-19 sales. This was partially offset by a decrease of $75,000 in share-based compensation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses were approximately $1,584,000 for fiscal 2023 compared to $1,812,000 for fiscal 2022, a decrease of
$228,000, or 13%, primarily as a result of decreases in costs related to the research, development and validation of COVID-19. See &#8220;Research
and Development&#8221; for a more extensive description of the research being conducted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
and Dividend Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
and dividend income for fiscal 2023 and 2022 was approximately $133,000 and $27,000, respectively. The $106,000 increase was due to higher
market interest rates on our higher cash balance due to the current fiscal year financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIQUIDITY
AND CAPITAL RESOURCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following are the principal sources of liquidity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,719,000</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,917,000</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
    capital including cash and cash equivalents</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,852,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,416,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, the Company had cash and cash equivalents of approximately $9,719,000 and $5,917,000, respectively. As of May
31, 2023 and 2022, the Company had working capital of approximately $10,852,000 and $7,416,000, respectively. Based on management&#8217;s analysis of the Company&#8217;s cash flow requirements through August 2024 and beyond,
we believe that the aggregate
of our existing cash and cash equivalents is sufficient to meet our operating cash requirements and strategic objectives for growth for
at least the next year. To satisfy our capital requirements, including ongoing future operations, beyond next year, we may seek to raise
additional financing through debt and equity financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2023, cash used in operating activities was approximately $5,474,000, as compared to $479,000 for fiscal 2022. The primary
factors that contributed to this were a loss of approximately $7,140,000, an increase in accounts receivable of $291,000, a decrease
in inventory reserves of $174,000, and a decrease in accounts payable and accrued expenses of $79,000. These were partially offset
by an increase in the allowance on accounts receivable of $342,000, a decrease in inventories of $534,000, and non-cash expenses of
approximately $1,237,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2022, the Company had a net loss of approximately $4,531,000, a decrease in inventory reserves of $772,000, and a decrease in
the allowance on accounts receivable of $684,000. These were partially offset by a decrease in accounts receivable of $1,365,000, a decrease
in inventories of $1,562,000, an increase in accounts payable and accrued expenses of $389,000, and non-cash expenses of approximately
$1,855,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2023, cash used in investing activities was approximately $78,000, as compared to $170,000 for fiscal 2022. During fiscal 2023,
the Company purchased approximately $64,000 of property and equipment and had $14,000 in expenditures related to patents. During fiscal
2022, the Company purchased approximately $57,000 of property and equipment and $113,000 in expenditures related to patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for fiscal 2023 was approximately $9,390,000 as compared to $2,394,000 for fiscal 2022. In fiscal 2023
and 2022, the Company had proceeds from the exercise of stock options of approximately $81,000 and $77,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2023 and 2022, the Company received approximately $9,309,000 and $2,317,000, respectively, in net proceeds from the sale of common
stock. The common stock sold and issued in fiscal 2022 and 2023 was issued under the Company&#8217;s shelf registration statement filed
with the SEC on July 21, 2020 (the &#8220;2020 Shelf Registration Statement&#8221;) and declared effective by the SEC on September 30,
2020, and under the prospectus supplement filed with the SEC on January 22, 2021 (&#8220;2021 Prospectus Supplement&#8221;), and the
prospectus supplement filed in conjunction with the Company&#8217;s underwritten public offering of common shares on March 7, 2023 (the
&#8220;2023 Prospectus Supplement&#8221;) (See Shareholders&#8217; Equity in the notes to the consolidated financial statements for further
details about SEC registration statements). The 2020 Shelf Registration Statement registers common shares that may be issued by the Company
in a maximum aggregate amount of up to $90,000,000. On January 22, 2021, we filed the 2021 Prospectus Supplement for the sale of up to
$15,000,000 of shares of our common stock in an at-the-market offering under the 2020 Shelf Registration Statement, of which $5,290,000
was issued through March 7, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, we terminated the at-the-market offering and sold 3,333,333 shares of our common stock in a firm commitment public offering
under the 2020 Shelf Registration Statement <span style="background-color: white">at a price to the public of $2.40 per share, for total
gross proceeds of $8,00<span style="background-color: white">0</span>,000, before deducting underwriting discounts and commissions and other offering-related expenses payable by
the Company.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 25, 2023, the date on which this Annual Report on Form 10-K for the fiscal year ended May 31, 2023, is filed with the SEC,
our 2020 Registration Statement remains subject to the offering limits set forth in General Instruction I.B.6 of Form S-3 because our
public float is less than $75 million. For so long as the Company&#8217;s public float is less than $75 million, the aggregate market
value of securities sold by the Company under the 2020 Shelf Registration Statement pursuant to Instruction I.B.6 to Form S-3 during
any 12 consecutive months may not exceed one-third of the Company&#8217;s public float. We have sold $7,631,000 of our common stock pursuant
to General Instruction I.B.6 of Form S-3 in the 12 calendar months preceding the date of filing this Annual Report on Form 10-K. For
purposes of this limitation, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was
$25,638,909, based on 15,538733 non-restricted shares of our outstanding common stock held by non-affiliates and a price of $1.65 per
share, which was the price at which our common stock was last sold on the Nasdaq Capital Market on August 3, 2023 (a date within 60 days
of the date hereof), calculated in accordance with General Instruction I.B.6 of Form S-3. After giving effect to the $8,546,303 offering
limit imposed by General Instruction I.B.6 of Form S-3, and after deducting the shares we sold within the preceding 12 months, as of
the date of filing this Annual Report, we may sell $915,3030 shares of our common stock at this time under the 2020 Shelf Registration
Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBSEQUENT
EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 3, 2023, the Company announced it had entered into a sales agreement with CVS Pharmacy wherein the Company&#8217;s EZ Detect&#8482;
colorectal disease screening test will be offered at approximately 7,000 CVS Pharmacy retail stores. Biomerica has shipped the EZ Detect
product to CVS Health distribution centers in the United States, and the product is projected to be on store shelves in September.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OFF
BALANCE SHEET ITEMS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no off-balance sheet arrangements as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CRITICAL
ACCOUNTING ESTIMATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of
America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts
of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions
or conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis,
we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates
and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates under different
future conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of
operations, in that they require subjective or complex judgments, form the basis for the accounting policies deemed to be most
critical to us. These relate to revenue recognition, bad debts, inventory overhead application, inventory reserve, lease liabilities,
and right-of-use assets. We believe estimates and assumptions related to these critical accounting policies are appropriate under
the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material
impact on our future financial conditions or results of operations. We suggest that our significant accounting policies be read in
conjunction with this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. Please refer to
Note 2 of the Company&#8217;s consolidated financial statements for information on Significant Accounting Policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUE
RECOGNITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has various contracts with customers. All the contracts specify that revenues from product sales are recognized at the time the
product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title
passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance
for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales
volumes. The Company regularly evaluates the status of these contracts and does not believe that any discounts will be given through
the end of the contract periods. Services for some contract work are invoiced and recognized for work that has been performed as the
project progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical
laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores
and e-commerce customers as well as to distributors. Physicians&#8217; office products are sold to physicians and distributors, all of
whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis
for domestic and international manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based
method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments
(options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that uses
assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The
Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based
on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options.
The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the
&#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as
historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under
the straight-line attribution method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VALUATION
OF INVENTORIES, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inventories are made up of raw materials, work in progress, and finished goods and are valued at <span style="background-color: white">the
lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record valuation reserves for inventory items with excess quantities and obsolescence exposure. These reserves are estimates of a reduction
in value to reflect inventory valuation at the lower of cost or net realizable value. <span style="background-color: white">Management
evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated
customer demand for current products and new product introductions.</span> Our inventory valuation reserves totaled $672,000 and $846,000
as of May 31, 2023 and 2022, representing approximately 25% and 26% of our inventory, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RECENT
ACCOUNTING PRONOUNCEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our consolidated financial statements for a listing of adopted and soon to be adopted accounting pronouncements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
99.3, &#8220;Biomerica, Inc. and Subsidiaries Consolidated Financial Statements&#8221; is incorporated herein by this reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached
as exhibits to this Form 10-K are certifications of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;)
that are required in accordance with Rule 13a-14 of the Exchange Act. This &#8220;Disclosure Controls and Procedures&#8221; section includes
information concerning the controls and controls evaluation referred to in the certifications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVALUATION
OF DISCLOSURE CONTROLS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934, as amended, or the Exchange Act as of the end of the period covered by this report. Our management recognizes
that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their
objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Our CEO and
CFO concluded that our disclosure controls and procedures are effective at a reasonable assurance level as of May 31, 2023. Based on
that evaluation the CEO and CFO concluded that information required to be disclosed in the reports that we file and submit under the
Exchange Act is (1) recorded, processed, summarized, and reported within the time periods specified in the Commission&#8217;s rules and
forms; and (2) accumulated and communicated to the Company&#8217;s management, including its CEO and CFO, as appropriate, to allow timely
decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
management, including the CEO and CFO concluded that, as of May 31, 2023, the Company&#8217;s internal control over financial reporting
was effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHANGES
IN INTERNAL CONTROL OVER FINANCIAL REPORTING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during
the quarter ended May 31, 2023, that have materially affected, or that are reasonably likely to affect, our internal control over financial
reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT&#8217;S
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f)
under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable
assurance to the Company&#8217;s management and Board of Directors regarding the reliability of financial reporting and the preparation
and fair presentation of financial statements for external purposes in accordance with accounting principles generally accepted in the
United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have
a material effect on the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of
judgment in designing, implementing, operating, and evaluating the controls and procedures. Because of these inherent limitations, internal
control over financial reporting cannot provide absolute assurance regarding the reliability of financial reporting and may not prevent
or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls
may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
management, with the participation of the CEO and the CFO, evaluated the effectiveness of the Company&#8217;s disclosure controls and
procedures as defined in Rules 13(a)-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act,
as of the end of the period covered by this report. In making this assessment, Management used the criteria set forth by the Committee
of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control - Integrated Framework (2013). Based
on this assessment, management, with the participation of the CEO and CFO, believes that, as of May 31, 2023, the Company&#8217;s internal
control over financial reporting was effective based on those criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures and its internal controls
over financial reporting on an ongoing basis and are committed to taking further action and implementing improvements, as necessary and
as funds allow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:
This 10-K does not include an attestation report of the Company&#8217;s independent registered public accounting firm regarding internal
control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s independent registered
public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only
management&#8217;s report in this 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9B. OTHER INFORMATION.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be disclosed in our definitive proxy statement on Schedule 14A (the &#8220;Proxy Statement&#8221;)
for our 2023 Annual Meeting of Stockholders and is incorporated by reference herein. Our Proxy Statement will be filed with the SEC within
120 days after the end of the Company&#8217;s fiscal year ended May 31, 2023, pursuant to Regulation 14A under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be disclosed in the Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be disclosed in the Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be disclosed in the Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be disclosed in the Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
15. EXHIBITS LIST AND FINANCIAL SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this Annual Report on Form 10-K:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    <i>Consolidated Financial Statements</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
    is made to the Index to the consolidated financial statements as set forth on page FS-1 of this Annual Report on Form
    10-K.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    <i>Consolidated Financial Statement Schedules</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    schedules have been omitted as the pertinent information is either not required, not applicable, or otherwise included in the financial
    statements and notes thereto.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    <i>Exhibits</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.75in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.1in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-1.htm">First Amended and Restated Certificate of Incorporation of Registrant filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant&#8217;s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-2.htm">Amended and Restated Bylaws, as adopted on July 24, 2023 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed July 26, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000089256999002463/0000892569-99-002463.txt" style="-sec-extract: exhibit">Specimen Stock Certificate of Common Stock of Registrant (incorporated by reference to Exhibit 4.1 filed with Registrant&#8217;s Registration Statement on Form SB-2, Commission No. 333-87231 filed on September 16, 1999).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Description of Capital Stock.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Standard Industrial/Commercial Single-Tenant Lease, dated June 18, 2009, by and between Registrant and CNH, LLC for 17571 Von Karman Avenue, Irvine, CA 92614 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s August 31, 2009 Form 10-Q filed October 16, 2009).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000151316214000555/def14a.htm" style="-sec-extract: exhibit">2014 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 29, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000151316217000270/def14a.htm" style="-sec-extract: exhibit">2017 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 28, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000151316220000207/def14a.htm" style="-sec-extract: exhibit">2020 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 25, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Executive Stock Option Agreement (attached herein).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-6.htm">Employment Agreement, dated March 1, 2023, by and between Biomerica, Inc. and Gary Lu.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">List of Subsidiaries (attached herein).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Independent Registered Public Accounting Firm (Haskell &amp; White LLP).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant and Subsidiaries Consolidated Financial Statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certifications attached as Exhibits 32.1 and 32.2 accompany this Annual Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, as amended, and shall not be deemed &#8220;filed&#8221; by the registrant for purposes
of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant&#8217;s filings under the Securities
Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIOMERICA, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
                                            Zackary S. Irani</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    S. Irani,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 25, 2023</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
and Capacity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Zackary S. Irani </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    S. Irani</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Gary Lu, CPA </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Lu, CPA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Allen Barbieri </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Barbieri</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Vice-Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jane Emerson, M.D., Ph.D. </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jane
    Emerson, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Moatazedi </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
                                            Moatazedi</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Catherine Coste, CPA </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 25, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catherine
    Coste, CPA </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="MS_001"></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIOMERICA,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firm (PCAOB ID <span id="xdx_90A_edei--AuditorFirmId_c20220601__20230531_zIeP8XmFqfEk"><span style="-sec-ix-hidden: xdx2ixbrl0044">0200</span></span>) </span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FS-2
</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
    FINANCIAL STATEMENTS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of May 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FS-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended May 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FS-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Shareholders&#8217; Equity for the Years Ended May 31, 2023 and 2022 </span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FS-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended May 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FS-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><a href="#SJ_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FS-7
    &#8211; FS-20</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Consolidated Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of <b><i>Biomerica, Inc. </i></b>(the &#8220;Company&#8221;) as of May 31,
2023 and 2022, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows
for each of the years then ended, and the related notes (collectively, the &#8220;consolidated financial statements&#8221;). In our
opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the
Company as of May 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the years then
ended, in conformity with U.S. generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 433pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matter</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current-period audit of the consolidated financial statements that
was communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material
to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical
audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating
the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which
they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><b><i>Inventory
Valuation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in Note 2 to the Company&#8217;s consolidated financial
statements, the Company values inventory at the lower of cost or net realizable value with cost inclusive of estimates for reasonable
allocations of labor and overhead costs. Also, management periodically reviews inventory for excess quantities and obsolescence. Management
evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated
customer demand for current products and new product introductions. Auditing the Company&#8217;s estimates for capitalized labor and overhead
was challenging due to the extensive use of estimates throughout this process, including the quantity of labor time allocable to each
inventory item. Auditing the Company&#8217;s estimates for slow-moving and obsolete inventories was challenging due to the inherently
judgmental nature of forecasting future sales and usage of a significant number of diverse inventory items.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
the Critical Audit Matter Was Addressed in the Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To test the valuation of the Company&#8217;s inventory, we performed
the following audit procedures:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained an understanding of the methodologies and policies used by
management to estimate capitalized labor and overhead and inventory reserves; we obtained an understanding of key internal controls and
assessed their overall appropriateness;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested the reasonableness of the production labor and overhead cost
pools and the quantities produced and recalculated the allocable labor and overhead rate per unit; we recalculated the amount of capitalized
labor and overhead based on quantities on hand at the end of the fiscal year; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested
the accuracy of key data inputs that are the primary drivers for determining the quantitative inventory reserves; these inputs included
inventory quantities on hand, approximate age of the inventory quantities, and estimated inventory reserve percentages.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--AuditorName_c20220601__20230531_zBPGxrgABq7e"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:AuditorName">HASKELL &amp; WHITE LLP</ix:nonNumeric></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--AuditorLocation_c20220601__20230531_zJh5iAjlSYFb"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" name="dei:AuditorLocation">Irvine,
California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
25, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_002"></span>BIOMERICA,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zCTj7IfcrER5" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230531_zT6VafK3mtU8" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220531_za5xAS3tM8y3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AssetsAbstract_iB_zTGoHhFDSaLc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_z5MeUICeCRW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACznW1_zohzuqnX0FT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,719,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,917,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_i02I_maACznW1_z9QPChRjkRm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">722,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--InventoryNet_i02I_maACznW1_zdnVYnEdiKfg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inventories, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,056,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACznW1_zWse2o99Zpu9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_mtACznW1_maAzIlR_zJ84rOwABeib" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,797,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,427,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzIlR_zMAhS30ocTRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment,
    net of accumulated depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzIlR_zuangNy324Of" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right-of-use assets, net
    of accumulated amortization of $<span id="xdx_900_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iI_c20230531_zLo2HBRevUAk" title="Accumulated amortization"><ix:nonFraction name="BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">617,000</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iI_c20220531_zLXtlOkFu8o2" title="Accumulated amortization"><ix:nonFraction name="BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">725,000</ix:nonFraction></span> as of May 31, 2023 and 2022, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,035,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,302,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Investments_i01I_maAzIlR_zEeWjPBPxwr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAzIlR_zvvapw0FBKwb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net
    of accumulated amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAssetsNoncurrent_i01I_maAzIlR_zdWYHZ46ikk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Assets_i01TI_mtAzIlR_zAj7ljK8N2ne" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,454,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,374,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zR1JbMqvT9xh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Liabilities and Shareholders&#8217;
    Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrentAbstract_i01B_zABfdn8uffu9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzb8g_zt61c2WNPdE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">892,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">972,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCzb8g_zRPGwR4x2dE5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">647,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ContractWithCustomerLiability_i02I_maLCzb8g_zUbQzGzuKGC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advance from customers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzb8g_z63726tki8a8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liabilities, current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">297,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzb8g_maLzjGE_zs8OUATQ7Bd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,945,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzjGE_zcnG1REKMNol" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liabilities, net of current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">785,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i01TI_mtLzjGE_maLASEzsqi_zRYLlVVhcHV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,730,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,049,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzsqi_zOmCvVltVcgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments and contingencies
    (Note 9)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0118">-</span></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0119">-</span></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_i01B_zmkcM8Zurpph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shareholders&#8217; Equity:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgH58ByVIzd8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred stock, Series
    A 5% convertible, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3ufQKhopGNb" title="Series A preferred stock, par value"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvMQsynD3D1j" title="Series A preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHaCnUwRo0ok" title="Series A preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20220531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6j5MwOneePb" title="Series A preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">571,429</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_dn_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6S6pFQmzQt4" title="Series A preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgQ4LFKBWlxi" title="Series A preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_dn_c20220531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zU6TMJzrdnGl" title="Series A preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20220531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoDi3WWwtGO7" title="Series A preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding as of May 31, 2023 and 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0124">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0125">-</span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_z3ZhuYWVZm48" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred stock, undesignated,
    <span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_do_c20230531_zHbg1Hy9Hzvc" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_do_c20220531_zIo95JDSzirc" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-05-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-05-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20230531_znE9dVC27yR5" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20220531_zQTLwb3Wc3s5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,428,571</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_dn_c20230531_zEIuDQabCe2j" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20230531_zWumXTpcMLja" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_dn_c20220531_zosgZSP366j" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20220531_zOSIGpjEyBYc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-05-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-05-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-05-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-05-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding as of May 31, 2023 and 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0143">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">-</span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockValue_i02I_maSEzAwN_zhx74lC9NjLf" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred stock, </span>value</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0162">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0163">-</span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--CommonStockValue_i02I_maSEzAwN_zSlWqwrCULrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230531_zFaYLXq4Vn4i" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220531_zOZ3WSlO8Txh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20230531_zGjqerKHEWe6" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20220531_zIWRlr8FGdG8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized, <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20230531_zu3D8YSI72H1" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20230531_zPFTD1E9WvU3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,821,646</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20220531_zRhDX8fv0YCj" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20220531_zDR5daTac6Tj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,867,924</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding at May 31, 2023 and 2022, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,346,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,029,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_i02I_maSEzAwN_zEqE0bMOnX8g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in-capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,705,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,447,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzAwN_z1Pu7JGtK556" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated other comprehensive
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">110,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">74,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzAwN_zmkyEwDbVmmk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,217,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,077,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i02TI_mtSEzAwN_maLASEzsqi_zCm71tBQqKt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Shareholders&#8217;
    Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,724,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,325,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzsqi_zufbFTkcqfGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities and
    Shareholders&#8217; Equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,454,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,374,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="SJ_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIOMERICA,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_zUUdzsW19BB4" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zGJFBgxRZMa1" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20210601__20220531_zplTuFPC0h9e" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_maGPz7zF_zBlVc1G1eWw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net sales</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,339,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,871,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_iN_di_msGPz7zF_zgrydGHNgs12" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,893,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,894,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--GrossProfit_iT_mtGPz7zF_maOILzPad_zcbKUcNiPJ3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,977,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zW9Gzpra8dr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzZQu_zNHGl3y7l7t2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,085,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,699,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzZQu_zhHiZea1eo8b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,584,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,812,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_msOILzPad_mtOEzZQu_zNkHanuLNdd4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,669,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,511,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_mtOILzPad_maILFCOzL1C_zZct1AhkEzY5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss from operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,223,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,534,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zdb8spsGTs48" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--InvestmentIncomeInterestAndDividend_i01_maNIEzwSV_zGOZfZE0yO5g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend and interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncome_i01_maNIEzwSV_zfnBvCcEfgze" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzwSV_maILFCOzL1C_zSbVMzsJZ9wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    other income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzL1C_maNILzBAb_zTWKQxTlSnIi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before income taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,089,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,507,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzBAb_zGluneHFhJPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Provision for income
    taxes</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzBAb_zRsaqyT20jVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,531,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_zrw4K77f5Oo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic net loss per common
    share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.50</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.36</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_z7OBuGGE01yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Diluted net loss per
    common share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.50</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.36</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zLdvWi6IWMPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted average number of common and</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">common equivalent shares:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zXSjVEe1mw3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,154,269</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,673,245</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_zKgcpK23lQhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,154,269</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,673,245</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iT_maCINOTzIO1_zXIPnImrMNre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,531,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_zs2RGpQHdTj8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other comprehensive loss, net of tax:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_i01_maCINOTzIO1_zkU6OgvDIKZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign currency translation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCINOTzIO1_zMJ2GnVKEKDc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Comprehensive loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,176,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,557,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_004"></span>BIOMERICA,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED MAY 31, 2023 AND 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_z1Su1KXe1U8e" summary="xdx: Statement - Consolidated Statements of Shareholders&apos; Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zzWi3o9mHDQ2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zaloQsfzEbrb" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zdi4qURIrLBa" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zKjW6rSVqLOj" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B5_zYHZGvIoCcC" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional
    Paid-in-Capital</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Other Comprehensive Loss</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Deficit</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    Stockholder&#8217;s Equity</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_434_c20210601__20220531_eus-gaap--StockholdersEquity_iS_zgeoY3PPGZV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances at May 31, 2021</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210601__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs7pg1iDTAi" title="Balance, shares" style="width: 6%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,307,157</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,000</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,837,000</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,000</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-05-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,546,000</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,228,000</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zHYsWhfm6u5e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercise of stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210601__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaLhmZUcO7v7" title="Exercise of stock options, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zK59uUTomZI8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from ATM</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSe6O9GOxKG7" title="Net proceeds from ATM, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">521,267</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,276,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,317,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_zn2Efxv5Vfve" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign currency translation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zRnzedULwwg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,260,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,260,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zfhClurskdcg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,531,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,531,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43B_c20220601__20230531_eus-gaap--StockholdersEquity_iS_zBsxh9G6zFD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances at May 31, 2022</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20220601__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztcVuH46Bwth" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,867,924</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,029,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,447,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">74,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,077,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,325,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_432_c20220601__20230531_eus-gaap--StockholdersEquity_iS_zOdjjJwB6o01" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20220601__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH7xER9cHeWf" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,867,924</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,029,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,447,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">74,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,077,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,325,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zCSUrmLTKwI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercise of stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220601__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlwshzEbhwVi" title="Exercise of stock options, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z289d8Lvlzji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from ATM</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220601__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIzUq9sO4RE4" title="Net proceeds from ATM, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">573,889</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,915,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,961,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_zsR1auGyjYLi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued in connection
    with public offering, net of offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_c20220601__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsBxCZr8qy58" title="Shares issued in connection with public offering, net of offering costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,333,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,081,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,348,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_zGsk5ev5ukfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign currency translation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zWdbVn7iE679" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_ziaJrqt9BSW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_433_c20220601__20230531_eus-gaap--StockholdersEquity_iE_zdI7UCbAt03k" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balances at May 31,
    2023</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20220601__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcLNWs32nBub" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,821,646</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,346,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,705,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">110,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,217,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,724,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_439_c20220601__20230531_eus-gaap--StockholdersEquity_iE_znyqZGAyKa15" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20220601__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxf9BgawKNj4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,821,646</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,346,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,705,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">110,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,217,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,724,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_005"></span>BIOMERICA,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zxktF7nJRUY8" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zCjrKvbjX1s6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20210601__20220531_zE5OxxeWyUDf" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z95gzWXkyvjj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from operating
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maNCPBUz3Jw_zkyg59fQic16" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,531,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zkaweO2sKHVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUz3Jw_zRICg22YbV48" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_msNCPBUz3Jw_zUb5GVXqY84" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss on disposal of property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUz3Jw_zRkKSaKTH939" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Provision for allowance on accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">684,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--InventoryLIFOReservePeriodCharge_i02_maNCPBUz3Jw_ze2NpYcg1g1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inventory reserve</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InventoryLIFOReservePeriodCharge" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">174,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InventoryLIFOReservePeriodCharge" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">772,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_maNCPBUz3Jw_zP5TxwQ2yLYa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,260,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUz3Jw_zbD6QpUf6fZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of right-of-use asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zKHULfq62zcf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUz3Jw_zny5M7ndn4Al" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,000</ix:nonFraction></span></td><td style="text-align: left">)</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,365,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUz3Jw_zJ4jwjaOf5j6" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">534,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,562,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUz3Jw_zy81aZtu8gli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msNCPBUz3Jw_zhPgM1ccqJNl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">169,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUz3Jw_zL7mZimny6Ge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i03_maNCPBUz3Jw_zhXi9UkSX1q1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">258,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maNCPBUz3Jw_z6Qg3DdGLAJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advance from customers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseInReductionInLeaseLiabilities_i03_maNCPBUz3Jw_zA8SOQIOOEAc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reduction in lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BMRA:IncreaseDecreaseInReductionInLeaseLiabilities" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">297,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BMRA:IncreaseDecreaseInReductionInLeaseLiabilities" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUz3Jw_maCCERCzqSx_zzce3b7crN09" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating
    activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,474,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">479,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zoR9dQJggvHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from investing
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzvjm_zh0apsdb1ez6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expenditure related to intangibles</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzvjm_zhUedTRLIsEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Purchases of property
    and equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzvjm_maCCERCzqSx_zJyq4QKvoJq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net cash used in investing
    activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zQ1Fi38m8am5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from financing
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzQT3_z5SHsDYcuRTk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross proceeds from sale of common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,014,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,402,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msNCPBUzQT3_zcM1u9B5QCx9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Costs from sale of common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">705,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzQT3_zYUKrQ4ntgQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds from exercise
    of stock options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzQT3_maCCERCzqSx_zSfNORQ2Ch6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by
    financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,390,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,394,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzqSx_zZfCPePqy1Mc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Effect of exchange rate
    changes in cash</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzqSx_zc629JO2GLMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,802,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,719,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z6skMlaDrcAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    at beginning of year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,917,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,199,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zV2fRX1wiV88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    at end of year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,719,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,917,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zvcsvcyr2ntb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental Disclosure of Cash Flow Information:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--CashPaidDuringYearForAbstract_i01B_zNjB0ekJFww5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid during the year
    for:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i02_zONVNyoIqaVb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zsQrvh6LVYz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash investing and financing
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment_i01_zvwErgg4JY1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Increase in right-of-use
    asset due to lease extension or establishment</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0495">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment_i01_zmIsdmCyYZz5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Increase in lease liability
    due to lease extension or establishment</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--WriteOffOfFixedAssetsCost_i01_zQtm9Z9cLrMd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Write off of fixed assets,
    cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfFixedAssetsCost" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfFixedAssetsCost" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">820,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WriteOffOfFixedAssetsAccumulatedDepreciation_i01_z9TpTyHd3Smk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Write off of fixed assets,
    accumulated depreciation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfFixedAssetsAccumulatedDepreciation" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfFixedAssetsAccumulatedDepreciation" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">767,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--WriteOffOfIntangibleAssetsCost_i01_zT40Xyu0CAHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Write off of intangible
    assets, cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfIntangibleAssetsCost" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfIntangibleAssetsCost" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--WriteOffOfIntangibleAssetsAccumulatedAmortization_i01_zfQlSNyXQ2j1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Write off of intangible
    assets, accumulated amortization</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfIntangibleAssetsAccumulatedAmortization" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:WriteOffOfIntangibleAssetsAccumulatedAmortization" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br />See
accompanying notes to consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="SJ_006"></span><b>BIOMERICA,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>YEARS
ENDED MAY 31, 2023 AND 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zaNIuuV29Ppj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1: <span id="xdx_82A_zcwwzjYuPkld">ORGANIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is a biomedical technology
company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians&#8217;
offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. Our diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis
of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens,
or other substances, which may exist in the human body in extremely small concentrations. The Company&#8217;s products are designed to
enhance the health and well-being of people, while reducing total healthcare costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided
therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other
inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address
very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that,
when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, and constipation. Instead of broad and difficult
to manage dietary restrictions, the InFoods&#174; IBS product works by identifying specific foods that may be causing an abnormally high
immune response in the patient. A food identified as positive, which is causing the abnormal immune response in the patient,
is simply removed from the diet to help alleviate IBS symptoms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our existing medical diagnostic products are sold worldwide primarily in
two markets: 1) clinical laboratories and 2) point-of-care (physicians&#8217; offices and over-the-counter drugstores like Walmart and
CVS Pharmacy). The diagnostic test kits are used to analyze blood, urine, nasal, or fecal specimens from patients in the diagnosis of
various diseases, food intolerances, and other medical complications, by measuring or detecting the existence and/or level of specific
bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely
small concentrations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the global COVID-19 pandemic, in March 2020, we began developing COVID-19 products to indicate if a person has been infected by COVID-19
or is currently infected. In fiscal 2022, we generated revenues from the international sale of our COVID-19 antigen tests. However, in
fiscal 2023, due to the decline in severity of COVID-19 and the corresponding lower sales volumes, we no longer sell these products.
Due to the relatively high volume of sales from these products in fiscal 2021 and fiscal 2022, we have seen significant fluctuations
in quarterly revenues over the past twelve quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
other existing products that contributed to our 2023 revenues are primarily focused on gastrointestinal diseases, food intolerances,
and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or
sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for
sale in the United States by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_z8PkU7pRtSK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2: <span id="xdx_82E_zpHuYaPeoOWk">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z7gFfpvpLaT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZwFKfOCmSdd">PRINCIPLES
OF CONSOLIDATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements for the years ended May 31, 2023 and 2022, include the accounts of Biomerica, Inc. (&#8220;Biomerica&#8221;)
as well as its wholly-owned German subsidiary (&#8220;BioEurope GmbH&#8221;) and Mexican subsidiary (&#8220;Biomerica de Mexico&#8221;).
All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zuySZ9CDyIC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zTPMeefF7g3j">ACCOUNTING
ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful
accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates,
which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of
materials; and lease liabilities and right-of-use assets, which are calculated based on certain assumptions such as the borrowing
rate on the lease commencement date and, the likelihood of lease extensions to occur, asset valuations, among other things; and other items that may be necessary to
estimate using current, historical and judgment based information. Actual results could materially differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the global COVID-19 pandemic, the Company&#8217;s operations have been negatively impacted. The Company has faced disruptions in the
following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s
manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping
and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or
sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer
credit risk, and general economic calamities. These pandemic related disruptions can materially negatively impact the Company&#8217;s
operations and financial performance and may continue to have significant material negative impacts on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="BMRA:LiquidityPolicyTextBlock"><p id="xdx_84E_ecustom--LiquidityPolicyTextBlock_zW6vUuWhG1Ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjOTo59chAK9">LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn6n6_di_c20230531_zR7wm3w9TnGd" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="-6" scale="6" sign="-" unitRef="USD">42</ix:nonFraction></span> million as
of May 31, 2023. Management expects to continue to incur significant costs as it advances its trials and development activities. As of
May 31, 2023, the Company had cash and cash equivalents of approximately $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230531_zI7WIQvdh0s9" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,719,000</ix:nonFraction></span> and working capital of approximately $<span id="xdx_908_ecustom--WorkingCapital_iNI_di_c20230531_zS9FSdFRDyN8" title="Working capital"><ix:nonFraction name="BMRA:WorkingCapital" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,852,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $<span id="xdx_90B_ecustom--ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_iI_c20210122_zNs4j3moD7f9" title="Shelf registration statement maximum authorized common stock issuance value"><ix:nonFraction name="BMRA:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" contextRef="AsOf2021-01-22" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span> in &#8220;at-the-market&#8221;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#8220;ATM Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#8217;s behalf all the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any shares under the ATM Offering, and may at any time suspend offers
under, or terminate the ATM Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zKcvJRy8jlm4" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">573,889</ix:nonFraction></span> shares of its common stock at prices ranging from $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zSjRvtL1zhQ" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-31_srt_MinimumMember_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></span> to $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zdRfY3Ch057a" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-31_srt_MaximumMember_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.26</ix:nonFraction></span> pursuant to the
ATM Agreement, which resulted in gross proceeds of approximately $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zgSVz1vLMHJ5" title="Sale of stock, consideration received on transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,014,000</ix:nonFraction></span> and net proceeds to the Company of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z7YVQm30GfFf" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,961,000</ix:nonFraction></span>, after deducting
commissions for each sale and legal, accounting, and other fees related to offering in the amount of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zFVG7Rapmvy7" title="Sale of stock expenses"><ix:nonFraction name="BMRA:SaleOfStockExpenses" contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2022, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zk6s2jb3LzFl" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">521,267</ix:nonFraction></span> shares of its common stock at prices ranging from $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBGjiqSfbqg2" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-31_srt_MinimumMember_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.02</ix:nonFraction></span> to $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1tHM7RXW0U2" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-31_srt_MaximumMember_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></span> pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBmMSveBMcal" title="Sale of stock, consideration received on transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,402,000</ix:nonFraction></span> and net proceeds to the Company of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zbgeua5vzmrd" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,317,000</ix:nonFraction></span>, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $<span id="xdx_906_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1J6pzOT4cAh" title="Sale of stock expenses"><ix:nonFraction name="BMRA:SaleOfStockExpenses" contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 7, 2023, the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zQQg5I8fRDzb" title="Net proceeds from ATM (in Shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-072023-03-07_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,333,333</ix:nonFraction></span> shares of common stock in a firm commitment public offering at a gross sales price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z2pu4lFTRZq" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-03-07_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></span>
per share, with net total proceeds, after deducting issuance fees and expenses of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zWIHolrzirAg" title="Sale of stock expenses"><ix:nonFraction name="BMRA:SaleOfStockExpenses" contextRef="From2023-03-072023-03-07_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span>, of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zqJEv3gsEkG7" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-03-072023-03-07_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,300,000</ix:nonFraction></span>. Since the closing
of the March 7, 2023 offering, the ATM has been withdrawn and is not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from such offerings for general corporate purposes, including, without limitation, sales and
marketing activities, clinical studies, product development, making acquisitions of assets, businesses, companies or securities,
capital expenditures, and for working capital needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has analyzed the cash requirements of the Company&#8217;s business through at least August 2024. As a result of cash and cash
equivalents on hand on May 31, 2023, largely from the public offering, and the ability to raise additional funds through another new
ATM agreement, management believes the Company has sufficient funds to operate through at least August 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zj7jiqvTvXB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMZUTNqxBcJ4">FAIR
VALUE OF FINANCIAL INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on
a historical basis. The Company&#8217;s consolidated financial instruments consist of its cash and cash equivalents, accounts receivable,
and accounts payable. The carrying amounts of the Company&#8217;s financial instruments approximate their fair values. The Company also
maintains an investment in privately held company (see below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zV6dJYlNhv9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z0QxvzjqIh57">CONCENTRATION
OF CREDIT RISK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time,
the Company has uninsured balances. The Company does not believe it is exposed to any significant credit risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company
performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net sales were approximately $<span id="xdx_900_eus-gaap--Revenues_c20220601__20230531_zgTugdKjmmsd" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,339,000</ix:nonFraction></span>
for fiscal 2023 compared to $<span id="xdx_903_eus-gaap--Revenues_c20210601__20220531_z5VE0EJrAB24" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,871,000</ix:nonFraction></span>
for fiscal 2022. For the fiscal years ended May 31, 2023 and 2022, the Company had one and two distributors, respectively, which
accounted for a total of <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorOneMember_zCfRW217Lbbh" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>%
and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorTwoMember_zGjQu8OVjkr8" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></span>%
of our net sales, respectively. Of this, for the fiscal years ended May 31, 2023 and 2022, the largest of the distributors mentioned
above accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zBZbRgFVmtve" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>%
and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zlgIgVsxXvWd" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">55</ix:nonFraction></span>%,
respectively, of net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
gross receivables on May 31, 2023 and 2022 were approximately $<span id="xdx_901_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230531_zeFH384WNPe" title="Other receivables, gross, current"><ix:nonFraction name="us-gaap:OtherReceivablesGrossCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">751,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OtherReceivablesGrossCurrent_iI_c20220531_zW8eMxbbRJU1" title="Other receivables, gross, current"><ix:nonFraction name="us-gaap:OtherReceivablesGrossCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">927,000</ix:nonFraction></span>, respectively. On May 31, 2023 and 2022, the Company
had one distributor which accounted for a total of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zaMA0Oy1OT4" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zeavQLNSShXh" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-06-012022-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%, respectively, of gross accounts receivable. Of the <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zLj8Yk8BKDr6" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></span>% as of May 31,
2023, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorsInAsiaMember_zdwAc3CJuy46" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorsInAsiaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% was owed by a distributor in Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended May 31, 2023, the Company did not have any significant concentration of vendor spend for raw materials. For the
fiscal year ended May 31, 2022, the Company had one vendor, which accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zKxusiWRt50j" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-06-012022-05-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_OneVendorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84</ix:nonFraction></span>% of our purchases of raw materials largely related
to COVID-19 products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="BMRA:ConcentrationRiskGeographicPolicyPolicyTextBlock"><p id="xdx_841_ecustom--ConcentrationRiskGeographicPolicyPolicyTextBlock_zas1WR54uYvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zcBx91ToEpJb">GEOGRAPHIC
CONCENTRATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, approximately $<span id="xdx_907_eus-gaap--InventoryGross_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zSVEX9SVBd11" title="Inventory, gross"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2023-05-31_country_MX" format="ixt:numdotdecimal" decimals="0" unitRef="USD">626,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--InventoryGross_iI_c20220531__srt--StatementGeographicalAxis__country--MX_zlaRxFv9kbVl" title="Inventory, gross"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2022-05-31_country_MX" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,000</ix:nonFraction></span>, respectively, of Biomerica&#8217;s gross inventory was located in Mexicali,
Mexico, respectively. As of May 31, 2023 and 2022, approximately $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zYBaLgKp5ADf" title="Property, plant and equipment, net"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20220531__srt--StatementGeographicalAxis__country--MX_ziH0FHnFTYf8" title="Property, plant and equipment, net"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-05-31_country_MX" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-05-31_country_MX" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></ix:nonFraction></span></span> of Biomerica&#8217;s property and equipment, net of accumulated
depreciation and amortization, was located in Mexicali, Mexico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9ZkeOdmCqf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zG3h0TU5Octl">CASH
AND CASH EQUIVALENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zF4Rf9LewHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNLY7qix7um5">ACCOUNTS
RECEIVABLE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until
they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.
Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in
credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and
adjusts the allowance for doubtful accounts accordingly. Balances over <span id="xdx_902_eus-gaap--ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_dc_c20220601__20230531_zmLrzVXcQFz5" title="Threshold period past due for write-off of trade accounts receivable"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt-sec:durwordsen" name="us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable">ninety days</ix:nonNumeric></span>
old are usually reserved for unless collection is reasonably assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occasionally
certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total
gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices
before shipping new sales orders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, the Company has established a reserve of approximately $<span id="xdx_90B_ecustom--AccountsReceivableCreditLossExpenseReversal_c20220601__20230531_zBplFjSnf2wh" title="Accounts receivable, credit loss expense (Reversal)"><ix:nonFraction name="BMRA:AccountsReceivableCreditLossExpenseReversal" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--AccountsReceivableCreditLossExpenseReversal_c20210601__20220531_zpZRmWKdXRal" title="Accounts receivable, credit loss expense (Reversal)"><ix:nonFraction name="BMRA:AccountsReceivableCreditLossExpenseReversal" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,000</ix:nonFraction></span>, respectively, for doubtful accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="BMRA:PrepaidExpensesAndOtherPolicyTextBlock"><p id="xdx_84F_ecustom--PrepaidExpensesAndOtherPolicyTextBlock_zbZ1vAqwJYSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zvMG2dPRgKA9">PREPAID
EXPENSES AND OTHER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company occasionally prepays for items such as inventory, insurance, and other items. These items are reported as prepaids, until either
the inventory is physically received or the insurance and other items are utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, the prepaids were approximately $<span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20230531_zTc4RwoJUK14" title="Prepaid expense and other assets"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20220531_zmcq7Mv3bvvh" title="Prepaid expense and other assets"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,000</ix:nonFraction></span>, respectively, composed of prepayments to insurance and
various other suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_z6EjOOLsoTgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z3XAflCbijqi">INVENTORIES,
NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out
methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates
quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer
demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision
included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs, and wasted material are recognized as
current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfXAx85nCdEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of approximate net inventories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B1_zbIIOEvcmUOj" style="display: none">SCHEDULE
OF NET INVENTORIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230531_zxJS0YOBkNe5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220531_zTXs9kF0FWxe" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zK9rFPjWIuBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,677,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,717,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zI5pUzxdZvg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">763,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z544N6uW1yC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished products</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">782,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_zxuDEwDW0kV3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,728,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,262,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zmvW1nT9x7vf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Inventory reserve</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">846,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_zMrcSIofgNza" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    inventory</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,056,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z2QADNWUiHM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserves
for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically
reserve for obsolete inventory. As of May 31, 2023 and 2022, inventory reserves were approximately $<span id="xdx_90C_eus-gaap--InventoryValuationReserves_iI_c20230531_zhcqT5mKlPVa" title="Inventory reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20220531_zx6uzyfls493" title="Inventory reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">846,000</ix:nonFraction></span>, respectively.
The Company has fully reserved COVID-19 antibody inventory in fiscal 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk6bOjyUlvKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zksGzV8gHEgh">PROPERTY
AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are
charged to operations as incurred. When property and equipment are sold, retired, or otherwise disposed of, the related cost and accumulated
depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements, and dispositions are credited
or charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization are provided over the estimated useful lives of the related assets, ranging from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MinimumMember_zzBbxxesTGV7" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2023-05-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MaximumMember_zkf43DLyWf04" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2023-05-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> years, using the straight-line
method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation
and amortization expense on property and equipment amounted to approximately $<span id="xdx_900_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zdt0SbTs22g2" title="Depreciation, depletion and amortization"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-06-012023-05-31_us-gaap_PropertyPlantAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zQRMq8oDZLx8" title="Depreciation, depletion and amortization"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-06-012022-05-31_us-gaap_PropertyPlantAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> for the years ended May 31, 2023 and
2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zHpEUEE6lTNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zaJlBQgBPHgf">INTANGIBLE
ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets include trademarks, product rights, technology rights, and patents, and are accounted for based on Accounting Standards Codification
(&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have
indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in
circumstances indicate that the asset might be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets are being amortized using the straight-line method over the useful life, not to exceed <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MarketingAndDistributionRightsMember_zyCruYyiK0ck" title="Finite-lived intangible asset, useful life"><ix:nonNumeric contextRef="AsOf2023-05-31_custom_MarketingAndDistributionRightsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">18</ix:nonNumeric></span> years for marketing and distribution
rights, <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedTechnologyRightsMember_zIk62ly12fKd" title="Finite-lived intangible asset, useful life"><ix:nonNumeric contextRef="AsOf2023-05-31_custom_PurchasedTechnologyRightsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></span> years for purchased technology use rights, and <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zENHs0nm4Poe" title="Finite-lived intangible asset, useful life"><ix:nonNumeric contextRef="AsOf2023-05-31_us-gaap_PatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> years for patents. Amortization amounted to approximately $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20220601__20230531_zMJVurcApaH4" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210601__20220531_zE1wenKkvlq5" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,000</ix:nonFraction></span>
for the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#8217;s balance over
its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine
whether there was any impairment. During the year ended May 31, 2023, there was <span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20220601__20230531_zpGA1bc1gRL4" title="Asset impairment charges"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-06-01to2023-05-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> impairment of intangible assets. During the year ended May 31, 2022, an impairment
adjustment was made of $<span id="xdx_908_eus-gaap--AssetImpairmentCharges_c20210601__20220531_zUVEsXBiWrDi" title="Asset impairment charges"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--InvestmentPolicyTextBlock_zIjX6nok2s9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_znhP4kr3dE21">INVESTMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has made investments in a privately held Polish
distributor, which is primarily engaged in distributing medical products and devices, including the distribution of the products
sold by the Company. The Company invested approximately $<span id="xdx_90E_eus-gaap--Investments_iI_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zNabs00JsA8b" title="Investments"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2023-05-31_custom_PolishDistributorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></span>
into the Polish distributor and owns approximately <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zYfiU0qnlX8d" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2023-05-31_custom_PolishDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%
of the investee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence (&#8220;Cost Method
Holdings&#8221;) are accounted for at the Company&#8217;s initial cost, minus any impairment (if any), plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends
received are recorded as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an
equity holding may not be recoverable. Management reviewed the underlying net assets of the Company&#8217;s equity method holding as
of May 31, 2023 and determined that the Company&#8217;s proportionate economic interest in the entity indicates that the equity holding
was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the
Company&#8217;s Cost Method Holding during the year ended May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zi5fht3J56mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zXu5Ufocrqtd">SHARE-BASED
COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based
method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments
(options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that uses
assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The
Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based
on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options.
The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the
&#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as
historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under
the straight-line attribution method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expensed approximately $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220601__20230531_z7zUYyTVKW7" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210601__20220531_z3tU1y95IeBa" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,260,000</ix:nonFraction></span> of share-based compensation during the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdEKYnJS0eH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for period ending May 31, 2023 and 2022: &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z9Q59AExJB38" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20220601__20230531_zwzgNCPGQTo4" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20210601__20220531_z223yB5oqmTd" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction>%</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z6diBBXCP6ck" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">98.81</ix:nonFraction></span>
                                            - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zkvWtpzDXNNk" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101.77</ix:nonFraction></span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zCLhxdQMqwa7" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102.54</ix:nonFraction></span>
- <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zo1OdHzsfXwk" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105.48</ix:nonFraction></span></span>%</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zwhwDa4nM9A8" title="Risk free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.12</ix:nonFraction></span>
                                            - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z29ZDWgpxT77" title="Risk free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.35</ix:nonFraction></span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>&#160;</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zMhegBQUmCDj" title="Risk free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.97</ix:nonFraction></span>
                                            - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zje1Rms6d7fg" title="Risk free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.75</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20220601__20230531_zdmQdYowvAH3" title="Expected term"><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span>
years</span></td><td style="text-align: left"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MinimumMember_zdvX2xmg7cd1" title="Expected term"><ix:nonNumeric contextRef="From2021-06-012022-05-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.50</ix:nonNumeric></span>
                                            - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MaximumMember_zJovgA4h7XD4" title="Expected term"><ix:nonNumeric contextRef="From2021-06-012022-05-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span> years </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AF_zADPwTqKuID8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zTgQf8Mt2FW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zqvIu7A6QYZi">REVENUE
RECOGNITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time
the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point
title passes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not typically allow for returns from customers except in the event of defective merchandise and therefore does not establish
an allowance for returns. In addition, the Company has contracts with customers wherein customers receive purchase discounts for achieving
specified sales volumes. The Company evaluated the status of these contracts during the years ended May 31, 2023 and 2022 and does not
believe that any additional discounts will be given through the end of the contract periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Services
for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project
progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories,
medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce
customers as well as to distributors. Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized
below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international
manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023, the Company had approximately $<span id="xdx_90D_eus-gaap--ProceedsFromCustomers_c20220601__20230531_zXS0hCVZoOn8" title="Proceeds from customers"><ix:nonFraction name="us-gaap:ProceedsFromCustomers" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span> of advances from certain foreign customers. These advances are prepayments on
orders that are expected to ship during our second fiscal quarter ending November 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregation
of revenue:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zanhIyCQdtLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of revenues according to primary markets to which the products are sold:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zNnuM8NBDbSj" style="display: none">SCHEDULE OF DISAGGREGATION REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220601__20230531_zP8e8gf5j2q3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20210601__20220531_ze3LkGjwz3Gh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zKHvA3J7tN2k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Clinical lab</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-06-012023-05-31_custom_ClinicalLabMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-06-012022-05-31_custom_ClinicalLabMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,064,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_z9Mve49dOEJd" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Over-the-counter</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-06-012023-05-31_custom_OverTheCounteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,169,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-06-012022-05-31_custom_OverTheCounteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,089,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_z9ypGqpq5I81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contract manufacturing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-06-012023-05-31_custom_ContractManufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">610,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-06-012022-05-31_custom_ContractManufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zkH4ktR4A8Nb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Physician&#8217;s office</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-06-012023-05-31_custom_PhysiciansOfficeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-06-012022-05-31_custom_PhysiciansOfficeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,259,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHpBiDu5C8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,339,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,871,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zvOxIDEPiRA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 for additional information regarding geographic revenue concentrations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_zvyO8kcbTwZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zo3bOhAblJwi">SHIPPING
AND HANDLING FEES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes shipping and handling fees billed to customers in net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoPDGTZ4ZYce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z5WBvU2kFJM2">RESEARCH
AND DEVELOPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. The Company expensed approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220601__20230531_zxrrWoRg1AA4" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,584,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210601__20220531_zNsRZitDXup9" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,812,000</ix:nonFraction></span> of research and development
costs during the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z7GpIgRB6l2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zHiFcLTqmP0a">INCOME
TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and
liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the
consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net
operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit
carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent
that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation
allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the
character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance
and income tax expense. As of May 31, 2023 and 2022, in accordance with ASC 740, the Company has a valuation allowance for
substantially all of its net deferred tax assets. During the year ended May 31, 2023, this valuation allowance was increased to
$<span id="xdx_906_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_zd5VCqoAt0z2" title="Deferred tax assets, valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,940,000</ix:nonFraction></span>,
which fully covers the net deferred tax asset of $<span id="xdx_905_eus-gaap--DeferredTaxAssetsGross_iI_c20230531_zdBMfhCgPHW2" title="Deferred tax assets, net"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,940,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions.
The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more
likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related
appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount
of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized
when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which
is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information
available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an
accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line
and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_841_eus-gaap--AdvertisingCostsPolicyTextBlock_zWTcxet7YGAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z47QZsQ6HMz1">ADVERTISING
COSTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately
$<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20220601__20230531_z9Fyj00nxcr4" title="Advertising expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20210601__20220531_zzixh9zoqbUl" title="Advertising expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,000</ix:nonFraction></span> for the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zKvticJLFUTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zLN0PxTX9iKi">FOREIGN
CURRENCY TRANSLATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the
U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries
are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates
for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive
loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May
31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z9YTFDd1Gp72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zf9MmdLbU2Oj">RIGHT-OF-USE
ASSETS AND LEASE LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standard update which requires lessees
to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from
the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value
of fixed lease payments over the lease term. Leases are classified as financing or operating which will drive the expense recognition
pattern. The Company has elected to exclude short-term leases. The Company leases office space and copy machines, all of which are operating
leases. Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options
to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The
leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited
by the expected lease term. For additional information, see Note 9-Commitments and Contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGhUn8gHrkwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zbplaaJ5ElFa">NET
LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss
per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible
securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation
for the years ended May 31, 2023 and 2022 were <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220601__20230531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z4slMFwctEC9" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,342,616</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210601__20220531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zob2BtJtsFyf" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,321,616</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zY7tmLByV8sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zGTwlBY8erm">SEGMENT
REPORTING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about
operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management
and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic
kits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaxSJgIMdnu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zqDWvQiTcYP">REPORTING
COMPREHENSIVE LOSS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly
as a component of shareholders&#8217; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments
for the years ended May 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zgusxlyi9MG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zKKValXlvOd7">RECENT
ACCOUNTING PRONOUNCEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as follows, recent
ASU&#8217;s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on
the Company&#8217;s present or future consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.
This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting
date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective
for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November
2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates, which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered
smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including
interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine
its impact on the Company&#8217;s consolidated results of operations and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2mUAY79V6jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3: <span id="xdx_82A_zzgKt5AWGAT6">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zJRhHLryw4j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of property and equipment, net of accumulated depreciation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zlMK1GYyzfsi">SCHEDULE
OF PROPERTY AND EQUIPMENT, NET</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230531_zJJG3CVuYsFl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220531_zmEdMEVTHcb9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQNjMA1Nd9d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-05-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,333,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-05-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,292,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndFixturesLeaseholdImprovementsMember_z3rFGVi7Fdhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture, fixtures and leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zS4848GSRXx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,331,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,305,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zhbLjnLUPcxc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    property and equipment</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zDflOk4HWhTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zHA2uFLvayQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4: <span id="xdx_828_z3a5eCjChvI8">INTANGIBLE ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zG20KfgYEmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of intangible assets, net of accumulated amortization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zzbG1t9TRIFg">SCHEDULE
OF INTANGIBLE ASSETS, NET</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230531_zjihxqZSSRye" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220531_zrOSrzsA1Dkl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_maIANEGzien_zyNp2gc4Ko4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--FiniteLivedPatentsAccumulatedAmortization_iNI_di_msIANEGzien_zpDvvbcHgjWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less accumulated amortization-patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BMRA:FiniteLivedPatentsAccumulatedAmortization" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BMRA:FiniteLivedPatentsAccumulatedAmortization" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_mtIANEGzien_zwmRWaZfiCml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AD_zNGOojLeHfjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zzIh9VajLBUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
amortization of intangible assets for the years ending May 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zA8QpIKu38kc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230531_ztK8HuiJZdT5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzv9t_zi3uv8CnjeCk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzv9t_zjjOwufWa3U3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzv9t_z5wWeWCfCUK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzv9t_zOT4Xl021mDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzv9t_zv00voJayX8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzv9t_zpBK3EQeMkqj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzv9t_zpOdlrYPbyM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zPNbKbPy9ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zYJXUqkQ19q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5: <span id="xdx_820_zianuoe2c8Gg">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zqarcDUnL0Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of accounts payable and accrued expenses balances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zdgR41Gp4EDf" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230531_zpP2PO4IGto" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20220531_zOTmbwRahvc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iI_maAPAALzPt0_zBnvfIc1m7A9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzPt0_zfot5l9CYtce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">548,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzPt0_ze1uDNAQZb39" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">892,000</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">972,000</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zZeUjVO1Soda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A7_zKKTZPhmXCe6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023, the Company had one vendor which accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zk17hb183dz3" title="Net sales percent"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-06-012023-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></span>% of accounts payable. As of May 31, 2022, the Company had two vendors
which accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoVendorMember_ztycs6s3KAi3" title="Net sales percent"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-06-012022-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoVendorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">69</ix:nonFraction></span>% of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbhHCfbkUw1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6: <span id="xdx_82E_zlOcBNuB8oA6">SHAREHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STOCK
OPTION AND RESTRICTED STOCK PLANS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2014, the Company adopted and shareholders approved a stock option and restricted stock plan (the &#8220;2014 Plan&#8221;).
Subsequently, in December 2017, the Company adopted and shareholders approved an stock option and restricted stock plan (the &#8220;2017
Plan&#8221;). In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;, and collectively with
the 2014 Plan and 2017 Plan, the &#8220;Equity Incentive Plans&#8221;) and on December 11, 2020, the shareholders of the Company approved
the 2020 Plan. The Equity Incentive Plans provide that non-qualified options and incentive stock options and restricted stock may be
granted to directors, affiliates, employees, or consultants of the Company. The Equity Incentive Plans authorize awards representing
up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20141231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandFourteenPlanMember_zChdBRNYvq83" title="Equity incentive plan, authorized shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandFourteenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,000</ix:nonFraction></span>, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zqUe9ja3kRL3" title="Equity incentive plan, authorized shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20200229__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zVsCruvCcDuj" title="Equity incentive plan, authorized shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-02-29_us-gaap_EmployeeStockOptionMember_custom_TwoThousandTwentyPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000</ix:nonFraction></span> shares of the Company&#8217;s common stock to be issued under the 2014 Plan, 2017 Plan, and 2020 Plan,
respectively. Awards granted under the Equity Incentive Plans typically vest over <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRMOVxSu8FG1" title="Vesting period"><ix:nonNumeric contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">4</ix:nonNumeric></span> years. Options granted under the Equity Incentive
Plans will be granted at prices not less than <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7k4A8tJCBr6" title="Award purchase price, percent"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the then fair market value of the common stock and will expire not more than <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXa8VUVJOk9" title="Expiration period"><ix:nonNumeric contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric></span>
years after the date of grant. The 2014 Plan expires in December 2024, the 2017 Plan expires in December 2027, and the 2020 Plan expires
in December 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziOpm9lSewRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense for the years ended May 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zy1dsdSDCvid">SCHEDULE
OF STOCK BASED COMPENSATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zL85zAK0Uv1k" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20210601__20220531_zbkLros4SRt1" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4iXckzSV6Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-06-012023-05-31_us-gaap_CostOfSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-06-012022-05-31_us-gaap_CostOfSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zePauF8bdOXi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-06-012023-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-06-012022-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3k0YNjrf0F3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-06-012023-05-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-06-012022-05-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_zLfJYM2Dp0G7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stock option expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,260,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

</ix:nonNumeric><p id="xdx_8A0_zKvAvFoS5Nve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zn7O30hYo6pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activity
as to aggregate stock options outstanding is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 4.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 4.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z2xMpyNzQEwc">SCHEDULE
OF ACTIVITY TO AGGREGATE STOCK OPTIONS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold">Options Outstanding at May 31, 2021</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210601__20220531_zo2hFF6bHUll" title="Options Outstanding, shares" style="width: 14%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,081,366</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210601__20220531_z6xdbLhxFGde" title="Options Outstanding Weighted Average Exercise Price" style="width: 14%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.59</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210601__20220531_zpGkCDe79Zmi" title="Options outstanding, Aggregate Intrinsic Value" style="width: 14%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,132,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210601__20220531_z3L1j5wDmyRh" title="Options granted, shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">344,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zvtGPLX1ai51" title="Options Granted Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210601__20220531_zk0473YWT7ia" title="Options exercised, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210601__20220531_zp0NqWNyUbNc" title="Options Exercised Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210601__20220531_zWCGTRMz3gJe" title="Options exercised, Aggregate IntrinsicValue" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options canceled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210601__20220531_zcDQAok5oJp5" title="Options cancelled or expired, shares" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zOpdLZXP0zal" title="Options canceled or expired Weighted Average Exercise Price" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Options Outstanding at May 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220601__20230531_zdQf3E23Vwq4" title="Options Outstanding, shares" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,321,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220601__20230531_zJkrnYufR07" title="Options Outstanding Weighted Average Exercise Price" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220601__20230531_z8ybYZsgdPNk" title="Options outstanding, Aggregate Intrinsic Value" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,838,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220601__20230531_zgwKqTJB8To" title="Options granted, shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zAu3aZ5yxF2" title="Options Granted Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220601__20230531_zLdr29QxUksd" title="Options exercised, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220601__20230531_zOGpuzaXaajf" title="Options Exercised Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220601__20230531_zJmB7dY3efQ7" title="Options exercised, Aggregate IntrinsicValue" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Options canceled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220601__20230531_z6WB0ibZSw2e" title="Options cancelled or expired, shares" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zrOx3pvwzgu7" title="Options canceled or expired Weighted Average Exercise Price" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.56</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Options Outstanding at May 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220601__20230531_zkwTS0lFVOSh" title="Options Outstanding, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,342,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220601__20230531_z1hi5b8H75y5" title="Options Outstanding Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.52</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220601__20230531_z2c8DqTMfm2i" title="Options outstanding, Aggregate Intrinsic Value" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at May 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20230531_zFwibW9Xxub3" title="Options vested and exercisable, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,841,933</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230531_zowGPBmgrFF7" title="Options vested and exercisable Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230531_zdU5FibUUaFi" title="Options vested and exercisable Aggregate Intrinsic Value" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_z0TzbMBTVfPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of options granted during 2023 and 2022 were $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQThWfjCcshi" title="Granted, weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.19</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210601__20220531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFgq46JWDkr7" title="Granted, weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember58847203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.43</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2023, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPj91oZmGO52" title="Compenation cost related to non-vested stock option"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,000</ix:nonFraction></span>.
The weighted-average period over which this amount is expected to be recognized is <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnrM0AFHGH8" title="Weighted average period expected term"><ix:nonNumeric contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.52</ix:nonNumeric></span> years. The weighted average remaining contractual
term of options that were exercisable on May 31, 2023 was <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWDaNsXJNQCi" title="Exercisable weighted average remaining contractual term"><ix:nonNumeric contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.97</ix:nonNumeric></span> years. The weighted average remaining contractual term of options that
were vested, exercisable, or expected to vest on May 31, 2023 was <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLLC6H5J3e8l" title="Vested, exercisable or expected to vest weighted average remaining contractual term"><ix:nonNumeric contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">5.67</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMON
STOCK ACTIVITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210122__20210122__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--ATMAgreementMember_zaJqgr6E1nuh" title="Consideration received on transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2021-01-222021-01-22_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span> in &#8220;at-the-market&#8221;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#8220;ATM Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, in conjunction with the Company&#8217;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#8217;s
annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210521__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z3u5hlzBj3nj" title="Share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-05-21_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock that could be issued under this Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend
offers under, or terminate the ATM Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2023, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zQWvxiQtBZP1" title="Sale of stock shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">573,889</ix:nonFraction></span> shares of its common stock at prices ranging from $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z7bSyUzPSDE3" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></span> to $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zs7aCSP9Mkf5" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.26</ix:nonFraction></span> pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zug3rQXYpOpi" title="Sale of stock gross proceeds"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,014,000</ix:nonFraction></span> and net proceeds to the Company of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zeQS9XUkloCe" title="Sale of stock, net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,961,000</ix:nonFraction></span>, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z0HVVTT6Sz1k" title="Sale of stock, offering expenses"><ix:nonFraction name="BMRA:SaleOfStockExpenses" contextRef="From2022-06-012023-05-31_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2022, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zZK2meEqkbw4" title="Sale of stock shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">521,267</ix:nonFraction></span> shares of its common stock at prices ranging from $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zfhtqETBlY09" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.02</ix:nonFraction></span> to $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zAouvBLmCJo9" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></span> pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zufG6d53VyK6" title="Sale of stock gross proceeds"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,402,000</ix:nonFraction></span> and net proceeds to the Company of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z3kOxhiIOwIl" title="Sale of stock, net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,317,000</ix:nonFraction></span>, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $<span id="xdx_90C_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zREuYEjknI2a" title="Sale of stock expenses"><ix:nonFraction name="BMRA:SaleOfStockExpenses" contextRef="From2021-06-012022-05-31_custom_ATMOfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 7, 2023, the Company closed on an underwritten sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230307__20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_zcEtYtDvhBNh" title="Sale of stock shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-03-072023-03-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,333,333</ix:nonFraction></span> shares of our registered common stock through an investment banking
firm, which shares were issued under our shelf registration. In this offering, the Company sold the registered shares at a gross sales
price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_zUSLHMp2TIyf" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-03-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></span> per share, with net proceeds, after deducting issuance fees and expenses of $<span id="xdx_908_ecustom--SaleOfStockExpenses_c20230307__20230307_zmNdRyFO5XUg" title="Sale of stock expenses"><ix:nonFraction name="BMRA:SaleOfStockExpenses" contextRef="From2023-03-072023-03-07" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span>, of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_z4HF9uWKXtN8" title="Sale of stock, net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-03-072023-03-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,300,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PREFERRED
STOCK ACTIVITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with
Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed
to purchase from the Company, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z5NxG1RtzGei" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">571,429</ix:nonFraction></span> shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zSGCnxnJ5xvj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></span> par value per share
for a purchase price of approximately $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20200224__20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_znG0WIEMDBI6" title="Preferred stock, purchase price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2020-02-242020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million, or $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zUIZ8j3Gkh51" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></span> per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase
Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s
common stock, subject to certain adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $<span id="xdx_90B_eus-gaap--DividendsPayableAmountPerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zy6Z1y2Tbnm4" title="Dividends payable, amount per share"><ix:nonFraction name="us-gaap:DividendsPayableAmountPerShare" contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.175</ix:nonFraction></span> per Series A 5% Convertible Preferred
Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay
such accruing dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2020, Palm converted <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20200304__20200324__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxLKRzngjOw7" title="Conversion of stock, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2020-03-042020-03-24_us-gaap_ConvertiblePreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of Convertible Preferred Stock into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20200304__20200324__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zasmcDMqdl4h" title="Conversion of stock, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2020-03-042020-03-24_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of unregistered common stock. On July
21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered <span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20200721__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuedvy7FJcI5" title="Conversion of stock, shares issued upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2020-07-21_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">571,429</ix:nonFraction></span> common shares
issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. On September 30, 2020, the Company
received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares. On January 21, 2021,
Palm Converted their remaining <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20210121__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGvFdWY8eRi3" title="Conversion of stock, shares issued upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2021-01-21_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,429</ix:nonFraction></span> Convertible Preferred Shares into registered common shares. On May 30, 2021, the Company had no
shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative dividends were
paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past
cumulative dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zY4kAUNlBHb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7: <span id="xdx_82E_zjBXGgx5oqyd">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zN1RjOEMDHg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
for income taxes for the years ended May 31 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zEdv7rDKFfD3">SCHEDULE
OF PROVISION FOR INCOME TAXES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zC8A2hrtPn6b" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20210601__20220531_zW6c9qy468jl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzN4S_zVPkhJ98LI4f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzN4S_zhSeGrRiyTv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign Taxes
    Subsidiaries</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzN4S_zs6t4Al7tRaf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State
    and local</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzN4S_maITEBz44d_zJSwJaeEK7N5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzeSN_z5EJuxrkvNvd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzeSN_z3rrGLRSjih" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzeSN_maITEBz44d_zaouIu8VrYq5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBz44d_zx5zSBw96vN" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_zkqKzrzEHToe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (<span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220601__20230531_z0NJJDom9wf8" title="Federal income tax rate"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210601__20220531_zlvPESmUANb9" title="Federal income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></ix:nonFraction></span></span>% for 2023
and 2022) to pretax income as a result of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwSclUVi4pBk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zY3eUHn24cJf">&#160;SCHEDULE
OF EFFECTIVE INCOME TAX RECONCILIATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20220601__20230531_zdJI70dx3xVl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20210601__20220531_zPT0Hx4RkPBh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maCITEBzLRi_zFnJYfux1Ws2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computed &#8220;expected&#8221;
    tax benefit</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,490,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">947,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maCITEBzLRi_zZD9Sq7KH1Hb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,973,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,022,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maCITEBzLRi_zouQNNB7pZS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income taxes, net of federal benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msCITEBzLRi_zW0GZGjlV8ge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maCITEBzLRi_zBLkiluNOQa8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent tax differences and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maCITEBzLRi_z0MsKHPsszE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maCITEBzLRi_zMZuhGRMn09j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign taxes of subsidiaries</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">113,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzLRi_zCbHblsos8G3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zQk8aWH9yqGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z6t9YwLvlCnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effect of significant temporary differences is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zKa0cnEl6IC">&#160;SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20230531_zcdSpE1advel" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220531_zz4jubQPL1s5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzl2T_zoJPLcS3oaN3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable,
    principally due to allowance for doubtful accounts</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzl2T_zyTgsXHyl9uh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inventory valuation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_maDTAGzl2T_zk8LFjL4wJbf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensated absences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzl2T_zR4790kv4XPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,817,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,349,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzl2T_zK6tOU68FhUk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credit carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,239,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_iI_maDTAGzl2T_zDZQkHcikds4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred rent expense/Capitalized leases</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DefferedTaxAssetsStockOptions_iI_maDTAGzl2T_zmkKMKaREBJ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:DefferedTaxAssetsStockOptions" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,296,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:DefferedTaxAssetsStockOptions" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,035,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsCapitalizedCosts_iI_maDTAGzl2T_z6LtUkQbqmsa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sec 174 capitalized costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:DeferredTaxAssetsCapitalizedCosts" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_iI_maDTAGzl2T_zUFMFuKsa3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Losses of foreign subsidiaries &amp; other,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccumulatedDepreciationAndAmortization_iI_maDTAGzl2T_zUO37fP95gvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BMRA:DeferredTaxAssetsAccumulatedDepreciationAndAmortization" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BMRA:DeferredTaxAssetsAccumulatedDepreciationAndAmortization" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzl2T_maDTANzFA8_zzMFePDOqVx3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,940,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,967,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFA8_zrhlaIp5jY1h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,940,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,967,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFA8_zJYyCrD9RqUg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax asset</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zWmyURdUshQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has provided a valuation allowance of approximately $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_ze734Z4lUAEk" title="Deferred tax assets, valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,940,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20220531_zcDoET38PTkh" title="Deferred tax assets, valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,967,000</ix:nonFraction></span> as of May 31, 2023 and 2022, respectively. The
net change in the valuation allowance for the years ended May 31, 2023 and 2022 was an increase of $<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220601__20230531_zQdExubQabfl" title="Increase in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,973,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210601__20220531_zHRYO3gq8yYk" title="Increase in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,063,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2023, the Company has Federal income tax net operating loss carryforwards of approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zPqi3ES2hLfj" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-05-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,958,000</ix:nonFraction></span>. On May 31, 2023, the
Company has California state income tax net operating loss carryforwards of approximately $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zOpAhQ8VXQF7" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,269,000</ix:nonFraction></span>. For tax reporting purposes, operating
loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in 2024 and
2038 for federal and state purposes, respectively. Federal net operating losses beginning in 2018 have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2023, the Company has Federal research and development tax credit carryforward of approximately $<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zQqy3RFzC9Gl" title="Tax credit carryforward"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2023-05-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">817,000</ix:nonFraction></span>. The Federal credits
begin to expire in 2028. The Company also had similar credit carryforwards for state purposes of $<span id="xdx_904_eus-gaap--TaxCreditCarryforwardAmount_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zvcL5mkbI1N9" title="Tax credit carryforward"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533,000</ix:nonFraction></span> on May 31, 2023, which do not
expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss (&#8220;NOL&#8221;)
and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections
382 and 383 of the IRC, the annual use of the Company&#8217;s NOLs and credit carryforwards would be limited if there is a cumulative
change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period). Management has
not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended May 31, 2023, the Company performed an analysis and has not identified any uncertain tax positions as
defined under ASC 740. Should such position be identified in the future, and should the Company owe interest and penalties as a result
of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The
Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zcp8WCGGJ4z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8: <span id="xdx_820_z9pn3jfZJG11">GEOGRAPHIC INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as <span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20220601__20230531_z6J7Ksl9YdH9" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2022-06-01to2023-05-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></span> segment. Geographic information regarding net sales is approximately as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zGGLNwuVGY9k" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z7cG5U7SlX8b">SCHEDULE
OF GEOGRAPHIC INFORMATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20220601__20230531_zJfyALI3Y6F9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20210601__20220531_zAIUzto5L65e" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revenues from sales to unaffiliated customers:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--AsiaMember_zQWtR9KMXSg7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Asia</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-012023-05-31_srt_AsiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,021,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31_srt_AsiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,375,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--EuropeMember_z3ylp06Qme38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Europe</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-012023-05-31_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,798,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,339,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--NorthAmericaMember_zbpKxULpKhTh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">North America</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-012023-05-31_srt_NorthAmericaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,470,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31_srt_NorthAmericaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">997,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zZIzZe0FWy96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Middle East</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-012023-05-31_us-gaap_MiddleEastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31_us-gaap_MiddleEastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--SouthAmericaMember_zT16pDj3POM3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">South America</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-012023-05-31_srt_SouthAmericaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31_srt_SouthAmericaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_zVsIXdCQwpva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,339,000</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,871,000</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zaI9zcEDAC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zYX2kOwmmqc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9: <span id="xdx_82A_zvcFWIup17c9">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING
LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases facilities in Irvine, California and Mexicali, Mexico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023, <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20230531__20230531_zdyr3kDXFQ31" title="Operating lease description"><ix:nonNumeric contextRef="From2023-05-312023-05-31" name="us-gaap:LesseeOperatingLeaseDescription">the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue
in Irvine, California. The lease for its headquarters expires in August 2026. The Company has the option to extend the lease for an additional
five-year term</ix:nonNumeric></span>. The Company made a security deposit of approximately $<span id="xdx_900_eus-gaap--SecurityDeposit_iI_c20230331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--BuildingInIrvineCaliforniaMember_zxo40vLrPuui" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-03-31_custom_BuildingInIrvineCaliforniaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20161130_zPHTP8zOzvEh" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2016-11-30" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">10</ix:nonNumeric></span>-year lease for approximately <span id="xdx_906_eus-gaap--AreaOfLand_iI_uSqft_c20230531_zsw5BBM5JbTa" title="Lease area"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">8,100</ix:nonFraction></span> square
feet of manufacturing space. The Company has one <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20161130_zhJ22IGPxyX7" title="Operating lease renewal term"><ix:nonNumeric contextRef="AsOf2016-11-30" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm">10</ix:nonNumeric></span>-year option to renew at the end of the initial lease period. Biomerica de Mexico
also leases a smaller unit on a month-to-month basis for use in the Company&#8217;s manufacturing process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany
subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of
the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising.
The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included
in the measurement of the right-of-use asset and related lease liabilities. Additionally, under these lease arrangements, the Company
may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable
and therefore not included in the measurement of the right-of-use asset and related lease liabilities but are instead recognized as variable
lease expense in the consolidated statements of operations and comprehensive loss when they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zJccOLgSar7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information on our operating leases for the years ended May 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z9hcafgkEkTd">SCHEDULE
OF OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20220601__20230531_zSzDegJAzyT6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20210601__20220531_zQ6uvSHpEBVh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseCost_maLCzsjE_zN9b0A329Qqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maLCzsjE_zTPhJXEV48ua" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term lease cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LeaseCost_mtLCzsjE_zKSdFz0elaw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A1_zxC4EHaOxkXi" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMFnK54RcJih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future minimum lease payments of the Company&#8217;s operating lease liabilities by fiscal year are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zACTi91hd6Ai">SCHEDULE
OF FUTURE MINIMUM LEASE PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Year Ending May 31:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20230531_zuR7SXjplLs8"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzfjE_zjXCJmEkQTEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzfjE_zAz6xE532JNi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzfjE_zWZRjsXHwgS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">376,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzfjE_z0aV6G8x0Yj5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzfjE_zaZRFkGJqlt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzfjE_mtOLLzK2p_zUh9Z1G7RAq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total minimum future lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_maOLLzK2p_zxa9kfLeFwn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_maOLLzK2p_zyNHw99PWPk1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total operating lease
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,082,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zHgbJopHfgO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="BMRA:ScheduleOfSupplementalLeaseInformationTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfSupplementalLeaseInformationTableTextBlock_z3mnnqSft9jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s other supplemental lease information for the years ended May 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zG6Y8pfXecUh">SCHEDULE
OF OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220601__20230531_zwIB7iGhv1g8" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20210601__20220531_zfkQ1bB7XCih" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeasePayments_zqcuHF6ogFGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for operating lease liabilities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-06-01to2023-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">347,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-06-012022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average remaining lease term (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230531_zG20xRD4gK87" title="Weighted average remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2023-05-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.27</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220531_zJZ4ZwmrD4f7" title="Weighted average remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2022-05-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.28</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230531_zQnLWfU6akt8" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.50</ix:nonFraction></span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220531_z1eVUJIjyLqg" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.50</ix:nonFraction></span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_zxi278JrRhUf" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has various insignificant leases for office equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RETIREMENT
SAVINGS PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute
to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404.
The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each
year. No contributions by the Company have been made since the plan&#8217;s inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LITIGATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is, from time to time, involved in legal proceedings, claims, and litigation arising in the ordinary course of business. While
the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that
exist. Therefore, it is possible the outcome of such legal proceedings, claims, and litigation could have a material effect on quarterly
or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes
such matters will not have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or
cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no legal proceedings pending as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTRACTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contracts
and Licensing Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products.
Royalty expense of approximately $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20220601__20230531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_zSkPdbkblpJl" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-06-012023-05-31_us-gaap_RoyaltyAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20210601__20220531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_z4csWzkUuQe7" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-06-012022-05-31_us-gaap_RoyaltyAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></span> is included in cost of sales for the agreement for each of the years ended May 31,
2023 and 2022, respectively. Sales of products manufactured under these agreements comprise approximately <span id="xdx_904_ecustom--RoyaltyExpensePercentageOfSales_dp_c20220601__20230531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_zDb8N2abyE39" title="Royalty expense percentage of sales"><ix:nonFraction name="BMRA:RoyaltyExpensePercentageOfSales" contextRef="From2022-06-012023-05-31_us-gaap_RoyaltyAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.1</ix:nonFraction></span>% and <span id="xdx_906_ecustom--RoyaltyExpensePercentageOfSales_dp_c20210601__20220531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_ziVgqX5EL2Q5" title="Royalty expense percentage of sales"><ix:nonFraction name="BMRA:RoyaltyExpensePercentageOfSales" contextRef="From2021-06-012022-05-31_us-gaap_RoyaltyAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>% of total sales
for the years ended May 31, 2023 and 2022, respectively. The Company may license other products or technology in the future as it deems
necessary for conducting business. The Company has other royalty agreements however they are not considered material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing
clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.
The initial budget was estimated to be approximately $<span id="xdx_90F_ecustom--ClinicalTrialAgreementMaximumBudgetedCosts_iI_c20170930__dei--LegalEntityAxis__custom--UniversityOFSouthernCaliforniaMember_z901oPW5eYb7" title="Clinical trial agreement maximum budgeted costs"><ix:nonFraction name="BMRA:ClinicalTrialAgreementMaximumBudgetedCosts" contextRef="AsOf2017-09-30_custom_UniversityOFSouthernCaliforniaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,000</ix:nonFraction></span>. The work started in October 2017 with charges for work performed being
invoiced and paid monthly. This study ended in February 2020. Approximately $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_c20220531__dei--LegalEntityAxis__custom--UniversityOFSouthernCaliforniaMember_zamhDWJ9hjQa" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-05-31_custom_UniversityOFSouthernCaliforniaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></span> in fees has been accrued for unbilled charges as
of May 31, 2022. There are no unbilled charges as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a Clinical Trial Agreement with a research institute for the purpose of conducting a clinical trial of the Biomerica
InFoods&#174; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly
for work performed in the previous month. The maximum budgeted costs will be approximately $<span id="xdx_901_ecustom--ClinicalTrialAgreementMaximumBudgetedCosts_iI_c20220531__dei--LegalEntityAxis__custom--BiomericaInFoodsMember_zGozQprfkaK7"><ix:nonFraction name="BMRA:ClinicalTrialAgreementMaximumBudgetedCosts" contextRef="AsOf2022-05-31_custom_BiomericaInFoodsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,000</ix:nonFraction></span>. This study ended in March 2022.
Approximately $<span id="xdx_900_eus-gaap--AccruedLiabilitiesCurrent_iI_c20220531__dei--LegalEntityAxis__custom--BiomericaInFoodsMember_zLOalagqTprc" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-05-31_custom_BiomericaInFoodsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction></span> in fees has been accrued for unbilled charges as of May 31, 2022. There are no unbilled charges as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-06-01to2023-05-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zZAureC8xYdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10: <span id="xdx_82A_zqBIax2NwMch">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 3, 2023, <span id="xdx_908_eus-gaap--SubsequentEventDescription_c20230803__20230803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrEmnUmfwd14" title="Subsequent event, description"><ix:nonNumeric contextRef="From2023-08-032023-08-03_us-gaap_SubsequentEventMember" name="us-gaap:SubsequentEventDescription">the Company announced it had entered into a sales agreement with CVS Pharmacy wherein the Company&#8217;s EZ Detect&#8482;
colorectal disease screening test will be offered at approximately 7,000 CVS Pharmacy retail stores</ix:nonNumeric></span>. Biomerica has shipped the EZ Detect
product to CVS Health distribution centers in the United States, and the product is projected to be on store shelves in September.</span></p>

</ix:nonNumeric><p id="xdx_812_ziikJDDzRS4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><br /></b></span></p>


<!-- Field: Page; Sequence: 20; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">FS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>
</body>
</html>
















</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST
AMENDED AND RESTATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
of INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOMERICA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &ldquo;Corporation&rdquo;)
does hereby certify as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Corporation filed its original Certificate of Incorporation with the Secretary of State of the State of Delaware on September 22,
1971 under the name of Nuclear Medical Systems, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
At a duly called meeting of the Board of Directors of the Corporation at which a quorum was present at all times, a resolution was duly
adopted, pursuant to Sections 242 and <I>245 of </I>the General Corporation Law of the State of Delaware (&ldquo;General Corporation
Law&rdquo;), setting forth the First Amended and Restated Certificate of Incorporation of the Corporation, declaring said First Amended
and Restated Certificate of Incorporation advisable and directing that said First Amended and Restated Certificate of Incorporation be
considered at the next annual meeting of the stockholders. The stockholders of the Corporation duly approved said proposed First Amended
and Restated Certificate of Incorporation at such annual meeting of the stockholders in accordance with Sections 222, 242 and 245 of
the General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The text of the Certificate of Incorporation of the Corporation, as amended, is hereby further amended and restated in its entirety as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of this Corporation is Biomerica, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTERED
OFFICE IN STATE AND REGISTERED AGENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
address of the registered office of this Corporation in the State of Delaware is 1013 Centre Road, City of Wilmington, County of New
Castle. The name of this Corporation&rsquo;s registered agent at such registered office is The Prentice-Hall Corporation System, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURPOSE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose for which this Corporation is organized is to engage in any lawful act or activity for which corporations may be organized under
the General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAPITAL
STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Corporation is authorized to issue two classes of shares designated respectively &ldquo;Common Stock&rdquo; and &ldquo;Preferred Stock&rdquo;
and referred to herein as Common Stock or Common Shares and Preferred Stock or Preferred Shares, respectively. The total number of shares
of all classes of stock which the Corporation shall have authority to issue is 30,000,000 shares, par value $.08, consisting of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
25,000,000 shares of Common Stock; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
5,000,000 shares of Preferred Stock. The Preferred Shares may be issued from time to time in one or more series. The board of directors
is authorized to fix the number of shares of any series of Preferred Stock and to determine the designation of any such series. The board
of directors is also authorized to determine or alter the rights, preferences, privileges and restrictions granted to or imposed upon
any wholly unissued series of Preferred Shares and, within the limits and restrictions stated in any resolution or resolutions of the
board of directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number
of shares of any such series then outstanding) the number of shares of any series subsequent to the issue of shares of that series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROVISIONS
FOR DEFINING, LIMITING AND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGULATING
CERTAIN POWERS of THIS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATION
AND of THE DIRECTORS AND STOCKHOLDERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1. <U>Number of Directors</U>. The number of directors which shall comprise the full Board of Directors of this Corporation shall be
fixed by, or in the manner provided in, the Bylaws of this Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2. <U>Power to Authorize Issuance</U> of <U>Stock</U>. The Board of Directors of this Corporation is hereby empowered to authorize the
issuance from time to time of shares of capital stock, whether now or hereafter authorized, for such consideration as the Board of Directors
may deem advisable, subject to such limitations as may be set forth in this Certificate of Incorporation or in the Bylaws of this Corporation
or in the General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3. <U>Limitation on Liability of Directors</U>. A director of this Corporation shall not be personally liable to this Corporation or
its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director&rsquo;s
duty of loyalty to this Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct
or a knowing violation of law as now in effect, or any successor provision thereto, (iii) under Section 174 of the General Corporation
Law, or (iv) for any transaction from which the director derived any improper personal benefit. If the General Corporation Law is amended
after approval by the stockholders of this Article V to authorize corporate action further eliminating or limiting the personal liability
of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the
General Corporation Law, as so amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
repeal or modification of this Section 3 of Article V by the stockholders of this Corporation shall not adversely affect any right or
protection of a director of this Corporation existing at the time of such repeal or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4. <U>Indemnification</U>. Each director, officer and employee of this Corporation shall be indemnified by this Corporation to the fullest
extent permitted by the General Corporation Law as now or hereafter in force.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5. <U>Bylaws</U>. In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the board of directors
of this Corporation is expressly authorized and empowered to make, alter, amend and repeal the Bylaws of this Corporation, subject to
the power of the stockholders of this Corporation to alter or repeal any Bylaw made by the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VI</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in this
Certificate of Incorporation, in the manner now or hereafter prescribed by statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, this Corporation has caused this First Amended and Restated Certificate of Incorporation to be signed by its President
and attested by its Secretary this 21 day of July, 2000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIOMERICA,
    INC.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Zackary Irani</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    Irani, President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTEST:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Janet Moore</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Janet
    Moore, Secretary</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ex3-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOMERICA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a
Delaware corporation)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adopted
by the Board of Directors on July 24, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The principal office of the Corporation shall be at 251 Little Falls Dr., City of Wilmington, State of Delaware, and the name of the
resident agent in charge thereof is CSC-Global.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Corporation may also have an office or offices at such other place or places, within or without the State of Delaware, as the Board
of Directors of the Corporation (the &ldquo;<B>Board</B>&rdquo;) may from time to time designate or the business of the Corporation may
require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo;
Meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Meetings of the stockholders of the Corporation may be held at such place, either within or without the State of Delaware, as may be
determined from time to time by the Board. The Board may, in its sole discretion, determine that the meeting shall not be held at any
place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (the &ldquo;<B>DGCL</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Unless members of the Board are elected by written consent in lieu of an annual meeting, as permitted by Section 211 of the Delaware
General Corporation Law (the &ldquo;<B>DGCL</B>&rdquo;) and these Bylaws, an annual meeting of stockholders shall be held for the election
of directors at such date and time as the Board shall each year fix. At such meeting the stockholders may elect the directors and transact
any business properly brought before the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Special meetings of the stockholders shall be held upon call of the Board, and shall be called by the Chairperson of the Board or the
President or the Secretary at the request in writing of the stockholders owning of record at least twenty-five percent of the issued
and outstanding capital stock of the Corporation entitled to vote thereat.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Notice of the purpose or purposes and of the time and place within or without the State of Delaware of every meeting of stockholders
shall be given by the Chairperson of the Board or the President or the Secretary or an Assistant Secretary either personally or by mail
or by telegraph or by any other lawful means of communication not less than ten nor more than sixty days before the meeting, to each
stockholder of record entitled to vote at such meeting. If mailed, such notice shall be directed to each stockholder at such stockholder&rsquo;s
address as it appears on the stock book unless such stockholder shall have filed with the Secretary of the Corporation a written request
that notices intended for him or her be mailed to some other address, in which case it shall be mailed or transmitted to the address
designated in such request. Such further notice shall be given as may be required by law. Except as otherwise expressly provided by statute,
no publication of any notice of meeting of stockholders shall be required to be given any stockholder who shall attend such meeting in
person or by proxy, or who shall, in person or by attorney thereunto authorized, waive notice in writing or by wireless communication
either before or after such meeting. Except where otherwise required by law, notice of any adjourned meeting of the stockholders of the
Corporation shall not be required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
A quorum at all meetings of stockholders shall consist of the holders of record of a majority of the shares of stock of the Corporation,
issued and outstanding, entitled to vote at the meeting, present in person or by proxy, except as otherwise provided by statute or the
Certificate of Incorporation. In the absence of a quorum at any meeting or any adjournment thereof, a majority of those present in person
or by proxy and entitled to vote may adjourn such meeting from time to time. At any such adjourned meeting at which a quorum is present
any business may be transacted which might have been transacted at the meeting as originally called.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
Meetings of the stockholders shall be presided over by a chairperson which shall be the chief executive officer (the &ldquo;<B>CEO</B>&rdquo;).
If the CEO is not present, the meetings of the stockholders shall be presided over by the Chairperson of the Board (the &ldquo;<B>Chairperson</B>&rdquo;),
or the Vice Chairperson (the &ldquo;<B>Vice Chairperson</B>&rdquo;). If neither the CEO the Chairperson, or the Vice Chairperson is present,
the meeting may be presided over by a chairperson to be chosen by a majority of the stockholders entitled to vote who are present in
person or by proxy at the meeting. The Secretary of the Corporation, or in his or her absence, an Assistant Secretary, shall act as secretary
of every meeting, but if neither the Secretary nor an Assistant Secretary is present, the meeting shall choose any person present to
act as secretary of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
Except as otherwise provided in these Bylaws, the Certificate of Incorporation, or in the laws of the State of Delaware, at every meeting
of the stockholders, each stockholder of the Corporation entitled to vote at such meeting shall have one vote in person or by proxy for
each share of stock having voting rights held by him or her and registered in his or her name on the books of the Corporation at the
time of such meeting. Any vote on shares of stock of the Corporation may be given by the stockholder entitled thereto in person or by
proxy appointed by an instrument in writing, subscribed by such stockholder or by his or her attorney thereunto authorized and delivered
to the secretary of the meeting. Except for the election of directors or as otherwise required by statute, by the Certificate of Incorporation
or these Bylaws, all matters coming before any meeting of the stockholders shall be decided by a majority vote of the stockholders of
the Corporation present in person or by proxy at such meetings and entitled to vote on the subject matter, a quorum being present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
A complete list of the stockholders entitled to vote at a meeting of stockholders, arranged in alphabetical order, and showing the address
of each stockholder and the number of shares registered in the name of each stockholder shall be prepared by the Secretary or other officer
of the Corporation having charge of the stock ledger. Such list shall be open to the examination of any stockholder for any purpose germane
to the meeting, for a period of at least ten days ending on the day before the meeting, either on a reasonably accessible electronic
network as permitted by law (provided that the information required to gain access to the list is provided with the notice of the meeting)
or during ordinary business hours at the principal place of business of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
At all elections of directors, or in any other case in which inspectors may act, an inspector, or inspectors, of election shall be appointed
by the Board or the chairperson of the meeting, except as otherwise provided by law. The inspectors of election shall take and subscribe
an oath faithfully to execute the duties of inspectors at such meeting with strict impartiality, and according to the best of their ability
and shall take charge of the polls and after the vote shall have been taken shall make a certificate of the result thereof. If there
be a failure to appoint an inspector or if any inspector appointed be absent or refuse to act, or if his or her office becomes vacant,
the chairperson present at the meeting may choose an inspector of election to fill the vacancy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The property, affairs and business of the Corporation shall be managed by the Board, consisting of not less than three nor more than
nine persons. The exact number of directors within the maximum and minimum limitations specified shall be fixed from time to time by
resolution of the Board. Except as hereinafter provided, directors shall be elected at the annual meeting of the stockholders by plurality
vote of the stockholders of the Corporation present in person or by proxy at such meeting and entitled to vote on the election of directors,
and each director shall be elected to serve for one year and until his or her successor shall be elected and shall qualify. Directors
need not be stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Meetings of the Board shall be held at such place within or outside the State of Delaware as may from time to time be fixed by resolution
of the Board, or as may be specified in the notice of the meeting. Regular meetings of the Board shall be held at such times as may from
time to time be fixed by resolution of the Board, and special meetings may be held at any time upon the call of the Chairperson of the
Board, the President, or a majority of the directors by oral, electronic or written notice duly served on or sent or mailed to each director
not less than one day before such meeting. A meeting of the Board may be held without notice immediately after annual meeting of the
stockholders. Notice need not be given of regular meetings of the Board. Meetings may be held at any time without prior notice if all
the directors are present, or if at any time before or after the meeting those not present waive notice of the meeting in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
A majority of the members of the Board then acting at a meeting duly assembled, shall constitute a quorum for the transaction of business,
but if at any meeting of the Board there shall be less than a quorum present, a majority of those present may adjourn the meeting, without
further notice, from time to time until a quorum shall have been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
In case one or more vacancies shall occur or exist in the Board by reason of death, resignation, increase in the number of directors
or otherwise except in so far as otherwise provided in these Bylaws, the remaining directors, even if less than a quorum, may, by a majority
vote, elect a successor or successors for the unexpired term or terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
At any special meeting of the stockholders, duly called as provided in these Bylaws, any director or directors may by the affirmative
vote of the holders of a majority of all the shares of stock outstanding and entitled to vote for election of directors be removed from
office, either with or without cause, and his or her successor or their successors may be elected at such meeting; or the remaining directors
may, to the extent vacancies are not filled by such election, fill any vacancy or vacancies created by such removal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B><U>Indemnification</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.
<B>Obligation and Power to Indemnify</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Actions, Suits, and Proceedings Other than By or In the Right of the Corporation</U>. Subject to the limitations set forth in <U>Section
6.2</U>, the Corporation will indemnify any Director or Executive Officer, and will indemnify and hold harmless any employee or agent
of the Corporation who is not a Director or Executive Officer, who was or is a party or is threatened to be made a party, including as
a witness, to any Proceeding (other than an action by or in the right of the Corporation) by reason of such person&rsquo;s Corporate
Status from and against all Expenses and Liabilities actually and reasonably incurred or paid by or on behalf of such person in connection
with such Proceeding or any claim, issue or matter therein, if such indemnitee acted in good faith and in a manner the indemnitee reasonably
believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding,
had no reasonable cause to believe the person&rsquo;s conduct was unlawful, to the fullest extent permitted by law as the same exists
or may hereafter be amended; <I>provided, however</I>, that except with respect to Proceedings to enforce rights to indemnification,
the Corporation will indemnify any such indemnitee in connection with a Proceeding (or part thereof) initiated by such indemnitee only
if such Proceeding (or part thereof) was authorized by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Actions, Suits, and Proceedings By or In the Right of the Corporation</U>. Subject to the limitations set forth in <U>Section 6.2</U>,
the Corporation will indemnify any Director or Executive Officer, and will indemnify and hold harmless any employee or agent of the Corporation
who is not a Director or Executive Officer, who was or is a party or is threatened to be made a party to any Proceeding (including as
a witness) by or in the right of the Corporation to procure a judgment in its favor by reason of such person&rsquo;s Corporate Status
from and against all Expenses actually and reasonably incurred or paid by or on behalf of such person in connection with such Proceeding
or any claim, issue or matter therein, if such indemnitee acted in good faith and in a manner the indemnitee reasonably believed to be
in, or not opposed to, the best interests of the Corporation; <I>provided, however</I>, that no indemnification will be made under this
<U>Section 6.1(b) </U>in respect of any claim, issue or matter as to which such person has been finally adjudged by a court of competent
jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery of the State of Delaware or
another court in which such Proceeding was brought determines upon application that, despite adjudication of liability, but in view of
all the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such Expenses that such court
deems proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>No Presumption</U>. The termination of any Proceeding by a judgment, order, settlement, conviction, or upon a plea of nolo contendere
or its equivalent, will not, of itself create a presumption that such person did not act in good faith and in a manner which such person
reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding,
had reasonable cause to believe that such person&rsquo;s conduct was lawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.
<B>Limitation on Indemnification</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Requirement for Determination of Eligibility for Indemnification by Disinterested Directors</U>. Any indemnification to be provided
under <U>Section 6.1</U> will (unless ordered by a court) be made by the Corporation only as authorized in the specific case upon a determination
that indemnification of the indemnitee is proper in the circumstances because such person has met the applicable standard of conduct
set forth in <U>Section 6.1</U>. Such determination will be made (a) by a majority vote of the Disinterested Directors (even though less
than a quorum); (b) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors (even though
less than a quorum); (c) if there are no Disinterested Directors or if the Disinterested Directors so direct, by independent legal counsel
in a written opinion; or (d) by the vote of a majority of the stockholders of the Corporation entitled to vote and voting on the matter.
To the extent, however, that the indemnitee has been successful on the merits or otherwise in defense of any Proceeding described in
<U>Section 6.1</U>, or in defense of any claim, issue or matter therein, such person will (in the case of a Director or Executive Officer)
and will (in the case of an employee or agent of the Corporation who is not a Director or Executive Officer) be indemnified against Expenses
actually and reasonably incurred by such person in connection therewith, without the necessity of authorization in the specific case.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>No Indemnification for Matters Initiated by Indemnitee</U>. Notwithstanding the provisions of <U>Section 6.1</U>, the Corporation
will indemnify any person seeking indemnification in connection with a Proceeding initiated by such person only if such Proceeding (including
any parts of such Proceeding not initiated by such person) was authorized in advance by the Board, unless such Proceeding was brought
to enforce such person&rsquo;s rights to indemnification or advancement of Expenses under these Bylaws in accordance with the provisions
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
The Corporation&rsquo;s obligation, if any, to indemnify or provide advancement of Expenses to any person under this <U>Section 6</U>
as a result of such person&rsquo;s Corporate Status will be reduced by any amount such person may collect as indemnification or advancement
of Expenses from another corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the &ldquo;<B>Primary Indemnitor</B>&rdquo;).
Any indemnification or advancement of Expenses under this <U>Section 6</U> owed by the Corporation as a result of a person serving, at
the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint
venture, trust, employee benefit plan or other enterprise will only be in excess of, and will be secondary to, the indemnification or
advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable insurance policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.
<B>Indemnification by a Court</B>. Notwithstanding any contrary determination in the specific case under <U>Section 6.2</U>, and notwithstanding
the absence of any determination thereunder, any party to a Proceeding by reason of their Corporate Status may apply to any court of
competent jurisdiction in the State of Delaware for indemnification to the extent otherwise permissible under <U>Section 6.1</U>. The
basis of such indemnification by a court will be a determination by such court that indemnification of the person is proper in the circumstances
because such person has met the applicable standards of conduct set forth in <U>Section 6.1</U>. Neither a contrary determination in
the specific case under <U>Section 6.2</U> nor the absence of any determination thereunder will be a defense to such application or create
a presumption that the person seeking indemnification has not met any applicable standard of conduct. The person seeking application
for indemnification pursuant to this <U>Section 6.3</U> must give notice of such filing to the Corporation before or promptly after the
filing of such application. If the person seeking indemnification pursuant to the foregoing is successful, in whole or in part, the Corporation
will also be obligated to pay such person&rsquo;s Expense of prosecuting such application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.
<B>Expenses Payable in Advance</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Advancement
                                            of Expenses to Directors and Executive Officers Prior to Final Disposition</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
The Corporation will advance all Expenses incurred by or on behalf of any Director or Executive Officer in connection with any Proceeding
in which such person is involved by reason of such person&rsquo;s Corporate Status within 30 days after the receipt by the Corporation
of a written statement from such person requesting such advance or advances from time to time, whether prior to or after final disposition
of such Proceeding. Such statement or statements must reasonably evidence the Expenses incurred by such person and be preceded or accompanied
by an undertaking by or on behalf of such person to repay any Expenses so advanced if it is ultimately determined that such person is
not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation will advance all Expenses incurred
by or on behalf of any Director or Executive Officer seeking advancement of expenses hereunder in connection with a Proceeding initiated
by such Director or Executive Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director)
was (A) authorized by the Board, or (B) brought to enforce such Director&rsquo;s or Executive Officer&rsquo;s rights to indemnification
or advancement of Expenses under these Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
If a claim for advancement of Expenses hereunder by a Director or Executive Officer is not paid in full by the Corporation within 30
days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director or Executive Officer may
at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in
part, such Director or Executive Officer will also be entitled to be paid the expenses of prosecuting such claim. The failure of the
Corporation (including its Board or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning
the permissibility of such advancement of Expenses under this <U>Section 6</U> will not be a defense to an action brought by a Director
or Executive Officer for recovery of the unpaid amount of an advancement claim and will not create a presumption that such advancement
is not permissible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
The burden of proving that a Director or Executive Officer is not entitled to an advancement of Expenses will be on the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
In any suit brought by the Corporation to recover an advancement of Expenses pursuant to the terms of an undertaking, the Corporation
will be entitled to recover such Expenses upon a final adjudication that the Director or Executive Officer has not met any applicable
standard for indemnification set forth in the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Advancement
                                            of Expenses to Officers and Non-Officer Employees Prior to Final Disposition</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 67.5pt; text-align: justify; text-indent: -22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
The Corporation may, at the discretion of the Board, advance any or all Expenses incurred by or on behalf of any employee or agent of
the Corporation that is not a Director or Executive Officer in connection with any Proceeding in which such person is involved by reason
of his or her Corporate Status upon the receipt by the Corporation of a statement or statements from such person requesting such advance
or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements must reasonably
evidence the Expenses incurred by such person and be preceded or accompanied by an undertaking by or on behalf of such person to repay
any Expenses so advanced if it is ultimately determined that such person is not entitled to be indemnified against such Expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation
will be entitled to recover such expenses upon a final adjudication that the employee or agent of the Corporation that is not a Director
or Executive Officer has not met any applicable standard for indemnification set forth in the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 135pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.
<B>Contractual Nature of Rights</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
The provisions of this <U>Section 6</U> constitute a contract between the Corporation and each Director and Executive Officer entitled
to the benefits hereof at any time while this <U>Section 6</U> is in effect, in consideration of such person&rsquo;s past or current
and any future performance of services in their Corporate Status. Neither amendment, repeal or modification of any provision of this
<U>Section 6</U>, nor the adoption of any provision of the Certificate of Incorporation inconsistent with this <U>Section 6</U> will
eliminate or reduce any right conferred by this <U>Section 6</U> in respect of any act or omission occurring, or any cause of action
or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption
of an inconsistent provision (even in the case of a Proceeding based on such a state of facts that is commenced after such time), and
all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission will vest at the time
of the act or omission in question, regardless of when or if any Proceeding with respect to such act or omission is commenced. The rights
to indemnification and to advancement of Expenses provided by, or granted pursuant to, this <U>Section 6</U> will continue notwithstanding
that the person has ceased to be a Director or Executive Officer and will inure to the benefit of the estate, heirs, executors, administrators,
legatees and distributes of such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If a claim for indemnification hereunder by a Director or Executive Officer is not paid in full by the Corporation within 60 days after
receipt by the Corporation of a written claim for indemnification, such Director or Executive Officer may at any time thereafter bring
suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Executive
Officer will also be entitled to be paid the Expenses of prosecuting such claim. The failure of the Corporation (including its Board
or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification
under this <U>Section 6</U> will not be a defense to an action brought by a Director or Executive Officer for recovery of the unpaid
amount of an indemnification claim and will not create a presumption that such indemnification is not permissible. The burden of proving
that a Director or Executive Officer is not entitled to indemnification will be on the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In any suit brought by a Director or Executive Officer to enforce a right to indemnification hereunder, it will be a defense that such
Director or Executive Officer has not met any applicable standard for indemnification set forth in the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6.
<B>Non-exclusivity</B>. The indemnification and advancement of expenses permitted by this <U>Section 6</U> are exclusive of any other
rights to which any person may be entitled under any statute, the Corporation&rsquo;s Amended and Restated Certificate of Incorporation
or these Bylaws, any agreement, vote of stockholders or Disinterested Directors or otherwise, both as to action in such person&rsquo;s
official capacity and as to action in another capacity while holding an office, and will continue as to a person who has ceased to be
a Director, Executive Officer, employee or agent of the Corporation and will inure to the benefit of the heirs, executors and administrators
of such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7.
<B>Indemnification Agreements</B>. The Corporation may enter into agreements with any person described in this <U>Section 6</U> for the
purpose of providing for the indemnification set forth in <U>Section 6.1(a)</U> and <U>Section 6.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8.
<B>Insurance</B>. The Corporation has the power to purchase and maintain insurance to protect itself and any person who is or was a Director,
Executive Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer,
employee or agent of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust or other
enterprise against any Expenses or Liabilities asserted against such person and incurred by such person by reason of their Corporate
Status, whether or not the Corporation would have the power to indemnify such person against such Expense or Liability under the provisions
of this <U>Section 6</U> or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9.
<B>Certain Definitions</B>. For purposes of this <U>Section 6</U>, references to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
a person&rsquo;s &ldquo;<B>Corporate Status</B>&rdquo; describes the status of a person who is serving or has served (i) as a Director,
(ii) as an Executive Officer, (iii) as an employee or agent of the Corporation, or (iv) as a director, partner, trustee, officer, employee
or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association,
organization or other legal entity that such person is or was serving at the request of the Corporation. For purposes of this <U>Section
6</U>, a Director, Executive Officer, employee or agent of the Corporation who is serving or has served as a director, partner, trustee,
officer, employee or agent of a Subsidiary will be deemed to be serving at the request of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
the &ldquo;<B>Corporation</B>&rdquo; means the current Corporation and includes any (i) resulting corporation in a merger of the Corporation
and (ii) constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its directors, executive officers, employees or agents, so that
any person who is or was a director, executive officer, employee or agent of such constituent corporation, or is or was serving at the
request of such constituent corporation as a director, executive officer, employee or agent of another corporation, limited liability
company, partnership, joint venture, employee benefit plan, trust or other enterprise, will stand in the same position under the provisions
of this <U>Section 6</U> with respect to the resulting or surviving corporation as such person would have with respect to such constituent
corporation if its separate existence had continued;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
a &ldquo;<B>Director</B>&rdquo; means any person who serves or has served the Corporation as a director on the Board;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
a &ldquo;<B>Disinterested Director</B>&rdquo; means, with respect to each Proceeding in respect of which indemnification is sought hereunder,
a Director of the Corporation who is not a party to such Proceeding;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
an &ldquo;<B>Executive Officer</B>&rdquo; means executive officer, as such term is defined in Rule 405 promulgated under the Securities
Act of 1933, as amended, of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
&ldquo;<B>Expenses</B>&rdquo; means all attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of expert witnesses, private
investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating
costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices,
costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service
fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing
to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
a &ldquo;<B>Proceeding</B>&rdquo; means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution
mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or
investigative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
&ldquo;<B>Liabilities</B>&rdquo; means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
&ldquo;<B>Subsidiary</B>&rdquo; means any corporation, partnership, limited liability company, joint venture, trust or other entity of
which the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i) a general partner,
managing member or other similar interest or (ii) (A) 50% or more of the voting power of the voting capital equity interests of such
corporation, partnership, limited liability company, joint venture or other entity, or (B) 50% or more of the outstanding voting capital
stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10.
<B>Severability</B>. If any word, clause, provision or provisions of this <U>Section 6</U> is held to be invalid, illegal or unenforceable
for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this <U>Section 6 </U>(including
each portion of any section of this <U>Section 6</U> containing any such provision held to be invalid, illegal or unenforceable, that
is not itself held to be invalid, illegal or unenforceable) will not in any way be affected or impaired thereby; and (b) to the fullest
extent possible, the provisions of this <U>Section 6</U> (including each such portion of any section of this <U>Section 6</U> containing
any such provision held to be invalid, illegal or unenforceable) will be construed so as to give effect to the intent manifested by the
provision held invalid, illegal or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
Any action required or permitted to be taken at any meeting of the Board or any committee thereof may be taken without a meeting if prior
to such action a written consent thereto is signed by all members of the Board or of the committee, as the case may be, and such written
consent is filed with the minutes of proceedings of the Board or the committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
Directors may, by resolution of the Board, be allowed a fixed sum and expenses of attendance for attendance at regular or special meetings
of the Board; provided that nothing herein contained shall be construed to preclude any director from serving the corporation in any
other capacity and receiving compensation therefor. Members of special or standing committees, and others who attend pursuant to direction,
may, by vote of the Board, be allowed a like fixed sum and expenses of attendance for attending committee meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
The Board, in its discretion, may appoint an Executive Committee consisting of three or more directors of the corporation, one of whom
shall be the President of the corporation, who shall serve during the pleasure of the Board for the terms fixed by it. Two members of
the Executive Committee shall constitute a quorum for the transaction of business. The Executive Committee shall have and may exercise
the powers of the Board in the management of the business and affairs of the corporation and may authorize the seal of the corporation
to be affixed to all papers. The Executive Committee shall meet at such intervals between regular meetings. The Board, as may from time
to time be fixed by the Board, shall keep regular records of its meetings and report the same to the Board when required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The officers of the Corporation shall be chosen by the Board and shall be a President, one or more Vice Presidents, a Secretary and a
Treasurer. From time to time the Board may also appoint a Chairperson of the Board a CEO, a Vice Chairperson of the Board, a Chief Financial
Officer, Assistant Secretaries, Assistant Treasurers and such other officers, agents and employees as it may deem proper. Any number
of offices, except the offices of President and Secretary, may be held by the same person. The Chairperson of the Board, if such office
exists, and the President shall be chosen from among the directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The term of office of all officers shall be one year or until their respective successors are elected and qualify by the Board, but any
officer may be removed from office, either with or without cause at any time by the affirmative vote of a majority of the members of
the Board then in office. A vacancy in any office arising from any cause may be filled for the unexpired portion of the term by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Unless otherwise ordered by the Board, the President shall have full power and authority on behalf of the Corporation to attend and to
act and to vote at any meetings of security holders of the corporations in which the Corporation may hold securities, and at such meeting
shall possess and may exercise any and all rights and powers incident to the ownership of such securities, and which as the owner thereof
the Corporation might have possessed and exercised, if present. The Board by resolution from time to time may confer like power upon
any other person or persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duties
of Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The President shall be chief executive officer of the Corporation and as such shall have general and active direction of the management
and supervision of the business operations of the Corporation. The President shall have such other duties and powers as may be assigned
from time to time by the Board and shall preside at all meetings of the stockholders and Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
During the absence or disability of the President (or the CEO if one is appointed), an officer designated by the Board, shall exercise
all the functions and duties of the President or the CEO. Each officer shall have such powers and discharge such duties as may be assigned
to him or her from time to time by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The Treasurer shall have the custody of all the funds and securities of the Corporation. When necessary or proper, the Treasurer shall
endorse on behalf of the Corporation, for collection, checks, notes and other obligations and shall deposit the same to the credit of
the Corporation in such bank, or banks, or depositories as may be designated by the Board, or by any officer acting under authority conferred
by the Board. The Treasurer shall enter regularly in books to be kept for the purpose a full and accurate account of all monies received
and paid on account of the Corporation. Whenever required by the Board, the Treasurer shall render an account of all transactions as
Treasurer and of the financial condition of the Corporation. The Treasurer shall at all reasonable times exhibit his or her books and
accounts to any director of the Corporation upon application at the office of the Corporation during business hours and shall perform
all things incident to the position of Treasurer, subject to the control of the Board. The Treasurer shall give bond for the faithful
discharge of his or her duties if the Board so require. The Treasurer shall do and perform such other duties as may be assigned from
time to time by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Assistant Treasurers, in the order of their seniority, shall, in the absence of or disability of the Treasurer, perform the duties
and exercise the powers of the Treasurer and shall perform such other duties as the Board shall prescribe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Secretary shall attend all meetings of the stockholders and all meetings of the Board, and record all votes and the minutes of all
proceedings in a book to be kept for that purpose; and shall perform like duties for other committees when so required. The Secretary
shall give, or cause to be given, notice of all meetings of stockholders and the Board and of committees and shall perform such other
duties as may be prescribed by the Board. The Secretary shall be sworn to the faithful discharge of his or her duties. The Secretary
shall do and perform such other duties as may be assigned from time to time by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
The Assistant Secretaries, in the order of their seniority, shall in the absence of or disability of the Secretary, perform the duties
and exercise the powers of the Secretary and shall perform such other duties as the Board shall prescribe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
In the case of absence or inability to act of any officer of the Corporation and of any person herein authorized to act in his or her
place, the Board may from time-to-time delegate the powers and duties of such officer to any other officer or any director or any other
person whom it may select.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certificates
of Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The interest of each stockholder of the Corporation shall be evidenced by certificates for shares of stock certifying the number of shares
represented thereby and in such form not inconsistent with the Certificate of Incorporation as the Board may from time to time prescribe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required by law, transfers of shares of stock of the Corporation shall be made only on the books of the Corporation by the
registered holder thereof, or by his or her attorney thereunto authorized by power of attorney duly executed and filed with the Secretary
of the Corporation, or with a transfer clerk or a transfer agent appointed as in <U>Section 4</U> of this Article provided, and on surrender
of the certificate or certificates for such shares properly endorsed and the payment of all taxes thereon. The person in whose name.
Shares of stock stand on the books of the Corporation shall be deemed the owner thereof for all purposes as regards the Corporation.
The Board may, from time to time, make such additional rules and regulations as it may deem expedient, not inconsistent with these Bylaws,
concerning the issue, transfer, and registration of certificates for shares of the capital stock of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certificates of stock shall be signed by the President or a Vice President and by the Secretary or an Assistant Secretary or the Treasurer
or an Assistant Treasurer, and sealed with the seal of the Corporation. Such seal may be a facsimile, engraved or printed. Where any
such certificate is signed by a transfer agent other than the Corporation or its employee, or by a registrar other than the Corporation
or its employee, the signatures of the President, Vice President, Secretary, Assistant Secretary, Treasurer or Assistant Treasurer upon
such certificate may be facsimiles, engraved or printed. In case any such officer who has signed or whose facsimile signature has been
placed upon such certificate shall have ceased to be such certificate is issued, it may be issued by the Corporation with the same effect
as if such officer had not ceased to be such at the time of its issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment
thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other
distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock
or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not be more than 60 nor less
than 10 days before the date of such meeting, nor more than 60 days prior to any other action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
no record date is fixed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business
on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding
the day on which the meeting is held.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts
the resolution relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment
of the meeting; provided, however, that the Board may fix a new record date for the adjournment meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
No certificate for shares of stock of the Corporation shall be issued in place of any certificate alleged to have been lost, destroyed
or stolen, except on production of such evidence of such loss, destruction or theft and on delivery to the Corporation, if the Board
shall so require, of a bond of indemnity in such amount (not exceeding twice the value of the shares represented by such certificate),
upon such terms and secured by such surety as the Board may in its discretion require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Board may appoint one or more transfer clerks or one or more transfer agents and one or more registrars, and may require all certificates
for shares of stock to bear the signature or signatures of any of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The books, accounts and records of the Corporation, except as may otherwise be required by statute, may be kept outside of the State
of Delaware, at such place or places as the Board may from time to time appoint. The Board shall determine whether and to what extent
the books, accounts and records of the Corporation, or any of them, other than the stock ledger, shall be open to the inspection of stockholders,
and no stockholder shall have any right to inspect any book, account or record of the Corporation except as conferred by statute or by
resolution of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Seal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate seal of the Corporation shall consist of two concentric circles, between which shall be the name of the Corporation, and its
state of incorporation, and in the center shall be inscribed the words, &ldquo;Corporate Seal.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VIII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws of the Corporation shall be subject to alteration, amendment or repeal, and new Bylaws not inconsistent with any provision of
the Certificates of Incorporation or statute, may be made, either by the affirmative vote of the holders of a majority in interest of
the stockholders of the Corporation present in person or by proxy at any annual or special meeting of the stockholders and entitled to
vote on the subject matter, a quorum being present, provided that notice of such proposed action shall have been given in the call for
the meeting, or by the affirmative vote of a majority of the whole Board, given at any regular or special meeting of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fiscal
Year</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fiscal year of the Corporation shall end on the last day of May in each year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
X</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forum</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Forum for Adjudication of Disputes</B>. Unless the Corporation consents in writing to the selection of an alternative forum, the Court
of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction,
any state or federal court located within the State of Delaware) shall be the sole and exclusive forum for: (a) any derivative action
or proceeding brought on behalf of the Corporation, (b) any action or proceeding asserting a claim of breach of a fiduciary duty owed
by any director, officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (c) any action
or proceeding asserting a claim against the Corporation or any director, officer or other employee of the Corporation arising pursuant
to, or seeking to enforce any right or remedy under, any provision of the DGCL, the Corporation&rsquo;s Certificate of Incorporation
or these Bylaws (in each case, as they may be amended and restated from time to time), (d) any action or proceeding asserting a claim
against the Corporation or any director, officer or other employee of the Corporation governed by the internal affairs doctrine, or (e)
any action or proceeding to interpret, apply, enforce, or determine the validity of any provision or provisions of the Corporation&rsquo;s
Certificate of Incorporation or these Bylaws (in each case, as they may be amended and restated from time to time), in all cases to the
full extent permitted by applicable law and subject to the court&rsquo;s having personal jurisdiction over the indispensable parties
named as defendants. Any person or entity purchasing, otherwise acquiring, or continuing to own any interest in shares of capital stock
of the Corporation shall be deemed to have notice of and to have consented to the provisions of this <U>Section 1</U> of Article X.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Federal Forum Selection</B>. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district
courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act of 1933, as amended. Any person or entity purchasing, otherwise acquiring, or continuing to own
any interest in shares of capital stock of the Corporation shall be deemed to have notice of and to have consented to the provisions
of this <U>Section 2</U> of Article X.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOMERICA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
Delaware Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Allen Barbieri, certify that I am Secretary of Biomerica, Inc., a Delaware corporation (the &ldquo;<B>Corporation</B>&rdquo;), that I
am duly authorized to make and deliver this certification and that the attached Bylaws are a true and complete copy of the Bylaws of
the Corporation in effect as of the date of this certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _____________, 2023</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Barbieri</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of all material characteristics of the capital stock of Biomerica, Inc. as set forth in our First Amended and
Restated Certificate of Incorporation (our &ldquo;<U>Charter</U>&rdquo;), Amended and Restated Bylaws (our &ldquo;<U>Bylaws</U>&rdquo;),
Series A Certificate of Designation, as corrected (the &ldquo;<U>Certificate of Designation</U>&rdquo;), and certain provisions of the
General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;). The summary does not purport to be complete and is
qualified in its entirety by reference to our Charter, Bylaws, and Certificate of Designation, copies of which have been filed as exhibits
to our public filings with the Securities and Exchange Commission, and applicable provisions of the DGCL. References to &ldquo;we,&rdquo;
&ldquo;our,&rdquo; &ldquo;us,&rdquo; or the &ldquo;Company&rdquo; refer to Biomerica, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I>.
We may issue shares of our common stock from time to time. We are authorized to issue 25,000,000 shares of our common stock, par value
$0.08 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I>. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of
the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I>.
Subject to preferences that may be applicable to any shares of preferred stock issued in the future, holders of common stock are entitled
to receive dividends on a pro rata basis out of funds legally available at the times and in the amounts that our board of directors may
determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
to Receive Liquidation Distributions</I>. In the event of a liquidation, dissolution or winding up of our Company holders of our common
stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any then outstanding
preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Preemptive or Similar Rights</I>. Holders of common stock have no preemptive rights and no right to convert their common stock into any
other securities. There are no redemption or sinking fund provisions applicable to the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of our Charter, our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to
5,000,000 shares of preferred stock, par value $0.08 per share, in one or more series, to establish from time to time the number of shares
to be included in each series, and to fix the designation, powers, preferences and rights of the shares of each series and any of its
qualifications, limitations or restrictions, in each case without further action by our stockholders. Our board of directors also can
increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding.
Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the
voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection
with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing
a change in our control or the removal of management and could adversely affect the market price of our common stock and the voting and
other rights of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
A Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I>.
On February 4, 2020, we filed a Certificate of Designations, Preferences and Rights of Series A 5% Convertible Preferred Stock with the
Secretary of State of the State of Delaware, which designated 571,429 of our preferred stock as Series A Preferred Stock (the &ldquo;<U>Series
A Preferred Stock</U>&rdquo;). Those shares of Series A Preferred Stock have since been converted into common stock and are no longer
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I>. Except as otherwise provided by the DGCL, other applicable law or as provided in the Certificate of Designations, the holders
of our Series A Preferred Stock are not entitled to vote on any matter submitted for a vote of holders of our common stock. The consent
of the holders of at least a majority of the outstanding shares of our Series A Preferred Stock will be required to, among other matters,
(i) alter, amend or change adversely any rights, preferences, or privileges of our Series A Preferred Stock, (ii) amend our First Amended
and Restated Certificate of Incorporation or Bylaws in any manner that would impair or reduce the rights of our Series A Preferred Stock,
or (iii) amend, alter, or repeal any provision of the Certificate of Designations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I>.
Shares of our Series A Preferred Stock accrue annual preferred dividends at a rate of $0.175 per share, which are payable when, as and
if declared by our board of directors. The holders of the outstanding shares of our Series A Preferred Stock are also entitled to receive
on each share of our Series A Preferred Stock dividends prior to, or simultaneously with, any dividend declared with respect to our common
stock equal to the greater of (i) the amount of dividends that have accrued on such share of our Series A Preferred Stock and (ii) the
dividend payable with respect to each share of our common stock issuable upon conversion of such share of our Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
to Receive Liquidation Distributions</I>. In the event of a liquidation, dissolution or winding up of the Company, or a Deemed Liquidation
Event (as defined in the Certificate of Designation) the holders of our Series A Preferred Stock are eligible to receive the greater
of (i) an amount equal to $3.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination,
or other similar recapitalization with respect to our Series A Preferred Stock) (the &ldquo;<U>Original Issue Price</U>&rdquo;), plus
an amount equal to accrued and unpaid dividends thereon, or (ii) such amount per share as would have been payable had all shares of our
Series A Preferred Stock been converted into our common stock immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I>.
Shares of our Series A Preferred Stock are convertible at the option of the holder at any time into shares of our common stock at a conversion
rate determined by dividing the Original Issue Price by $3.50 per share (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination, recapitalizations, dividends, distributions and certain issuances of common stock) (the &ldquo;<U>Conversion
Price</U>&rdquo;). This formula initially results in a one-to-one conversion ratio. The Conversion Price is subject to customary weighted
average anti-dilution adjustments in the event of certain dilutive issuances of shares of our common stock or convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may require the conversion of all of the outstanding shares of our Series A Preferred Stock if the closing sale price of our common stock
equals or exceeds $9.00 for a period of five (5) consecutive trading days with a minimum average trading volume of 35,000 shares per
day over such period; provided, that, on such date, the shares of our common stock issuable upon conversion of our Series A Preferred
Stock are registered for resale under the Securities Act or are otherwise eligible for resale pursuant to Rule 144 thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, prior to the receipt of all approvals, if any, of the shareholders of the Company necessary for purposes of the rules
and regulations of the applicable trading market, our Series A Preferred Shares shall not be converted into shares of common stock: (i)
in the aggregate into more than 19.99% of the shares of common stock outstanding immediately prior to the issuance date, subject to appropriate
adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization, or (ii) by any beneficial holder
(as such term is defined under Rule 13d-3 of the Exchange Act) or &ldquo;group&rdquo; (as such term is defined under Rule 13d-5 of the
Exchange Act) (such beneficial holder or group, a &ldquo;<U>Capped Holder</U>&rdquo;), if (A) the aggregate number of shares of common
stock issued to such Capped Holder upon such conversion and any conversion shares then held by the Capped Holders, plus (B) the number
of shares of common stock underlying our Series A Preferred Shares that would be held at such time by the Capped Holders (after giving
effect to such conversion), plus (C) the aggregate number of shares of common stock held by such Capped Holder as of immediately prior
to the issuance date, would in the aggregate exceed more than 19.99% of the shares of common stock outstanding immediately prior to the
issuance date (without regard to any limitation on conversion pursuant to this Section 5(n)), then such Capped Holder shall be entitled
to convert such number of our Series A Preferred Shares as would result in the sum of clauses (A), (B) and (C) (after giving effect to
such conversion) being equal to 19.99% of the shares of common stock outstanding immediately prior to the issuance date, in each case,
subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization. Any Series
A Preferred Shares which a holder has elected to convert but which, by reason of the previous sentence are not so converted, shall be
treated as if the holder had not made such election to convert and such Series A Preferred Shares shall remain outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Law and Certain Charter and Bylaw Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of DGCL, as well as certain terms of our Charter and Bylaws, may have the effect of delaying, deferring or discouraging another
person from acquiring control of us by means of a tender offer, a proxy contest or otherwise, or removing incumbent officers and directors.
These provisions, some of which are summarized below, are expected to discourage certain types of coercive takeover practices and takeover
bids that our board of directors may consider inadequate and to encourage any person seeking to acquire control of us to first negotiate
with our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delaware
Law</I>. We are governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a public Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after
the date such stockholder became an &ldquo;interested stockholder&rdquo;. A &ldquo;business combination&rdquo; includes mergers, asset
sales or other transactions resulting in a financial benefit to the stockholder. An &ldquo;interested stockholder&rdquo; is a person
who, together with affiliates and associates, owns, or within three years did, prior to the determination of interested stockholder status,
own, 15% or more of the corporation&rsquo;s outstanding voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Charter
and Bylaw Provisions. </I>Each of our Charter and Bylaws include a number of other provisions that may have the effect of deterring hostile
takeovers or delaying or preventing changes in control or our management, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuance
                                            of Undesignated Preferred Stock</I>. Our board of directors has the authority, to issue up
                                            to 5,000,000 shares of our preferred stock with rights and preferences designated from time
                                            to time by our board of directors, 571,429 of which have been designated as Series A Preferred
                                            Stock, and none of which are outstanding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
                                            Cumulative Voting</I>. The DGCL provides that stockholders are denied the right to cumulate
                                            votes in the election of directors unless our Charter provides otherwise. Our Charter does
                                            not provide for cumulative voting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Size
                                            of Board and Vacancies</I>. Our Charter and Bylaws provide that the number of directors on
                                            our board of directors shall consist of not less than three nor more than nine members as
                                            fixed from time to time by resolution of our board of directors. Newly created directorships
                                            resulting from any increase in our authorized number of directors, and any vacancies resulting
                                            from death, resignation, retirement, disqualification, removal from office or other cause,
                                            will generally be filled by a majority of the remaining members of our board of directors
                                            then in office.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>ex10-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.5</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOMERICA,
INC.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-STATUTORY
STOCK OPTION AGREEMENT FOR MEMBERS OF THE BOARD OF DIRECTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Optionee:
</B>[[FIRSTNAME]] [[LASTNAME]]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.
of shares: </B>[[SHARESGRANTED]]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue
Date: </B>[[<FONT STYLE="color: #2B2105">GRANTDATE]]</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
Date: </B>[[<FONT STYLE="color: #2B2105">GRANTEXPIRATIONDATE]]</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
Price: </B>[[MARKETPRICEATAWARD]] per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vesting
Schedule: 12 Months from Issue Date</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[[ALLVESTSEGS]]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Stock Option Agreement (the &ldquo;Agreement&rdquo;) is made and entered into effective as of the date set forth on the Signature Page
attached hereto by and between Biomerica, Inc., a Delaware corporation (the &ldquo;Corporation&rdquo;), and that person identified on
the Signature Page below and attached hereto (the &ldquo;Optionee&rdquo;). This option is not intended to qualify and will not be treated
as an &ldquo;incentive stock option&rdquo; with the meaning of Section 422 of the Internal Revenue Code (the &ldquo;Code.&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant hereunder is in connection with and in furtherance of the Corporation&rsquo;s compensatory benefit plan for participation of the
Corporation&rsquo;s employees. This Agreement and the stock option granted hereunder are subject to the terms and conditions found in
the Biomerica, Inc. 2022 Stock Incentive Plan (the &ldquo;Plan&rdquo;), and the &ldquo;Compensation Policy for Executive Officers and
Directors&rdquo; adopted by the Board of Directors (the &ldquo;Board&rdquo;) on December20, 2018. All defined terms not explicitly defined
in this Agreement but defined in the Plan shall have the same definitions as in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Grant
of Option</U>. Subject to the vesting provisions of Section 3 and/or as set forth on the Signature Page attached hereto, the Corporation
hereby grants to Optionee, as of the date hereof the right and option to purchase, on the terms and conditions hereinafter set forth,
all or any part of the aggregate number of shares of Common Stock set forth on the Signature Page attached hereto (the &ldquo;Option&rdquo;),
subject to adjustment in accordance with the provisions of The Plan and Section 18 below. It is understood and acknowledged that the
Option is designated as a Nonstatutory Stock Option which will not qualify as an Incentive Stock Option under Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Exercise
Price</U>. The price to be paid for the shares of Common Stock to be issued upon exercise of the Option or any part thereof shall be
as set forth on the Signature Page below (the &ldquo;Exercise Price.&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <U>Right
to Exercise</U>. The option shall vest 100% on the twelve-month anniversary of the Issue Date. Subject to the provisions of the 2022
Stock Incentive Plan, and the terms of this Agreement, all vested options shall be exercisable in full or in part at any time until <B>[[</B><FONT STYLE="color: #2B2105">GRANTEXPIRATIONDATE]]</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <U>Securities
Law Requirements</U>. <B>No part of the Option shall be exercised if counsel to the Corporation determines that any applicable registration
requirement under the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;), or any other applicable requirement of Federal
or state law has not been met.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <U>Term
of Option</U>. The Option shall terminate in any event on the earliest of (a) the Expiration Date set forth on the Signature Page, (b)
the expiration of the period described in Section 6 below, or (c) the expiration of the period described in Section 7 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Exercise
Following Termination, Except by Death, Disability or Retirement</U>. If the Optionee&rsquo;s service as a member of the Board is terminated
either; a) for reasons other than by death or for Cause, or b) by the Member&rsquo;s resignation, or c) by vote of the shareholders at
an annual meeting, then all issued, outstanding and vested options shall remain owned by the Member and shall remain exercisable until
the Expiration Date listed herein. For this purpose, &ldquo;Cause&rdquo; shall mean conviction of a felony, misappropriation of assets
of the Corporation or any subsidiary, gross negligence in carrying out the duties of a Member and acts of malfeasance toward the Company.
If Optionee is removed from the Board of Directors for Cause, either by resignation or otherwise, all outstanding, unexercised options
shall become void and un-exercisable, and all of Optionee&rsquo;s rights under this Agreement shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <U>Exercise
Following Death</U>. If the Optionee&rsquo;s service with the Corporation terminates by reason of the Optionee&rsquo;s death, or if the
Optionee dies after termination of service but while the Option would have been exercisable hereunder, the vested portion of the Option
(to the extent it has not previously been exercised and is then exercisable) may be exercised within twelve (12) months after the date
of Optionee&rsquo;s death (but not later than the Expiration Date set forth on the signature page below). The exercise may be made by
the by the Optionee&rsquo;s representative or by the person entitled thereto under Optionee&rsquo;s will or the laws of descent and distribution;
provided that such representative or such person consents in writing to abide by and be subject to the terms of this Agreement and the
2022 Stock Incentive Plan and such writing is delivered to the CEO of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <U>Nontransferability</U>.
Unless the Corporation otherwise consents in writing, the Option and all rights and privileges granted hereunder shall be non-assignable
and non-transferable by the Optionee, either voluntarily or by operation of law, except by will, by operation of the laws of descent
and distribution, by instrument to an inter vivos or testamentary trust in which the Option is to be passed to beneficiaries upon the
death of the trustor, or by gift to the Optionee&rsquo;s immediate family, shall not be pledged or hypothecated in any way, and shall
be exercisable during lifetime only by the Optionee. Except as otherwise provided herein, any attempted alienation, assignment, pledge,
hypothecation, attachment, execution or similar process, whether voluntary or involuntary, with respect to all or any part of the Option
or any right thereunder, shall be null and void and, at the Corporation&rsquo;s option, shall cause all of Optionee&rsquo;s rights under
this Agreement to terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <U>Effect
of Exercise</U>. Upon exercise of all or any part of the Option, the number of shares of Common Stock subject to option under this Agreement
shall be reduced by the number of shares with respect to which such exercise is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <U>Partial
Exercise</U>. Any exercisable portion of the Option or the entire Option, if then wholly vested and exercisable, may be exercised in
whole or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section 5; provided, however,
that each partial exercise shall be for not less than one hundred (100) shares and shall be for whole shares only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <U>Method
of Exercise</U>. Each exercise of the Option shall be by means of a written notice delivered to the Secretary or the Chief Financial
Officer (CFO) of the Corporation at its principal office and accompanied by payment in full of the Exercise Price for each share of Common
Stock purchased under the Option. Such notice shall specify the number of shares of Common Stock with respect to which the Option is
exercised and shall be signed by the person exercising the Option. If the Option is exercised by a person other than the Optionee, such
notice shall be accompanied by proof, reasonably satisfactory to the Corporation, of such person&rsquo;s right to exercise the Option.
The Secretary or the CFO may instruct Optionee on other requirements for exercising such option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exercise Price specified in Section 2 above shall be paid in full upon the exercise of the Option (i) by cash, in United States dollars.
The Board of Directors may, but is not obligated to, accept a secured recourse promissory note of Optionee (bearing such rate of interest
and such other terms as they may reasonably determine) as payment of the Exercise Price; <U>provided</U>, <U>however</U>, no stock certificate
representing the shares be released until the note shall have been paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <U>Withholding
Taxes</U>. If the Optionee is an employee or former employee of the Corporation when all or part of the Option is exercised, the Corporation
may require the Optionee to deliver payment of any withholding taxes (in addition to the Exercise Price) in cash with respect to the
difference between the Exercise Price and the Fair Market Value of the Common Stock acquired upon exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <U>Issuance
of Shares</U>. Subject to the foregoing conditions, the Corporation, as soon as reasonably practicable after receipt of a proper notice
of exercise and without transfer or issue tax or other incidental expense to the person exercising the Option, shall deliver to such
person at the principal office of the Corporation, or such other location as may be acceptable to the Corporation and such person, one
or more certificates for the shares of Common Stock with respect to which the Option has been exercised. Such shares shall be fully paid
and nonassessable and shall be issued in the name of such person. However, at the request of the Optionee, such shares may be issued
in the names of the Optionee and his or her spouse (a) as joint tenants with right of survivorship, (b) as community property or (c)
as tenants in common without right of survivorship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. <U>Limitation
of Optionee&rsquo;s Rights</U>. Neither Optionee nor any person entitled to exercise the Option shall be or have any of the rights of
a shareholder of the Corporation in respect of any share issuable upon the exercise of the Option unless and until a certificate or certificates
representing shares of Common Stock shall have been issued and delivered upon exercise of the Option in full or in part. No adjustment
shall be made for dividends or other rights for which the record date is prior to the date such stock certificates are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Consent Required to Transfer</U>. In connection with any underwritten public offering by the Corporation of its equity securities
pursuant to an effective registration statement filed under the 1933 Act, Optionee shall not sell, make any short sale of, loan, hypothecate,
pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing
transactions with respect to, any shares of Common Stock purchased under the Option without the prior written consent of the Corporation
or its underwriters. Such limitations shall be in effect for such period of time from and after the effective date of such registration
statement as may be requested by the Corporation or such underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. <U>Recapitalizations</U>.
Subject to the provision of the Plan, if the outstanding shares of the class then subject to this Option are adjusted for any increase
or decrease in the number of issued shares of Common Stock resulting from a subdivision or consolidation of Common Stock or the payment
of a stock dividend (but only of Common Stock) or any other increase or decrease in the number of issued shares of Common Stock effected
without receipt of consideration by the Corporation for the issuance of such shares, appropriate adjustments shall be made in the number
and /or kind of shares or securities for which the unexercised portions of this Option may thereafter be exercised, all without any change
in the aggregated Exercise Price applicable to the unexercised portions of this Option, but with a corresponding adjustment in the Exercise
Price per share and/or an adjustment in the number of shares available under this Option agreement. Subject to the provisions of the
Plan, if the Corporation is the surviving corporation in any merger or consolidation, this Option shall pertain and apply to the securities
to which a holder of the number of Common Stock subject to the Option would have been entitled. In the event of a merger or consolidation
in which the Corporation is not the surviving corporation, the date of exercisability of this Option shall be accelerated to a date prior
to such merger or consolidation, unless, in order to qualify for &ldquo;pooling-of-interest&rdquo; treatment, the agreement of merger
or consolidation provides for the assumption of the Option by the successor to the Corporation. To the extent that the foregoing adjustments
relate to securities of the Corporation, such adjustments shall be made by the Board, whose determination shall be conclusive and binding
on all persons. Except as expressly provided in this Section 16, the Optionee shall have no rights by reason of subdivision or consolidation
of shares of Common Stock of any class, the payment of any Common Stock dividend or any other increase or decrease in the number of shares
of Common Stock of any class or by reason of any dissolution, liquidation, merger or consolidation or spin-off of assets or common stock
of another corporation, and any issue by the Corporation of shares of Common Stock of any class, or securities convertible into shares
of Common Stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the Exercise Price
or the number or Common Stock subject to this Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17. <U>Restricted
Stock Provisions</U>. In addition to certain Federal and state securities laws restrictions, the shares of Common Stock issued on exercise
of this Option shall upon issuance be subject to the following restrictions (and, as used herein, &ldquo;restricted stock&rdquo; means
shares issued on exercise of this Option which are still subject to the restrictions imposed under this Section that have not yet expired
or terminated):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Such shares of restricted stock may not be sold or otherwise transferred or hypothecated;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The restrictions imposed under Section 17 shall apply as well to all shares or other securities issued in respect of restricted stock
in connection with any stock split, reverse stock split, stock dividend, recapitalization, reclassification, spin-off, split-off merger,
consolidation or reorganization, but such restrictions imposed under Section 17 shall expire or terminate on the earliest to occur of
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The ninetieth (90th) day after the date on which shares of the same class of Common Stock as such restricted stock first become registered
pursuant to the Exchange Act (which term for this purpose has the same meaning as set forth in the Plan);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The fifth (5th) anniversary of the date of grant hereof; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The occurrence of any event or transaction upon which this Option terminated by reason of the provisions of Section 19 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Unless the shares to be acquired by the Optionee have been registered under the 1933 Act and any other applicable securities laws
of any state</B>, all certificates representing shares of Common Stock purchased upon the exercise of the Option shall bear the following
legends:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;THE
SALE OF THE SECURITIES REPRESENTED HEREBY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &ldquo;ACT&rdquo;). ANY TRANSFER
OF SUCH SECURITIES WILL BE INVALID UNLESS A REGISTRATION STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH TRANSFER OR IN THE OPINION OF
COUNSEL FOR THE ISSUER SUCH REGISTRATION IS UNNECESSARY IN ORDER FOR SUCH TRANSFER TO COMPLY WITH THE ACT.&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18. <U>Stock
Incentive Plan</U>. This Agreement is subject to, and the Corporation and the Optionee agree to be bound by, all of the terms and conditions
of the Plan under which this Option was granted, as the same shall have been amended from time to time in accordance with the terms thereof,
provided that no such amendment shall deprive the Optionee, without his or her consent, of this Option or any of his or her rights hereunder.
Pursuant to said Plan, the Board of Directors of the Corporation or its Committee established for such purposes is vested with final
authority to interpret and construe the Plan and this Option, and is authorized to adopt rules and regulations for carrying out the Plan.
A copy of the Plan in its present form is available for inspection during business hours by the Optionee or other persons entitled to
exercise this Option at the Corporation&rsquo;s principal office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19. <U>Notices</U>.
Any notice to the Corporation contemplated by this Agreement shall be addressed to it in care of its CEO; any notice to the Optionee
shall be addressed to him or her at the address on file with the Corporation on the date hereof or at such other address as Optionee
may hereafter designate in a writing delivered to the Corporation as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20. <U>Interpretation</U>.
The interpretation, construction, performance and enforcement of this Agreement shall lie within the sole discretion of the Board, and
the Board&rsquo;s determinations shall be conclusive and binding on all interested persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21. <U>Governing
Law</U>. This Agreement has been made, executed and delivered in, and the interpretation, performance and enforcement hereof shall be
governed by and construed under the laws of the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22. <U>Information
to Optionee</U>. The Corporation hereby agrees to provide the Optionee with the Corporation&rsquo;s audited annual financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-STATUTORY
STOCK OPTION AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURSUANT
TO BIOMERICA, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022
STOCK INCENTIVE PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Grant: [[<FONT STYLE="color: #2B2105">GRANTDATE]]</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
Price: [[MARKETPRICEATAWARD]] per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
Vesting:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[[ALLVESTSEGS]]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
number of shares: [[SHARESGRANTED]] shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
Date: [[<FONT STYLE="color: #2B2105">GRANTEXPIRATIONDATE]]</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this Non-Statutory Stock Option Agreement, which was adopted for use in connection with the 2022 Stock Incentive Plan.
I have also received and reviewed a copy of the 2022 Stock Incentive Plan. As Optionee, I hereby acknowledge that as of the date of grant
of this Option, it sets forth the entire understanding between the undersigned Optionee and the Corporation and its Affiliates regarding
the acquisition of stock in the Corporation and supersedes all prior oral and written agreements on that subject with the exception of
any other option awards previously granted and delivered in writing to the undersigned Optionee under the stock incentive plans of the
Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, this Non-Statutory Stock Option Agreement has been delivered, adopted and accepted in full by the Parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    [[SIGNATURE_DATE]]</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[[SIGNATURE]]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[[FIRSTNAME]]
    [[LASTNAME]]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation hereby agrees to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
the terms of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
Irani</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>ex10-6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>17571
    VON KARMAN AVE.,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IRVINE,
    CALIFORNIA 92614</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PH
    949-645-2111 FAX 949-553-1231</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>www.biomerica.com</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
31, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
Lu, CPA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12136
Ahern Ct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tustin,
CA 92782</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
&nbsp;&nbsp;&nbsp;<U>Employment Offer</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Gary:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pleased to extend to you an offer to join Biomerica, Inc. (the &ldquo;Company&rdquo;). The purpose of this letter is to set forth
in writing the terms and conditions of your new employment relationship with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment will commence as of March 1, 2023 (or mutually decided day within that week)<B>. </B>Your job title will be Chief Financial
Officer (CFO). Your duties will be such assignments as may be assigned to you by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
base full-time salary will be two hundred and sixty thousand ($260,000) per year (the &ldquo;Base Salary&rdquo;) and will be payable
at such intervals as is normal for the payment of compensation to the Company&rsquo;s employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Base Salary, the Company shall grant to you an initial stock option to purchase 75,000 shares of the Company&rsquo;s
common stock at an exercise price equal to the fair market value of the Company&rsquo;s common stock on the date of grant. The Option
grant date will be determined by the Board of Directors as soon as practicable after your hire date. The option shall vest over a period
of four (4) years, with 25% vesting on the first anniversary of the date of grant and each subsequent year thereafter for the next three
(3) years. The option shall have a term of ten (10) years. Other terms and conditions of the stock option grant will be set forth in
the option issuance agreement you will be issued, and language in the Biomerica stock option plan, which you will receive a copy of.
You will be issued additional options or equity grants annually along with other executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
performance and compensation will be reviewed from time to time, and your compensation may be increased by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will also be entitled to the standard employment benefit package that is available to all Company employees which package is subject
to change from time to time, but which initially will include group health, dental, long-term disability and life insurance for you as
per Company policy. Dependent coverage is also available for medical and dental insurance; however, it will be at fifty percent of the
cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will have time off with pay on the major holidays which are recognized by the Company, plus an additional 20 days of paid time off based
on full employment and according to company policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be entitled to such other employment benefits as the Company generally makes available to its employees and all benefits will be
subject to change from time to time and will be provided in accordance with the Company&rsquo;s employment policies, to which you will
be subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>17571 VON KARMAN AVE.,</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>IRVINE, CALIFORNIA 92614</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>PH 949-645-2111 FAX 949-553-1231</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>www.biomerica.com</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
agree to review in detail the Employee Handbook, the Company Insider Trading Policy, and all other employee policies, rules and regulations,
and be bound entirely by such.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
also agree to execute and be bound by the terms of the Inventions Assignment and Non-Disclosure Agreement attached hereto as Exhibit
A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
acceptance of this offer, either party may terminate the employment relationship, with or without cause, by giving the other party written
notice of intention to do so (&ldquo;At Will&rdquo; employment). No other provision of this offer is intended to imply that employment
will continue for any definite term or period. Upon the termination of your employment you shall be entitled to payment of all accrued
compensation to the date of such termination plus any unreimbursed expenses accruing to the date of such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is made and entered into in the State of California, and shall in all respects be interpreted, enforced and governed by and
under the laws of the State of California. All disputes arising under this agreement or relating to the Company&rsquo;s employment of
you shall be governed by the laws of the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter, together with the Employee Handbook, any Arbitration Agreement, and the Non-Disclosure Agreement, is intended to set forth our
entire agreement regarding your employment relationship with the Company, thus it supersedes any other agreement on this subject, including
any inconsistent provisions contained in any employee manual or policy of the Company. This agreement will not be modifiable except by
a mutual written agreement between you and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and return this letter to me to indicate your acceptance and agreement to the terms set forth in this letter. You may keep a copy
for your own records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zack
    Irani</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTANCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have read the foregoing letter and agree with the terms and conditions of my employment as set forth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%">Gary Lu</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>17571
    VON KARMAN AVE.,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IRVINE,
    CALIFORNIA 92614</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PH
    949-645-2111 FAX 949-553-1231</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>www.biomerica.com</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIOMERICA,
INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>NONDISCLOSURE,
INVENTIONS ASSIGNMENT AND NON-COMPETE AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned employee (the &ldquo;EMPLOYEE&rdquo;) of BIOMERICA, INC. and/or its subsidiaries (herein collectively called the &ldquo;Company&rdquo;),
having been engaged to perform services for the benefit of the Company, and in consideration of said employment, does hereby agree to
perform such duties for the Company as shall be designated by the Company from time to time, and the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
EMPLOYEE will not, while serving as an EMPLOYEE of the Company, or thereafter, divulge, disclose or communicate to, anyone without the
express written authorization of the Company, any trade secrets or any other information and data of a private, internal or confidential
nature, relating or pertaining to the Company&rsquo;s business, methods of manufacture, processes, customer list, distributors, formulas, operations
or other information that the EMPLOYEE may have acquired, directly or indirectly, during the course of his employment by the Company.
The EMPLOYEE acknowledges that the Company in its operation maintains in secrecy certain of its methods, processes, marketing and strategic
plans, customer and distributor data and technical information (herein called the &ldquo;Confidential Information&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is mutually understood and agreed that all documents furnished by and generated by the EMPLOYEE or the Company during the course of EMPLOYEE&rsquo;s
employment with the Company shall be the property of the Company and its subsidiaries and shall be returned promptly, with all copies
made thereof, if formally requested by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of the EMPLOYEE set forth above shall not apply to any portion of information and matters disclosed or exhibited to the EMPLOYEE
which has become generally available to the public through no act or failure to act on the part of the EMPLOYEE. The EMPLOYEE hereby
acknowledges that all Confidential Information which is disclosed to EMPLOYEE by the Company hereunder, and all tangible forms thereof,
are the property of the Company and EMPLOYEE shall obtain no right, title or interest in any secret or Confidential Information or any
tangible forms thereof. EMPLOYEE shall hereafter (a) exercise all reasonable efforts to prevent unauthorized persons from gaining access
to Confidential Information; (b) promptly mark any Confidential Information placed by it in documentary or other tangible form with the
legend &ldquo;Secret&rdquo;; (c) not assert prior knowledge of any item of Confidential Information which the EMPLOYEE cannot so prove
by clear and convincing documentary evidence; (d) promptly deliver or destroy, as the Company may direct in writing, all tangible forms
of Confidential Information, whether or not such tangible forms were prepared by the EMPLOYEE or the Company and whether or not such
tangible forms contain or embody information other than Confidential information; and (e) not represent that he or she, or permit any
representative or agent of the EMPLOYEE to represent that he, she or it, has a claim or interest in such &lsquo;Secret&rsquo; or &lsquo;Confidential
Information&rsquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 107.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
U.S. Defend Trade Secrets Act. Notwithstanding the foregoing, the U.S. Defend Trade Secrets Act of 2016 (&ldquo;DTSA&rdquo;)
provides that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the
disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or
indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (iii)
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, DTSA
provides that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may
disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the
individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except
pursuant to court order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>17571
    VON KARMAN AVE.,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IRVINE,
    CALIFORNIA 92614</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PH
    949-645-2111 FAX 949-553-1231</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>www.biomerica.com</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
Other Permitted Disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
(a) Nothing in this Agreement prohibits or restricts the Employee (or Employee&rsquo;s attorney) from initiating communications directly with,
responding to an inquiry from, or providing testimony before the Securities and Exchange Commission (SEC), the Financial Industry Regulatory
Authority (FINRA), any other self-regulatory organization, or any other federal or state regulatory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
(b) Nothing in this agreement prevents you from discussing or disclosing information about unlawful acts in the workplace, such as harassment
or discrimination or any other conduct that you have reason to believe is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
(c) Nothing in this Agreement in any way prohibits or is intended to restrict or impede the Employee from discussing the terms and conditions
of his or her employment with coworkers or union representatives/exercising protected rights under Section 7 of the National Labor Relations
Act/exercising protected rights to the extent that such rights cannot be waived by agreement disclosing information as permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The EMPLOYEE further hereby transfers and assigns to the Company, its successors and assignees, or to any person or entity designated
by it, the EMPLOYEE&rsquo;s entire right, title and interest in and to all inventions, discoveries, ideas, disclosures, improvements and suggestions,
patentable or not (herein collectively called &ldquo;Inventions&rdquo;), and copyrightable material, made or conceived by Employee, solely
or jointly, during the course of his or her employment with the Company (herein the &ldquo;Invention Period&rdquo;) which relate to methods,
formulas, designs, products, components or devices, sold, leased, used or under consideration or development by the Company, or which
otherwise relate or pertain to the business, e-commerce strategy, functions, or operations of the Company, including,, but not limited
to, the manufacture, design or development of systems, methods, components, and/or products. All such Inventions and copyrightable material
disclosed or developed within one year after the termination of employment shall be presumed to have been made or conceived during the
Invention Period. PROVIDED, HOWEVER, THAT THIS AGREEMENT DOES NOT APPLY TO ANY INVENTION WHICH QUALIFIES FULLY UNDER THE PROVISIONS OF
SECTION 2870 OF THE CALIFORNIA LABOR CODE, THE PROVISIONS OF WHICH ARE ATTACHED HERETO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
With respect to the inventions, ideas, disclosures, improvements and suggestions referred to in paragraph 2, Employee further agrees
to communicate promptly and disclose to the Company, in such form as Employee may be called upon to do so, all information, details and
data pertaining thereto, and to execute and deliver such formal transfers and assignments, and such other papers and documents as may
be required of the EMPLOYEE to enable the Company, or any person or entity designated by the Company, to file and prosecute patent applications,
and as to copyrightable material to effect copyright thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMPLOYEE attaches hereto a complete list of all inventions, patented or unpatented, made or conceived by Employee prior to his or her
employment by the Company. Such inventions, if any, and improvements, extensions or modifications thereof shall be deemed excluded from
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
attached list, if any, shall be entitled &ldquo;Exclusions to Attached Agreement,&rdquo; shall be signed by the Employee, and shall bear
an &ldquo;Exclusions Noted&rdquo; line at the bottom to be signed by the Company.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>17571
    VON KARMAN AVE.,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IRVINE,
    CALIFORNIA 92614</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PH
    949-645-2111 FAX 949-553-1231</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>www.biomerica.com</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
RESTRICTIVE COVENANTS<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
Executive acknowledges that (i) he has a major responsibility for the operation, administration, development and growth of the Company&rsquo;s
business, (ii) his work for the Company has brought him and will continue to bring him into close contact with confidential information
of the Company and its customers, and (iii) the agreements and covenants contained in this Section 4 are essential to protect the business
interest of the Company and that the Company will not enter into this Agreement but for such agreements and covenants. Accordingly, the
EMPLOYEE covenants and agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1(a)
Except as otherwise provided for in this Agreement, during the Term of employment with the Company or any of its subsidiaries, the EMPLOYEE
shall not, directly or indirectly, compete with respect to any services or products of the Company which are either offered or are being
developed by the Company; or, without limiting the generality of the foregoing, be or become, or agree to be or become, interested in
or associated with, in any capacity (whether as a partner, shareholder, owner, officer, director, Executive, principal, agent, creditor,
trustee, consultant, co-venturer or otherwise) with any individual, corporation, firm, association, partnership, joint venture or other
business entity, which competes with respect to any services or products of the Company which are either offered or are being developed
by the Company; provided, however, that the EMPLOYEE may own, solely as an investment, not more than one percent (1%) of any class of
securities of any publicly held corporation in competition with the Company whose securities are traded on any national securities exchange
in the United States of America, and may retain his ownership interest in those entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1(b)
During the term of Employment, the EMPLOYEE shall not, directly or indirectly, (i) induce or attempt to influence any other employee
of the Company to leave its employ, (ii) aid or agree to aid any competitor, customer or supplier of the Company in any attempt to hire
any person who shall have been employed by the Company within the one (1) year period preceding such requested aid, or (iii) induce or
attempt to influence any person or business entity who was a customer or supplier of the Company during any portion of said period to
transact business with a competitor of the Company in Company&rsquo;s business. Employee agrees and covenants to not utilize any Confidential
Information to (i) induce or attempt to influence any other employee of the Company to leave its employ, (ii) aid or agree to aid any
competitor, customer or supplier of the Company in any attempt to hire any person who is or was employed by the Company, or (iii) induce
or attempt to influence any person or business entity who was a customer or supplier of the Company during any portion of said period
to transact business with a competitor of the Company in Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1(c)
During the Term of Employment, and for ten (10) years thereafter, the EMPLOYEE shall not other than in the performance of his duties
disclose to anyone any Confidential Information, including, without limitation, trade secrets, trade &ldquo;know-how&rdquo;, inventions,
customer lists, business plans, operational methods, pricing policies, marketing plans, sales plans, identity of suppliers or customers,
sales, profits or other financial information, which is confidential to the Company or is not generally known in the relevant trade,
nor shall the EMPLOYEE make use of any such information for his own benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>17571
    VON KARMAN AVE.,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IRVINE,
    CALIFORNIA 92614</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PH
    949-645-2111 FAX 949-553-1231</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>www.biomerica.com</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
If the EMPLOYEE breaches, or threatens to commit a breach of Section 4.1 (the &ldquo;Restrictive Covenants&rdquo;), the Company shall have
the following rights and remedies, each of which shall be enforceable, and each of which is in addition to, and not in lieu of, any other
rights and remedies available to the Company at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2(a)
The EMPLOYEE shall account for and pay over to the Company all compensation, profits, and other benefits, after taxes, which inure to
EMPLOYEE&rsquo;s benefit which are derived or received by the EMPLOYEE or any person or business entity controlled by the EMPLOYEE resulting
from any action or transactions constituting a breach of any of the Restrictive Covenants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2(b)
Notwithstanding the provisions of subsection 4.2(a) above, the EMPLOYEE acknowledges and agrees that in the event of a violation or threatened
violation of any of the provisions of this Agreement, the Company shall have no adequate remedy at law and shall therefore be entitled
to enforce each such provision by temporary or permanent injunctive or mandatory relief obtained in any court of competent jurisdiction
without the necessity of proving damages, posting any bond or other security, and without prejudice to any other rights and remedies
which may be available at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
If any of the Restrictive Covenants, or any part thereof, is held to be invalid or unenforceable, the same shall not affect the remainder
of the covenant or covenants, which shall be given full effect, without regard to the invalid or unenforceable portions. Without limiting
the generality of the foregoing, if any of the Restrictive Covenants, or any part thereof, is held to be unenforceable because of the
duration of such provision or the area covered thereby, the parties hereto agree that the court making such termination shall have the
power to reduce the duration and/or area of such provision and, in its reduced form, such provision shall then be enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
The parties hereto intend to and hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction
within the geographical scope of such Restrictive Covenants. In the event that the courts of any one or more of such jurisdictions shall
hold such Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the
parties hereto that such determination not bar or in any way affect the Company&rsquo;s right to the relief provided above in the courts of
any other jurisdictions within the geographical scope of such Restrictive Covenants, as to breaches of such covenants in such other respective
jurisdictions, the above covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent
covenants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>17571
    VON KARMAN AVE.,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IRVINE,
    CALIFORNIA 92614</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PH
    949-645-2111 FAX 949-553-1231</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>www.biomerica.com</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, I have hereunto set my hand and seal as of the day and year stated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    IN PRESENCE OF</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYEE:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Witness</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME
    &ndash; Gary Lu</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATED:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXCLUSIONS
    TO ATTACHED AGREEMENT</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME
    &ndash; Gary Lu</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusions:
(inventions, discoveries etc.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________________________________________________________________________<BR>
_______________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    ______________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATED:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><IMG SRC="ex10-6_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>17571
    VON KARMAN AVE.,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IRVINE,
    CALIFORNIA 92614</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PH
    949-645-2111 FAX 949-553-1231</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>www.biomerica.com</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CALIFORNIA
LABOR CODE, SECTION 2870</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2870 of the California Labor Code applies to any employment agreement entered into after January 1, 1980 which is governed by the laws
of California. Unless otherwise stipulated in a written agreement, the rights and duties of all employees of the Company who are primarily
employed at a facility within California are governed by California law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2870 of the California Labor Code prohibits an employment agreement from assigning to the employer any rights of an employee in an invention
&ldquo;for which no equipment, supplies, facility, or trade secret information of the employer was used and which was developed entirely
on the employee&rsquo;s own time, and (4) which does not relate (1) to the business of the employer (2) &lsquo;to the employer&rsquo;s actual or demonstrably
anticipated, research or -development, or (b) which does not result from any work performed by the employee for the employer.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>8
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIST
    OF SUBSIDIARIES</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME
    OF SUBSIDIARY</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTRY
    OF INCORPORATION</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioEurope
    GmbH</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica
    de Mexico</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-239980), as amended, and the
Registration Statements on Form S-8 (Nos. 333-179443, 333-204410, 333-224836 and 333-256377) of Biomerica, Inc. (the
&ldquo;Company&rdquo;) of our report dated August 25, 2023, relating to our audits of the Company&rsquo;s consolidated financial
statements as of May 31, 2023 and 2022, and for each of the years then ended, included in the Company&rsquo;s Annual Report on Form
10-K for the fiscal year ended May 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ HASKELL &amp; WHITE LLP</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HASKELL &amp; WHITE LLP</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Irvine,
California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
25, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Zackary S. Irani, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of our internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or other
persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Zackary S. Irani</I></FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary S. Irani</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 25, 2023</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Gary Lu, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of our internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or other
persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Gary Lu</I></FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Lu</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 25, 2023</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Biomerica, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended May 31, 2023, as filed
with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Zackary Irani, Chief Executive Officer
of the Company, certify, to the best of my knowledge, pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes Oxley Act of 2002, as amended:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Zackary S.
  Irani</I></FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary S. Irani</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 25, 2023</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>13
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Biomerica, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended May 31, 2023, as filed
with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Gary Lu, Chief Financial Officer of the
Company, certify, to the best of my knowledge, pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes Oxley Act of 2002, as amended:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Gary Lu</I></FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Lu</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 25, 2023</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
























</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M.:P:XGO0T6RU6TO%O;86!MYLS3-+:WXN$/E(L)_>#2H **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,@]"#0 4444
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MN?3@$_H 32UDZXADTN[16D1VB<(8MHE+A68)$SLL:32X,4+RL(EF>/>&'RD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CI14<LBQ1M(^2JC)P,G
M!('0D9ZT ?P0_P#!:#P^OB7_ (+,_%OPW=_#/6_BY9:_^RMH@E\ >'/B#/\
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M3]M#X_6]N(=5GLO@9E+KP]''>::XM_C+\/+>2ZL[BU@ALX=%N-,GN-0@9);
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MFA?#>'XE7.J0>/K/XAZC\-M4T%["<>'FU;1?%>I&P\6V^I:%J=E:2Z3J4]J
M?>U%>6?"KXBZE\2_"EKXEO\ P+XF^']X^L^+= U/PMXN&FC7M$U/P=XOUKP?
M?1W8TB^U+3KJSU*?0Y=:T+5M,U"]TS5=!U'3-1M+B6"Y60^I]: "BBC_ #^5
M !7(>(O'7A7PHHD\1Z_HVAQ-=06:S:MJ,-C#)<W)C6&VAEE'ERW9>>V\RTC9
MKB"*YMIYXXX;FV>;JY)%CC:1F555=Q9CM55&-S,3P H.23P!R:_DJ_X+Q_%'
MP9\8?VB_!_[+&O\ Q$\6^#/#WP8^!_CC]H:XU?P%X(\?^+]3/[0VL>']0T7]
MG'PMJ@\(>&->LM.TRVD&L^(;OQ+J,-W9Z'H7B;58TETW4K]8]3+=>FV^M_3]
M3.=2,/B;77:_5KIZ']3NN_$KP7X7?1XO$_B;P[X:N-?NXK#1[3Q%K^E:%>ZE
M?SV\]U#I]E::I<VLTU_+%;3[;7"R;HF#!<5C:U\;_A)X=\9:-\.=>^)?P_T7
MXA^(0#HG@36/&?A[2_%^J;FN%C-AX<OK^#5[R.7[%J!AEMK25+E;"Z:T-PL$
MQC_C-_X*%_%>?_@H_P# S_@E%\0?!VJNGQ'\<^ OVH]"U[4HH]2CUG3?VC?A
M#\)O"'B.7PW)INE0W,6K:QJOQ+\%0+X?TZS:+Q%JVC:WI+P69BUBR\WA?AI\
M:=>_;#_X*3?L2_MS:KJUI;^"M2_:I_9O_9C\$6MX]Q;W,]_I_P"R3X3^)'Q3
MO9=1-EHUI!)-\8?'GB"QMK.VMK6&75]5@M].AN+N2YB <L\54]HX0I+D?+RU
MG-:MJ[7LVN:T?=C>_P!JZO9G]>EU_P %#?V(K&:SMKW]JGX"VUWJ":.]G:-\
M3O#,]Q./$,)N=&*):7EP6%Y:@7#[0QL8Y;;^T!:/<P+)ZSX9_:/^#GC/Q;\0
M? OA/QWX=\1^+OA3<V=C\0_#FCWLMWK'A/4=0MM8OK32]5L6M(I?[7>QT'4+
MZ?2++[9J-A8"VU'4[:ST^^T^[NOY'O\ @G'\'_CCJ'[,_P ,/%FC1?\ !*70
M/".C^,OB5;OXA_::^'\7BGX\:5'H/QC\36'BV._NY[=8VUWP[;>'KS7/"EI+
M=IYFDW-M9Q7K6-G)96\NKS?&7X*_\%!/^"CG[>/P,;Q!XIL/@!^U'\/-!_:%
M^$N@:5&;3Q[^R-\0_AY=:Y\0/$L.GIIUXMWXQ\$WF@V7B:TN2?.T[2X+SQ%J
MT=I;"^L9 N6(M"+3]YVYKJW1ZI/?5+I;7[OZ7_&7_!3?]A#X?^"O"/Q%\7_M
M/?"G1_!?CZW\37G@G7WUJ_O+7Q9:^"]>C\,^*V\/PZ=I-Y>:G<:#K\BZ-?V%
MO;&]35&BLHX)))X2^KIW_!1K]BS6_@AXM_:2\/\ [0'@OQ'\#/ *:0?'/Q#\
M.1>(_$&F^%)/$&H:;I>B6VMZ=H^@7NO6=[?7FJV:FQDTH7EK;22W]Y!!86MU
M<P?RH_L-^,_AIX?N/^"''Q&^(OC+PMX=^'%E\1?^"LGAC6O&_P 0]7\->'_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5K5:\M4C25KB%(Y-GEN[A5?S2HA"$D;FE,D8C49,A<! Q(H L+(C,ZJZ,T9
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MX*J78&5,H@,JEWY^5089@6; !BDR1L;$YEC )+@!02Q)P$ 9E)<G 4!D<9;
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MMM*O[7P]I<^J7DNDW&BZIITGTEJ?[>OQS^$&M_">T^-MGX:_X17QF/CIJ'Q
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MC5?:9X!\(?LUGX]_#?PSH^EW>C^&-"^'D?Q4\"^$/"ND67P]TB(65K;)XO\
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M:_#+X6_\%.-3\/Z#JWQ!\5^,?!'B/PUJ?@2Q\*:?J?QF\-Z[X8G\'ZI^U?\
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M5V\,07']F3_\(]J_A+6KFYT5K#6]"DTC7V"54A)V4DW:^]NRZV6[77J?FMX
M_89_;X.EZ5=^(/C'X^7Q1\/-/UCQ/X&T?5/VN?'^HRW?Q5TN?]GV7P_XDU"Z
M\/W$D7B+P'XL?PK\>8+_ $+QLUYIUS;_ !%U32W\)>#_  MXB3PKX2R?#?\
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M6T=R+73_ -FOXX/,T,N%B99;CP-;V(,DQ:W7-V,S1R _NT\R@F45*+B]GO\
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M/EFM/!WQ E$;">=\2Q3>/K5I%:T\B-2DBL+L3,ZI"T2D HS?LI_LTW$#03_
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MWNMZM<,A626]U&XENI7D;SY)I1)/+U%% !1110 4444 %%%% !1110 4444
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MAOX>ATJZN/#?]A^&=.;P_9^'M#>R\*:/\3:Y_P $9?%/BOP#IGAC4OC+\-M
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MI\5?BKX$E?P[=:UX2\177A_Q/;^#?&.C6'C?1=1U?P/X<N=5T_QM9^([._\
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M** "BBB@ HHHH **** "BBB@ HHHH ^9_P!KC2_&]]\$?$.K?#.P\0:S\1?
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M_#.W^/FI?&3PUXTTW3/!_B6ZUG4/$K_#G4OCOXMN/BU-=^#_  MI'AW4]?\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D?QP^$/@KX\_#3Q?\
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M0-U.3SUX(Y.<'/3[O'/.*0P0L &B1@%91N4-\KG+KSG*L?O*>""01@D5+10
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'^SO\"XKS5O"EGX&O;J'X5^"UNKSPA96&F:7%X8NW_L8H_AB+2_#_AS3;30
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M&A=054V[W#RO;J%+!8X&C10S@*-S9U0 H 4  = !@#OP*^4;S]MC]FF#X@^
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M@=GACT* $VJ#D ="/P)R1^?-,,2%Q(02X&W.YL8!R 5SM."25R"5/*XJ2B@
MHHHH *C>)'.6!SC&0S*<;@V,J0>H'X9'1F!DHH :JA<X& 3NY.3N;[V3D]_P
MYXXIU%% !@9S_GM_@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP/\  O7M L/^$D>2&TU&ZTW5=4\0#P)=O<17.O6VH:C#I4.I1W1OC\>^-_\
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M.M^._/\ B'X;L_$?[/%Q?1_!GP%\>;WX<6=O'\-OVEK?QA?Z]\(/"/QF\/\
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M07@#4/VA/M*M<G3_ !%J=UKF@PZ3XGU74Y6L?#7_ ()!Z!HGC[7O$_Q+\0^
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MO4M,^O/C'_P4"^"?P>\)Z=\1A<3>.?!7BGPC\2_&VB>)/ -U'K&EZSH?P<\
MZO\ $'QWJ%OJ=I%)=>7IWAW0-8M++4-4MHO#XUO2[C2]0U71[6SU?4=([+2_
MV\?V2M3\1>%O"4OQ<TNS\7^(]0DTNQTW5_#7Q T.\TS6+'Q;J'PZ;3/%D^N>
M!]#C\!W[^,[?4?!^FVOC<>&KG5?$$&I:-IT$]Y#=1T%.<5)1;2D]EWUM^C/F
M:V^-O[4V@_LC?LC^/_"WA>\^(?Q!\=^&O#'AKXH2^(_"_BFV\5>'_B;XW\(6
MVE^"?B;XW\%Z-_PC&K7/A!OB;=Z;I?Q!T--(T]_#^F>/-.\4AH(?"L^M6ORE
MJ'[0W[?/C*\^(,NA^&_']UXH^$/COQ1K_P +;F?X3^/O#^A^([Y/AE^UUX&/
M@GQ#X?L+LZ7XY$'C#P1\#]?_ ++TN]\:^'=)UGXC06EIXJN+Z(PZ']Z>(?\
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MK&B^"/ U[!<W'BV*?PM\,/#^G>'=5GU+19]7UC7-,O#IVF7FHZEIVF^CQ?\
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MB7H/PY'A7QS^TWX%\4:UJGPQ\%>.M7UKQ7'\7KOX0> O%'AJR.MZ1:>#M/\
MB\5NIM5?2/#OB?Q8 ?5OC7]C7XR^*HOC3X*M_B;\,K#X3_$OXUP_'?1=.N?
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M7OKW6;N^NPT.E:;IFD:=9PS1:?I.C:;I^D:79V6G65O;)Z#10 4444 %%%%
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M]=O;+P[I&CW-SJ>CGPKXZ\%1Z#J6F7ES:^,?%FLS^"M&NG\6VEW91_/NA?\
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M+^,FG:/X<U'PW?:IXGL8_"6NZC=W7BOPI/?:2LFG2W>E:_K4,%_#-^3EZO\
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MTT$<<TKNVR2 I8Y  )/<@ 9/3.3],^U4I-1M8HQ+(Y2,NB*[(RJ[2,B1B-B
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M(S*J1B-79V9@%4%B0!FOPC_:(_:E_::N/VG?B[^SO\*/&VK:=J]WK/A#P]\
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M5^%_&OQ!MOA[\;9O"^N?%V'7/@OXDUO0OB'#X:\*:KIOC+P?X7M8_$5[XP\
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M2&+X4I;W!C?:#"9K;SN3]HCD"D_2%(0",$ @]01D?D: /F9H/VK;]P]CJGP
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M/VDOAS:WTEA=S_$BXNI[N[%C##\"OC=';I DA@BBN+X_#EK/<9"K1W#72)/
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MWU9;"#QKJ6D:)>RV]E9:?';ZOHNA_P!G66L6&VQCEDL+U'M)))Y6N8K@NYD
M/7J*!_4_SHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1+[4M;U7Q!H^A:OJVHP7>C2Z%I-UJ=C/J?\ PAFB^%8=:U?6]<BU34[GY_\
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M3)\>/@I;07%U=_%_X5P6]IYQN[B7X@>$X(K06Z%YOM+3:P/*,*@^;NP8L'>
M <9$_P"TS^SS;SW%K+\=/@[!=6:2/=V]Q\2_!MO);F.5+<P3K-K,;VUP;B6*
M,1S1JQ+@ 9930)I--/9II^C/(/@)^QEH?P#^(,OC71_B?XZ\1Z+9Z'\3-!\%
M_#/5M+^'VF>!?AW:_&#XCZ3\5OB$?"D?ACP9H?B()J_C'1;&XL;#6=?U/1]
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MM_V<_BT[3VEA=W=B+VQMVT:.[O(=1DM!>:>D-N]Z^GW-M-/I\0F5B <=IO\
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M(D=M);(5$X:*NOPT_:>;49)[G]I+PK;60D<6UGX=_9\TRP$-K)*LLB/=:_\
M%/Q1+<W&Q/*BGDB5(F8R?8V7*U]0>>JR+$P<,YPKB-RA81[V!<*8U(4<*S*6
MPP .#5B@#YI'PK^.-SIUW87_ .TOXEAGG2&.+6-$^%?PJTW4;=HWCD\^T%[I
M>OV.^;RVBNEO--GB>*9U@AMV D5LWP.^)\XC\[]K+X[92!(_^)=X:_9RLA)(
MOF!IIC)\$)9 [Q.L:+;R0"*6-)T96+"OIC'Z<?Y_*H)9A%N^1WV(SL5Z <GE
MF*IP 3RP( P!S@@'S3%^S_XW*"*__:K_ &EM3 >9C+)<_ ;26(E$@2,GP_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBKH?_"O#<>#HK^SC\36M_%?_ &#2Y]'UO7<F^/[,GCOQ1\,K*W^"OQU\=?\
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MG1FT[1KOR87OXKC:^#?A3X@?!+7FF\+_ +/7QD\2Z3::&G@3P-IWBWQM\ =
MLOA9\+] NM<UKPS\/=#_ .$>^(.H1^(-*T2/5='\'Z)XA\26Y\4P^$/#G@_3
M-6UW6Y=/NM7U"+]I#P7XT^('Q$^%&LZ /$GA^S67X&W'A&[TO6K#PS=?#/Q'
MX;^-&C^,OBNOCDQWIM]+GUSX()J'A_2[&^M_$&F:KJ.A:WX/W:-JFLZ+/KK?
MV;K+4?!_QF^('BWQ1=Z)X7TO5?$/QQTKQEX@U?QMH>H)\3-2U3X[^*_%'P%\
M3Z?<MXRUF\72O!OP2U:U\%0V/B*WTO5-!_M31?!FD:7=Z%X>AO-#RC3<:DI\
MS:E?W;:*]NM_*W0IM+5M+U:7YM?F?3UE\7?CQ?).\7[+6K:=#%#!]FEUGXP?
M#*WBN;A_+\\JVD7NMJNFVJR"5K^(SRRPQ3^38-,L4$_4^&O''Q?U+Q-I>G^(
MO@QI7A+09EE75M;E^*6GZM=:>?(F>T2PT33O"OE:Q)).+:VG+ZQIT, FG:VD
MOGLIH3U<OQ7^$VFP"XN?B;\.[&RC787G\9>&+6TC<=?WCZC'&AQD;=P  / J
M'1?C9\&?$NL67A_PY\6_ACK^OZE*]OIVB:+X]\*ZKK%_/':S7TD%EIMCJT][
M=2QV5O<7CQP0R.MK!-<,HBBD==1GIU%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7PO\
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M:]SW']F?Q7X6^)WC#7/ OBK]G3X-> [BTU[]I/PIX'^)O@;PW\/],TSQ19?
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MNA:_H<?@[Q/H]O=:MXJUCQ,NDZ_8QZ?I^LVEW?SRZK +/P_?-=6DD=D/"_\
MA6/P=D^!'A**QUS2-4^"^L>*_AYHGA[1/#7["W[.>@:+X/\ %/Q$\<Z-\.O"
M.KZQ\-?&O@,V_AB]T/XEZ3X=T:]%]X4LM4\%:GX-TI/%UG'%H<NI#+L_A%\2
M-%^.=O\ 'VPN/CIJWB*Z\.>(?#.K:=)^SUXPL+76(I?A;86&G:AXJA\3_'[P
M[X8OK+2_''A/P[?:;8)IT6H>(H9DT;Q;J-W!8Z=XD\,]'J'@']HO6?@_#\.I
M;'X[?VY_PG6A_$#3M:T[X"_L]6EM9WGA;XI)\=]/TZ'P;XY_:;U>SE6V\?:
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M&IMXMT+XM^ O"'C>X;Q#%(FCW]U'>WR?4'P>D^.WPM\&>&/A]%^SIHND>&_
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MQ!XY\-Z5\$;?5;U?%NIW#:)K U?R='\2Z-I]A80V\MAJ3+IF7XC^$?Q/\">
MO$G@CXA:G^RMIOP\^)7Q7\8^-/&FL_$+XR?&OPYJFK?$_P")'C^V\:>%]'\/
M^)O#VD^ )-FF11Z!X?T'3;75UUR;1O#]I;7ESJ]Q?ZO=L4Y5))^TCRN^EE;2
MR?=]>]OF9JE%1E&[:ENWJ]DM[=EUOY:)(RM.\,Z9=Z'\'/&=I^S!X4L?#GQF
MO/AK97GAKQE\3/BW%XTT'7/'%];:9XC_ .$9\"ZWH,2VUAIW@FV\6?$JULM4
MMO"?BK6_"@FG^(/@_P #:K!K&EV.Q\"Y_@GXU^.WQ5^#WCK]E;X5>#;S1K/Q
MMJ_AN"_^&NNW6N:CX3^#7Q&L/A=_:7C:]\:>$K/0-53QG!K/@_XJ?"_^Q9;N
M";X>>.M+BC2[GM+S5[[T#1?!'Q)\'Q^#?#GB/XD_LLZ+>> I?&7C[P):>+_"
MGQ8\3^(] L/#VCZMX:\?^.;KQ5XX^/ \6ZXFG>$_B+<>&_%WB7QC-//9MXJ>
MZFO(%N-,DU*3X8>!M<^+:^+?B1\,_C3^SAXQ\+?$J+5K'Q#XJT/X(?$'QK=7
MD<6HV,^H>$)O$OB/]J+7AHVE6]W/KE]%X'TW1](T6Q_MFVO=-MU\NTO9]"HQ
M45RK:[[=?1+\BE^T!/\ !;X%^(-'D\)_ ']GF32?#'PK\=?%KQ1IE[\*_#X\
M0ZMX<T75O!WA2/2/ 7]CZ# ;;6;^]\9%#J4DNN6^H:B=-\$2>'TN/&=KXH\-
M4?A>W@7Q[^T3J_@;_A0_P!D\!BV^/>E:2T'P1L]!\3>&]6_9Q^)W@+X>7,>L
MZOJ&D:GH/BO2_%NK>.-3U7PO)I*>&5TZR\-AH'U.]N=773VZC\/?#]YXD^'G
MP.\1?%GX"WVM_!C3+#4?#'@^/]G"VLXO#5CX=M-'\0/I?AR;4?BU?>'K*YT?
M1-$\.>(M0T-Y=0UG0]/LO#OBF_BM)+GPM<WOIGPOT[2OB?JOC+Q?\(?CGIEK
MXKGU7_A'_'/C7PK\$?!GAC77UN7PIX,\8Z5IWB'3?&WAZ_UO4A=>"=?\(ZY8
MWRS6UI?:/>:'=&;4(OLAMPS<93DXS5H)WBU9-V[[]^R_1_5R?!OX3K%'$WPQ
M^'@CC6']P/!/A?[.C0 >5LB_L@(OD$#R6559 !M(P,=-9>$/"^F7,-UI^@Z/
M8SVZ+':O9Z5IUK);*-ZGR);>UCFCWB9PY$G(D<# =]WE%M\+OBU&T3W7[2_Q
M NC'(\CQ1^!?@M:0SJTBNMO+CX=7,R1K&#"LD4JR@$N[2MBK%A\*?'UMXHTO
M7[[]H;XKZOI>FWT-W+X1N-,^$%AH&L110)&UEJTVD_"RS\0-:32IYLJZ=K>F
MS%L!9T5YUD#5*VA[I]?\_P Z*0=^<\_EP./Z_C2T#"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OCS]L#QY\1O!'P\T:_^&WB.Z\!ZE>>-+73M3\5'PI<^(+&PT'3_"GB[Q->
M+=:TO@[XCZ!\-=.U:XT6TT:Y^)7C/X?>+_#N@RW=MI<F@R:EK^F:II/V'7R1
M^UE!\/\ 1/!%MXP\?:7\2]9TNR\1^%=#:P^&WQ'\0_#>^D;Q;K^F>&H'US7=
M/\;?#_0K7PA9W]SI.K>*KGQ3XLT/0;+3M)^WWMS>75O8:9>@'P_HO[5/[2@\
M5?LG_#UO!?C2W\/?$7X>_ S7=?\ &/CSX:>-VUSQSJ?B;6O&W@[XCZ7-J'@Z
M?4=#\)>(/"UNOP]^*PL?$$5AI;:%>SIXN_L3P9K.LWW@7D?"/QS_ &S/B1\*
MH/$GA;34N8?$OPZ^%7Q5_MCPE^S]X]\,Z7X%\3'X@^$)_%OPGTK1O%WC/4=0
M^+EN?A7K'B*_O/$'A6UM=0M7\,1Z+?:AJ.H:QI>DV/H'@?Q/^Q#JR^ 8_&M]
M\8_"GQ ^+6D>'UM? 7B;XG_M#ZG>:'+K<EOIOAS2O%)\'_$GQAX$\,?\)QK8
MD\.^ %U+7K33OBIXEL=4TOP+<>(IX[NU@Y>UD_X)N^ ? =SJ_P )_@W\4+CP
MGX(L9#X5\/?!3P;^T'HUEJ?AO4/&?]@>*/$7PQ\,1:OX3T/Q/X7\-^,_$5_8
M>/=;\'PW)\/ZM=1V5X\&J^(?!:>(@SDJG-'E:Y/M)VO\M-OG<]$^+OQA_:OT
M/5O@0/ OP[UOXA_#KQ#;VZ>-O&FN?#WQ[X%U:\\0S^+='TK5-.OOAC-X*UOQ
M-\,]+MOA9'XH\9P>(?$92U76-3M8([R\O_!7_"#>/?BGQWJO_!0WXI>'-9\/
M^(M,^*-Y=:CHMAX@\#>*_!GPILOA?XP\)_&'P7\2?ACJ&C:@EU<^-? JZGH-
M]X'T_P"(.CS^$?$.J0>!D8VEG\0O$DD7BG3+O1?LSQW'_P $\O"&I?"OP9\9
M/A_I&C>-OB!)97^@^'/&4_B>;7(7U/5XOAU'J&J6OB?Q6_B>TM8]8UE/#]VE
M_;3S6J7.H7US8BSL;V^M/GC7_'?_  3WMFGM?!G[%FD_:-#7PJFJM\4OV?+C
MP%HUUX0\0?$_P/X,\77V@2>(_#_B'5;SQWX1/C-]7T/P-XOTOPK!\14NC9:#
MK=_;W-K+>!$U7YGR-*-M+\NCT_NMV\KFQ\0?BU^W)X:CLKKPU=V/A*PM_%OQ
M>\-V_B;Q)X.^$LWQ+^(%M>:E\,O$WPOUKQ;X.UVXT71?#&A^+[V#XL>'I?#^
MB:EX=UV#P_9^$-9\8:3\/KZYO]>T3Z;^$OQ3U3Q)\>_B;JGCOXH67A?X<:9I
MVEZ1\([>/QG\ =0\"/ITO@GP!;>+]3N=:7QIK/Q1O_$]_P".Y=;E\#KXAM&T
M+2-)T[7I+AM:?6M/:+YU\7_$C_@FGX#?1[?Q3^SE\*?!'C:]N/%<7B'P/JO[
M.'P97XF>$O\ A"O$GA;PKKNKZQX3EOGOM=FT?^W=-L[6;X5M\0=0\:-#?W/@
M:'5;:)X+_P"P_A7X?^"WB+XK^// /AG]D33?#FD_"B>7PSK/CN[^$O[/_AWP
MW;^(;K0O#/BK3O#/AZ30M:D\7ZL]SX;U?2=5%[8>$[+2[33-7T-Y]9@OIC H
M0Z=::M-IKM=)-[=$G:VO76VFAPO[:7C_ .#_ (OT+X<WWA[Q-\)OB!X@^'_Q
M>^$'C^WDC^*/PD%UX#O/!OQJ^&GBG5M>TZ3Q=XOT^+1]3OO ^G_$/17FT.XM
M-7O]*OM0M+Q[G2H;N,>N:)^W9\%M;^(NM^#-;U_X5^'O#N@_#OP#XO@\8:G\
M:?AAJ8U7QAXPU+Q?#X@\!Z-H&DZK?SWA\ Z+X?T75/$7BVTU"72+JY\8:;I6
MDQ7KVUU=U-\>DLOA1XC_ &>W\&^"O@[9^#_B5\9/#_PI^(VF:WX+TV+7I+'Q
M7INIOH=QX.U_3&TRRTOQ')KVG:9I=XWB!]7MM2L;H66CV4.N26>HP^W:1XA^
M!>J>,;SX=^%[[P+J?BO2](\+ZUK6@^&7\/76I:%H>JQZE=^#=0UR'3&:[L+/
M7;31=0F\.O<KMU6QL&N+436:><0ZELO0^+OVKOVE_@GXR\-^&O#?@3XE_ /Q
M7XBTGXC>'KO5++7?',MMK7A[PUJOA;Q'9:UJ_P .[K0-'UNX@^)-[I>I7'A[
MP["FVU73?$FJZKJO]H:=:7'A_4_F.;Q!\*],\8_#(^&_B+\'8_AEX-;X">/]
M"T^;Q#\0?&GB'X3)\$OAKXM\*ZIX)\.2W/@6_N_'4/C^W\06FAS>+9KOP]K-
MGX6O?&%W>V6J:UK7A_1O$7W9^UO\8-5^%E[\.]-\"_&'X<^#?&GC;Q+<6GA[
MPEXLT+1_$-[XGMO#B6VM>+-3O;T^)O#%SX!^$?@SPC;>*M:^,/Q'::\E\)Z5
M;Z%;>'8XO%.HZ9I/B'Q>W_:(^)OBC]J36/A!I?Q-U+PCX::]^*WANUT;5?!F
ME:FFDZ%X2^&WPT\>?#KXV:CXA\0Z/I%ZO@'Q;X@UWQAX,>\GCU?PC\0&M%T_
MP%XLDO?#7B?4(@#Y\U'XT^$/&G@3XF>!+#Q-;:(GB#]I;P-\>OAZ? &C_M8Q
M:R=*A\4?#CXA>*/#USXI\*_LM6.I?#GQ#X@UOP[X^MKJ_P##VE^+-6TVS\2R
M>&_$6@Z5KNIZGJ.B?8W[-?QL\$_#3]G;X2_#&\NOB9XIUGP=\.M!T/6]6TS]
MG7]H>P@>6PTJS@GGTHVOP-TFTU)8&D1?[0M]"\.WFH.PU:Y\+:+?3W>CVGR1
MK7[7?Q-U']EWX<_$_P"'?QO@\:>.8_$WQE^'VI7^E^)_@W9>,?B'XST%?B)H
MW@3PEX+\$7OAO5--\9^*?$Y\/^ OB+#X&\(^'M,\1^)/!UE/K_@RZ.C>([B\
MN?UQT3Q)XRUGX/Z?XB&AGPYXRUGP8NJP:!JR7<Y\.:]=Z$UW:Z%KZ(SW_P!I
MTW53%HVL6]C:W5VM_'=6]C;79^SSW !^).E>"/"'A[P;\7OAKX9\,65GX-^,
M'[0UC\:M7@TG]C[]IS_A)/%WV7]JCQ1^TEJ7@S7K>+P9X5TN:RTSPU=P>"M#
MG\/:CJ\D]TFM>/(IK>#63X$CLZ;\$O#VB:I\!;K4OAKXF\?>$_@!XD^.#^!/
M!FO_ +!/QOUBSD^'?Q:^/.A?$?PCX7T35/+@M?!OB'X/>&-!70?"MS/H.K>$
MK#4=?2^T"QT=?"5HIN6/QZ_:6\7:7^SO\1/ _P 5? NM_$^\N?&OP^^*7@KP
M[X ^*6H_"#P]XNL?@'>?%*/X:_%/2;DV6I77Q[\.?$+PAI_A>]LU\9_#NTT7
MQ5XT;PWXH\"VOB#4-#TJ?Z8MOVK_ -JWQEJB6OPL\&^'+J2U_94\#_'[3OA[
MXU^&'Q5\/?$'Q_\ $;Q;X*\0:Q/\$='^(7B?_A!_A;H<FB>([?P'INL>)]4T
M>#48+3QM;Z9'X:CU[2-6N2&3K03:=]';;K>VFO=6V_-7^6/$O[-6DPS^+[SP
M[\-OVA[RXUH^.(M)U#PI^QWHGA/QYKNK>./CWX-^.2>(_B_XR\:?$OPQI?Q8
MU+POX\\"Z/\ \(O<77_""W5A::@;SPW;:;=?:-?L/.?CC^SU\3?B+X2\;26G
M[,?Q,\<?$CQSK?QRT74++QE\,OV;_AUX7M_"G[46KZ;?ZS;^$Q\1OCUXX\1^
M'?$>D?$*/PYIC_&K2+C5O%=GIWBC7I(_!%Y>Z59::OW;8?M7?M0F:ZO4\ >*
M?%'@:PU_3+34/%^A_L9_&SP?XDM=)\:_#CQ'=^&FTWX*>,OB$_Q>U:3P3\7?
M#MIX.\5:W/X6TO1[S3_%%LSII:>#?%6L-X9XE^,W[3WQ1\0_"+PW\6+'7/AK
MI_[07@+P1X$\7?#/1O@KKGAO5-1\*:[^RSX^^)'QPU"S^(VN^.;'QM\,_&0^
M)V@_$;X;:1X3TW3=>UCPYX6\)Z!XYTZ'Q%=ZYI_C;PX"]O"U_>2\XOK_ %OU
MUML>G_#;P_\ $+P1XWL/'VB?L]_M!K-_PM3XX>-+KPEID'['.@:7K'_"]]'\
M*Q0:/)J^D?'W4;Z?3?!4?@O3;32-4GD37/$IMHH_%%F++2+2'3_0/CROQE^+
M6J^'O%_AWX%_'/X7>)O!GA[XA?#^/QAH'B_]D?Q%-_PBOQ0/A&ZU:,Z-XY^)
M>M>&$@M_%7@;PI?>'/$8T74]?L=4\.&."WM-)U+5K;5-_P#X)[>(OV@1H]WX
M)^.?A_Q[MTGX._ 'Q)IWB_Q[\+=9^&]W_P )?XN\)75_\2?AC++J$S6WB:7X
M<^)72UM=7NUN_%\R:M=6'C+Q%XHU'3K?4QY]\8_ WQE'[0NL:QX7M/'<7C@?
M%CX;^+/@=XW?XA>)+C]G[P9\)3X=\*Z3\:/"GQH\+7OQ)\+Z;'=:]:V?Q:OY
M-!T/0_$GB#63J?P=\2^%+N*+P9JEEX4/,'4YKQA=3Z<T6E?SO?3>VFO3N8'@
M+X9?&/X8^(R/A5\)?B#X5^&*0^!;V?X+ZQ\?/@EI^C/J'@CX9:5\&-!TF]\3
MKIOQ&\;>'?#%EX&\+^$-?C\/Z/XOT^"3Q4MWJ4+2S:IJ,=WF6'[/WQWT3P)X
M,\/Z/INM^'K3X.>&--T/X2>+++]K_P !>%]:^&/@&P\%)X(;P_H,EA^R_/HT
MNA2>#I+S2]4'C_2_%UW_ &O;Z7XKT/7/#NM>'O#NI:;S6G>#OCAJ_P .+"Z\
M:?%/X_:9XZT'6OV=/$OBY(OB)^S!H#Q3^']9LM?_ &D;#X;:GIT,=]IGA>32
M[C4M0T+2_%4LV@W?A[P[I%EX1\31ZCXMU1(7^/?%WQ9D^*/@R&XU&WO?ATV@
M_!^Q;1?$?QM_9MN] G\!>(E\7V_[5/A3]H?1M6\=V?\ PL;XBRZ7?:;I/@;4
M? $?B'X?:3%J_AR\.I:0ECXWFU0)4JE/WJKO%JVG*]7JM(J-K6>K?;0QM*_9
MQ^-O@+4M/M_!_P $_ 4'A"VUOX->)M&TGQI^V[\1/$/@OQ-KWP5\#:%X7^%_
MBSQ#HA_9N-[=ZYX.T_PAX:DL;FV\:W$/BK5]+T+Q+XPA\7JG@Y/#_H7@#]CW
MQWX3^&%Q\'?"?PS^%7@SX;ZOJOPGU'2? Z_M/?M!HO@ZZ^"^MP>.? >F>'=>
M\-_"_P -Z]<:7:>*=+@U/4+_ ,3ZQK/B?Q3IEM!X:\:ZWK?AS2?#FFZ7\-^"
M(_C+IGP=^'/PCT7XW>$OA^WA3X;_  1\->)?AGXF_::^#&NIJNJ^!=-;P7KV
M@_L]ZW\*?C5HU]\*?AS<^ =)L9]$M->\0?#6TU;7%ATW0KCP]XKU>U^(NC_2
M/P]\;>&=/\;_ +/GBSXE_M"^"]7M/"?PA@L/B7K=Y^WQ\/?#46J>.M>U_P ,
MR>"?'?COP7\/?%>C^"?%.N:-H/@S5X+[4_#0'ASQG-XJ\*Z!J,WB:P^&4.NZ
M*%T_:7FY-<KU@M+VNVKV2Z6ZO\V_T9O=;_:&^%7A&*Z\7:Q^S7X>\+:#!I.B
MVVM^-?'WQ7U.X19633-.'B/QEXIM;6;7;]Y3:F]U*]=K_5IC=S3;KN8M)\FV
M'P5L_%NI^(M!LO%W[-E\/VDO!&JWYU'3O%_[17BO6/B'X"_MVQUZZL_"'BO_
M (7_ &>KI\/DE^+4VNZGIO@6Z\+^&+Y?B+)XATF&YU'Q'JJ:/]'?%K]K+X$^
M)OAK._@;XN_!KQWKVM>']1=+#P[\?;/PP+?3XHK"W\3:EHWC/P"/&&KZ7XQT
M&*[G;P#=:9ITETGC3^Q;>SUG0M0F@U6'X:^#WBK5O %W^RIH^G^,/#WBJV^!
M7AGXD>'_ !MJ&G^&_P!HO5]8CTCXI-H;7'ASPU!I'[+\,GQ.UCX:>&-"\.B/
MXG>/;SP5J_Q#\5SW$/C+2=,\27.J:BH:GVIIW[(GCW3_ !?\,O&NE?$/X9Z+
MK?P?\*_$#PI\.H8_AM\0O%FGZ):?%"'2HO&MQ=S^+_C?>:OJ>H3MH.@VUKK%
MUJ,U^+&R>R>..SU"XA7C?C/!J.I:Y9_ [X]?M(? G78/B7*7T'X?:M^S#X@U
M>ROS8ZO#J>CV.L:C>?&+5_#&B:C>ZII'V/P??>)+WPYJFO\ BJQ@A\,2WVJV
M,,%>D?#/]HEM*LO&'B;Q]X-\>6T5QXW\<S^!M#^''[+G[2NJWR?"5M9MK#P1
M=:]'9_#*\>Y\;:C::?#KOB*/288-(^S:Q9VL N[[1[Z^NO)OC FO^-_CE\-/
M%-CH7B&?P#X%?3]??PWXN_9N^.EW:6?CJ?Q!H_B75?',VH6GPWLM)GUO1/#V
MC:9:?#+7]2OKFW\"?$2'4O&&KZ9J.NZ)X8UFR /)3IGP[\0:%=2^#/CU\%;K
M2OV>I=#UW0=%\(?L/+JVI>%-3E\=^)8/#%W\'?!6HS>()=?L]:^*/A'7SX9U
M3X9:=KAU#Q]X/DAT36&U71M0N8Z4,'@_3M8TZ_C_ &C/#HUCXZ:)::CXD\;>
M&OV.OA';VGC7PQ\2?'FB^ ]7T7XE>*QX&U'3;6_^(WC^2Q\)W7A+Q[K&F^)=
M8\=6]WX<M=$NSX:UU]*[/P_\-_&_ASPAXYB\$>)O%OA#Q/J7A;1OAO\ #&[N
M/V>/C%H>M^&OA9I/Q)^(_P 19=&\81GQ_P"%-4U?5[C0/%'B/P)+XW\$:C\/
M#X1>\T?QOH%[I7B*?1-,TWAK?PQXJTW_ (5CHR?"?XHZ#/X%TSX?^&_$7A7P
M3^S3K^G^ M9\ ?!/XR'XO_"JQ\ QZS\6=5OO".NZ7?:;#H(\3ZQK_BR]U30=
M2UC6]7\,Z3XRN[&P\)AE)PI7F[KF=G:[5WUM>RVZ>A]@>$_V>O%L\:^&=._:
ME\2?\(]X-UBP9/"7A+X._LN:#;>%8K>/5;[1["VTM_@;K,6A#4X=6_X2'3+^
M.TTN_M[#4GOK&YU*PUJUNI/3-3^"7Q!M+5I=5_;&_:.BA/V>VD$&E_LPZ?#-
M+>&*QRUP?V;KB>&?4;F0QJD-Y:VEI+=(;*.P\BUDA\H^&7Q-\3>#_$'Q6\5Q
M_ 3X_P"IV_Q0\6Z1XSM=&A^"OP\\&ZII#6OA'PAX0U33M6U>'Q9H=]XOU:6;
M0;G6;74/&%WJVMZ98R+X-L-3C\,^&] A;UJ^^._CV\LKF[C_ &7?C[##I=Q!
M#>R7$?P7M)9&-W9,TFB0ZQ\;-&DO[22-;B./4)ELVMW\F:XLE7=& U6NI\"7
M,WP-\+>$-=\4R?M6?M6^)?#>A_$#PM\'?B+#;_%_X8Z!9?#K4?B%X_/P:D\=
M^-M/TOP=X%L-+\/7/CN2]UW7M?OHY/%-]JOB77=?U318+74[@7'K,8_97U5?
M [ZI^UU\:]1L_B TR^!Y+K]JOXI:?H^OZE:>+;'PA=F"[\):WX=L9IAXPT]/
M#2)X@D2RC\6KJFC6$*ZI+J &3?\ P8\8:A9^,-,M/!G[3'AS1?%_Q0\,?M':
M+\.=>\9_LHPV'@_XN:+\;O!WQ\MCIUU'XM\1ZZVD:Q\2/"3W-V-8U/5K/3;;
MQ+K_ (:LC=Q0>'K?0^'C_8^U:?QEH7Q&M_@]\19_%>C>._B=XHFOO$OQ"_9<
MN5UC3/BI\</%WQ\U;P:][K?P>\4W-OX:T+Q[XOU:_P#"6M^#(/#7C*?3M:U.
MTUGQYK<]MIMU;!+BFU)WNMG=KSMHTK7?5,]X^+'PP_9]^#?A9_'/QO\ BS^T
M-I_A*TN_"VDZM<6'[0'[6/B..>]\8ZK:>$O#5D+3P'XQN=>UR/7/%WBK3M)M
MFATR:4W^J6-JR6]O.]PWG5IXL_X)^:\G@[Q5H_BWXL^.;/Q TUQI6JP_$G]K
M_P 5>'=)TO5]4TWPC-XE^(UQK/C*+PG\//!'B'6+6/1-,U[XI'PSX6\57>E-
M<Z7=W]MHUS/!ZK\5;?XZ?&33D\%S? #3K+1-*\2> _%43ZY^T:/#5EJNL?#K
MQ5H7CCPHT0\-_ +XI'Q!X7O/$'ACP]_;L>I8%Q=HVE"Q>*66XF^=O ?[&C66
MG:WI>G_#?X=ZIHFH6^@Z=JFEVW[87QK\1WGBWPWX970-2\">&?'-M:_ O0[S
M7?!,WB+P[?ZKJ?AN]O9]#U5-:\;M>V6JZ/X@U[37#.4J4:C;3Y[:M*3TLEZ?
M=?4V]=\??L&^'-'^,=GX<^%?Q"\7Z]\#/#/Q!\4>(-%B\*_'C0[?59/ACX@O
M_ WC/3?!GB+QE/I6@^-;GPIXPUB_TG74\):[K<<+P:QJEH]_<:9;F>37=9_9
M6\,^,O"7A7Q1^S1XS;P1K/@>XUBPU77?A?XYFO?#MG%XZTSX4ZW-XP\!ZAX=
MM;OP'X3N]2\7Z1?G6M;O;[6-9LO^$D*>$ET+39M4O.@UG]F/Q99:OXCO-2T+
MX&BWO]/_ &BM0\0Q>,/CK\=]8T271/CY-?>-/'UCJ/A>U\->$O#<VC^)?%<<
M.O:G-J<M[+X6L]!MG\%G2X+*UMM'HW/[/]M=SVO@'Q5=_ #5-:U#X>>+?"EG
M8ZS\8/VD=<\?:G\/WU?P+XNUFRU)-:\<Q^+9O"T'B:S^%$FM7$TM['93^(=!
MTFREL9?&]K!J07&I&;:5[K>ZMUMW9J:[X-_91\"ZC\=O%/Q7_96^"QL_V:)8
M=?TK6]$^'6@>.-2N_!OBCP[::A%KS0:GX8;7;+7_  [X7M#'K%II5Y)8R:/:
M:@;>75K/1]/O:]8^'7PW_8N^)W@C6?%/AG]GKX0>(=%TGQ'XJ\*?\)':_"_X
M;76F>)+[P)J4=AJFL:%K5NLNFZGI]_K%C,=,U<ZHDJ:M:3&ZGL;RP$R>8Z!\
M-M>\7^,OCMJ7PV^+OP+\#?$&%8_#7Q0UVVT'XG>,/%/@7Q/J>C:V;C5-3\*>
M-OBS;>!_"[W]Q?:KK'A_3;CP%;Z1<^&M6NK_ $B4-KEYJ(]1^%'P#^+GPX^'
M>@?#+PI\</@[J_A_X?Z1H/A@3Q?!;4I]6,V@::NFO<^)'TWXQVUE<>(;\ ZQ
MJK+IEC>7.O2"]1($>.V0+/COPO\ %SX(>%_&WQ4T?XA_LE?L\:!86UY\:SX%
MO?#/PI%O+XIU?X._$[PS\*-/\'QS>(?@KX?M_$.I3VMQ:^)=6U+0-;\17'A1
MIWL+W2HM+F\(-?=C)^W5\$?!_A+P#X_\-?LS/_9_CKQ3\5_"WBVZU/PUX/\
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MLKO[)%<WHM;.Y .IHJM:RO-%YC[?F(*;5D0%"BD$K*%D5LELJZJR_=(XR;-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7S5^T[HNN^*/AW)IGAZSA%S::]H&LW.M:G\1$^%
MVG>&['1+E]7FUV7Q!<>#_'UCJ-O;36T%EJ.@:MX1U71;ZVNI?[7^RVT/FO\
M2M?'7[<=I97WP \3Z-=VN@7LFOZMX(M=+M?$7B*[\,Z;)K6@^,M(\96MQ'?1
M^!_B/I<FJZ?%X;GU71-.\4>#]7\%:[JVG66@>/HU\&:GK<B 'RCX6_8VDT;4
M/ 7B3P_\'?A:EIX$FT35M'\3Z'\?/$S:SXYT[1_'^K_&#2;WQ"WA[X >'K#4
MM-N_''B/QWXPM;+09?#_ (<FU+Q_KFBQVUQX$U"/2[;G?"?[)OQ+\!_#B^T+
MXLW'[/?C.76],^)^F>(->\6?%+]HWPQHEOX!^(>M_P#"=^,_!?AI?%$WBM_
MN@/=VUMK6OR> ]8\)6]WJ'A#PGJ\%AX?3PC%:CYZEL_&WA%?@Q9>!OC+X.T/
MP'X%UGQQ<W/@/P'-KOPDT_P3-IGQ;\.^.O"/C>2+PI\"/%/ACXI>(M-^'NG:
M_P""_'/@B/POX-^'^J^(=1OY]*\->&-)\7:B?"N!X&\"7OQ2A^/.G:OXRGTK
MP9X^TC]L[X;PZ7XOT[]K"[OOB+!\4_CCK?B+]FW4KGPQK&BW_A?P3\(_A_\
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MF35-7\+>'=>\27WQ.BU]O#GAGQ9XA\1ZU9Z-H]SH\&M'7[R/5;=]%_M;0-:
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M;X ^#7Q1\7KX:TB>3Q/\$M0\(P"RFL/V@].^ WB+Q;\7/!C^#;.[^".DO?\
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M6O-"UFT!N(8?-:QU73[NRDF@\ZSFD@:2SNKJV:.>3J* "BBB@ HHHH ****
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MQ-]H%QI>G &Z/AI_P3;\!^(?'^N)X*_9!\%>*_AY%IGB3XK:G%I?PF\/>(_
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MY*JBWHHZM4W?1==WJ[F-'J'[5EQ'/YO@WX#::Q)^SJGQ-^(&I,N(HPCR2_\
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M TZ*9;-;ZZ6$3/K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY,6<OP7_ &@I9)B_[7_Q!C@G24)';?"#X 6\MMNCV*T,]SX!U*-R'&[;<P7
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M&]8_'_PGJD8DT[PG\9Y0[A46\^ OQIT.4KY@A,DMMK_@+2[RV191*A^U6T+
M0LY4(R%@#D+?PQ^V6UU&;WXS_LVPV:R2>8++]G+XF2RR0M PB0)<_M/ILF6Z
M*&287&QX,JD$4F&K9TOP9^TU;63P:K\=_A?J-ZX(-]:_L^:WIX0_9(;>-X;6
M;X]:G&C++$UW*)'DBDFEE BCB*JO32_%KR[R"*/P#\4[BWO!;"">'P!JJ06[
M2B1F%[)>-:26C* JW#74,%O:,'62X+>4):FI?&BXTVVN+L_!WXUWZ6\T$ AT
MWP?IUW>7#SQ22[[:T7Q"LTEO L82XN6"0QS2Q1!F=R% ,/4/ /[1EU;Q_8OV
MAO#FF7RVDL3R0? [2I].EO"ET+>[-C>>/+F]6))9+5I[1=74S0V[QQ7%M).9
MH\2V^%'[2ITVSBU/]K"23686,EUJ&B_ SP!I>F73O;30R1KI&I:AX@N8+9)9
M1<VL3:Q<31/! ES=7BB43=_+\6M8,\5M9?!;XO7KS7,]N)6T[P9IEI&(+..]
M\^>ZUCQOIZ1P7 D%G:, [S:B&M#''M,@Q/\ A<GQ!>[2W@_9@^-+P%8VDOIO
M$'P M($WH68)!<_&R._E\IODD/V1"&Z X. #D?\ A2/[0$ES8R3_ +97Q/2T
MM?,-U9Z?\+OV>;/^T@;5(K>.6ZO?A?K%Q:F.Y0W,TEN3YXG>$)"J1D6[+X%?
M%F"SMXKK]K3XX75W'&D,MR-%^ 4,3 6$EHTL4$?P0.)%ED2ZB$QEW3VL<LS,
M9YEK4F^,?Q9DLI)]+_9G\;WEZ;>.6UTN[\>_"K3[F207<EO<Q7=PGBN]L+'R
M88Q>Q9NYY[FWN+11;1W,LD$&HOQ%^-$QMVB_9_GA1]YN3??%3P1#]F0B,V_%
MDFI":6;>Q94=8HU0%)Y68+0!SFK_  $\>7<6ZU_:7^/+S!H=D,NJ_#+2;4AI
M<7<D\NB_"6"[8I \DEI!%)$C7,<"3.MMYJF>T_9YU2&-EN?CU^T->2222RO)
M)\1M/7R3-;+"8+9+;PE9KY$,J?:K8SB:2.>:5'+V\<4*:#>/?CQ-/.D7P'\/
MP62;2+V_^--C:.9UNIK>YCDM5\"7S10PPPK<K-&\B3JY$:C'F/,?&'QXWSA?
M@]\/<)<V\-NDGQUU:.XGAD2%Y[F6*/X.O;6WD>:S);K<RRW,:J\*98I& <O!
M^RYI0</?_%/]HW4?*N+B6.)_VE?B_917*2"X2..^33->L8C&L;0N(((8H%F:
M0L)4BB5J&H?L<_#G5]*N] U+Q7^T!/H>I:+JWAV_TAOVJ_VCY=/ET/6=/?2-
M0TY8F^(\<R+<:8QMXI_-,EB[-<V?EW*I*OH5QK?[0,D48C\"_!O2;B5YXVF;
MXL^.?$4$,0$RQ2^3'\'_  N7$DQLA*5NHY;6-IM@N3@KP=O??M=RQSW,F@?L
MYV%Y]DE2WMT\<?&;5[5-42"6*8W N_ ^A"XTZ.[CC*F*P6=8&FN(D:9@9 !(
M/V+O@-;6,-BVD?$.]M;+2X-+MQK'Q^_:!UI6T^UBEBCM)8]0^)\R/;K%-(BQ
M;5B"E$6)8XH4CBM_V._V8Q+<3W7P@TUY;JWLM((O=9\5WP6QLKJ6\LEMXK[Q
M'<16:FY9[J26T2&>XDD=KEYRS$[.L1_M126=K=V&N_ S19O-47>G3>"/B)XS
MGN+=%CFN+>UDM_B!X/BLKZ:VCOK2%[B6\TU;E[21;A!)),9/^$._:?O+K>OQ
MC^"NG06\+"!;?X#^-K^8W$RWQ>5WN_CY:PK'!-+:-;+Y4_G1PRX%L'VT 78?
MV1/V9X)Y;C_A3'@BY>>[DO9$U'3I-4MOM$TPFG=+/49[JTB69QB:**!(98P(
M9(VA_=UH0_LK_LVVTD\MK\"_A9;23S+<3/;^"="@9Y1'?1[\Q6B8(CU*^4*N
MU1YY.W*1%)+OP-\=9[58;7XR^"-,G68.+NR^#.HO)%#EP;:VBO?BQ=PI$4,8
MW3)<NK"9]_[P")X\"?'%Y9'N/CCX?$4EM;Q_9[/X/6$*?:HK<17%VTE[XUU*
M8BXF'VA;=)(X[9OW4)$0"@)E",E:48R5[VE%27W--;77HV:C_L\_ 5X(K:3X
M+?">6&%&C5+GX>>$;H%)"C2[S=:1,9&D>-)99)"\DDB^8[L[,QOVWP+^"=E&
M8;/X/_"ZSC)B9H[3P!X4M4<PEFBW)!I,:L(RSE%8%1N< 89LU!X+^*9V";XR
M'8$D6;R/AYX:1V9K&&!)8S<W%Y'$T=['-?A6BF1A<-9E?(B@,?(S?"#XNR7O
MV@?M0>/(;!+F21-(@^&_P.-K]CE&&L9)[CX=7%^R0H/*M9H[J&00O,M[]N9H
MY(0K;1:):)+9);)'I]C\+/AII)B;2OA_X,TUH8HH838>&-%MA%'"&6+:D5DJ
M;HPY"N59\$ G@%=:U\$^#[(7(MO"WAV WLYN;PP:'ID/VNX,:Q&>X$-J@EE\
MJ-(S(P+,%&22<UY!??"'XKW.G7%G;?M1_$W3KAXXX[?4K?P!\ 9[FW5"Y9_L
M]Y\)KG3YI0''D;K-8(6BC+V\P,HEST^"GCBTCF?6?VG_ (WZE+=K:V"74&F?
M!72'@<7$4D%W%;Z7\'XK1;MYUE>[Q +-S<S"VM+"W2V@@ WT>J>Z/HR&PL[;
M(MK:&V#%B5MD%NI9VW,Q6'8I=FR6?&XDG).3ER6L*1F-%=(\,H1)ID55< ,%
M59 $Z' 7&TDE<,S$^-1?!W4)[1K;4OC#\8[^*>"UAE*^*-*T>YVVV3OBOO#W
MA[2+RWN+E]KWEQ;3PO*4\N(06\CP5D7G[.7A.Z4R7/C#XYW,L*WKPK%^TM^T
M7HD<C7)D9(KA?#WQ/T]72%7$4,GD22VXCCEA42*XE 22V27HK?D>XW%A;+!<
MHD,Q^U,/.$4L[22M+)&K2.3,I+!0@:0L'2"/:"8XUCJ&QBM186J+83QPL[R+
M#+$@EBDED::1YHEED*.TC,\K;G8R%RV2Q)^?KG]F#P5=K:M=>(?C!<11V\L,
ML%W^TO\ M1W;R?:2[&(W0^-%HERD;-!##+>V,USY,1+3"1R5M6/[+/PEMXXR
M;3QS-*/M#2->_&GXY:D5DN_-:Y4-J/Q,NW8>;<3XW2$(I18@GDQD 'O\<]MY
MTT26\Z&)'=W:VF\MD2>57$3JK GS(BR1@ R*5:%74'9&M_ RY:SOTV2F)D:U
MF=XCY0ER_E&4+#L90N2$#E0!U*>+VG[,WP=M[K[?/X174[Y[33K.:?6O$WC?
M7UFM]'_M+^R8GAU_Q/JD;I8?VQJ+0>:)7669)@_F6]L8*FM?LH_L]>(K*73-
M=^#WP_UC39UC6:SU+0DO+601[ @:VN)I8VV)%$B] 8T2)E:*-54 ]X^T0,ZQ
M?9KCYU>0DP.!MC)SPV)&.1&OR(^TRQ@E=_%'^W=%529;NVMHX0S%[FZ@M55!
M(T+/F6:,^5YF]/-($+2 1JYE 0>6R_LV? :[T]M)U'X._"_5-,8V6=-U;P%X
M9U73U_LP+_9C1V6H:;/:JVG[46U(B,<:(JB/(R+^D?L\_ 70I#-H_P $/@_I
M,S0I;M-I?PT\&:?*\,3S/'&S6FBP_NU>XG<(,(KS2LJCS&H [0^,?"_DAIM6
ML;8Q(LSP7FJ6%G<6\9VG=<QW-]"T*B,F4^>5!C1\;I%*5R]S\<O@W:?:!=?%
M/X=P26L*7$L3^-_"HE,#,P694_M;F$A"YE)5(T):1D*.%TI?A)\+IMV_X;>
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M9+<(0\,A;%";3/VB9Y4%EXP^$&FWIBMC-+?_  \^(FO6$4C/.]W';0VWQ/\
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M(UNV\/W.H:8=;TO6]<M[G?KDD$'@NE?\$H].TZ;QA,MY\-M%O\7/A_X;^)M
M\'ZZGB;0O &M>(_VKKSQ1H&JSV^HV]HC>)]$_:+TR'Q+:Z?%>6OBO7/"<^L^
M+Y]>EO-&?0/VDHH ^!_V6_V-;S]GCXQ?&KXJ3^+=!UE_B[:Z';:C8Z)X7\3:
M-=W5_I.KZWKCZ]XCU3Q1\0/',NI:G)-K]Y:Q_P!A_P!A:5,DUQ=3:9;N\&F:
M=]\444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX@_#KP_/^SAX2^$>B^()3HFI6^J#Q7\+?B-\+/B)8^)_"FJ7&GZW=7^AWO\
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M6%QI-QX(^$?Q5UO4_P"U4\-2:$\?@#X-?%_P)\0OB ]UJ(F\)^'=36ULDO\
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M#!Y9)$:-UZHZLK ,"* )**:'! *D,#RN&!## .0<X(P<\9XY[U%). A>+;*
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M%OA#3?$WQ(@@\6#]I]/#VH^/Y=)\8ZY<:W?7=FVA:MIOA"UURPCX+Q!\"/\
M@I_XRN_B-K%WK=WX=M?%ESFQ\,7GQ-AU"U\*>)/#/B^]7P;XS\*:OJ'B[Q5J
M=E WAC4]7U%[OPGHWP0OM)U+1?!DVGZ)K'B+2H?&]N ?O\)XFQM8MN"D;4<Y
M#' (PIR.F3T ()(!!+6NH$C:<R?N0&)E"NT8"*[,=ZJ5P C G.-^U/ONBM^9
M5U^SS^TC:?LZ_M4_#G2?BGXOT[QCXSTG2(?@?XI\2_$_QUX_\2>$]3_X4A\)
MK#Q'<2^,;2V_X2^+2G^,NC?$*[TZRT:ULGTI=5U/6-(TNVT7Q3:Z%IOD]_\
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M !1110 4444 %%%% !1110 4444 %%%% !14$\IA4,%W<A0O(R6S@E@#M"D
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MO\)_#SZUJ5I\8?$EU;^#OBIJVI_$*S^/TGC+5O$T^H7GQ)T;XD^'-9^%EO\
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MG8^"_"^N^&?#OB#QKJ7@_P#X5POB>P\+Z/JOBW2H+O5;C2MEW$MW<Z/'J5O
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M;EHT>=/,\N5TC:2)9519$BD*&2..3RU+HC@.PRP-6:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJO<7,=LGF2DA "2V5 0 99G9V554<#)/4T 6
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *:S!1EC@949Y/+':!@#N2 #ZGG%.IKJKC##(W*V/=6# ]1T(!^@QSTH
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MV3Q/\0=!\9?$W2-8TSQ$=$;X>R6EFVN>$=!\$W=SI\^M_#O6=;U:"RT3PSI
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M<3;XT?*-N13NC;=&>.J-_$A))4]2,9YJ3I0,**.M'^?\_P">.] !11_G_/\
MG^1HH *K7EE::A;RVE]:V]Y:SHT<]M<Q)/!+&V-R212*R.C8&58$' R*LT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449YQ^/\ G_//..AH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***/\ /^?I_P#JH ^ /VU?VU-3_9,U7X8Z38>
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M@:KXSTS1]>BAU6"\\*VF@Z/K&D>)=*U'7E/A[4+NNUT']GG_ ()W^(/%&O>
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MF^"+7QE\18-1U;PL_B6UTK1]'\):CI.@^'?^$:?Q;I$_]O1>)GT/Q)9>(=-
M/U->14 +' +!03G&3P,D X&>"3P#UJ,W,()!+ @9/[N3(X4@$;<Y8,"H )8*
MY Q&^W\</'O[47QS\?\ A7X6OI]BG@=?$>B_LY_$749/#GP^\:_$.Z\2ZAJO
MQEU/0OCGX(\&>(;ZY\&1:-H?@3P-X<TT^*+;Q'X+O_$_B/2_B2HT[0=-TB>V
MUJR^Y?VLKOQ!I'[.?Q'/@!/'>F^+'^'GCI?!R_#>V\6_\)M;^-X?!FMZCX*&
MD6'@;3-;UXSW'BR#2[:\^SZ=>6:VUQ.VHPSV:NR 'U7Y\?OC>(R2IP&(!4,?
MX=P*[2<;BZ 9+J"X2J0&&<$*02,#YMI7GL2&! .#R!UKXE\2>.9-1^)?[/?B
M+PROC_2K#Q/J&MZ/XDTH_!SXT6T]A;:GI6OZ?:Z]K[G0K&VT*U/C+3-(T"Z3
MXB:%#;6NCW]UXUTJYTW3+1O$+?//B_XG_M>ZMJOBY9?AQ\6M"\/:3\0_A#XF
M\(0Z-X3?6/$6B^'[;]H*X\,>/])EE\,R^$/#7BO2+3X)Z%9_$*30;OQ#XS$L
M_BF]M[N_\23QP^ -) /U:DNXT0%,RNRLT<2%1))LSD*&*@'@YW8P1@X/%1/?
MPP6MY>7):&"SCDGFDDC:-%@CA$[.'D"HZ)'DO(K&-2&5V5D<+^;?A?Q1\>H?
M$?[/5SX]T'QMJEM-XV^,VF>*[[2_ >DVJV_A+4K/Q?I?PR\>^*FTO[98^#_B
M/)I<&BW'B[0=%U4^%DM->UN^TC1=/DL;#0K/,UZ;QUIGAG]N[PKH_P +?B3X
M5B^(UA_PDOPEFUO5/@U_9?Q!\1^(?@[H6B>(]#\-Z-XN\6ZC8:0-0\2>']=O
MO&EAXQTS3=,?1Y=<UW0VN()!>1 'Z=0WL,J*^[9O5'565T<1RJ&0R*ZKM8\A
M@"0I!&20V+#RJF =QR<?*CM@XSSM!P,="< ],YK\SM0O?B'??$[]G[XG3>*?
MB+X9T?P_\/[WPIXR^'-K\5_@+X:AU#5+SXA_#2[N/&?B_P 'OXB\4^#[CPO=
MZ%X*\6F2Y\#^._$OBJ+3-<L?">BV_@1;C6KVLSX7?M >$[#XN?'B\^(7[4OA
M*'X;_"KQSXD\(6.H?$7XC^"_"FD^)M;\7ZS8^/+'3H[R2]T"TTZ'X,:49OAO
MH:)9WD7BKP_J$6L:O?ZAJ\<MX0#]1P00".AY'^32U\[6'[6W[+^I7!L-)_:)
M^".MW\4EO%+::/\ %?X>ZG>+]J&+662VL/$4S)'=2;(8VVC$LL>]8XRSK;M?
MVIOV>;V>TM;3XN>";N[OFG2WM;+6K74)V>WM[J[E1H]/>Z*%;6RN9LMA=L>W
M/F,B, :_[0WPP\"?&;X*_$GX8?$R?5K;P'XU\,7FC^*)]"U5M#UJ'325N3+I
M6L+'*VF:C'/!$]G>(N^*Y6(QLLFTU^5\_P"P?\!M6^(_@:^\*?&[1O&3_#[X
M^>&_VE/C'<>+O%>G^/OCKX\U7X9_#^3X9^#?"#ZIX5\0:7H/@+X;V6J:1I<G
MC[P_9_#/3H-=N/".CVDLL>JZ8;B/]8=+\?\ @/XK^%O$W_"(>)UU338+:]TC
M4M3TJ[O]'NM*N9X+J!G@U$&QU#2]1L_+>Y@O;5X+K3KF%)HYH+J']U^36E_#
M^S\,_%[XR?$.72_"^N>%M:B_:+\,CPW W[1/C*X\8Z=\0I_#$-CHFLW7A?\
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M#-I\;1R&/TNH?)C+(_SDQG*9EEVY*XRRE]KM@]7#'))SDDU-0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!'-*L$;2R<1H"SM@G:H!);
M!)Z ?CGM4%C=&\MUG:+R2Y<K&9!(WEAB(W8A5*F1 LFPJ"H8 Y/-/N7DCADD
MA0R2QI(T<>&.]A&Q52%RQ#, . 3V')K)\/W"75A'/&)5BEDNG1;CYI@HO;B,
M!V*J6<-$W!R4C\I<G&2 ;U%%% !1110 4444 %%%% '!_%+3/&>M_#3XAZ+\
M.=?L/"GQ"UGP/XKTCP'XIU6TN;_2_#7C34]"O['PMX@U*QLIK>]O-/T77)['
M4KVTLYX;NYMK>6&VE29HV&7\$]-^)FB_"+X::/\ &?7?#?B?XMZ7X(\,Z?\
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M63<+F,+EDE">T8'H/3IV]*7 ]* /%-'^)'Q#U W2W_P6UC1)+2\GA:*Y\=>
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M\++8RK<1&>'X;>+)KF(.W^C3P,OQ(L;6.Y2-GCG9;189B$DC2%U<O[\%"@
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MS-&6.H"ZDV.O<444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$Y/H.,9]2*;'*)"0%88&<G'^.:+.U^GJO\[_ (!9[]/E_G?\![*'4JPR&!#
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M2R* Y +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &3KMQ):Z/J=U#ITFL36EC<W<6DPR
MV4$VIRVL,EQ%80SZE=66G6\U[)$MM!<ZA=VUC!+(LUY/%;1RR+^5WB#_ (*$
M_"OPOX,\0^//C!^R_P#$?X<:%X<O/'7A368?%P^!.O:M=^*?V?(+W7O$?A/2
M=-\+_$+Q';ZA:>!A;ZWJVG:U<:AI/ANW2PO-0TJ^,=U9_;/UBF3S(RH ))&
M20"<CKCJ.Y'0]#@'-?$7CC_@G_\  3XA:7XIT7Q#;>*1IGB_Q_\ &KXG:E!I
M_B*6V:V\7?'_ .'7B'X9_$>YTLS6US#86MYH_B&76=+M8K81Z7XKL;?Q"@GO
MKG4&N@#S#PW_ ,%"/V19_$7A3PW?23>'/B5XHG\9-X9\$1>&)-0\8OJ/AGQ)
M\4?AH;$VVBZ?-!8>)/%]A\ _&;>$O#UP]KK6M:%X5ETFSL#<64NG)^B6E165
M_9Q7ZV=S;/?"#4BM];O;ZBDDUHD,;W*SHMQ;W26Z1PO ZQRVR(+62.,*\5?
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MP!)+;W4M]!)+X3T29X;V>WO+2:[B:6R<I<RVNH7UN\ZD2M#=W$98I*P->[^
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M9L$$<,PZ8 N44 5WMH9%*.NY6VDJQ+*65@RNR'Y&=2JLKLI9656!RHP\1 9
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ME:3W=S%%'I&CWLT\Z);2?N8(I96 C"(SRQJ_TJFGV%LC>7;6\,>W$H2&)4=
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ME;Z(7^S%U8C_ (27Q'HGEK)Y9-NTYA%R&0P;_,3/T,-3L#)Y2W,;2X<[!N+
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ME=[B[C1"N0&9F" CEQUKD[OXR_"BRTF]UR;XD> (-(L8]]UJTWC7PM'IEL7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^4/A?_@DK\?_ !3\*=7^&WQ=_:?U?5EL-%^/]AX3-CXO^(^NZ/8^+OC#XD^
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M _C;4"M]X1O[#3M4TH1ZI9:9>V09QE*4I)QLEL]==6NJMM9Z7W/F+XA^+_\
M@DUX;^(GB/Q/KWAKX?>,?B-+KOQ UKQ#JVA?![XC?&,6OB[Q7\:-:_9_\<:5
MKEGX6\->(-+\/>(OB3\9K#QUX T+PK"]C=>/_':>-+G0=#UK7SJLFH8US^W1
M_P $RO"OA+5;?1VM8?!6@_$K2/'?C;2?#OP*^+CZGIGB']E_1O"VMZ3\7+K3
M-!\#6MQ>>#?@UX&^"OAB^MO']_:W/AW3_#7PCFAO;N[DT.]BN_L+PG_P3U^
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MOJL:Z[X5^*G_  DGAYVBA>'7/#7C?X<^&?%UCXAOC:SZ/)^9WQ+\5?MP^$_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5\ !CMAN[E-I8H?.9F4LL;)<HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA2V#M#$9(4G&2!D#.*2/?L3S%59-BEPI+*)"/G"D@$J&)"L>2.H% 'Q%XO\
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MW_B36])UK2#XCTJ_TG1+>X;5=275/#"3>)-*33+*^34]$@FU*SGDL8IKF/\
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M+>&(;WE6"&.:>4HUQ=/%$D1GNGB2-)KB0(#)*(UR2=JJN%%R@ HHHH ****
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MK+Q+X-T;P1VNJ?\ !&[QAX@_X2&:Y^-W@&*[GT/XE?#OPYJ&K_!/4?$&IO\
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M_:D_M7C#_@FY\+/'/B[XAZAK/Q1^/%G\,/B=J7Q4\4^*/@!H7CK3M'^$L_Q
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MDLDD*NL7E QPL[)$ I.(H52(LQD>-YL2@-(IJ*3=VMWWW_K^F?SB?%CXY_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 9(ADC=%<H71E#J%+*64J& =67*DAAN5E)&"I&14%I;R6T0CENI[Q
MP7)N+D0B:0-(SKY@MX8( 8U81)Y<,8\M%R"V6-JB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"'?*)D3
MR6,3)*3,'CVQLAB")(K/YK-,'=HV1&11%()61FB#S4?THH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex10-6_001.jpg
<TEXT>
begin 644 ex10-6_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  F ,@# 2(  A$! Q$!_\0
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MN=4T4OK"ZEJ>L74VG6FH:9<71L]#T:_F41W:B-RLCJZH5KX,_9R^/'_!<O\
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M^*<HI0E.\>;.<)E&';E3E4J8>[Y?Z.?A3_P4J_84^-$EO:^ _P!IWX57&IW
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M_P M_$KPWXS\(.+LQX%\1<GJ<.\29;&A6GAJM6EBL)C<#BXSG@LTRG,L'[;
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MH366CEHQ//X'^&:_\)7XOUNY#G%OI%AK,G@K1Y;UAY:ZAKUC%D*99(YOAO\
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M:F!RS"2JSEC,6XSQ6(Q.+Q^85:V.QN-KUJ]><$Z5"C)L4G)4'MT%&Q/[J_\
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6B@/+I=NW2[W=MKOJ]WU;%HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>bmra-20230531.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaFObP9z5Z8GekhvWB0bRlKzysm4HJhEiRcnuLWMaUN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:BMRA="http://biomerica.com/20230531" elementFormDefault="qualified" targetNamespace="http://biomerica.com/20230531">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://biomerica.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/StatementsOfShareholdersEquity" id="StatementsOfShareholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/Organization" id="Organization">
          <link:definition>00000007 - Disclosure - ORGANIZATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
          <link:definition>00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
          <link:definition>00000010 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
          <link:definition>00000011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ShareholdersEquity" id="ShareholdersEquity">
          <link:definition>00000012 - Disclosure - SHAREHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000013 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/GeographicInformation" id="GeographicInformation">
          <link:definition>00000014 - Disclosure - GEOGRAPHIC INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
          <link:definition>00000019 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
          <link:definition>00000020 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
          <link:definition>00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
          <link:definition>00000022 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000023 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/GeographicInformationTables" id="GeographicInformationTables">
          <link:definition>00000024 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfNetInventoriesDetails" id="ScheduleOfNetInventoriesDetails">
          <link:definition>00000026 - Disclosure - SCHEDULE OF NET INVENTORIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" id="ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails">
          <link:definition>00000027 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails" id="ScheduleOfDisaggregationRevenueDetails">
          <link:definition>00000028 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails" id="ScheduleOfPropertyAndEquipmentNetDetails">
          <link:definition>00000030 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails" id="ScheduleOfIntangibleAssetsNetDetails">
          <link:definition>00000031 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" id="ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails">
          <link:definition>00000032 - Disclosure - SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" id="ScheduleOfAccountsPayableAndAccruedExpensesDetails">
          <link:definition>00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" id="AccountsPayableAndAccruedExpensesDetailsNarrative">
          <link:definition>00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails" id="ScheduleOfStockBasedCompensationExpenseDetails">
          <link:definition>00000035 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails" id="ScheduleOfActivityToAggregateStockOptionsDetails">
          <link:definition>00000036 - Disclosure - SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
          <link:definition>00000037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>00000038 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxReconciliationDetails">
          <link:definition>00000039 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
          <link:definition>00000040 - Disclosure -  SCHEDULE OF DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000041 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfGeographicInformationDetails" id="ScheduleOfGeographicInformationDetails">
          <link:definition>00000042 - Disclosure - SCHEDULE OF GEOGRAPHIC INFORMATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/GeographicInformationDetailsNarrative" id="GeographicInformationDetailsNarrative">
          <link:definition>00000043 - Disclosure - GEOGRAPHIC INFORMATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfOperatingLeasesDetails" id="ScheduleOfOperatingLeasesDetails">
          <link:definition>00000044 - Disclosure - SCHEDULE OF OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" id="ScheduleOfFutureMinimumLeasePaymentsDetails">
          <link:definition>00000045 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails" id="ScheduleOfOtherSupplementalLeaseInformationDetails">
          <link:definition>00000046 - Disclosure - SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biomerica.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20230531_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20230531_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20230531_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20230531_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="BMRA_ATMAgreementMember" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DistributorOneMember" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DistributorTwoMember" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_OneDistributorMember" name="OneDistributorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DistributorsInAsiaMember" name="DistributorsInAsiaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_OneVendorMember" name="OneVendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_MarketingAndDistributionRightsMember" name="MarketingAndDistributionRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PurchasedTechnologyRightsMember" name="PurchasedTechnologyRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PolishDistributorMember" name="PolishDistributorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ClinicalLabMember" name="ClinicalLabMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_OverTheCounteMember" name="OverTheCounteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ContractManufacturingMember" name="ContractManufacturingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PhysiciansOfficeMember" name="PhysiciansOfficeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" name="FurnitureAndFixturesLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoVendorMember" name="TwoVendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandFourteenPlanMember" name="TwoThousandFourteenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandSeventeenPlanMember" name="TwoThousandSeventeenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandTwentyPlanMember" name="TwoThousandTwentyPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ATMOfferingMember" name="ATMOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_BuildingInIrvineCaliforniaMember" name="BuildingInIrvineCaliforniaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_UniversityOFSouthernCaliforniaMember" name="UniversityOFSouthernCaliforniaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_BiomericaInFoodsMember" name="BiomericaInFoodsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" name="StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" name="StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities" name="IncreaseDecreaseInReductionInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_CashPaidDuringYearForAbstract" name="CashPaidDuringYearForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" name="IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" name="IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_WriteOffOfFixedAssetsCost" name="WriteOffOfFixedAssetsCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation" name="WriteOffOfFixedAssetsAccumulatedDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_WriteOffOfIntangibleAssetsCost" name="WriteOffOfIntangibleAssetsCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization" name="WriteOffOfIntangibleAssetsAccumulatedAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" name="ConcentrationRiskGeographicPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PrepaidExpensesAndOtherPolicyTextBlock" name="PrepaidExpensesAndOtherPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" name="ScheduleOfSupplementalLeaseInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" name="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_SaleOfStockExpenses" name="SaleOfStockExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_AccountsReceivableCreditLossExpenseReversal" name="AccountsReceivableCreditLossExpenseReversal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_FiniteLivedPatentsAccumulatedAmortization" name="FiniteLivedPatentsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DefferedTaxAssetsStockOptions" name="DefferedTaxAssetsStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DeferredTaxAssetsCapitalizedCosts" name="DeferredTaxAssetsCapitalizedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" name="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" name="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_RoyaltyExpensePercentageOfSales" name="RoyaltyExpensePercentageOfSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts" name="ClinicalTrialAgreementMaximumBudgetedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_FiniteLivedLicensesAccumulatedAmortization" name="FiniteLivedLicensesAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoDistributorsMember" name="TwoDistributorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>bmra-20230531_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biomerica.com/role/Cover" xlink:href="bmra-20230531.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/BalanceSheets" xlink:href="bmra-20230531.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/BalanceSheetsParenthetical" xlink:href="bmra-20230531.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="bmra-20230531.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfShareholdersEquity" xlink:href="bmra-20230531.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfCashFlows" xlink:href="bmra-20230531.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/Organization" xlink:href="bmra-20230531.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/PropertyAndEquipmentNet" xlink:href="bmra-20230531.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IntangibleAssetsNet" xlink:href="bmra-20230531.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpenses" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquity" xlink:href="bmra-20230531.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxes" xlink:href="bmra-20230531.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformation" xlink:href="bmra-20230531.xsd#GeographicInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingencies" xlink:href="bmra-20230531.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SubsequentEvents" xlink:href="bmra-20230531.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/PropertyAndEquipmentNetTables" xlink:href="bmra-20230531.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IntangibleAssetsNetTables" xlink:href="bmra-20230531.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquityTables" xlink:href="bmra-20230531.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxesTables" xlink:href="bmra-20230531.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformationTables" xlink:href="bmra-20230531.xsd#GeographicInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingenciesTables" xlink:href="bmra-20230531.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfNetInventoriesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfNetInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails" xlink:href="bmra-20230531.xsd#ScheduleOfDisaggregationRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="bmra-20230531.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="bmra-20230531.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="bmra-20230531.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfActivityToAggregateStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquityDetailsNarrative" xlink:href="bmra-20230531.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxesDetailsNarrative" xlink:href="bmra-20230531.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfGeographicInformationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfGeographicInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformationDetailsNarrative" xlink:href="bmra-20230531.xsd#GeographicInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="bmra-20230531.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SubsequentEventsDetailsNarrative" xlink:href="bmra-20230531.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaapInvestmentIncomeInterestAndDividend" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterestAndDividend" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge" xlink:label="loc_us-gaapInventoryLIFOReservePeriodCharge" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryLIFOReservePeriodCharge" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_IncreaseDecreaseInReductionInLeaseLiabilities" xlink:label="loc_BMRAIncreaseDecreaseInReductionInLeaseLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BMRAIncreaseDecreaseInReductionInLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/Organization" xlink:title="00000007 - Disclosure - ORGANIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/PropertyAndEquipmentNet" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IntangibleAssetsNet" xlink:title="00000010 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - SHAREHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformation" xlink:title="00000014 - Disclosure - GEOGRAPHIC INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/PropertyAndEquipmentNetTables" xlink:title="00000019 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IntangibleAssetsNetTables" xlink:title="00000020 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquityTables" xlink:title="00000022 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxesTables" xlink:title="00000023 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformationTables" xlink:title="00000024 - Disclosure - GEOGRAPHIC INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfNetInventoriesDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF NET INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:label="loc_BMRAFiniteLivedPatentsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_BMRAFiniteLivedPatentsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:title="00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:title="00000039 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000040 - Disclosure -  SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DefferedTaxAssetsStockOptions" xlink:label="loc_BMRADefferedTaxAssetsStockOptions" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_BMRADefferedTaxAssetsStockOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsCapitalizedCosts" xlink:label="loc_BMRADeferredTaxAssetsCapitalizedCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_BMRADeferredTaxAssetsCapitalizedCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:label="loc_BMRADeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_BMRADeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:label="loc_BMRADeferredTaxAssetsAccumulatedDepreciationAndAmortization" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_BMRADeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000041 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfGeographicInformationDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF GEOGRAPHIC INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformationDetailsNarrative" xlink:title="00000043 - Disclosure - GEOGRAPHIC INFORMATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_BMRALesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_BMRALesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>bmra-20230531_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biomerica.com/role/Cover" xlink:href="bmra-20230531.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/BalanceSheets" xlink:href="bmra-20230531.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/BalanceSheetsParenthetical" xlink:href="bmra-20230531.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="bmra-20230531.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfShareholdersEquity" xlink:href="bmra-20230531.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfCashFlows" xlink:href="bmra-20230531.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/Organization" xlink:href="bmra-20230531.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/PropertyAndEquipmentNet" xlink:href="bmra-20230531.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IntangibleAssetsNet" xlink:href="bmra-20230531.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpenses" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquity" xlink:href="bmra-20230531.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxes" xlink:href="bmra-20230531.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformation" xlink:href="bmra-20230531.xsd#GeographicInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingencies" xlink:href="bmra-20230531.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SubsequentEvents" xlink:href="bmra-20230531.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/PropertyAndEquipmentNetTables" xlink:href="bmra-20230531.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IntangibleAssetsNetTables" xlink:href="bmra-20230531.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquityTables" xlink:href="bmra-20230531.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxesTables" xlink:href="bmra-20230531.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformationTables" xlink:href="bmra-20230531.xsd#GeographicInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingenciesTables" xlink:href="bmra-20230531.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfNetInventoriesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfNetInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails" xlink:href="bmra-20230531.xsd#ScheduleOfDisaggregationRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="bmra-20230531.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="bmra-20230531.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="bmra-20230531.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfActivityToAggregateStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquityDetailsNarrative" xlink:href="bmra-20230531.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxesDetailsNarrative" xlink:href="bmra-20230531.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfGeographicInformationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfGeographicInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformationDetailsNarrative" xlink:href="bmra-20230531.xsd#GeographicInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="bmra-20230531.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SubsequentEventsDetailsNarrative" xlink:href="bmra-20230531.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapInventoryNet_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapInvestments_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapOtherAssetsNoncurrent_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapContractWithCustomerLiability_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommitmentsAndContingencies_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAdditionalPaidInCapital_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_BMRAOperatingLeaseRightOfUseAssetAccumulatedAmortization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BMRAOperatingLeaseRightOfUseAssetAccumulatedAmortization_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:label="loc_BMRAStockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BMRAStockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:label="loc_BMRAStockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BMRAStockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_60" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/Organization" xlink:title="00000007 - Disclosure - ORGANIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/PropertyAndEquipmentNet" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/IntangibleAssetsNet" xlink:title="00000010 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - SHAREHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformation" xlink:title="00000014 - Disclosure - GEOGRAPHIC INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/PropertyAndEquipmentNetTables" xlink:title="00000019 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/IntangibleAssetsNetTables" xlink:title="00000020 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquityTables" xlink:title="00000022 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxesTables" xlink:title="00000023 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformationTables" xlink:title="00000024 - Disclosure - GEOGRAPHIC INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfNetInventoriesDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF NET INVENTORIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_50" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ClinicalLabMember" xlink:label="loc_BMRAClinicalLabMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAClinicalLabMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OverTheCounteMember" xlink:label="loc_BMRAOverTheCounteMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAOverTheCounteMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ContractManufacturingMember" xlink:label="loc_BMRAContractManufacturingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAContractManufacturingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PhysiciansOfficeMember" xlink:label="loc_BMRAPhysiciansOfficeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAPhysiciansOfficeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMAgreementMember" xlink:label="loc_BMRAATMAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BMRAATMAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="loc_us-gaapCostOfGoodsProductLineMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsProductLineMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorOneMember" xlink:label="loc_BMRADistributorOneMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRADistributorOneMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorTwoMember" xlink:label="loc_BMRADistributorTwoMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRADistributorTwoMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneDistributorMember" xlink:label="loc_BMRAOneDistributorMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRAOneDistributorMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorsInAsiaMember" xlink:label="loc_BMRADistributorsInAsiaMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRADistributorsInAsiaMember_190" xlink:type="arc" order="193" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneVendorMember" xlink:label="loc_BMRAOneVendorMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRAOneVendorMember_200" xlink:type="arc" order="203" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MX" xlink:label="loc_countryMX_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMX_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_MarketingAndDistributionRightsMember" xlink:label="loc_BMRAMarketingAndDistributionRightsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BMRAMarketingAndDistributionRightsMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PurchasedTechnologyRightsMember" xlink:label="loc_BMRAPurchasedTechnologyRightsMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BMRAPurchasedTechnologyRightsMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PolishDistributorMember" xlink:label="loc_BMRAPolishDistributorMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BMRAPolishDistributorMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WorkingCapital" xlink:label="loc_BMRAWorkingCapital_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRAWorkingCapital_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:label="loc_BMRAShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRAShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_SaleOfStockExpenses" xlink:label="loc_BMRASaleOfStockExpenses_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRASaleOfStockExpenses_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharePrice_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaapOtherReceivablesGrossCurrent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherReceivablesGrossCurrent_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryGross_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:label="loc_us-gaapThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_340" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_AccountsReceivableCreditLossExpenseReversal" xlink:label="loc_BMRAAccountsReceivableCreditLossExpenseReversal_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRAAccountsReceivableCreditLossExpenseReversal_340" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets_340" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_340" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_340" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_340" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_340" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_340" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_340" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInvestments_340" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_340" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_340" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCustomers" xlink:label="loc_us-gaapProceedsFromCustomers_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromCustomers_340" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_340" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_340" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_340" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense_340" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_340" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" xlink:label="loc_BMRAFurnitureAndFixturesLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BMRAFurnitureAndFixturesLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:title="00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneVendorMember" xlink:label="loc_BMRAOneVendorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRAOneVendorMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoVendorMember" xlink:label="loc_BMRATwoVendorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRATwoVendorMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_BMRATwoThousandTwentyStockIncentivePlanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_BMRATwoThousandTwentyStockIncentivePlanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandFourteenPlanMember" xlink:label="loc_BMRATwoThousandFourteenPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BMRATwoThousandFourteenPlanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandSeventeenPlanMember" xlink:label="loc_BMRATwoThousandSeventeenPlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BMRATwoThousandSeventeenPlanMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandTwentyPlanMember" xlink:label="loc_BMRATwoThousandTwentyPlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BMRATwoThousandTwentyPlanMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaapEquityInterestIssuedOrIssuableByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapEquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEquityInterestIssuedOrIssuableByTypeAxis" xlink:to="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEquityInterestIssuedOrIssuableByTypeAxis" xlink:to="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMAgreementMember" xlink:label="loc_BMRAATMAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_BMRAATMAgreementMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMOfferingMember" xlink:label="loc_BMRAATMOfferingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BMRAATMOfferingMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockPurchaseAgreementMember" xlink:label="loc_BMRAStockPurchaseAgreementMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BMRAStockPurchaseAgreementMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_SaleOfStockExpenses" xlink:label="loc_BMRASaleOfStockExpenses_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_BMRASaleOfStockExpenses_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_260" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_260" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare_260" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_260" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_260" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_260" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:title="00000039 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000040 - Disclosure -  SCHEDULE OF DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000041 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfGeographicInformationDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF GEOGRAPHIC INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="loc_srtNorthAmericaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtNorthAmericaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MiddleEastMember" xlink:label="loc_us-gaapMiddleEastMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapMiddleEastMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SouthAmericaMember" xlink:label="loc_srtSouthAmericaMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtSouthAmericaMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenues_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformationDetailsNarrative" xlink:title="00000043 - Disclosure - GEOGRAPHIC INFORMATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_BuildingInIrvineCaliforniaMember" xlink:label="loc_BMRABuildingInIrvineCaliforniaMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_BMRABuildingInIrvineCaliforniaMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="loc_us-gaapRoyaltyAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapRoyaltyAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_UniversityOFSouthernCaliforniaMember" xlink:label="loc_BMRAUniversityOFSouthernCaliforniaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BMRAUniversityOFSouthernCaliforniaMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_BiomericaInFoodsMember" xlink:label="loc_BMRABiomericaInFoodsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BMRABiomericaInFoodsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSecurityDeposit_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRoyaltyExpense_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_RoyaltyExpensePercentageOfSales" xlink:label="loc_BMRARoyaltyExpensePercentageOfSales_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_BMRARoyaltyExpensePercentageOfSales_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:label="loc_BMRAClinicalTrialAgreementMaximumBudgetedCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_BMRAClinicalTrialAgreementMaximumBudgetedCosts_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biomerica.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>bmra-20230531_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMAgreementMember" xlink:label="BMRA_ATMAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ATMAgreementMember" xlink:to="BMRA_ATMAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ATMAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorOneMember" xlink:label="BMRA_DistributorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorOneMember" xlink:to="BMRA_DistributorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_DistributorOneMember_lbl" xml:lang="en-US">Distributor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorTwoMember" xlink:label="BMRA_DistributorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorTwoMember" xlink:to="BMRA_DistributorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_DistributorTwoMember_lbl" xml:lang="en-US">Distributor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneDistributorMember" xlink:label="BMRA_OneDistributorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OneDistributorMember" xlink:to="BMRA_OneDistributorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_OneDistributorMember_lbl" xml:lang="en-US">One Distributor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorsInAsiaMember" xlink:label="BMRA_DistributorsInAsiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorsInAsiaMember" xlink:to="BMRA_DistributorsInAsiaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_DistributorsInAsiaMember_lbl" xml:lang="en-US">Distributors In Asia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneVendorMember" xlink:label="BMRA_OneVendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OneVendorMember" xlink:to="BMRA_OneVendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_OneVendorMember_lbl" xml:lang="en-US">One Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MX" xlink:label="country_MX" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MX_lbl" xml:lang="en-US">MEXICO</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_MarketingAndDistributionRightsMember" xlink:label="BMRA_MarketingAndDistributionRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_MarketingAndDistributionRightsMember" xlink:to="BMRA_MarketingAndDistributionRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_MarketingAndDistributionRightsMember_lbl" xml:lang="en-US">Marketing and Distribution Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PurchasedTechnologyRightsMember" xlink:label="BMRA_PurchasedTechnologyRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PurchasedTechnologyRightsMember" xlink:to="BMRA_PurchasedTechnologyRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_PurchasedTechnologyRightsMember_lbl" xml:lang="en-US">Purchased Technology Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PolishDistributorMember" xlink:label="BMRA_PolishDistributorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PolishDistributorMember" xlink:to="BMRA_PolishDistributorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_PolishDistributorMember_lbl" xml:lang="en-US">Polish Distributor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ClinicalLabMember" xlink:label="BMRA_ClinicalLabMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ClinicalLabMember" xlink:to="BMRA_ClinicalLabMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ClinicalLabMember_lbl" xml:lang="en-US">Clinical Lab [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OverTheCounteMember" xlink:label="BMRA_OverTheCounteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OverTheCounteMember" xlink:to="BMRA_OverTheCounteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_OverTheCounteMember_lbl" xml:lang="en-US">Over The Counte [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ContractManufacturingMember" xlink:label="BMRA_ContractManufacturingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ContractManufacturingMember" xlink:to="BMRA_ContractManufacturingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ContractManufacturingMember_lbl" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PhysiciansOfficeMember" xlink:label="BMRA_PhysiciansOfficeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PhysiciansOfficeMember" xlink:to="BMRA_PhysiciansOfficeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_PhysiciansOfficeMember_lbl" xml:lang="en-US">Physicians Office [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" xlink:label="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" xlink:to="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember_lbl" xml:lang="en-US">Furniture and Fixtures Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoVendorMember" xlink:label="BMRA_TwoVendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoVendorMember" xlink:to="BMRA_TwoVendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_TwoVendorMember_lbl" xml:lang="en-US">Two Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandFourteenPlanMember" xlink:label="BMRA_TwoThousandFourteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandFourteenPlanMember" xlink:to="BMRA_TwoThousandFourteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_TwoThousandFourteenPlanMember_lbl" xml:lang="en-US">2014 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandSeventeenPlanMember" xlink:label="BMRA_TwoThousandSeventeenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandSeventeenPlanMember" xlink:to="BMRA_TwoThousandSeventeenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandTwentyPlanMember" xlink:label="BMRA_TwoThousandTwentyPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandTwentyPlanMember" xlink:to="BMRA_TwoThousandTwentyPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_TwoThousandTwentyPlanMember_lbl" xml:lang="en-US">2020 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandTwentyStockIncentivePlanMember" xlink:label="BMRA_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandTwentyStockIncentivePlanMember" xlink:to="BMRA_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMOfferingMember" xlink:label="BMRA_ATMOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ATMOfferingMember" xlink:to="BMRA_ATMOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ATMOfferingMember_lbl" xml:lang="en-US">ATM Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockPurchaseAgreementMember" xlink:label="BMRA_StockPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_StockPurchaseAgreementMember" xlink:to="BMRA_StockPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US">North America [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MiddleEastMember" xlink:label="us-gaap_MiddleEastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MiddleEastMember_lbl" xml:lang="en-US">Middle East [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SouthAmericaMember" xlink:label="srt_SouthAmericaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SouthAmericaMember_lbl" xml:lang="en-US">South America [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_BuildingInIrvineCaliforniaMember" xlink:label="BMRA_BuildingInIrvineCaliforniaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_BuildingInIrvineCaliforniaMember" xlink:to="BMRA_BuildingInIrvineCaliforniaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_BuildingInIrvineCaliforniaMember_lbl" xml:lang="en-US">Building in Irvine California [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xml:lang="en-US">Royalty Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_UniversityOFSouthernCaliforniaMember" xlink:label="BMRA_UniversityOFSouthernCaliforniaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_UniversityOFSouthernCaliforniaMember" xlink:to="BMRA_UniversityOFSouthernCaliforniaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_UniversityOFSouthernCaliforniaMember_lbl" xml:lang="en-US">University Of Southern California [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_BiomericaInFoodsMember" xlink:label="BMRA_BiomericaInFoodsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_BiomericaInFoodsMember" xlink:to="BMRA_BiomericaInFoodsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_BiomericaInFoodsMember_lbl" xml:lang="en-US">Biomerica in Foods [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets, net of accumulated amortization of $617,000 and $725,000 as of May 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Advance from customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liabilities, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.08 par value, 25,000,000 shares authorized, 16,821,646 and 12,867,924 issued and outstanding at May 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Dividend and interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of common and</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:label="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:to="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Shares issued in connection with public offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:label="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:to="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Shares issued in connection with public offering, net of offering costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for allowance on accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Inventory reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Advance from customers</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_IncreaseDecreaseInReductionInLeaseLiabilities" xlink:label="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities" xlink:to="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities_lbl" xml:lang="en-US">Reduction in lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Expenditure related to intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_CashPaidDuringYearForAbstract" xlink:label="BMRA_CashPaidDuringYearForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_CashPaidDuringYearForAbstract" xlink:to="BMRA_CashPaidDuringYearForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" xlink:label="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" xlink:to="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment_lbl" xml:lang="en-US">Increase in right-of-use asset due to lease extension or establishment</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" xlink:label="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" xlink:to="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment_lbl" xml:lang="en-US">Increase in lease liability due to lease extension or establishment</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfFixedAssetsCost" xlink:label="BMRA_WriteOffOfFixedAssetsCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfFixedAssetsCost" xlink:to="BMRA_WriteOffOfFixedAssetsCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_WriteOffOfFixedAssetsCost_lbl" xml:lang="en-US">Write off of fixed assets, cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:label="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:to="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation_lbl" xml:lang="en-US">Write off of fixed assets, accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfIntangibleAssetsCost" xlink:label="BMRA_WriteOffOfIntangibleAssetsCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfIntangibleAssetsCost" xlink:to="BMRA_WriteOffOfIntangibleAssetsCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_WriteOffOfIntangibleAssetsCost_lbl" xml:lang="en-US">Write off of intangible assets, cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:label="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:to="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Write off of intangible assets, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">PRINCIPLES OF CONSOLIDATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">ACCOUNTING ESTIMATES</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_LiquidityPolicyTextBlock" xlink:label="BMRA_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_LiquidityPolicyTextBlock" xlink:to="BMRA_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">CONCENTRATION OF CREDIT RISK</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:label="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl" xml:lang="en-US">GEOGRAPHIC CONCENTRATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PrepaidExpensesAndOtherPolicyTextBlock" xlink:label="BMRA_PrepaidExpensesAndOtherPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PrepaidExpensesAndOtherPolicyTextBlock" xlink:to="BMRA_PrepaidExpensesAndOtherPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_PrepaidExpensesAndOtherPolicyTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">INVENTORIES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">INVESTMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">SHIPPING AND HANDLING FEES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">ADVERTISING COSTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">FOREIGN CURRENCY TRANSLATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">REPORTING COMPREHENSIVE LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DISAGGREGATION REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GEOGRAPHIC INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" xlink:label="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" xlink:to="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished products</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Total gross inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Net inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rate minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest rate maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WorkingCapital" xlink:label="BMRA_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WorkingCapital" xlink:to="BMRA_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMRA_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:label="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl" xml:lang="en-US">Shelf registration statement maximum authorized common stock issuance value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_SaleOfStockExpenses" xlink:label="BMRA_SaleOfStockExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_SaleOfStockExpenses" xlink:to="BMRA_SaleOfStockExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_SaleOfStockExpenses_lbl" xml:lang="en-US">Sale of stock expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Net proceeds from ATM (in Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="us-gaap_OtherReceivablesGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Other receivables, gross, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_2_lbl" xml:lang="en-US">Inventory, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl" xml:lang="en-US">Threshold period past due for write-off of trade accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_AccountsReceivableCreditLossExpenseReversal" xlink:label="BMRA_AccountsReceivableCreditLossExpenseReversal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_AccountsReceivableCreditLossExpenseReversal" xlink:to="BMRA_AccountsReceivableCreditLossExpenseReversal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_AccountsReceivableCreditLossExpenseReversal_lbl" xml:lang="en-US">Accounts receivable, credit loss expense (Reversal)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expense and other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xml:lang="en-US">Depreciation, depletion and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from customers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Furniture, fixtures and leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_3_lbl" xml:lang="en-US">Net property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:label="BMRA_FiniteLivedPatentsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:to="BMRA_FiniteLivedPatentsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMRA_FiniteLivedPatentsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization-patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_2_lbl" xml:lang="en-US">Net sales percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Total stock option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Outstanding Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Granted Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Exercised Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options exercised, Aggregate IntrinsicValue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options cancelled or expired, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options canceled or expired Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Options vested and exercisable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options vested and exercisable Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Options vested and exercisable Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based payment award, number of shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Award purchase price, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted, weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Compenation cost related to non-vested stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested, exercisable or expected to vest weighted average remaining contractual term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Preferred stock, purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Sale of stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Sale of stock, net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends payable, amount per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of stock, shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Conversion of stock, shares issued upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign Taxes Subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent tax differences and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Stock based compensation benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign taxes of subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable, principally due to allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US">Compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US">Deferred rent expense/Capitalized leases</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DefferedTaxAssetsStockOptions" xlink:label="BMRA_DefferedTaxAssetsStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DefferedTaxAssetsStockOptions" xlink:to="BMRA_DefferedTaxAssetsStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_DefferedTaxAssetsStockOptions_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsCapitalizedCosts" xlink:label="BMRA_DeferredTaxAssetsCapitalizedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsCapitalizedCosts" xlink:to="BMRA_DeferredTaxAssetsCapitalizedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_DeferredTaxAssetsCapitalizedCosts_lbl" xml:lang="en-US">Sec 174 capitalized costs</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:label="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl" xml:lang="en-US">Losses of foreign subsidiaries &amp; other, net</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:label="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Increase in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum future lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operating lease description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Lease area</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease renewal term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_RoyaltyExpensePercentageOfSales" xlink:label="BMRA_RoyaltyExpensePercentageOfSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_RoyaltyExpensePercentageOfSales" xlink:to="BMRA_RoyaltyExpensePercentageOfSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_RoyaltyExpensePercentageOfSales_lbl" xml:lang="en-US">Royalty expense percentage of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:label="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts_lbl" xml:lang="en-US">Clinical trial agreement maximum budgeted costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" xlink:to="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember_doc" xml:lang="en-US">Furniture and Fixtures Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_FiniteLivedLicensesAccumulatedAmortization" xlink:label="BMRA_FiniteLivedLicensesAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FiniteLivedLicensesAccumulatedAmortization" xlink:to="BMRA_FiniteLivedLicensesAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_FiniteLivedLicensesAccumulatedAmortization_doc" xml:lang="en-US">Finite lived licenses accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:to="BMRA_FiniteLivedPatentsAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_FiniteLivedPatentsAccumulatedAmortization_doc" xml:lang="en-US">Finite lived patents accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoVendorMember" xlink:to="BMRA_TwoVendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoVendorMember_doc" xml:lang="en-US">Two Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OneVendorMember" xlink:to="BMRA_OneVendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_OneVendorMember_doc" xml:lang="en-US">One Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandFourteenPlanMember" xlink:to="BMRA_TwoThousandFourteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandFourteenPlanMember_doc" xml:lang="en-US">2014 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandSeventeenPlanMember" xlink:to="BMRA_TwoThousandSeventeenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandSeventeenPlanMember_doc" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandTwentyPlanMember" xlink:to="BMRA_TwoThousandTwentyPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandTwentyPlanMember_doc" xml:lang="en-US">2020 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:to="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_doc" xml:lang="en-US">Stock issued during period value shares issued in connection with public offering net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:to="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts_doc" xml:lang="en-US">Stock issued during period shares issued in connection with public offering net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities" xlink:to="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_IncreaseDecreaseInReductionInLeaseLiabilities_doc" xml:lang="en-US">Increase decrease in reduction in lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_CashPaidDuringYearForAbstract" xlink:to="BMRA_CashPaidDuringYearForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_CashPaidDuringYearForAbstract_doc" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" xlink:to="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment_doc" xml:lang="en-US">Increase in right of use asset due to lease extension or establishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" xlink:to="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment_doc" xml:lang="en-US">Increase in lease liability due to lease extension or establishment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfFixedAssetsCost" xlink:to="BMRA_WriteOffOfFixedAssetsCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_WriteOffOfFixedAssetsCost_doc" xml:lang="en-US">Write off of fixed assets cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:to="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation_doc" xml:lang="en-US">Write off of fixed assets accumulated depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfIntangibleAssetsCost" xlink:to="BMRA_WriteOffOfIntangibleAssetsCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_WriteOffOfIntangibleAssetsCost_doc" xml:lang="en-US">Write off of intangible assets cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:to="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization_doc" xml:lang="en-US">Write off of intangible assets accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_LiquidityPolicyTextBlock" xlink:to="BMRA_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WorkingCapital" xlink:to="BMRA_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_doc" xml:lang="en-US">Shelf registration statement maximum authorized common stock issuance value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ATMAgreementMember" xlink:to="BMRA_ATMAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ATMAgreementMember_doc" xml:lang="en-US">ATM Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ATMOfferingMember" xlink:to="BMRA_ATMOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ATMOfferingMember_doc" xml:lang="en-US">ATM Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoDistributorsMember" xlink:label="BMRA_TwoDistributorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoDistributorsMember" xlink:to="BMRA_TwoDistributorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoDistributorsMember_doc" xml:lang="en-US">Two Distributors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OneDistributorMember" xlink:to="BMRA_OneDistributorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_OneDistributorMember_doc" xml:lang="en-US">One Distributor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorsInAsiaMember" xlink:to="BMRA_DistributorsInAsiaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DistributorsInAsiaMember_doc" xml:lang="en-US">Distributors In Asia [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_SaleOfStockExpenses" xlink:to="BMRA_SaleOfStockExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_SaleOfStockExpenses_doc" xml:lang="en-US">Sale of stock expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PrepaidExpensesAndOtherPolicyTextBlock" xlink:to="BMRA_PrepaidExpensesAndOtherPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PrepaidExpensesAndOtherPolicyTextBlock_doc" xml:lang="en-US">Prepaid Expenses and Other [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_StockPurchaseAgreementMember" xlink:to="BMRA_StockPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_StockPurchaseAgreementMember_doc" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_MarketingAndDistributionRightsMember" xlink:to="BMRA_MarketingAndDistributionRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_MarketingAndDistributionRightsMember_doc" xml:lang="en-US">Marketing and Distribution Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PurchasedTechnologyRightsMember" xlink:to="BMRA_PurchasedTechnologyRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PurchasedTechnologyRightsMember_doc" xml:lang="en-US">Purchased Technology Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DefferedTaxAssetsStockOptions" xlink:to="BMRA_DefferedTaxAssetsStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DefferedTaxAssetsStockOptions_doc" xml:lang="en-US">Deffered tax assets stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_doc" xml:lang="en-US">Deferred tax assets losses of foreign subsidiaries other net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ClinicalLabMember" xlink:to="BMRA_ClinicalLabMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ClinicalLabMember_doc" xml:lang="en-US">Clinical Lab [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_doc" xml:lang="en-US">Deferred Tax Assets Accumulated Depreciation and Amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ContractManufacturingMember" xlink:to="BMRA_ContractManufacturingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ContractManufacturingMember_doc" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsCapitalizedCosts" xlink:to="BMRA_DeferredTaxAssetsCapitalizedCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DeferredTaxAssetsCapitalizedCosts_doc" xml:lang="en-US">Deferred tax assets capitalized costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PhysiciansOfficeMember" xlink:to="BMRA_PhysiciansOfficeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PhysiciansOfficeMember_doc" xml:lang="en-US">Physicians Office [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock_doc" xml:lang="en-US">Concentration Risk Geographic Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_BuildingInIrvineCaliforniaMember" xlink:to="BMRA_BuildingInIrvineCaliforniaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_BuildingInIrvineCaliforniaMember_doc" xml:lang="en-US">Building in Irvine California [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Lessee operating lease liability payments due after year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" xlink:to="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock_doc" xml:lang="en-US">Schedule of Supplemental Lease Information [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_RoyaltyExpensePercentageOfSales" xlink:to="BMRA_RoyaltyExpensePercentageOfSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_RoyaltyExpensePercentageOfSales_doc" xml:lang="en-US">Royalty expense percentage of sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ClinicalTrialAgreementMaximumBudgetedCosts_doc" xml:lang="en-US">Clinical trial agreement maximum budgeted costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_UniversityOFSouthernCaliforniaMember" xlink:to="BMRA_UniversityOFSouthernCaliforniaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_UniversityOFSouthernCaliforniaMember_doc" xml:lang="en-US">University Of Southern California [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_BiomericaInFoodsMember" xlink:to="BMRA_BiomericaInFoodsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_BiomericaInFoodsMember_doc" xml:lang="en-US">Biomerica in Foods [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_AccountsReceivableCreditLossExpenseReversal" xlink:to="BMRA_AccountsReceivableCreditLossExpenseReversal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_AccountsReceivableCreditLossExpenseReversal_doc" xml:lang="en-US">Accounts receivable credit loss expense reversal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PolishDistributorMember" xlink:to="BMRA_PolishDistributorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PolishDistributorMember_doc" xml:lang="en-US">Polish Distributor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OverTheCounteMember" xlink:to="BMRA_OverTheCounteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_OverTheCounteMember_doc" xml:lang="en-US">Over The Counte [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandTwentyStockIncentivePlanMember" xlink:to="BMRA_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization_doc" xml:lang="en-US">Operating loease right of use asset accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorOneMember" xlink:to="BMRA_DistributorOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DistributorOneMember_doc" xml:lang="en-US">Distributor One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorTwoMember" xlink:to="BMRA_DistributorTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DistributorTwoMember_doc" xml:lang="en-US">Distributor Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Cost of Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WorkingCapital" xlink:to="BMRA_WorkingCapital_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_WorkingCapital_3_lbl" xml:lang="en-US">WorkingCapital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:to="BMRA_FiniteLivedPatentsAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_FiniteLivedPatentsAccumulatedAmortization_3_lbl" xml:lang="en-US">FiniteLivedPatentsAccumulatedAmortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>bmra-20230531_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biomerica.com/role/Cover" xlink:href="bmra-20230531.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/BalanceSheets" xlink:href="bmra-20230531.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/BalanceSheetsParenthetical" xlink:href="bmra-20230531.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="bmra-20230531.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfShareholdersEquity" xlink:href="bmra-20230531.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/StatementsOfCashFlows" xlink:href="bmra-20230531.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/Organization" xlink:href="bmra-20230531.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/PropertyAndEquipmentNet" xlink:href="bmra-20230531.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IntangibleAssetsNet" xlink:href="bmra-20230531.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpenses" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquity" xlink:href="bmra-20230531.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxes" xlink:href="bmra-20230531.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformation" xlink:href="bmra-20230531.xsd#GeographicInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingencies" xlink:href="bmra-20230531.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SubsequentEvents" xlink:href="bmra-20230531.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/PropertyAndEquipmentNetTables" xlink:href="bmra-20230531.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IntangibleAssetsNetTables" xlink:href="bmra-20230531.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquityTables" xlink:href="bmra-20230531.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxesTables" xlink:href="bmra-20230531.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformationTables" xlink:href="bmra-20230531.xsd#GeographicInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingenciesTables" xlink:href="bmra-20230531.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfNetInventoriesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfNetInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails" xlink:href="bmra-20230531.xsd#ScheduleOfDisaggregationRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="bmra-20230531.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="bmra-20230531.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="bmra-20230531.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:href="bmra-20230531.xsd#AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="bmra-20230531.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfActivityToAggregateStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ShareholdersEquityDetailsNarrative" xlink:href="bmra-20230531.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/IncomeTaxesDetailsNarrative" xlink:href="bmra-20230531.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfGeographicInformationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfGeographicInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/GeographicInformationDetailsNarrative" xlink:href="bmra-20230531.xsd#GeographicInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="bmra-20230531.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="bmra-20230531.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:href="bmra-20230531.xsd#ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="bmra-20230531.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biomerica.com/role/SubsequentEventsDetailsNarrative" xlink:href="bmra-20230531.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_BMRAOperatingLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BMRAOperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaapInvestmentIncomeInterestAndDividend" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterestAndDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:label="loc_BMRAStockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BMRAStockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:label="loc_BMRAStockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BMRAStockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge" xlink:label="loc_us-gaapInventoryLIFOReservePeriodCharge" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryLIFOReservePeriodCharge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_IncreaseDecreaseInReductionInLeaseLiabilities" xlink:label="loc_BMRAIncreaseDecreaseInReductionInLeaseLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_BMRAIncreaseDecreaseInReductionInLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_CashPaidDuringYearForAbstract" xlink:label="loc_BMRACashPaidDuringYearForAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_BMRACashPaidDuringYearForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMRACashPaidDuringYearForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" xlink:label="loc_BMRAIncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_BMRAIncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" xlink:label="loc_BMRAIncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_BMRAIncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfFixedAssetsCost" xlink:label="loc_BMRAWriteOffOfFixedAssetsCost" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_BMRAWriteOffOfFixedAssetsCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:label="loc_BMRAWriteOffOfFixedAssetsAccumulatedDepreciation" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_BMRAWriteOffOfFixedAssetsAccumulatedDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfIntangibleAssetsCost" xlink:label="loc_BMRAWriteOffOfIntangibleAssetsCost" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_BMRAWriteOffOfIntangibleAssetsCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:label="loc_BMRAWriteOffOfIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_BMRAWriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/Organization" xlink:title="00000007 - Disclosure - ORGANIZATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/PropertyAndEquipmentNet" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IntangibleAssetsNet" xlink:title="00000010 - Disclosure - INTANGIBLE ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - SHAREHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformation" xlink:title="00000014 - Disclosure - GEOGRAPHIC INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_LiquidityPolicyTextBlock" xlink:label="loc_BMRALiquidityPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BMRALiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:label="loc_BMRAConcentrationRiskGeographicPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BMRAConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PrepaidExpensesAndOtherPolicyTextBlock" xlink:label="loc_BMRAPrepaidExpensesAndOtherPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BMRAPrepaidExpensesAndOtherPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/PropertyAndEquipmentNetTables" xlink:title="00000019 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IntangibleAssetsNetTables" xlink:title="00000020 - Disclosure - INTANGIBLE ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquityTables" xlink:title="00000022 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxesTables" xlink:title="00000023 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformationTables" xlink:title="00000024 - Disclosure - GEOGRAPHIC INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" xlink:label="loc_BMRAScheduleOfSupplementalLeaseInformationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_BMRAScheduleOfSupplementalLeaseInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfNetInventoriesDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF NET INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ClinicalLabMember" xlink:label="loc_BMRAClinicalLabMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAClinicalLabMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OverTheCounteMember" xlink:label="loc_BMRAOverTheCounteMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAOverTheCounteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ContractManufacturingMember" xlink:label="loc_BMRAContractManufacturingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAContractManufacturingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PhysiciansOfficeMember" xlink:label="loc_BMRAPhysiciansOfficeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_BMRAPhysiciansOfficeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMAgreementMember" xlink:label="loc_BMRAATMAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BMRAATMAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="loc_us-gaapCostOfGoodsProductLineMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsProductLineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorOneMember" xlink:label="loc_BMRADistributorOneMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRADistributorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorTwoMember" xlink:label="loc_BMRADistributorTwoMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRADistributorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneDistributorMember" xlink:label="loc_BMRAOneDistributorMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRAOneDistributorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DistributorsInAsiaMember" xlink:label="loc_BMRADistributorsInAsiaMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRADistributorsInAsiaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneVendorMember" xlink:label="loc_BMRAOneVendorMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRAOneVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtStatementGeographicalAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MX" xlink:label="loc_countryMX" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMX" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_MarketingAndDistributionRightsMember" xlink:label="loc_BMRAMarketingAndDistributionRightsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BMRAMarketingAndDistributionRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PurchasedTechnologyRightsMember" xlink:label="loc_BMRAPurchasedTechnologyRightsMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BMRAPurchasedTechnologyRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_PolishDistributorMember" xlink:label="loc_BMRAPolishDistributorMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BMRAPolishDistributorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_WorkingCapital" xlink:label="loc_BMRAWorkingCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRAWorkingCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:label="loc_BMRAShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRAShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_SaleOfStockExpenses" xlink:label="loc_BMRASaleOfStockExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRASaleOfStockExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaapOtherReceivablesGrossCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherReceivablesGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:label="loc_us-gaapThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_AccountsReceivableCreditLossExpenseReversal" xlink:label="loc_BMRAAccountsReceivableCreditLossExpenseReversal" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_BMRAAccountsReceivableCreditLossExpenseReversal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCustomers" xlink:label="loc_us-gaapProceedsFromCustomers" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" xlink:label="loc_BMRAFurnitureAndFixturesLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BMRAFurnitureAndFixturesLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:label="loc_BMRAFiniteLivedPatentsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_BMRAFiniteLivedPatentsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:title="00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_OneVendorMember" xlink:label="loc_BMRAOneVendorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRAOneVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoVendorMember" xlink:label="loc_BMRATwoVendorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BMRATwoVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_BMRATwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_BMRATwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandFourteenPlanMember" xlink:label="loc_BMRATwoThousandFourteenPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BMRATwoThousandFourteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandSeventeenPlanMember" xlink:label="loc_BMRATwoThousandSeventeenPlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BMRATwoThousandSeventeenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_TwoThousandTwentyPlanMember" xlink:label="loc_BMRATwoThousandTwentyPlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BMRATwoThousandTwentyPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaapEquityInterestIssuedOrIssuableByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapEquityInterestIssuedOrIssuableByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityInterestIssuedOrIssuableByTypeAxis" xlink:to="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityInterestIssuedOrIssuableTypeDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMAgreementMember" xlink:label="loc_BMRAATMAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_BMRAATMAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ATMOfferingMember" xlink:label="loc_BMRAATMOfferingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BMRAATMOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_StockPurchaseAgreementMember" xlink:label="loc_BMRAStockPurchaseAgreementMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BMRAStockPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_SaleOfStockExpenses" xlink:label="loc_BMRASaleOfStockExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_BMRASaleOfStockExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails" xlink:title="00000039 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000040 - Disclosure -  SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DefferedTaxAssetsStockOptions" xlink:label="loc_BMRADefferedTaxAssetsStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BMRADefferedTaxAssetsStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsCapitalizedCosts" xlink:label="loc_BMRADeferredTaxAssetsCapitalizedCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BMRADeferredTaxAssetsCapitalizedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:label="loc_BMRADeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BMRADeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:label="loc_BMRADeferredTaxAssetsAccumulatedDepreciationAndAmortization" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BMRADeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000041 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfGeographicInformationDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF GEOGRAPHIC INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="loc_srtNorthAmericaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtNorthAmericaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MiddleEastMember" xlink:label="loc_us-gaapMiddleEastMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapMiddleEastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SouthAmericaMember" xlink:label="loc_srtSouthAmericaMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtSouthAmericaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/GeographicInformationDetailsNarrative" xlink:title="00000043 - Disclosure - GEOGRAPHIC INFORMATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_BMRALesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_BMRALesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_BuildingInIrvineCaliforniaMember" xlink:label="loc_BMRABuildingInIrvineCaliforniaMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_BMRABuildingInIrvineCaliforniaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="loc_us-gaapRoyaltyAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapRoyaltyAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_UniversityOFSouthernCaliforniaMember" xlink:label="loc_BMRAUniversityOFSouthernCaliforniaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BMRAUniversityOFSouthernCaliforniaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_BiomericaInFoodsMember" xlink:label="loc_BMRABiomericaInFoodsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BMRABiomericaInFoodsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_RoyaltyExpensePercentageOfSales" xlink:label="loc_BMRARoyaltyExpensePercentageOfSales" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_BMRARoyaltyExpensePercentageOfSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmra-20230531.xsd#BMRA_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:label="loc_BMRAClinicalTrialAgreementMaximumBudgetedCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_BMRAClinicalTrialAgreementMaximumBudgetedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202656688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Aug. 25, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--05-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMERICA,
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000073290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-2645573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">17571
Von Karman Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">645-2111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,738,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,821,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement on Schedule 14A relating to the registrant&#8217;s
2023 annual meeting of stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal
year covered by this Annual Report on Form 10-K, are incorporated by reference in Part III, Items 10 through 14 of this Annual Report
on Form 10-K. Except for the portions of the Proxy Statement specifically incorporated by reference in this Form 10-K, the Proxy Statement
and related proxy solicitation materials shall not be deemed to be filed as part hereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">HASKELL & WHITE LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine,
California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202312768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,719,000<span></span>
</td>
<td class="nump">$ 5,917,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">722,000<span></span>
</td>
<td class="nump">774,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,056,000<span></span>
</td>
<td class="nump">2,416,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">12,797,000<span></span>
</td>
<td class="nump">9,427,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net of accumulated amortization of $617,000 and $725,000 as of May 31, 2023 and 2022, respectively</a></td>
<td class="nump">1,035,000<span></span>
</td>
<td class="nump">1,302,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">14,454,000<span></span>
</td>
<td class="nump">11,374,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">892,000<span></span>
</td>
<td class="nump">972,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">696,000<span></span>
</td>
<td class="nump">647,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Advance from customers</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">297,000<span></span>
</td>
<td class="nump">341,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,945,000<span></span>
</td>
<td class="nump">2,011,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">785,000<span></span>
</td>
<td class="nump">1,038,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,730,000<span></span>
</td>
<td class="nump">3,049,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.08 par value, 25,000,000 shares authorized, 16,821,646 and 12,867,924 issued and outstanding at May 31, 2023 and 2022, respectively</a></td>
<td class="nump">1,346,000<span></span>
</td>
<td class="nump">1,029,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">52,705,000<span></span>
</td>
<td class="nump">42,447,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(110,000)<span></span>
</td>
<td class="num">(74,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(42,217,000)<span></span>
</td>
<td class="num">(35,077,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">11,724,000<span></span>
</td>
<td class="nump">8,325,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">14,454,000<span></span>
</td>
<td class="nump">11,374,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379201565296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">$ 617,000<span></span>
</td>
<td class="nump">$ 725,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">4,428,571<span></span>
</td>
<td class="nump">4,428,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,821,646<span></span>
</td>
<td class="nump">12,867,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,821,646<span></span>
</td>
<td class="nump">12,867,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loease right of use asset accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379208548768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 5,339,000<span></span>
</td>
<td class="nump">$ 18,871,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="num">(4,893,000)<span></span>
</td>
<td class="num">(15,894,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">446,000<span></span>
</td>
<td class="nump">2,977,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">6,085,000<span></span>
</td>
<td class="nump">5,699,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,584,000<span></span>
</td>
<td class="nump">1,812,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">7,669,000<span></span>
</td>
<td class="nump">7,511,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,223,000)<span></span>
</td>
<td class="num">(4,534,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividend and interest income</a></td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">134,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(7,089,000)<span></span>
</td>
<td class="num">(4,507,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(51,000)<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,140,000)<span></span>
</td>
<td class="num">$ (4,531,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common and</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">14,154,269<span></span>
</td>
<td class="nump">12,673,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">14,154,269<span></span>
</td>
<td class="nump">12,673,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">$ (36,000)<span></span>
</td>
<td class="num">$ (26,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (7,176,000)<span></span>
</td>
<td class="num">$ (4,557,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202684784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at May. 31, 2021</a></td>
<td class="nump">$ 985,000<span></span>
</td>
<td class="nump">$ 38,837,000<span></span>
</td>
<td class="num">$ (48,000)<span></span>
</td>
<td class="num">$ (30,546,000)<span></span>
</td>
<td class="nump">$ 9,228,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at May. 31, 2021</a></td>
<td class="nump">12,307,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">2,276,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,317,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM, shares</a></td>
<td class="nump">521,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,531,000)<span></span>
</td>
<td class="num">(4,531,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at May. 31, 2022</a></td>
<td class="nump">$ 1,029,000<span></span>
</td>
<td class="nump">42,447,000<span></span>
</td>
<td class="num">(74,000)<span></span>
</td>
<td class="num">(35,077,000)<span></span>
</td>
<td class="nump">8,325,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at May. 31, 2022</a></td>
<td class="nump">12,867,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">1,915,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,961,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM, shares</a></td>
<td class="nump">573,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,185,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,140,000)<span></span>
</td>
<td class="num">(7,140,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts', window );">Shares issued in connection with public offering, net of offering costs</a></td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="nump">7,081,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,348,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts', window );">Shares issued in connection with public offering, net of offering costs, shares</a></td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at May. 31, 2023</a></td>
<td class="nump">$ 1,346,000<span></span>
</td>
<td class="nump">$ 52,705,000<span></span>
</td>
<td class="num">$ (110,000)<span></span>
</td>
<td class="num">$ (42,217,000)<span></span>
</td>
<td class="nump">$ 11,724,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at May. 31, 2023</a></td>
<td class="nump">16,821,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issued in connection with public offering net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value shares issued in connection with public offering net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379208465296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,140,000)<span></span>
</td>
<td class="num">$ (4,531,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">339,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">53,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for allowance on accounts receivable</a></td>
<td class="nump">342,000<span></span>
</td>
<td class="num">(684,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Inventory reserve</a></td>
<td class="num">(174,000)<span></span>
</td>
<td class="num">(772,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,185,000<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(291,000)<span></span>
</td>
<td class="nump">1,365,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">534,000<span></span>
</td>
<td class="nump">1,562,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(80,000)<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Advance from customers</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_IncreaseDecreaseInReductionInLeaseLiabilities', window );">Reduction in lease liabilities</a></td>
<td class="num">(297,000)<span></span>
</td>
<td class="num">(244,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,474,000)<span></span>
</td>
<td class="num">(479,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditure related to intangibles</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="num">(113,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(64,000)<span></span>
</td>
<td class="num">(57,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(78,000)<span></span>
</td>
<td class="num">(170,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">10,014,000<span></span>
</td>
<td class="nump">2,402,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs from sale of common stock</a></td>
<td class="num">(705,000)<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,390,000<span></span>
</td>
<td class="nump">2,394,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes in cash</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">3,802,000<span></span>
</td>
<td class="nump">1,719,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">5,917,000<span></span>
</td>
<td class="nump">4,199,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">9,719,000<span></span>
</td>
<td class="nump">5,917,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_CashPaidDuringYearForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment', window );">Increase in right-of-use asset due to lease extension or establishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment', window );">Increase in lease liability due to lease extension or establishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_WriteOffOfFixedAssetsCost', window );">Write off of fixed assets, cost</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">820,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation', window );">Write off of fixed assets, accumulated depreciation</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">767,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_WriteOffOfIntangibleAssetsCost', window );">Write off of intangible assets, cost</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">247,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization', window );">Write off of intangible assets, accumulated amortization</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Year For [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_IncreaseDecreaseInReductionInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in reduction in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_IncreaseDecreaseInReductionInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in lease liability due to lease extension or establishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in right of use asset due to lease extension or establishment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of fixed assets accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_WriteOffOfFixedAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of fixed assets cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_WriteOffOfFixedAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of intangible assets accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_WriteOffOfIntangibleAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of intangible assets cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_WriteOffOfIntangibleAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379203934064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zaNIuuV29Ppj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1: <span id="xdx_82A_zcwwzjYuPkld">ORGANIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica,
Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is a biomedical technology
company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians&#8217;
offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. Our diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis
of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens,
or other substances, which may exist in the human body in extremely small concentrations. The Company&#8217;s products are designed to
enhance the health and well-being of people, while reducing total healthcare costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided
therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other
inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address
very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that,
when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, and constipation. Instead of broad and difficult
to manage dietary restrictions, the InFoods&#174; IBS product works by identifying specific foods that may be causing an abnormally high
immune response in the patient. A food identified as positive, which is causing the abnormal immune response in the patient,
is simply removed from the diet to help alleviate IBS symptoms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our existing medical diagnostic products are sold worldwide primarily in
two markets: 1) clinical laboratories and 2) point-of-care (physicians&#8217; offices and over-the-counter drugstores like Walmart and
CVS Pharmacy). The diagnostic test kits are used to analyze blood, urine, nasal, or fecal specimens from patients in the diagnosis of
various diseases, food intolerances, and other medical complications, by measuring or detecting the existence and/or level of specific
bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely
small concentrations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the global COVID-19 pandemic, in March 2020, we began developing COVID-19 products to indicate if a person has been infected by COVID-19
or is currently infected. In fiscal 2022, we generated revenues from the international sale of our COVID-19 antigen tests. However, in
fiscal 2023, due to the decline in severity of COVID-19 and the corresponding lower sales volumes, we no longer sell these products.
Due to the relatively high volume of sales from these products in fiscal 2021 and fiscal 2022, we have seen significant fluctuations
in quarterly revenues over the past twelve quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
other existing products that contributed to our 2023 revenues are primarily focused on gastrointestinal diseases, food intolerances,
and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or
sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for
sale in the United States by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379204103024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_z8PkU7pRtSK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2: <span id="xdx_82E_zpHuYaPeoOWk">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z7gFfpvpLaT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZwFKfOCmSdd">PRINCIPLES
OF CONSOLIDATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements for the years ended May 31, 2023 and 2022, include the accounts of Biomerica, Inc. (&#8220;Biomerica&#8221;)
as well as its wholly-owned German subsidiary (&#8220;BioEurope GmbH&#8221;) and Mexican subsidiary (&#8220;Biomerica de Mexico&#8221;).
All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zuySZ9CDyIC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zTPMeefF7g3j">ACCOUNTING
ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful
accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates,
which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of
materials; and lease liabilities and right-of-use assets, which are calculated based on certain assumptions such as the borrowing
rate on the lease commencement date and, the likelihood of lease extensions to occur, asset valuations, among other things; and other items that may be necessary to
estimate using current, historical and judgment based information. Actual results could materially differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the global COVID-19 pandemic, the Company&#8217;s operations have been negatively impacted. The Company has faced disruptions in the
following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s
manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping
and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or
sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer
credit risk, and general economic calamities. These pandemic related disruptions can materially negatively impact the Company&#8217;s
operations and financial performance and may continue to have significant material negative impacts on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--LiquidityPolicyTextBlock_zW6vUuWhG1Ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjOTo59chAK9">LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn6n6_di_c20230531_zR7wm3w9TnGd" title="Accumulated deficit">42</span> million as
of May 31, 2023. Management expects to continue to incur significant costs as it advances its trials and development activities. As of
May 31, 2023, the Company had cash and cash equivalents of approximately $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230531_zI7WIQvdh0s9" title="Cash and cash equivalents">9,719,000</span> and working capital of approximately $<span id="xdx_908_ecustom--WorkingCapital_iNI_di_c20230531_zS9FSdFRDyN8" title="Working capital">10,852,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $<span id="xdx_90B_ecustom--ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_iI_c20210122_zNs4j3moD7f9" title="Shelf registration statement maximum authorized common stock issuance value">15,000,000</span> in &#8220;at-the-market&#8221;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#8220;ATM Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#8217;s behalf all the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any shares under the ATM Offering, and may at any time suspend offers
under, or terminate the ATM Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zKcvJRy8jlm4" title="Sale of stock, number of shares issued in transaction">573,889</span> shares of its common stock at prices ranging from $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zSjRvtL1zhQ" title="Sale of stock, price per share">3.15</span> to $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zdRfY3Ch057a" title="Sale of stock, price per share">4.26</span> pursuant to the
ATM Agreement, which resulted in gross proceeds of approximately $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zgSVz1vLMHJ5" title="Sale of stock, consideration received on transaction">2,014,000</span> and net proceeds to the Company of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z7YVQm30GfFf" title="Proceeds from issuance of common stock">1,961,000</span>, after deducting
commissions for each sale and legal, accounting, and other fees related to offering in the amount of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zFVG7Rapmvy7" title="Sale of stock expenses">53,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2022, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zk6s2jb3LzFl" title="Sale of stock, number of shares issued in transaction">521,267</span> shares of its common stock at prices ranging from $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBGjiqSfbqg2" title="Sale of stock, price per share">4.02</span> to $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1tHM7RXW0U2" title="Sale of stock, price per share">5.63</span> pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBmMSveBMcal" title="Sale of stock, consideration received on transaction">2,402,000</span> and net proceeds to the Company of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zbgeua5vzmrd" title="Proceeds from issuance of common stock">2,317,000</span>, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $<span id="xdx_906_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1J6pzOT4cAh" title="Sale of stock expenses">85,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 7, 2023, the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zQQg5I8fRDzb" title="Net proceeds from ATM (in Shares)">3,333,333</span> shares of common stock in a firm commitment public offering at a gross sales price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z2pu4lFTRZq" title="Share price">2.40</span>
per share, with net total proceeds, after deducting issuance fees and expenses of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zWIHolrzirAg" title="Sale of stock expenses">700,000</span>, of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zqJEv3gsEkG7" title="Proceeds from issuance of common stock">7,300,000</span>. Since the closing
of the March 7, 2023 offering, the ATM has been withdrawn and is not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from such offerings for general corporate purposes, including, without limitation, sales and
marketing activities, clinical studies, product development, making acquisitions of assets, businesses, companies or securities,
capital expenditures, and for working capital needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has analyzed the cash requirements of the Company&#8217;s business through at least August 2024. As a result of cash and cash
equivalents on hand on May 31, 2023, largely from the public offering, and the ability to raise additional funds through another new
ATM agreement, management believes the Company has sufficient funds to operate through at least August 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zj7jiqvTvXB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMZUTNqxBcJ4">FAIR
VALUE OF FINANCIAL INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on
a historical basis. The Company&#8217;s consolidated financial instruments consist of its cash and cash equivalents, accounts receivable,
and accounts payable. The carrying amounts of the Company&#8217;s financial instruments approximate their fair values. The Company also
maintains an investment in privately held company (see below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zV6dJYlNhv9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z0QxvzjqIh57">CONCENTRATION
OF CREDIT RISK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time,
the Company has uninsured balances. The Company does not believe it is exposed to any significant credit risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company
performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net sales were approximately $<span id="xdx_900_eus-gaap--Revenues_c20220601__20230531_zgTugdKjmmsd" title="Revenues">5,339,000</span>
for fiscal 2023 compared to $<span id="xdx_903_eus-gaap--Revenues_c20210601__20220531_z5VE0EJrAB24" title="Revenues">18,871,000</span>
for fiscal 2022. For the fiscal years ended May 31, 2023 and 2022, the Company had one and two distributors, respectively, which
accounted for a total of <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorOneMember_zCfRW217Lbbh" title="Concentration risk, percentage">35</span>%
and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorTwoMember_zGjQu8OVjkr8" title="Concentration risk, percentage">65</span>%
of our net sales, respectively. Of this, for the fiscal years ended May 31, 2023 and 2022, the largest of the distributors mentioned
above accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zBZbRgFVmtve" title="Concentration risk, percentage">35</span>%
and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zlgIgVsxXvWd" title="Concentration risk, percentage">55</span>%,
respectively, of net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
gross receivables on May 31, 2023 and 2022 were approximately $<span id="xdx_901_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230531_zeFH384WNPe" title="Other receivables, gross, current">751,000</span> and $<span id="xdx_909_eus-gaap--OtherReceivablesGrossCurrent_iI_c20220531_zW8eMxbbRJU1" title="Other receivables, gross, current">927,000</span>, respectively. On May 31, 2023 and 2022, the Company
had one distributor which accounted for a total of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zaMA0Oy1OT4" title="Concentration risk, percentage">36</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zeavQLNSShXh" title="Concentration risk, percentage">50</span>%, respectively, of gross accounts receivable. Of the <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zLj8Yk8BKDr6" title="Concentration risk, percentage">36</span>% as of May 31,
2023, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorsInAsiaMember_zdwAc3CJuy46" title="Concentration risk, percentage">100</span>% was owed by a distributor in Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended May 31, 2023, the Company did not have any significant concentration of vendor spend for raw materials. For the
fiscal year ended May 31, 2022, the Company had one vendor, which accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zKxusiWRt50j" title="Concentration risk, percentage">84</span>% of our purchases of raw materials largely related
to COVID-19 products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--ConcentrationRiskGeographicPolicyPolicyTextBlock_zas1WR54uYvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zcBx91ToEpJb">GEOGRAPHIC
CONCENTRATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, approximately $<span id="xdx_907_eus-gaap--InventoryGross_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zSVEX9SVBd11" title="Inventory, gross">626,000</span> and $<span id="xdx_903_eus-gaap--InventoryGross_iI_c20220531__srt--StatementGeographicalAxis__country--MX_zlaRxFv9kbVl" title="Inventory, gross">621,000</span>, respectively, of Biomerica&#8217;s gross inventory was located in Mexicali,
Mexico, respectively. As of May 31, 2023 and 2022, approximately $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zYBaLgKp5ADf" title="Property, plant and equipment, net"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20220531__srt--StatementGeographicalAxis__country--MX_ziH0FHnFTYf8" title="Property, plant and equipment, net">17,000</span></span> of Biomerica&#8217;s property and equipment, net of accumulated
depreciation and amortization, was located in Mexicali, Mexico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9ZkeOdmCqf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zG3h0TU5Octl">CASH
AND CASH EQUIVALENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zF4Rf9LewHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNLY7qix7um5">ACCOUNTS
RECEIVABLE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until
they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.
Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in
credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and
adjusts the allowance for doubtful accounts accordingly. Balances over <span id="xdx_902_eus-gaap--ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_dc_c20220601__20230531_zmLrzVXcQFz5" title="Threshold period past due for write-off of trade accounts receivable">ninety days</span>
old are usually reserved for unless collection is reasonably assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occasionally
certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total
gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices
before shipping new sales orders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, the Company has established a reserve of approximately $<span id="xdx_90B_ecustom--AccountsReceivableCreditLossExpenseReversal_c20220601__20230531_zBplFjSnf2wh" title="Accounts receivable, credit loss expense (Reversal)">29,000</span> and $<span id="xdx_905_ecustom--AccountsReceivableCreditLossExpenseReversal_c20210601__20220531_zpZRmWKdXRal" title="Accounts receivable, credit loss expense (Reversal)">153,000</span>, respectively, for doubtful accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84F_ecustom--PrepaidExpensesAndOtherPolicyTextBlock_zbZ1vAqwJYSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zvMG2dPRgKA9">PREPAID
EXPENSES AND OTHER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company occasionally prepays for items such as inventory, insurance, and other items. These items are reported as prepaids, until either
the inventory is physically received or the insurance and other items are utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, the prepaids were approximately $<span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20230531_zTc4RwoJUK14" title="Prepaid expense and other assets">300,000</span> and $<span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20220531_zmcq7Mv3bvvh" title="Prepaid expense and other assets">320,000</span>, respectively, composed of prepayments to insurance and
various other suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_z6EjOOLsoTgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z3XAflCbijqi">INVENTORIES,
NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out
methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates
quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer
demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision
included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs, and wasted material are recognized as
current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfXAx85nCdEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of approximate net inventories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B1_zbIIOEvcmUOj" style="display: none">SCHEDULE
OF NET INVENTORIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230531_zxJS0YOBkNe5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220531_zTXs9kF0FWxe" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zK9rFPjWIuBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,717,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zI5pUzxdZvg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">869,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">763,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z544N6uW1yC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished products</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">182,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">782,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_zxuDEwDW0kV3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,728,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,262,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zmvW1nT9x7vf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Inventory reserve</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(672,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(846,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_zMrcSIofgNza" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    inventory</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,056,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,416,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_z2QADNWUiHM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserves
for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically
reserve for obsolete inventory. As of May 31, 2023 and 2022, inventory reserves were approximately $<span id="xdx_90C_eus-gaap--InventoryValuationReserves_iI_c20230531_zhcqT5mKlPVa" title="Inventory reserves">672,000</span> and $<span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20220531_zx6uzyfls493" title="Inventory reserves">846,000</span>, respectively.
The Company has fully reserved COVID-19 antibody inventory in fiscal 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk6bOjyUlvKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zksGzV8gHEgh">PROPERTY
AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are
charged to operations as incurred. When property and equipment are sold, retired, or otherwise disposed of, the related cost and accumulated
depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements, and dispositions are credited
or charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization are provided over the estimated useful lives of the related assets, ranging from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MinimumMember_zzBbxxesTGV7" title="Property, plant and equipment, useful life">5</span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MaximumMember_zkf43DLyWf04" title="Property, plant and equipment, useful life">10</span> years, using the straight-line
method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation
and amortization expense on property and equipment amounted to approximately $<span id="xdx_900_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zdt0SbTs22g2" title="Depreciation, depletion and amortization">66,000</span> and $<span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zQRMq8oDZLx8" title="Depreciation, depletion and amortization">100,000</span> for the years ended May 31, 2023 and
2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zHpEUEE6lTNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zaJlBQgBPHgf">INTANGIBLE
ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets include trademarks, product rights, technology rights, and patents, and are accounted for based on Accounting Standards Codification
(&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have
indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in
circumstances indicate that the asset might be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets are being amortized using the straight-line method over the useful life, not to exceed <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MarketingAndDistributionRightsMember_zyCruYyiK0ck" title="Finite-lived intangible asset, useful life">18</span> years for marketing and distribution
rights, <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedTechnologyRightsMember_zIk62ly12fKd" title="Finite-lived intangible asset, useful life">10</span> years for purchased technology use rights, and <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zENHs0nm4Poe" title="Finite-lived intangible asset, useful life">20</span> years for patents. Amortization amounted to approximately $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20220601__20230531_zMJVurcApaH4" title="Amortization of intangible assets">18,000</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210601__20220531_zE1wenKkvlq5" title="Amortization of intangible assets">239,000</span>
for the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#8217;s balance over
its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine
whether there was any impairment. During the year ended May 31, 2023, there was <span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20220601__20230531_zpGA1bc1gRL4" title="Asset impairment charges">no</span> impairment of intangible assets. During the year ended May 31, 2022, an impairment
adjustment was made of $<span id="xdx_908_eus-gaap--AssetImpairmentCharges_c20210601__20220531_zUVEsXBiWrDi" title="Asset impairment charges">210,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84E_eus-gaap--InvestmentPolicyTextBlock_zIjX6nok2s9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_znhP4kr3dE21">INVESTMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has made investments in a privately held Polish
distributor, which is primarily engaged in distributing medical products and devices, including the distribution of the products
sold by the Company. The Company invested approximately $<span id="xdx_90E_eus-gaap--Investments_iI_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zNabs00JsA8b" title="Investments">165,000</span>
into the Polish distributor and owns approximately <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zYfiU0qnlX8d" title="Equity method investment, ownership percentage">6</span>%
of the investee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence (&#8220;Cost Method
Holdings&#8221;) are accounted for at the Company&#8217;s initial cost, minus any impairment (if any), plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends
received are recorded as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an
equity holding may not be recoverable. Management reviewed the underlying net assets of the Company&#8217;s equity method holding as
of May 31, 2023 and determined that the Company&#8217;s proportionate economic interest in the entity indicates that the equity holding
was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the
Company&#8217;s Cost Method Holding during the year ended May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zi5fht3J56mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zXu5Ufocrqtd">SHARE-BASED
COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based
method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments
(options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that uses
assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The
Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based
on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options.
The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the
&#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as
historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under
the straight-line attribution method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expensed approximately $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220601__20230531_z7zUYyTVKW7" title="Share-based payment arrangement, expense">1,185,000</span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210601__20220531_z3tU1y95IeBa" title="Share-based payment arrangement, expense">1,260,000</span> of share-based compensation during the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdEKYnJS0eH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for period ending May 31, 2023 and 2022: &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z9Q59AExJB38" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20220601__20230531_zwzgNCPGQTo4" title="Dividend yield">0</span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20210601__20220531_z223yB5oqmTd" title="Dividend yield">0%</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z6diBBXCP6ck" title="Expected volatility minimum">98.81</span>
                                            - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zkvWtpzDXNNk" title="Expected volatility maximum">101.77</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zCLhxdQMqwa7" title="Expected volatility minimum">102.54</span>
- <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zo1OdHzsfXwk" title="Expected volatility maximum">105.48</span></span>%</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zwhwDa4nM9A8" title="Risk free interest rate minimum">3.12</span>
                                            - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z29ZDWgpxT77" title="Risk free interest rate maximum">3.35</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>&#160;</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zMhegBQUmCDj" title="Risk free interest rate minimum">0.97</span>
                                            - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zje1Rms6d7fg" title="Risk free interest rate maximum">2.75</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20220601__20230531_zdmQdYowvAH3" title="Expected term">6.25</span>
years</span></td><td style="text-align: left"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MinimumMember_zdvX2xmg7cd1" title="Expected term">5.50</span>
                                            - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MaximumMember_zJovgA4h7XD4" title="Expected term">6.25</span> years </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_8AF_zADPwTqKuID8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zTgQf8Mt2FW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zqvIu7A6QYZi">REVENUE
RECOGNITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time
the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point
title passes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not typically allow for returns from customers except in the event of defective merchandise and therefore does not establish
an allowance for returns. In addition, the Company has contracts with customers wherein customers receive purchase discounts for achieving
specified sales volumes. The Company evaluated the status of these contracts during the years ended May 31, 2023 and 2022 and does not
believe that any additional discounts will be given through the end of the contract periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Services
for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project
progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories,
medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce
customers as well as to distributors. Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized
below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international
manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023, the Company had approximately $<span id="xdx_90D_eus-gaap--ProceedsFromCustomers_c20220601__20230531_zXS0hCVZoOn8" title="Proceeds from customers">60,000</span> of advances from certain foreign customers. These advances are prepayments on
orders that are expected to ship during our second fiscal quarter ending November 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregation
of revenue:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zanhIyCQdtLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of revenues according to primary markets to which the products are sold:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zNnuM8NBDbSj" style="display: none">SCHEDULE OF DISAGGREGATION REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220601__20230531_zP8e8gf5j2q3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20210601__20220531_ze3LkGjwz3Gh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zKHvA3J7tN2k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Clinical lab</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,310,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,064,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_z9Mve49dOEJd" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Over-the-counter</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,169,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,089,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_z9ypGqpq5I81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contract manufacturing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">610,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">459,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zkH4ktR4A8Nb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Physician&#8217;s office</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,259,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHpBiDu5C8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,339,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,871,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zvOxIDEPiRA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 for additional information regarding geographic revenue concentrations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_zvyO8kcbTwZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zo3bOhAblJwi">SHIPPING
AND HANDLING FEES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes shipping and handling fees billed to customers in net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoPDGTZ4ZYce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z5WBvU2kFJM2">RESEARCH
AND DEVELOPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. The Company expensed approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220601__20230531_zxrrWoRg1AA4" title="Research and development expense">1,584,000</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210601__20220531_zNsRZitDXup9" title="Research and development expense">1,812,000</span> of research and development
costs during the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z7GpIgRB6l2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zHiFcLTqmP0a">INCOME
TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and
liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the
consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net
operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit
carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent
that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation
allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the
character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance
and income tax expense. As of May 31, 2023 and 2022, in accordance with ASC 740, the Company has a valuation allowance for
substantially all of its net deferred tax assets. During the year ended May 31, 2023, this valuation allowance was increased to
$<span id="xdx_906_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_zd5VCqoAt0z2" title="Deferred tax assets, valuation allowance">8,940,000</span>,
which fully covers the net deferred tax asset of $<span id="xdx_905_eus-gaap--DeferredTaxAssetsGross_iI_c20230531_zdBMfhCgPHW2" title="Deferred tax assets, net">8,940,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions.
The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more
likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related
appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount
of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized
when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which
is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information
available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an
accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line
and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--AdvertisingCostsPolicyTextBlock_zWTcxet7YGAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z47QZsQ6HMz1">ADVERTISING
COSTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately
$<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20220601__20230531_z9Fyj00nxcr4" title="Advertising expense">156,000</span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20210601__20220531_zzixh9zoqbUl" title="Advertising expense">76,000</span> for the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zKvticJLFUTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zLN0PxTX9iKi">FOREIGN
CURRENCY TRANSLATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the
U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries
are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates
for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive
loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May
31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z9YTFDd1Gp72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zf9MmdLbU2Oj">RIGHT-OF-USE
ASSETS AND LEASE LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standard update which requires lessees
to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from
the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value
of fixed lease payments over the lease term. Leases are classified as financing or operating which will drive the expense recognition
pattern. The Company has elected to exclude short-term leases. The Company leases office space and copy machines, all of which are operating
leases. Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options
to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The
leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited
by the expected lease term. For additional information, see Note 9-Commitments and Contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGhUn8gHrkwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zbplaaJ5ElFa">NET
LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss
per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible
securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation
for the years ended May 31, 2023 and 2022 were <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220601__20230531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z4slMFwctEC9" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)">2,342,616</span> and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210601__20220531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zob2BtJtsFyf" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)">2,321,616</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zY7tmLByV8sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zGTwlBY8erm">SEGMENT
REPORTING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about
operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management
and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic
kits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaxSJgIMdnu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zqDWvQiTcYP">REPORTING
COMPREHENSIVE LOSS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly
as a component of shareholders&#8217; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments
for the years ended May 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zgusxlyi9MG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zKKValXlvOd7">RECENT
ACCOUNTING PRONOUNCEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as follows, recent
ASU&#8217;s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on
the Company&#8217;s present or future consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.
This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting
date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective
for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November
2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates, which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered
smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including
interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine
its impact on the Company&#8217;s consolidated results of operations and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379205557072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2mUAY79V6jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3: <span id="xdx_82A_zzgKt5AWGAT6">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zJRhHLryw4j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of property and equipment, net of accumulated depreciation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zlMK1GYyzfsi">SCHEDULE
OF PROPERTY AND EQUIPMENT, NET</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230531_zJJG3CVuYsFl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220531_zmEdMEVTHcb9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQNjMA1Nd9d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,333,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,292,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndFixturesLeaseholdImprovementsMember_z3rFGVi7Fdhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture, fixtures and leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">211,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">227,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zS4848GSRXx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,331,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,305,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zhbLjnLUPcxc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    property and equipment</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">214,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zDflOk4HWhTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202524800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zHA2uFLvayQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4: <span id="xdx_828_z3a5eCjChvI8">INTANGIBLE ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zG20KfgYEmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of intangible assets, net of accumulated amortization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zzbG1t9TRIFg">SCHEDULE
OF INTANGIBLE ASSETS, NET</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230531_zjihxqZSSRye" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220531_zrOSrzsA1Dkl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_maIANEGzien_zyNp2gc4Ko4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">196,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">189,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--FiniteLivedPatentsAccumulatedAmortization_iNI_di_msIANEGzien_zpDvvbcHgjWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less accumulated amortization-patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(31,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_mtIANEGzien_zwmRWaZfiCml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">165,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">170,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p id="xdx_8AD_zNGOojLeHfjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zzIh9VajLBUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
amortization of intangible assets for the years ending May 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zA8QpIKu38kc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230531_ztK8HuiJZdT5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzv9t_zi3uv8CnjeCk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzv9t_zjjOwufWa3U3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzv9t_z5wWeWCfCUK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzv9t_zOT4Xl021mDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzv9t_zv00voJayX8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzv9t_zpBK3EQeMkqj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzv9t_zpOdlrYPbyM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">165,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zPNbKbPy9ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379203333232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zYJXUqkQ19q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5: <span id="xdx_820_zianuoe2c8Gg">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zqarcDUnL0Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of accounts payable and accrued expenses balances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zdgR41Gp4EDf" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230531_zpP2PO4IGto" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20220531_zOTmbwRahvc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iI_maAPAALzPt0_zBnvfIc1m7A9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">344,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">736,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzPt0_zfot5l9CYtce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">548,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzPt0_ze1uDNAQZb39" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">892,000</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">972,000</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zZeUjVO1Soda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A7_zKKTZPhmXCe6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023, the Company had one vendor which accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zk17hb183dz3" title="Net sales percent">23</span>% of accounts payable. As of May 31, 2022, the Company had two vendors
which accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoVendorMember_ztycs6s3KAi3" title="Net sales percent">69</span>% of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379207028224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbhHCfbkUw1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6: <span id="xdx_82E_zlOcBNuB8oA6">SHAREHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STOCK
OPTION AND RESTRICTED STOCK PLANS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2014, the Company adopted and shareholders approved a stock option and restricted stock plan (the &#8220;2014 Plan&#8221;).
Subsequently, in December 2017, the Company adopted and shareholders approved an stock option and restricted stock plan (the &#8220;2017
Plan&#8221;). In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;, and collectively with
the 2014 Plan and 2017 Plan, the &#8220;Equity Incentive Plans&#8221;) and on December 11, 2020, the shareholders of the Company approved
the 2020 Plan. The Equity Incentive Plans provide that non-qualified options and incentive stock options and restricted stock may be
granted to directors, affiliates, employees, or consultants of the Company. The Equity Incentive Plans authorize awards representing
up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20141231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandFourteenPlanMember_zChdBRNYvq83" title="Equity incentive plan, authorized shares">850,000</span>, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zqUe9ja3kRL3" title="Equity incentive plan, authorized shares">900,000</span> and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20200229__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zVsCruvCcDuj" title="Equity incentive plan, authorized shares">900,000</span> shares of the Company&#8217;s common stock to be issued under the 2014 Plan, 2017 Plan, and 2020 Plan,
respectively. Awards granted under the Equity Incentive Plans typically vest over <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRMOVxSu8FG1" title="Vesting period">4</span> years. Options granted under the Equity Incentive
Plans will be granted at prices not less than <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7k4A8tJCBr6" title="Award purchase price, percent">80</span>% of the then fair market value of the common stock and will expire not more than <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXa8VUVJOk9" title="Expiration period">10</span>
years after the date of grant. The 2014 Plan expires in December 2024, the 2017 Plan expires in December 2027, and the 2020 Plan expires
in December 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziOpm9lSewRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense for the years ended May 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zy1dsdSDCvid">SCHEDULE
OF STOCK BASED COMPENSATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zL85zAK0Uv1k" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20210601__20220531_zbkLros4SRt1" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4iXckzSV6Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">143,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">159,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zePauF8bdOXi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">971,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,021,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3k0YNjrf0F3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">80,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_zLfJYM2Dp0G7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stock option expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,260,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p id="xdx_8A0_zKvAvFoS5Nve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zn7O30hYo6pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activity
as to aggregate stock options outstanding is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 4.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 4.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z2xMpyNzQEwc">SCHEDULE
OF ACTIVITY TO AGGREGATE STOCK OPTIONS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold">Options Outstanding at May 31, 2021</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210601__20220531_zo2hFF6bHUll" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding, shares">2,081,366</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210601__20220531_z6xdbLhxFGde" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price">3.59</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210601__20220531_zpGkCDe79Zmi" style="width: 14%; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value">2,132,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210601__20220531_z3L1j5wDmyRh" style="text-align: right" title="Options granted, shares">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zvtGPLX1ai51" style="text-align: right" title="Options Granted Weighted Average Exercise Price">4.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210601__20220531_zk0473YWT7ia" style="text-align: right" title="Options exercised, shares">(39,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210601__20220531_zp0NqWNyUbNc" style="text-align: right" title="Options Exercised Weighted Average Exercise Price">1.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210601__20220531_zWCGTRMz3gJe" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue">90,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options canceled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210601__20220531_zcDQAok5oJp5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares">(64,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zOpdLZXP0zal" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price">4.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Options Outstanding at May 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220601__20230531_zdQf3E23Vwq4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding, shares">2,321,616</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220601__20230531_zJkrnYufR07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price">3.72</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220601__20230531_z8ybYZsgdPNk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value">1,838,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220601__20230531_zgwKqTJB8To" style="text-align: right" title="Options granted, shares">243,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zAu3aZ5yxF2" style="text-align: right" title="Options Granted Weighted Average Exercise Price">2.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220601__20230531_zLdr29QxUksd" style="text-align: right" title="Options exercised, shares">(46,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220601__20230531_zOGpuzaXaajf" style="text-align: right" title="Options Exercised Weighted Average Exercise Price">1.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220601__20230531_zJmB7dY3efQ7" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue">90,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Options canceled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220601__20230531_z6WB0ibZSw2e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares">(175,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zrOx3pvwzgu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price">5.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Options Outstanding at May 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220601__20230531_zkwTS0lFVOSh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding, shares">2,342,616</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220601__20230531_z1hi5b8H75y5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price">3.52</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220601__20230531_z2c8DqTMfm2i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value">146,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at May 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20230531_zFwibW9Xxub3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable, shares">1,841,933</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230531_zowGPBmgrFF7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Weighted Average Exercise Price">3.38</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230531_zdU5FibUUaFi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Aggregate Intrinsic Value">146,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A9_z0TzbMBTVfPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of options granted during 2023 and 2022 were $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQThWfjCcshi" title="Granted, weighted average grant date fair value">2.19</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210601__20220531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFgq46JWDkr7" title="Granted, weighted average grant date fair value">4.43</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2023, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPj91oZmGO52" title="Compenation cost related to non-vested stock option">1,145,000</span>.
The weighted-average period over which this amount is expected to be recognized is <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnrM0AFHGH8" title="Weighted average period expected term">2.52</span> years. The weighted average remaining contractual
term of options that were exercisable on May 31, 2023 was <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWDaNsXJNQCi" title="Exercisable weighted average remaining contractual term">4.97</span> years. The weighted average remaining contractual term of options that
were vested, exercisable, or expected to vest on May 31, 2023 was <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLLC6H5J3e8l" title="Vested, exercisable or expected to vest weighted average remaining contractual term">5.67</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMON
STOCK ACTIVITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210122__20210122__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--ATMAgreementMember_zaJqgr6E1nuh" title="Consideration received on transaction">15,000,000</span> in &#8220;at-the-market&#8221;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#8220;ATM Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, in conjunction with the Company&#8217;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#8217;s
annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210521__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z3u5hlzBj3nj" title="Share-based payment award, number of shares authorized">900,000</span> shares of the Company&#8217;s
common stock that could be issued under this Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend
offers under, or terminate the ATM Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2023, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zQWvxiQtBZP1" title="Sale of stock shares issued">573,889</span> shares of its common stock at prices ranging from $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z7bSyUzPSDE3" title="Sale of stock, price per share">3.15</span> to $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zs7aCSP9Mkf5" title="Sale of stock, price per share">4.26</span> pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zug3rQXYpOpi" title="Sale of stock gross proceeds">2,014,000</span> and net proceeds to the Company of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zeQS9XUkloCe" title="Sale of stock, net proceeds">1,961,000</span>, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z0HVVTT6Sz1k" title="Sale of stock, offering expenses">53,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2022, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zZK2meEqkbw4" title="Sale of stock shares issued">521,267</span> shares of its common stock at prices ranging from $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zfhtqETBlY09" title="Sale of stock, price per share">4.02</span> to $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zAouvBLmCJo9" title="Sale of stock, price per share">5.63</span> pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zufG6d53VyK6" title="Sale of stock gross proceeds">2,402,000</span> and net proceeds to the Company of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z3kOxhiIOwIl" title="Sale of stock, net proceeds">2,317,000</span>, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $<span id="xdx_90C_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zREuYEjknI2a" title="Sale of stock expenses">85,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 7, 2023, the Company closed on an underwritten sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230307__20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_zcEtYtDvhBNh" title="Sale of stock shares issued">3,333,333</span> shares of our registered common stock through an investment banking
firm, which shares were issued under our shelf registration. In this offering, the Company sold the registered shares at a gross sales
price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_zUSLHMp2TIyf" title="Sale of stock, price per share">2.40</span> per share, with net proceeds, after deducting issuance fees and expenses of $<span id="xdx_908_ecustom--SaleOfStockExpenses_c20230307__20230307_zmNdRyFO5XUg" title="Sale of stock expenses">700,000</span>, of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_z4HF9uWKXtN8" title="Sale of stock, net proceeds">7,300,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PREFERRED
STOCK ACTIVITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with
Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed
to purchase from the Company, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z5NxG1RtzGei" title="Preferred stock, shares issued">571,429</span> shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zSGCnxnJ5xvj" title="Preferred stock, par value">0.08</span> par value per share
for a purchase price of approximately $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20200224__20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_znG0WIEMDBI6" title="Preferred stock, purchase price">2</span> million, or $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zUIZ8j3Gkh51" title="Sale of stock, price per share">3.50</span> per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase
Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s
common stock, subject to certain adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $<span id="xdx_90B_eus-gaap--DividendsPayableAmountPerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zy6Z1y2Tbnm4" title="Dividends payable, amount per share">0.175</span> per Series A 5% Convertible Preferred
Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay
such accruing dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2020, Palm converted <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20200304__20200324__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxLKRzngjOw7" title="Conversion of stock, shares converted">250,000</span> shares of Convertible Preferred Stock into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20200304__20200324__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zasmcDMqdl4h" title="Conversion of stock, shares issued">250,000</span> shares of unregistered common stock. On July
21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered <span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20200721__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuedvy7FJcI5" title="Conversion of stock, shares issued upon conversion">571,429</span> common shares
issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. On September 30, 2020, the Company
received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares. On January 21, 2021,
Palm Converted their remaining <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20210121__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGvFdWY8eRi3" title="Conversion of stock, shares issued upon conversion">321,429</span> Convertible Preferred Shares into registered common shares. On May 30, 2021, the Company had no
shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative dividends were
paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past
cumulative dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379204126320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zY4kAUNlBHb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7: <span id="xdx_82E_zjBXGgx5oqyd">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zN1RjOEMDHg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
for income taxes for the years ended May 31 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zEdv7rDKFfD3">SCHEDULE
OF PROVISION FOR INCOME TAXES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zC8A2hrtPn6b" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20210601__20220531_zW6c9qy468jl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzN4S_zVPkhJ98LI4f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzN4S_zhSeGrRiyTv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign Taxes
    Subsidiaries</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzN4S_zs6t4Al7tRaf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State
    and local</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzN4S_maITEBz44d_zJSwJaeEK7N5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51,000</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24,000</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzeSN_z5EJuxrkvNvd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzeSN_z3rrGLRSjih" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzeSN_maITEBz44d_zaouIu8VrYq5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBz44d_zx5zSBw96vN" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>


<p id="xdx_8AE_zkqKzrzEHToe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (<span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220601__20230531_z0NJJDom9wf8" title="Federal income tax rate"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210601__20220531_zlvPESmUANb9" title="Federal income tax rate">21</span></span>% for 2023
and 2022) to pretax income as a result of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwSclUVi4pBk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zY3eUHn24cJf">&#160;SCHEDULE
OF EFFECTIVE INCOME TAX RECONCILIATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20220601__20230531_zdJI70dx3xVl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20210601__20220531_zPT0Hx4RkPBh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maCITEBzLRi_zFnJYfux1Ws2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computed &#8220;expected&#8221;
    tax benefit</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,490,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">947,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maCITEBzLRi_zZD9Sq7KH1Hb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,973,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,022,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maCITEBzLRi_zouQNNB7pZS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income taxes, net of federal benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">583,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msCITEBzLRi_zW0GZGjlV8ge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maCITEBzLRi_zBLkiluNOQa8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent tax differences and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(197,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maCITEBzLRi_z0MsKHPsszE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maCITEBzLRi_zMZuhGRMn09j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign taxes of subsidiaries</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(129,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(113,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzLRi_zCbHblsos8G3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p id="xdx_8A1_zQk8aWH9yqGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z6t9YwLvlCnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effect of significant temporary differences is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zKa0cnEl6IC">&#160;SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20230531_zcdSpE1advel" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220531_zz4jubQPL1s5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzl2T_zoJPLcS3oaN3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable,
    principally due to allowance for doubtful accounts</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzl2T_zyTgsXHyl9uh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inventory valuation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">237,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_maDTAGzl2T_zk8LFjL4wJbf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensated absences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">120,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzl2T_zR4790kv4XPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,817,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,349,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzl2T_zK6tOU68FhUk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credit carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,239,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,096,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_iI_maDTAGzl2T_zDZQkHcikds4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred rent expense/Capitalized leases</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DefferedTaxAssetsStockOptions_iI_maDTAGzl2T_zmkKMKaREBJ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,296,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,035,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsCapitalizedCosts_iI_maDTAGzl2T_z6LtUkQbqmsa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sec 174 capitalized costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">284,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_iI_maDTAGzl2T_zUFMFuKsa3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Losses of foreign subsidiaries &amp; other,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccumulatedDepreciationAndAmortization_iI_maDTAGzl2T_zUO37fP95gvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzl2T_maDTANzFA8_zzMFePDOqVx3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,940,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,967,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFA8_zrhlaIp5jY1h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,940,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,967,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFA8_zJYyCrD9RqUg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax asset</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zWmyURdUshQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has provided a valuation allowance of approximately $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_ze734Z4lUAEk" title="Deferred tax assets, valuation allowance">8,940,000</span> and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20220531_zcDoET38PTkh" title="Deferred tax assets, valuation allowance">6,967,000</span> as of May 31, 2023 and 2022, respectively. The
net change in the valuation allowance for the years ended May 31, 2023 and 2022 was an increase of $<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220601__20230531_zQdExubQabfl" title="Increase in valuation allowance">1,973,000</span> and $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210601__20220531_zHRYO3gq8yYk" title="Increase in valuation allowance">1,063,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2023, the Company has Federal income tax net operating loss carryforwards of approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zPqi3ES2hLfj" title="Operating loss carryforwards">21,958,000</span>. On May 31, 2023, the
Company has California state income tax net operating loss carryforwards of approximately $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zOpAhQ8VXQF7" title="Operating loss carryforwards">17,269,000</span>. For tax reporting purposes, operating
loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in 2024 and
2038 for federal and state purposes, respectively. Federal net operating losses beginning in 2018 have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2023, the Company has Federal research and development tax credit carryforward of approximately $<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zQqy3RFzC9Gl" title="Tax credit carryforward">817,000</span>. The Federal credits
begin to expire in 2028. The Company also had similar credit carryforwards for state purposes of $<span id="xdx_904_eus-gaap--TaxCreditCarryforwardAmount_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zvcL5mkbI1N9" title="Tax credit carryforward">533,000</span> on May 31, 2023, which do not
expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss (&#8220;NOL&#8221;)
and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections
382 and 383 of the IRC, the annual use of the Company&#8217;s NOLs and credit carryforwards would be limited if there is a cumulative
change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period). Management has
not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended May 31, 2023, the Company performed an analysis and has not identified any uncertain tax positions as
defined under ASC 740. Should such position be identified in the future, and should the Company owe interest and penalties as a result
of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The
Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379207024704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC INFORMATION</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zcp8WCGGJ4z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8: <span id="xdx_820_z9pn3jfZJG11">GEOGRAPHIC INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as <span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20220601__20230531_z6J7Ksl9YdH9" title="Number of operating segments">one</span> segment. Geographic information regarding net sales is approximately as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zGGLNwuVGY9k" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z7cG5U7SlX8b">SCHEDULE
OF GEOGRAPHIC INFORMATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20220601__20230531_zJfyALI3Y6F9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20210601__20220531_zAIUzto5L65e" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revenues from sales to unaffiliated customers:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--AsiaMember_zQWtR9KMXSg7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Asia</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,021,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,375,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--EuropeMember_z3ylp06Qme38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Europe</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,798,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,339,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--NorthAmericaMember_zbpKxULpKhTh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">North America</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,470,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">997,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zZIzZe0FWy96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Middle East</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--SouthAmericaMember_zT16pDj3POM3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">South America</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,000</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_zVsIXdCQwpva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>5,339,000</b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>18,871,000</b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zaI9zcEDAC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379205561952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zYX2kOwmmqc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9: <span id="xdx_82A_zvcFWIup17c9">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING
LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases facilities in Irvine, California and Mexicali, Mexico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023, <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20230531__20230531_zdyr3kDXFQ31" title="Operating lease description">the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue
in Irvine, California. The lease for its headquarters expires in August 2026. The Company has the option to extend the lease for an additional
five-year term</span>. The Company made a security deposit of approximately $<span id="xdx_900_eus-gaap--SecurityDeposit_iI_c20230331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--BuildingInIrvineCaliforniaMember_zxo40vLrPuui" title="Security deposit">22,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20161130_zPHTP8zOzvEh" title="Operating lease term">10</span>-year lease for approximately <span id="xdx_906_eus-gaap--AreaOfLand_iI_uSqft_c20230531_zsw5BBM5JbTa" title="Lease area">8,100</span> square
feet of manufacturing space. The Company has one <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20161130_zhJ22IGPxyX7" title="Operating lease renewal term">10</span>-year option to renew at the end of the initial lease period. Biomerica de Mexico
also leases a smaller unit on a month-to-month basis for use in the Company&#8217;s manufacturing process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany
subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of
the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising.
The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included
in the measurement of the right-of-use asset and related lease liabilities. Additionally, under these lease arrangements, the Company
may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable
and therefore not included in the measurement of the right-of-use asset and related lease liabilities but are instead recognized as variable
lease expense in the consolidated statements of operations and comprehensive loss when they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zJccOLgSar7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information on our operating leases for the years ended May 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z9hcafgkEkTd">SCHEDULE
OF OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20220601__20230531_zSzDegJAzyT6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20210601__20220531_zQ6uvSHpEBVh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseCost_maLCzsjE_zN9b0A329Qqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">352,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maLCzsjE_zTPhJXEV48ua" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term lease cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LeaseCost_mtLCzsjE_zKSdFz0elaw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p id="xdx_8A1_zxC4EHaOxkXi" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMFnK54RcJih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future minimum lease payments of the Company&#8217;s operating lease liabilities by fiscal year are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zACTi91hd6Ai">SCHEDULE
OF FUTURE MINIMUM LEASE PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Year Ending May 31:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20230531_zuR7SXjplLs8"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzfjE_zjXCJmEkQTEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">356,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzfjE_zAz6xE532JNi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">366,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzfjE_zWZRjsXHwgS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">376,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzfjE_z0aV6G8x0Yj5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzfjE_zaZRFkGJqlt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzfjE_mtOLLzK2p_zUh9Z1G7RAq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total minimum future lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,199,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_maOLLzK2p_zxa9kfLeFwn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_maOLLzK2p_zyNHw99PWPk1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total operating lease
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,082,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zHgbJopHfgO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p id="xdx_898_ecustom--ScheduleOfSupplementalLeaseInformationTableTextBlock_z3mnnqSft9jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s other supplemental lease information for the years ended May 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zG6Y8pfXecUh">SCHEDULE
OF OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220601__20230531_zwIB7iGhv1g8" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20210601__20220531_zfkQ1bB7XCih" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeasePayments_zqcuHF6ogFGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for operating lease liabilities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">347,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average remaining lease term (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230531_zG20xRD4gK87" title="Weighted average remaining lease term (years)">3.27</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220531_zJZ4ZwmrD4f7" title="Weighted average remaining lease term (years)">4.28</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230531_zQnLWfU6akt8" title="Weighted-average discount rate">6.50</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220531_z1eVUJIjyLqg" title="Weighted-average discount rate">6.50</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p id="xdx_8A2_zxi278JrRhUf" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has various insignificant leases for office equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RETIREMENT
SAVINGS PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute
to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404.
The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each
year. No contributions by the Company have been made since the plan&#8217;s inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LITIGATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is, from time to time, involved in legal proceedings, claims, and litigation arising in the ordinary course of business. While
the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that
exist. Therefore, it is possible the outcome of such legal proceedings, claims, and litigation could have a material effect on quarterly
or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes
such matters will not have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or
cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no legal proceedings pending as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTRACTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contracts
and Licensing Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products.
Royalty expense of approximately $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20220601__20230531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_zSkPdbkblpJl" title="Royalty expense">13,000</span> and $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20210601__20220531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_z4csWzkUuQe7" title="Royalty expense">19,000</span> is included in cost of sales for the agreement for each of the years ended May 31,
2023 and 2022, respectively. Sales of products manufactured under these agreements comprise approximately <span id="xdx_904_ecustom--RoyaltyExpensePercentageOfSales_dp_c20220601__20230531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_zDb8N2abyE39" title="Royalty expense percentage of sales">2.1</span>% and <span id="xdx_906_ecustom--RoyaltyExpensePercentageOfSales_dp_c20210601__20220531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_ziVgqX5EL2Q5" title="Royalty expense percentage of sales">1.5</span>% of total sales
for the years ended May 31, 2023 and 2022, respectively. The Company may license other products or technology in the future as it deems
necessary for conducting business. The Company has other royalty agreements however they are not considered material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing
clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.
The initial budget was estimated to be approximately $<span id="xdx_90F_ecustom--ClinicalTrialAgreementMaximumBudgetedCosts_iI_c20170930__dei--LegalEntityAxis__custom--UniversityOFSouthernCaliforniaMember_z901oPW5eYb7" title="Clinical trial agreement maximum budgeted costs">82,000</span>. The work started in October 2017 with charges for work performed being
invoiced and paid monthly. This study ended in February 2020. Approximately $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_c20220531__dei--LegalEntityAxis__custom--UniversityOFSouthernCaliforniaMember_zamhDWJ9hjQa" title="Accrued liabilities">17,000</span> in fees has been accrued for unbilled charges as
of May 31, 2022. There are no unbilled charges as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a Clinical Trial Agreement with a research institute for the purpose of conducting a clinical trial of the Biomerica
InFoods&#174; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly
for work performed in the previous month. The maximum budgeted costs will be approximately $<span id="xdx_901_ecustom--ClinicalTrialAgreementMaximumBudgetedCosts_iI_c20220531__dei--LegalEntityAxis__custom--BiomericaInFoodsMember_zGozQprfkaK7">107,000</span>. This study ended in March 2022.
Approximately $<span id="xdx_900_eus-gaap--AccruedLiabilitiesCurrent_iI_c20220531__dei--LegalEntityAxis__custom--BiomericaInFoodsMember_zLOalagqTprc" title="Accrued liabilities">28,000</span> in fees has been accrued for unbilled charges as of May 31, 2022. There are no unbilled charges as of May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379207024704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zZAureC8xYdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10: <span id="xdx_82A_zqBIax2NwMch">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 3, 2023, <span id="xdx_908_eus-gaap--SubsequentEventDescription_c20230803__20230803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrEmnUmfwd14" title="Subsequent event, description">the Company announced it had entered into a sales agreement with CVS Pharmacy wherein the Company&#8217;s EZ Detect&#8482;
colorectal disease screening test will be offered at approximately 7,000 CVS Pharmacy retail stores</span>. Biomerica has shipped the EZ Detect
product to CVS Health distribution centers in the United States, and the product is projected to be on store shelves in September.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379201605184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">PRINCIPLES OF CONSOLIDATION</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z7gFfpvpLaT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZwFKfOCmSdd">PRINCIPLES
OF CONSOLIDATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements for the years ended May 31, 2023 and 2022, include the accounts of Biomerica, Inc. (&#8220;Biomerica&#8221;)
as well as its wholly-owned German subsidiary (&#8220;BioEurope GmbH&#8221;) and Mexican subsidiary (&#8220;Biomerica de Mexico&#8221;).
All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">ACCOUNTING ESTIMATES</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zuySZ9CDyIC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zTPMeefF7g3j">ACCOUNTING
ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful
accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates,
which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of
materials; and lease liabilities and right-of-use assets, which are calculated based on certain assumptions such as the borrowing
rate on the lease commencement date and, the likelihood of lease extensions to occur, asset valuations, among other things; and other items that may be necessary to
estimate using current, historical and judgment based information. Actual results could materially differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the global COVID-19 pandemic, the Company&#8217;s operations have been negatively impacted. The Company has faced disruptions in the
following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s
manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping
and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or
sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer
credit risk, and general economic calamities. These pandemic related disruptions can materially negatively impact the Company&#8217;s
operations and financial performance and may continue to have significant material negative impacts on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_LiquidityPolicyTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p id="xdx_84E_ecustom--LiquidityPolicyTextBlock_zW6vUuWhG1Ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjOTo59chAK9">LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn6n6_di_c20230531_zR7wm3w9TnGd" title="Accumulated deficit">42</span> million as
of May 31, 2023. Management expects to continue to incur significant costs as it advances its trials and development activities. As of
May 31, 2023, the Company had cash and cash equivalents of approximately $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230531_zI7WIQvdh0s9" title="Cash and cash equivalents">9,719,000</span> and working capital of approximately $<span id="xdx_908_ecustom--WorkingCapital_iNI_di_c20230531_zS9FSdFRDyN8" title="Working capital">10,852,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $<span id="xdx_90B_ecustom--ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_iI_c20210122_zNs4j3moD7f9" title="Shelf registration statement maximum authorized common stock issuance value">15,000,000</span> in &#8220;at-the-market&#8221;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#8220;ATM Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#8217;s behalf all the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any shares under the ATM Offering, and may at any time suspend offers
under, or terminate the ATM Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zKcvJRy8jlm4" title="Sale of stock, number of shares issued in transaction">573,889</span> shares of its common stock at prices ranging from $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zSjRvtL1zhQ" title="Sale of stock, price per share">3.15</span> to $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zdRfY3Ch057a" title="Sale of stock, price per share">4.26</span> pursuant to the
ATM Agreement, which resulted in gross proceeds of approximately $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zgSVz1vLMHJ5" title="Sale of stock, consideration received on transaction">2,014,000</span> and net proceeds to the Company of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z7YVQm30GfFf" title="Proceeds from issuance of common stock">1,961,000</span>, after deducting
commissions for each sale and legal, accounting, and other fees related to offering in the amount of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zFVG7Rapmvy7" title="Sale of stock expenses">53,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended May 31, 2022, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zk6s2jb3LzFl" title="Sale of stock, number of shares issued in transaction">521,267</span> shares of its common stock at prices ranging from $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBGjiqSfbqg2" title="Sale of stock, price per share">4.02</span> to $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1tHM7RXW0U2" title="Sale of stock, price per share">5.63</span> pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBmMSveBMcal" title="Sale of stock, consideration received on transaction">2,402,000</span> and net proceeds to the Company of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zbgeua5vzmrd" title="Proceeds from issuance of common stock">2,317,000</span>, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $<span id="xdx_906_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1J6pzOT4cAh" title="Sale of stock expenses">85,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 7, 2023, the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zQQg5I8fRDzb" title="Net proceeds from ATM (in Shares)">3,333,333</span> shares of common stock in a firm commitment public offering at a gross sales price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z2pu4lFTRZq" title="Share price">2.40</span>
per share, with net total proceeds, after deducting issuance fees and expenses of $<span id="xdx_907_ecustom--SaleOfStockExpenses_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zWIHolrzirAg" title="Sale of stock expenses">700,000</span>, of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zqJEv3gsEkG7" title="Proceeds from issuance of common stock">7,300,000</span>. Since the closing
of the March 7, 2023 offering, the ATM has been withdrawn and is not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from such offerings for general corporate purposes, including, without limitation, sales and
marketing activities, clinical studies, product development, making acquisitions of assets, businesses, companies or securities,
capital expenditures, and for working capital needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has analyzed the cash requirements of the Company&#8217;s business through at least August 2024. As a result of cash and cash
equivalents on hand on May 31, 2023, largely from the public offering, and the ability to raise additional funds through another new
ATM agreement, management believes the Company has sufficient funds to operate through at least August 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zj7jiqvTvXB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMZUTNqxBcJ4">FAIR
VALUE OF FINANCIAL INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on
a historical basis. The Company&#8217;s consolidated financial instruments consist of its cash and cash equivalents, accounts receivable,
and accounts payable. The carrying amounts of the Company&#8217;s financial instruments approximate their fair values. The Company also
maintains an investment in privately held company (see below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">CONCENTRATION OF CREDIT RISK</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zV6dJYlNhv9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z0QxvzjqIh57">CONCENTRATION
OF CREDIT RISK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time,
the Company has uninsured balances. The Company does not believe it is exposed to any significant credit risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company
performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net sales were approximately $<span id="xdx_900_eus-gaap--Revenues_c20220601__20230531_zgTugdKjmmsd" title="Revenues">5,339,000</span>
for fiscal 2023 compared to $<span id="xdx_903_eus-gaap--Revenues_c20210601__20220531_z5VE0EJrAB24" title="Revenues">18,871,000</span>
for fiscal 2022. For the fiscal years ended May 31, 2023 and 2022, the Company had one and two distributors, respectively, which
accounted for a total of <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorOneMember_zCfRW217Lbbh" title="Concentration risk, percentage">35</span>%
and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorTwoMember_zGjQu8OVjkr8" title="Concentration risk, percentage">65</span>%
of our net sales, respectively. Of this, for the fiscal years ended May 31, 2023 and 2022, the largest of the distributors mentioned
above accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zBZbRgFVmtve" title="Concentration risk, percentage">35</span>%
and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zlgIgVsxXvWd" title="Concentration risk, percentage">55</span>%,
respectively, of net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
gross receivables on May 31, 2023 and 2022 were approximately $<span id="xdx_901_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230531_zeFH384WNPe" title="Other receivables, gross, current">751,000</span> and $<span id="xdx_909_eus-gaap--OtherReceivablesGrossCurrent_iI_c20220531_zW8eMxbbRJU1" title="Other receivables, gross, current">927,000</span>, respectively. On May 31, 2023 and 2022, the Company
had one distributor which accounted for a total of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zaMA0Oy1OT4" title="Concentration risk, percentage">36</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zeavQLNSShXh" title="Concentration risk, percentage">50</span>%, respectively, of gross accounts receivable. Of the <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zLj8Yk8BKDr6" title="Concentration risk, percentage">36</span>% as of May 31,
2023, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorsInAsiaMember_zdwAc3CJuy46" title="Concentration risk, percentage">100</span>% was owed by a distributor in Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended May 31, 2023, the Company did not have any significant concentration of vendor spend for raw materials. For the
fiscal year ended May 31, 2022, the Company had one vendor, which accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zKxusiWRt50j" title="Concentration risk, percentage">84</span>% of our purchases of raw materials largely related
to COVID-19 products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock', window );">GEOGRAPHIC CONCENTRATION</a></td>
<td class="text"><p id="xdx_841_ecustom--ConcentrationRiskGeographicPolicyPolicyTextBlock_zas1WR54uYvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zcBx91ToEpJb">GEOGRAPHIC
CONCENTRATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, approximately $<span id="xdx_907_eus-gaap--InventoryGross_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zSVEX9SVBd11" title="Inventory, gross">626,000</span> and $<span id="xdx_903_eus-gaap--InventoryGross_iI_c20220531__srt--StatementGeographicalAxis__country--MX_zlaRxFv9kbVl" title="Inventory, gross">621,000</span>, respectively, of Biomerica&#8217;s gross inventory was located in Mexicali,
Mexico, respectively. As of May 31, 2023 and 2022, approximately $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zYBaLgKp5ADf" title="Property, plant and equipment, net"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20220531__srt--StatementGeographicalAxis__country--MX_ziH0FHnFTYf8" title="Property, plant and equipment, net">17,000</span></span> of Biomerica&#8217;s property and equipment, net of accumulated
depreciation and amortization, was located in Mexicali, Mexico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9ZkeOdmCqf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zG3h0TU5Octl">CASH
AND CASH EQUIVALENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zF4Rf9LewHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNLY7qix7um5">ACCOUNTS
RECEIVABLE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until
they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.
Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in
credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and
adjusts the allowance for doubtful accounts accordingly. Balances over <span id="xdx_902_eus-gaap--ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_dc_c20220601__20230531_zmLrzVXcQFz5" title="Threshold period past due for write-off of trade accounts receivable">ninety days</span>
old are usually reserved for unless collection is reasonably assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occasionally
certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total
gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices
before shipping new sales orders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, the Company has established a reserve of approximately $<span id="xdx_90B_ecustom--AccountsReceivableCreditLossExpenseReversal_c20220601__20230531_zBplFjSnf2wh" title="Accounts receivable, credit loss expense (Reversal)">29,000</span> and $<span id="xdx_905_ecustom--AccountsReceivableCreditLossExpenseReversal_c20210601__20220531_zpZRmWKdXRal" title="Accounts receivable, credit loss expense (Reversal)">153,000</span>, respectively, for doubtful accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_PrepaidExpensesAndOtherPolicyTextBlock', window );">PREPAID EXPENSES AND OTHER</a></td>
<td class="text"><p id="xdx_84F_ecustom--PrepaidExpensesAndOtherPolicyTextBlock_zbZ1vAqwJYSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zvMG2dPRgKA9">PREPAID
EXPENSES AND OTHER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company occasionally prepays for items such as inventory, insurance, and other items. These items are reported as prepaids, until either
the inventory is physically received or the insurance and other items are utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023 and 2022, the prepaids were approximately $<span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20230531_zTc4RwoJUK14" title="Prepaid expense and other assets">300,000</span> and $<span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20220531_zmcq7Mv3bvvh" title="Prepaid expense and other assets">320,000</span>, respectively, composed of prepayments to insurance and
various other suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">INVENTORIES, NET</a></td>
<td class="text"><p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_z6EjOOLsoTgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z3XAflCbijqi">INVENTORIES,
NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out
methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates
quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer
demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision
included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs, and wasted material are recognized as
current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfXAx85nCdEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of approximate net inventories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B1_zbIIOEvcmUOj" style="display: none">SCHEDULE
OF NET INVENTORIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230531_zxJS0YOBkNe5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220531_zTXs9kF0FWxe" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zK9rFPjWIuBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,717,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zI5pUzxdZvg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">869,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">763,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z544N6uW1yC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished products</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">182,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">782,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_zxuDEwDW0kV3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,728,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,262,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zmvW1nT9x7vf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Inventory reserve</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(672,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(846,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_zMrcSIofgNza" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    inventory</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,056,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,416,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_z2QADNWUiHM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserves
for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically
reserve for obsolete inventory. As of May 31, 2023 and 2022, inventory reserves were approximately $<span id="xdx_90C_eus-gaap--InventoryValuationReserves_iI_c20230531_zhcqT5mKlPVa" title="Inventory reserves">672,000</span> and $<span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20220531_zx6uzyfls493" title="Inventory reserves">846,000</span>, respectively.
The Company has fully reserved COVID-19 antibody inventory in fiscal 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk6bOjyUlvKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zksGzV8gHEgh">PROPERTY
AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are
charged to operations as incurred. When property and equipment are sold, retired, or otherwise disposed of, the related cost and accumulated
depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements, and dispositions are credited
or charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization are provided over the estimated useful lives of the related assets, ranging from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MinimumMember_zzBbxxesTGV7" title="Property, plant and equipment, useful life">5</span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MaximumMember_zkf43DLyWf04" title="Property, plant and equipment, useful life">10</span> years, using the straight-line
method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation
and amortization expense on property and equipment amounted to approximately $<span id="xdx_900_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zdt0SbTs22g2" title="Depreciation, depletion and amortization">66,000</span> and $<span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zQRMq8oDZLx8" title="Depreciation, depletion and amortization">100,000</span> for the years ended May 31, 2023 and
2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zHpEUEE6lTNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zaJlBQgBPHgf">INTANGIBLE
ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets include trademarks, product rights, technology rights, and patents, and are accounted for based on Accounting Standards Codification
(&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have
indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in
circumstances indicate that the asset might be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets are being amortized using the straight-line method over the useful life, not to exceed <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MarketingAndDistributionRightsMember_zyCruYyiK0ck" title="Finite-lived intangible asset, useful life">18</span> years for marketing and distribution
rights, <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedTechnologyRightsMember_zIk62ly12fKd" title="Finite-lived intangible asset, useful life">10</span> years for purchased technology use rights, and <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zENHs0nm4Poe" title="Finite-lived intangible asset, useful life">20</span> years for patents. Amortization amounted to approximately $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20220601__20230531_zMJVurcApaH4" title="Amortization of intangible assets">18,000</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210601__20220531_zE1wenKkvlq5" title="Amortization of intangible assets">239,000</span>
for the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#8217;s balance over
its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine
whether there was any impairment. During the year ended May 31, 2023, there was <span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20220601__20230531_zpGA1bc1gRL4" title="Asset impairment charges">no</span> impairment of intangible assets. During the year ended May 31, 2022, an impairment
adjustment was made of $<span id="xdx_908_eus-gaap--AssetImpairmentCharges_c20210601__20220531_zUVEsXBiWrDi" title="Asset impairment charges">210,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">INVESTMENTS</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--InvestmentPolicyTextBlock_zIjX6nok2s9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_znhP4kr3dE21">INVESTMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has made investments in a privately held Polish
distributor, which is primarily engaged in distributing medical products and devices, including the distribution of the products
sold by the Company. The Company invested approximately $<span id="xdx_90E_eus-gaap--Investments_iI_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zNabs00JsA8b" title="Investments">165,000</span>
into the Polish distributor and owns approximately <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zYfiU0qnlX8d" title="Equity method investment, ownership percentage">6</span>%
of the investee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence (&#8220;Cost Method
Holdings&#8221;) are accounted for at the Company&#8217;s initial cost, minus any impairment (if any), plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends
received are recorded as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an
equity holding may not be recoverable. Management reviewed the underlying net assets of the Company&#8217;s equity method holding as
of May 31, 2023 and determined that the Company&#8217;s proportionate economic interest in the entity indicates that the equity holding
was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the
Company&#8217;s Cost Method Holding during the year ended May 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zi5fht3J56mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zXu5Ufocrqtd">SHARE-BASED
COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based
method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments
(options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that uses
assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The
Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based
on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options.
The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the
&#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as
historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under
the straight-line attribution method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expensed approximately $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220601__20230531_z7zUYyTVKW7" title="Share-based payment arrangement, expense">1,185,000</span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210601__20220531_z3tU1y95IeBa" title="Share-based payment arrangement, expense">1,260,000</span> of share-based compensation during the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdEKYnJS0eH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for period ending May 31, 2023 and 2022: &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z9Q59AExJB38" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20220601__20230531_zwzgNCPGQTo4" title="Dividend yield">0</span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20210601__20220531_z223yB5oqmTd" title="Dividend yield">0%</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z6diBBXCP6ck" title="Expected volatility minimum">98.81</span>
                                            - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zkvWtpzDXNNk" title="Expected volatility maximum">101.77</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zCLhxdQMqwa7" title="Expected volatility minimum">102.54</span>
- <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zo1OdHzsfXwk" title="Expected volatility maximum">105.48</span></span>%</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zwhwDa4nM9A8" title="Risk free interest rate minimum">3.12</span>
                                            - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z29ZDWgpxT77" title="Risk free interest rate maximum">3.35</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>&#160;</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zMhegBQUmCDj" title="Risk free interest rate minimum">0.97</span>
                                            - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zje1Rms6d7fg" title="Risk free interest rate maximum">2.75</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20220601__20230531_zdmQdYowvAH3" title="Expected term">6.25</span>
years</span></td><td style="text-align: left"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MinimumMember_zdvX2xmg7cd1" title="Expected term">5.50</span>
                                            - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MaximumMember_zJovgA4h7XD4" title="Expected term">6.25</span> years </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_8AF_zADPwTqKuID8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zTgQf8Mt2FW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zqvIu7A6QYZi">REVENUE
RECOGNITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time
the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point
title passes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not typically allow for returns from customers except in the event of defective merchandise and therefore does not establish
an allowance for returns. In addition, the Company has contracts with customers wherein customers receive purchase discounts for achieving
specified sales volumes. The Company evaluated the status of these contracts during the years ended May 31, 2023 and 2022 and does not
believe that any additional discounts will be given through the end of the contract periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Services
for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project
progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories,
medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce
customers as well as to distributors. Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized
below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international
manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 31, 2023, the Company had approximately $<span id="xdx_90D_eus-gaap--ProceedsFromCustomers_c20220601__20230531_zXS0hCVZoOn8" title="Proceeds from customers">60,000</span> of advances from certain foreign customers. These advances are prepayments on
orders that are expected to ship during our second fiscal quarter ending November 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregation
of revenue:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zanhIyCQdtLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of revenues according to primary markets to which the products are sold:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zNnuM8NBDbSj" style="display: none">SCHEDULE OF DISAGGREGATION REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220601__20230531_zP8e8gf5j2q3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20210601__20220531_ze3LkGjwz3Gh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zKHvA3J7tN2k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Clinical lab</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,310,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,064,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_z9Mve49dOEJd" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Over-the-counter</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,169,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,089,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_z9ypGqpq5I81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contract manufacturing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">610,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">459,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zkH4ktR4A8Nb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Physician&#8217;s office</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,259,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHpBiDu5C8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,339,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,871,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zvOxIDEPiRA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 for additional information regarding geographic revenue concentrations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">SHIPPING AND HANDLING FEES</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_zvyO8kcbTwZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zo3bOhAblJwi">SHIPPING
AND HANDLING FEES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes shipping and handling fees billed to customers in net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoPDGTZ4ZYce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z5WBvU2kFJM2">RESEARCH
AND DEVELOPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. The Company expensed approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220601__20230531_zxrrWoRg1AA4" title="Research and development expense">1,584,000</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210601__20220531_zNsRZitDXup9" title="Research and development expense">1,812,000</span> of research and development
costs during the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z7GpIgRB6l2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zHiFcLTqmP0a">INCOME
TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and
liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the
consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net
operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit
carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent
that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation
allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the
character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance
and income tax expense. As of May 31, 2023 and 2022, in accordance with ASC 740, the Company has a valuation allowance for
substantially all of its net deferred tax assets. During the year ended May 31, 2023, this valuation allowance was increased to
$<span id="xdx_906_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_zd5VCqoAt0z2" title="Deferred tax assets, valuation allowance">8,940,000</span>,
which fully covers the net deferred tax asset of $<span id="xdx_905_eus-gaap--DeferredTaxAssetsGross_iI_c20230531_zdBMfhCgPHW2" title="Deferred tax assets, net">8,940,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions.
The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more
likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related
appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount
of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized
when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which
is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information
available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an
accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line
and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">ADVERTISING COSTS</a></td>
<td class="text"><p id="xdx_841_eus-gaap--AdvertisingCostsPolicyTextBlock_zWTcxet7YGAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z47QZsQ6HMz1">ADVERTISING
COSTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately
$<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20220601__20230531_z9Fyj00nxcr4" title="Advertising expense">156,000</span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20210601__20220531_zzixh9zoqbUl" title="Advertising expense">76,000</span> for the years ended May 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">FOREIGN CURRENCY TRANSLATION</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zKvticJLFUTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zLN0PxTX9iKi">FOREIGN
CURRENCY TRANSLATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the
U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries
are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates
for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive
loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May
31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z9YTFDd1Gp72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zf9MmdLbU2Oj">RIGHT-OF-USE
ASSETS AND LEASE LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standard update which requires lessees
to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from
the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value
of fixed lease payments over the lease term. Leases are classified as financing or operating which will drive the expense recognition
pattern. The Company has elected to exclude short-term leases. The Company leases office space and copy machines, all of which are operating
leases. Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options
to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The
leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited
by the expected lease term. For additional information, see Note 9-Commitments and Contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGhUn8gHrkwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zbplaaJ5ElFa">NET
LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss
per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible
securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation
for the years ended May 31, 2023 and 2022 were <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220601__20230531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z4slMFwctEC9" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)">2,342,616</span> and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210601__20220531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zob2BtJtsFyf" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)">2,321,616</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zY7tmLByV8sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zGTwlBY8erm">SEGMENT
REPORTING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about
operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management
and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic
kits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">REPORTING COMPREHENSIVE LOSS</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaxSJgIMdnu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zqDWvQiTcYP">REPORTING
COMPREHENSIVE LOSS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly
as a component of shareholders&#8217; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments
for the years ended May 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zgusxlyi9MG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zKKValXlvOd7">RECENT
ACCOUNTING PRONOUNCEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as follows, recent
ASU&#8217;s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on
the Company&#8217;s present or future consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.
This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting
date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective
for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November
2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates, which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered
smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including
interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine
its impact on the Company&#8217;s consolidated results of operations and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk Geographic Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_PrepaidExpensesAndOtherPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_PrepaidExpensesAndOtherPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379205559264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF NET INVENTORIES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfXAx85nCdEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of approximate net inventories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B1_zbIIOEvcmUOj" style="display: none">SCHEDULE
OF NET INVENTORIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230531_zxJS0YOBkNe5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220531_zTXs9kF0FWxe" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zK9rFPjWIuBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,717,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zI5pUzxdZvg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">869,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">763,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z544N6uW1yC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished products</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">182,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">782,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_zxuDEwDW0kV3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,728,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,262,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zmvW1nT9x7vf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Inventory reserve</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(672,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(846,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_zMrcSIofgNza" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    inventory</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,056,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,416,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdEKYnJS0eH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for period ending May 31, 2023 and 2022: &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z9Q59AExJB38" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20220601__20230531_zwzgNCPGQTo4" title="Dividend yield">0</span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20210601__20220531_z223yB5oqmTd" title="Dividend yield">0%</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z6diBBXCP6ck" title="Expected volatility minimum">98.81</span>
                                            - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zkvWtpzDXNNk" title="Expected volatility maximum">101.77</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zCLhxdQMqwa7" title="Expected volatility minimum">102.54</span>
- <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zo1OdHzsfXwk" title="Expected volatility maximum">105.48</span></span>%</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zwhwDa4nM9A8" title="Risk free interest rate minimum">3.12</span>
                                            - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z29ZDWgpxT77" title="Risk free interest rate maximum">3.35</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>&#160;</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zMhegBQUmCDj" title="Risk free interest rate minimum">0.97</span>
                                            - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zje1Rms6d7fg" title="Risk free interest rate maximum">2.75</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20220601__20230531_zdmQdYowvAH3" title="Expected term">6.25</span>
years</span></td><td style="text-align: left"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MinimumMember_zdvX2xmg7cd1" title="Expected term">5.50</span>
                                            - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MaximumMember_zJovgA4h7XD4" title="Expected term">6.25</span> years </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">SCHEDULE OF DISAGGREGATION REVENUE</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zanhIyCQdtLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of revenues according to primary markets to which the products are sold:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zNnuM8NBDbSj" style="display: none">SCHEDULE OF DISAGGREGATION REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220601__20230531_zP8e8gf5j2q3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20210601__20220531_ze3LkGjwz3Gh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zKHvA3J7tN2k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Clinical lab</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,310,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,064,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_z9Mve49dOEJd" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Over-the-counter</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,169,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,089,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_z9ypGqpq5I81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contract manufacturing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">610,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">459,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zkH4ktR4A8Nb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Physician&#8217;s office</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,259,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHpBiDu5C8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,339,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,871,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379203969232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zJRhHLryw4j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of property and equipment, net of accumulated depreciation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zlMK1GYyzfsi">SCHEDULE
OF PROPERTY AND EQUIPMENT, NET</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230531_zJJG3CVuYsFl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220531_zmEdMEVTHcb9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQNjMA1Nd9d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,333,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,292,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndFixturesLeaseholdImprovementsMember_z3rFGVi7Fdhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture, fixtures and leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">211,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">227,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zS4848GSRXx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,331,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,305,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zhbLjnLUPcxc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    property and equipment</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">214,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379203903616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zG20KfgYEmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of intangible assets, net of accumulated amortization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zzbG1t9TRIFg">SCHEDULE
OF INTANGIBLE ASSETS, NET</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230531_zjihxqZSSRye" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220531_zrOSrzsA1Dkl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_maIANEGzien_zyNp2gc4Ko4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">196,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">189,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--FiniteLivedPatentsAccumulatedAmortization_iNI_di_msIANEGzien_zpDvvbcHgjWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less accumulated amortization-patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(31,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_mtIANEGzien_zwmRWaZfiCml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">165,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">170,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zzIh9VajLBUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
amortization of intangible assets for the years ending May 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zA8QpIKu38kc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230531_ztK8HuiJZdT5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzv9t_zi3uv8CnjeCk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzv9t_zjjOwufWa3U3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzv9t_z5wWeWCfCUK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzv9t_zOT4Xl021mDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzv9t_zv00voJayX8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzv9t_zpBK3EQeMkqj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzv9t_zpOdlrYPbyM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">165,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379205166224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zqarcDUnL0Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an approximate breakdown of accounts payable and accrued expenses balances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zdgR41Gp4EDf" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230531_zpP2PO4IGto" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20220531_zOTmbwRahvc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iI_maAPAALzPt0_zBnvfIc1m7A9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">344,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">736,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzPt0_zfot5l9CYtce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">548,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzPt0_ze1uDNAQZb39" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">892,000</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">972,000</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379204104752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziOpm9lSewRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense for the years ended May 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zy1dsdSDCvid">SCHEDULE
OF STOCK BASED COMPENSATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zL85zAK0Uv1k" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20210601__20220531_zbkLros4SRt1" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4iXckzSV6Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">143,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">159,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zePauF8bdOXi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">971,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,021,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3k0YNjrf0F3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">80,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_zLfJYM2Dp0G7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stock option expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,260,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zn7O30hYo6pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activity
as to aggregate stock options outstanding is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 4.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 4.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z2xMpyNzQEwc">SCHEDULE
OF ACTIVITY TO AGGREGATE STOCK OPTIONS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold">Options Outstanding at May 31, 2021</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210601__20220531_zo2hFF6bHUll" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding, shares">2,081,366</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210601__20220531_z6xdbLhxFGde" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price">3.59</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210601__20220531_zpGkCDe79Zmi" style="width: 14%; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value">2,132,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210601__20220531_z3L1j5wDmyRh" style="text-align: right" title="Options granted, shares">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zvtGPLX1ai51" style="text-align: right" title="Options Granted Weighted Average Exercise Price">4.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210601__20220531_zk0473YWT7ia" style="text-align: right" title="Options exercised, shares">(39,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210601__20220531_zp0NqWNyUbNc" style="text-align: right" title="Options Exercised Weighted Average Exercise Price">1.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210601__20220531_zWCGTRMz3gJe" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue">90,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options canceled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210601__20220531_zcDQAok5oJp5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares">(64,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zOpdLZXP0zal" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price">4.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Options Outstanding at May 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220601__20230531_zdQf3E23Vwq4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding, shares">2,321,616</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220601__20230531_zJkrnYufR07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price">3.72</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220601__20230531_z8ybYZsgdPNk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value">1,838,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220601__20230531_zgwKqTJB8To" style="text-align: right" title="Options granted, shares">243,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zAu3aZ5yxF2" style="text-align: right" title="Options Granted Weighted Average Exercise Price">2.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220601__20230531_zLdr29QxUksd" style="text-align: right" title="Options exercised, shares">(46,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220601__20230531_zOGpuzaXaajf" style="text-align: right" title="Options Exercised Weighted Average Exercise Price">1.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220601__20230531_zJmB7dY3efQ7" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue">90,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Options canceled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220601__20230531_z6WB0ibZSw2e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares">(175,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zrOx3pvwzgu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price">5.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Options Outstanding at May 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220601__20230531_zkwTS0lFVOSh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding, shares">2,342,616</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220601__20230531_z1hi5b8H75y5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price">3.52</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220601__20230531_z2c8DqTMfm2i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value">146,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at May 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20230531_zFwibW9Xxub3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable, shares">1,841,933</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230531_zowGPBmgrFF7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Weighted Average Exercise Price">3.38</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230531_zdU5FibUUaFi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Aggregate Intrinsic Value">146,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379208716928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF PROVISION FOR INCOME TAXES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zN1RjOEMDHg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
for income taxes for the years ended May 31 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zEdv7rDKFfD3">SCHEDULE
OF PROVISION FOR INCOME TAXES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220601__20230531_zC8A2hrtPn6b" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20210601__20220531_zW6c9qy468jl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzN4S_zVPkhJ98LI4f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzN4S_zhSeGrRiyTv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign Taxes
    Subsidiaries</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzN4S_zs6t4Al7tRaf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State
    and local</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzN4S_maITEBz44d_zJSwJaeEK7N5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51,000</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24,000</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzeSN_z5EJuxrkvNvd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzeSN_z3rrGLRSjih" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzeSN_maITEBz44d_zaouIu8VrYq5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBz44d_zx5zSBw96vN" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwSclUVi4pBk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zY3eUHn24cJf">&#160;SCHEDULE
OF EFFECTIVE INCOME TAX RECONCILIATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20220601__20230531_zdJI70dx3xVl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20210601__20220531_zPT0Hx4RkPBh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maCITEBzLRi_zFnJYfux1Ws2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computed &#8220;expected&#8221;
    tax benefit</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,490,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">947,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maCITEBzLRi_zZD9Sq7KH1Hb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,973,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,022,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maCITEBzLRi_zouQNNB7pZS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income taxes, net of federal benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">583,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msCITEBzLRi_zW0GZGjlV8ge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maCITEBzLRi_zBLkiluNOQa8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent tax differences and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(197,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maCITEBzLRi_z0MsKHPsszE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maCITEBzLRi_zMZuhGRMn09j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign taxes of subsidiaries</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(129,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(113,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzLRi_zCbHblsos8G3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z6t9YwLvlCnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effect of significant temporary differences is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zKa0cnEl6IC">&#160;SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20230531_zcdSpE1advel" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220531_zz4jubQPL1s5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzl2T_zoJPLcS3oaN3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable,
    principally due to allowance for doubtful accounts</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzl2T_zyTgsXHyl9uh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Inventory valuation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">237,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_maDTAGzl2T_zk8LFjL4wJbf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensated absences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">120,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzl2T_zR4790kv4XPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,817,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,349,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzl2T_zK6tOU68FhUk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credit carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,239,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,096,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_iI_maDTAGzl2T_zDZQkHcikds4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred rent expense/Capitalized leases</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DefferedTaxAssetsStockOptions_iI_maDTAGzl2T_zmkKMKaREBJ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,296,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,035,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsCapitalizedCosts_iI_maDTAGzl2T_z6LtUkQbqmsa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sec 174 capitalized costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">284,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_iI_maDTAGzl2T_zUFMFuKsa3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Losses of foreign subsidiaries &amp; other,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccumulatedDepreciationAndAmortization_iI_maDTAGzl2T_zUO37fP95gvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzl2T_maDTANzFA8_zzMFePDOqVx3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,940,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,967,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFA8_zrhlaIp5jY1h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,940,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,967,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFA8_zJYyCrD9RqUg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax asset</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379204903056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">SCHEDULE OF GEOGRAPHIC INFORMATION</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zGGLNwuVGY9k" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z7cG5U7SlX8b">SCHEDULE
OF GEOGRAPHIC INFORMATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20220601__20230531_zJfyALI3Y6F9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20210601__20220531_zAIUzto5L65e" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revenues from sales to unaffiliated customers:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--AsiaMember_zQWtR9KMXSg7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Asia</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,021,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,375,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--EuropeMember_z3ylp06Qme38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Europe</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,798,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,339,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--NorthAmericaMember_zbpKxULpKhTh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">North America</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,470,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">997,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zZIzZe0FWy96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Middle East</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--SouthAmericaMember_zT16pDj3POM3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">South America</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,000</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_zVsIXdCQwpva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>5,339,000</b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>18,871,000</b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202656672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF OPERATING LEASES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zJccOLgSar7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information on our operating leases for the years ended May 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z9hcafgkEkTd">SCHEDULE
OF OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20220601__20230531_zSzDegJAzyT6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20210601__20220531_zQ6uvSHpEBVh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseCost_maLCzsjE_zN9b0A329Qqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">352,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maLCzsjE_zTPhJXEV48ua" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term lease cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LeaseCost_mtLCzsjE_zKSdFz0elaw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMFnK54RcJih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future minimum lease payments of the Company&#8217;s operating lease liabilities by fiscal year are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zACTi91hd6Ai">SCHEDULE
OF FUTURE MINIMUM LEASE PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Year Ending May 31:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20230531_zuR7SXjplLs8"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzfjE_zjXCJmEkQTEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">356,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzfjE_zAz6xE532JNi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">366,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzfjE_zWZRjsXHwgS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">376,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzfjE_z0aV6G8x0Yj5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzfjE_zaZRFkGJqlt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzfjE_mtOLLzK2p_zUh9Z1G7RAq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total minimum future lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,199,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_maOLLzK2p_zxa9kfLeFwn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_maOLLzK2p_zyNHw99PWPk1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total operating lease
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,082,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock', window );">SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfSupplementalLeaseInformationTableTextBlock_z3mnnqSft9jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s other supplemental lease information for the years ended May 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zG6Y8pfXecUh">SCHEDULE
OF OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220601__20230531_zwIB7iGhv1g8" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20210601__20220531_zfkQ1bB7XCih" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended May 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeasePayments_zqcuHF6ogFGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for operating lease liabilities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">347,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average remaining lease term (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230531_zG20xRD4gK87" title="Weighted average remaining lease term (years)">3.27</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220531_zJZ4ZwmrD4f7" title="Weighted average remaining lease term (years)">4.28</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230531_zQnLWfU6akt8" title="Weighted-average discount rate">6.50</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220531_z1eVUJIjyLqg" title="Weighted-average discount rate">6.50</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Supplemental Lease Information [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202631888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF NET INVENTORIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">$ 1,677,000<span></span>
</td>
<td class="nump">$ 1,717,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">869,000<span></span>
</td>
<td class="nump">763,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="nump">782,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total gross inventory</a></td>
<td class="nump">2,728,000<span></span>
</td>
<td class="nump">3,262,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="num">(672,000)<span></span>
</td>
<td class="num">(846,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net inventory</a></td>
<td class="nump">$ 2,056,000<span></span>
</td>
<td class="nump">$ 2,416,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379201694208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="nump">98.81%<span></span>
</td>
<td class="nump">102.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="nump">101.77%<span></span>
</td>
<td class="nump">105.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate minimum</a></td>
<td class="nump">3.12%<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate maximum</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379201522544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DISAGGREGATION REVENUE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 5,339,000<span></span>
</td>
<td class="nump">$ 18,871,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=BMRA_ClinicalLabMember', window );">Clinical Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">3,310,000<span></span>
</td>
<td class="nump">3,064,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=BMRA_OverTheCounteMember', window );">Over The Counte [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">1,169,000<span></span>
</td>
<td class="nump">1,089,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=BMRA_ContractManufacturingMember', window );">Contract Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">610,000<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=BMRA_PhysiciansOfficeMember', window );">Physicians Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 14,259,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=BMRA_ClinicalLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=BMRA_ClinicalLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=BMRA_OverTheCounteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=BMRA_OverTheCounteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=BMRA_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=BMRA_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=BMRA_PhysiciansOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=BMRA_PhysiciansOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379197441472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jan. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,217,000<span></span>
</td>
<td class="nump">$ 35,077,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,719,000<span></span>
</td>
<td class="nump">5,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue', window );">Shelf registration statement maximum authorized common stock issuance value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,014,000<span></span>
</td>
<td class="nump">2,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_SaleOfStockExpenses', window );">Sale of stock expenses</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,339,000<span></span>
</td>
<td class="nump">18,871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other receivables, gross, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751,000<span></span>
</td>
<td class="nump">927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,728,000<span></span>
</td>
<td class="nump">3,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable', window );">Threshold period past due for write-off of trade accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_AccountsReceivableCreditLossExpenseReversal', window );">Accounts receivable, credit loss expense (Reversal)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="nump">846,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, depletion and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">339,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185,000<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Proceeds from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,000<span></span>
</td>
<td class="nump">1,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,940,000<span></span>
</td>
<td class="nump">6,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,940,000<span></span>
</td>
<td class="nump">6,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,000<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,342,616<span></span>
</td>
<td class="nump">2,321,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BMRA_PolishDistributorMember', window );">Polish Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BMRA_MarketingAndDistributionRightsMember', window );">Marketing and Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BMRA_PurchasedTechnologyRightsMember', window );">Purchased Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, depletion and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,000<span></span>
</td>
<td class="nump">621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributor One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributor Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributors In Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember', window );">Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member] | One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,889<span></span>
</td>
<td class="nump">521,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,014,000<span></span>
</td>
<td class="nump">$ 2,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">1,961,000<span></span>
</td>
<td class="nump">2,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_SaleOfStockExpenses', window );">Sale of stock expenses</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMAgreementMember', window );">ATM Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMAgreementMember', window );">ATM Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_AccountsReceivableCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable credit loss expense reversal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_AccountsReceivableCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_SaleOfStockExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_SaleOfStockExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf registration statement maximum authorized common stock issuance value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period past due for trade accounts receivable to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BMRA_PolishDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BMRA_PolishDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BMRA_MarketingAndDistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BMRA_MarketingAndDistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BMRA_PurchasedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BMRA_PurchasedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_OneDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_OneDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_DistributorsInAsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_DistributorsInAsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379201945616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">$ (1,331,000)<span></span>
</td>
<td class="num">$ (1,305,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and leasehold improvements</a></td>
<td class="nump">1,333,000<span></span>
</td>
<td class="nump">1,292,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BMRA_FurnitureAndFixturesLeaseholdImprovementsMember', window );">Furniture and Fixtures Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and leasehold improvements</a></td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="nump">$ 227,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BMRA_FurnitureAndFixturesLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BMRA_FurnitureAndFixturesLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379205549136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">$ 196,000<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_FiniteLivedPatentsAccumulatedAmortization', window );">Less accumulated amortization-patents</a></td>
<td class="num">(31,000)<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_FiniteLivedPatentsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived patents accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_FiniteLivedPatentsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202287312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)<br></strong></div></th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 165,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379197403408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="nump">$ 736,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">548,000<span></span>
</td>
<td class="nump">236,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 892,000<span></span>
</td>
<td class="nump">$ 972,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202213024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative) - Accounts Payable [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net sales percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Two Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net sales percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_TwoVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BMRA_TwoVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202212032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock option expense</a></td>
<td class="nump">$ 1,185,000<span></span>
</td>
<td class="nump">$ 1,260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock option expense</a></td>
<td class="nump">143,000<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock option expense</a></td>
<td class="nump">971,000<span></span>
</td>
<td class="nump">1,021,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock option expense</a></td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379202294016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, shares</a></td>
<td class="nump">2,321,616<span></span>
</td>
<td class="nump">2,081,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,838,000<span></span>
</td>
<td class="nump">$ 2,132,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, shares</a></td>
<td class="nump">243,000<span></span>
</td>
<td class="nump">344,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options Granted Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="num">(46,500)<span></span>
</td>
<td class="num">(39,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options Exercised Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised, Aggregate IntrinsicValue</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled or expired, shares</a></td>
<td class="num">(175,500)<span></span>
</td>
<td class="num">(64,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="nump">$ 4.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, shares</a></td>
<td class="nump">2,342,616<span></span>
</td>
<td class="nump">2,321,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="nump">$ 1,838,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, shares</a></td>
<td class="nump">1,841,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and exercisable Aggregate Intrinsic Value</a></td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379194587392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2023</div></th>
<th class="th"><div>Jan. 22, 2021</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 21, 2021</div></th>
<th class="th"><div>Jan. 21, 2021</div></th>
<th class="th"><div>Jul. 21, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,014,000<span></span>
</td>
<td class="nump">$ 2,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_SaleOfStockExpenses', window );">Sale of stock expenses</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMOfferingMember', window );">ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_SaleOfStockExpenses', window );">Sale of stock expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock shares issued</a></td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of stock, net proceeds</a></td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Preferred stock, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,014,000<span></span>
</td>
<td class="nump">$ 2,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,889<span></span>
</td>
<td class="nump">521,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,961,000<span></span>
</td>
<td class="nump">$ 2,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Preferred stock, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable, amount per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member] | ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member] | ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Preferred stock, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock [Member] | ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Award purchase price, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compenation cost related to non-vested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested, exercisable or expected to vest weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | 2014 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | 2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=BMRA_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_SaleOfStockExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_SaleOfStockExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=BMRA_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=BMRA_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=BMRA_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=BMRA_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=BMRA_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BMRA_TwoThousandFourteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BMRA_TwoThousandFourteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BMRA_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BMRA_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BMRA_TwoThousandTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BMRA_TwoThousandTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=BMRA_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=BMRA_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379201948784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROVISION FOR INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign Taxes Subsidiaries</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(51,000)<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (51,000)<span></span>
</td>
<td class="num">$ (24,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379207687552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed &#8220;expected&#8221; tax benefit</a></td>
<td class="nump">$ 1,490,000<span></span>
</td>
<td class="nump">$ 947,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(1,973,000)<span></span>
</td>
<td class="num">(1,022,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">583,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent tax differences and other</a></td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(197,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock based compensation benefit</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign taxes of subsidiaries</a></td>
<td class="num">(129,000)<span></span>
</td>
<td class="num">(113,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">$ (51,000)<span></span>
</td>
<td class="num">$ (24,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379197400480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable, principally due to allowance for doubtful accounts</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory valuation</a></td>
<td class="nump">188,000<span></span>
</td>
<td class="nump">237,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Compensated absences</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">5,817,000<span></span>
</td>
<td class="nump">4,349,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,239,000<span></span>
</td>
<td class="nump">1,096,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent expense/Capitalized leases</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_DefferedTaxAssetsStockOptions', window );">Stock Options</a></td>
<td class="nump">1,296,000<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_DeferredTaxAssetsCapitalizedCosts', window );">Sec 174 capitalized costs</a></td>
<td class="nump">284,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet', window );">Losses of foreign subsidiaries &amp; other, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">8,940,000<span></span>
</td>
<td class="nump">6,967,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(8,940,000)<span></span>
</td>
<td class="num">(6,967,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Accumulated Depreciation and Amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_DeferredTaxAssetsCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_DeferredTaxAssetsCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets losses of foreign subsidiaries other net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_DefferedTaxAssetsStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deffered tax assets stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_DefferedTaxAssetsStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379208551360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 8,940,000<span></span>
</td>
<td class="nump">$ 6,967,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">1,973,000<span></span>
</td>
<td class="nump">$ 1,063,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">21,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">17,269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379208469600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GEOGRAPHIC INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 5,339,000<span></span>
</td>
<td class="nump">$ 18,871,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">2,021,000<span></span>
</td>
<td class="nump">13,375,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">1,798,000<span></span>
</td>
<td class="nump">4,339,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">1,470,000<span></span>
</td>
<td class="nump">997,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember', window );">Middle East [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember', window );">South America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_MiddleEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_SouthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379204143776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2023 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379207828224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 353,000<span></span>
</td>
<td class="nump">$ 352,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 358,000<span></span>
</td>
<td class="nump">$ 357,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379205490944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)<br></strong></div></th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 356,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">376,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">101,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum future lease payments</a></td>
<td class="nump">1,199,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">117,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,082,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379208493680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="nump">$ 338,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">3 years 3 months 7 days<span></span>
</td>
<td class="text">4 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379200466064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue
in Irvine, California. The lease for its headquarters expires in August 2026. The Company has the option to extend the lease for an additional
five-year term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease area | ft&#178;</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 548,000<span></span>
</td>
<td class="nump">$ 548,000<span></span>
</td>
<td class="nump">$ 236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=BMRA_UniversityOFSouthernCaliforniaMember', window );">University Of Southern California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical trial agreement maximum budgeted costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=BMRA_BiomericaInFoodsMember', window );">Biomerica in Foods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical trial agreement maximum budgeted costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMRA_RoyaltyExpensePercentageOfSales', window );">Royalty expense percentage of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=BMRA_BuildingInIrvineCaliforniaMember', window );">Building in Irvine California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_ClinicalTrialAgreementMaximumBudgetedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical trial agreement maximum budgeted costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_ClinicalTrialAgreementMaximumBudgetedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMRA_RoyaltyExpensePercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense percentage of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMRA_RoyaltyExpensePercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMRA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BMRA_UniversityOFSouthernCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BMRA_UniversityOFSouthernCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BMRA_BiomericaInFoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BMRA_BiomericaInFoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=BMRA_BuildingInIrvineCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=BMRA_BuildingInIrvineCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140379201451696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative)<br></strong></div></th>
<th class="th"><div>Aug. 03, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">the Company announced it had entered into a sales agreement with CVS Pharmacy wherein the Company&#8217;s EZ Detect&#8482;
colorectal disease screening test will be offered at approximately 7,000 CVS Pharmacy retail stores<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BMRA="http://biomerica.com/20230531"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bmra-20230531.xsd" xlink:type="simple"/>
    <context id="From2022-06-01to2023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2023-08-25</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2021-06-012022-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_srt_MinimumMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_srt_MaximumMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-31_srt_MinimumMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_srt_MaximumMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2023-03-072023-03-07_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-07_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorsInAsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:DistributorsInAsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_OneVendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_country_MX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_country_MX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_custom_MarketingAndDistributionRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BMRA:MarketingAndDistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_custom_PurchasedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BMRA:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_custom_PolishDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BMRA:PolishDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_custom_ClinicalLabMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ClinicalLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_custom_ClinicalLabMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ClinicalLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_custom_OverTheCounteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:OverTheCounteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_custom_OverTheCounteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:OverTheCounteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_custom_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_custom_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_custom_PhysiciansOfficeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:PhysiciansOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_custom_PhysiciansOfficeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">BMRA:PhysiciansOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BMRA:FurnitureAndFixturesLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BMRA:FurnitureAndFixturesLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:OneVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoVendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BMRA:TwoVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandFourteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BMRA:TwoThousandFourteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BMRA:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-02-29_us-gaap_EmployeeStockOptionMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BMRA:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember58847203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2021-01-222021-01-22_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">BMRA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-22</startDate>
            <endDate>2021-01-22</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-21_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BMRA:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-21</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BMRA:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2023-03-072023-03-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="From2023-03-072023-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BMRA:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-24</instant>
        </period>
    </context>
    <context id="From2020-02-242020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BMRA:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-24</startDate>
            <endDate>2020-02-24</endDate>
        </period>
    </context>
    <context id="From2020-03-042020-03-24_us-gaap_ConvertiblePreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-04</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="From2020-03-042020-03-24_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-04</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-21_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-21</instant>
        </period>
    </context>
    <context id="AsOf2021-01-21_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_srt_NorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_srt_NorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_MiddleEastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_MiddleEastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_srt_SouthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_srt_SouthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2023-05-312023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_BuildingInIrvineCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">BMRA:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2016-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="From2022-06-012023-05-31_us-gaap_RoyaltyAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2021-06-012022-05-31_us-gaap_RoyaltyAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-09-30_custom_UniversityOFSouthernCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BMRA:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_UniversityOFSouthernCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BMRA:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_BiomericaInFoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BMRA:BiomericaInFoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2023-08-032023-08-03_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-03</startDate>
            <endDate>2023-08-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>BMRA:Segment</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-06-01to2023-05-31">0000073290</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-06-01to2023-05-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-06-01to2023-05-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AuditorFirmId contextRef="From2022-06-01to2023-05-31" id="xdx2ixbrl0044">200</dei:AuditorFirmId>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-05-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-05-31"
      id="xdx2ixbrl0119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-05-31"
      id="xdx2ixbrl0143"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-05-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-05-31"
      id="xdx2ixbrl0162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-05-31"
      id="xdx2ixbrl0163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2021-06-012022-05-31"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts
      contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts
      contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <BMRA:IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <BMRA:IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl0982"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      id="xdx2ixbrl0983"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl0994"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      id="xdx2ixbrl0995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl0997"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      id="xdx2ixbrl0998"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl1000"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      id="xdx2ixbrl1001"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-06-01to2023-05-31"
      id="xdx2ixbrl1021"
      unitRef="USD"
      xsi:nil="true"/>
    <BMRA:DeferredTaxAssetsCapitalizedCosts
      contextRef="AsOf2022-05-31"
      id="xdx2ixbrl1060"
      unitRef="USD"
      xsi:nil="true"/>
    <BMRA:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet
      contextRef="AsOf2023-05-31"
      id="xdx2ixbrl1062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-05-31"
      id="xdx2ixbrl1074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-05-31"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <BMRA:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2023-05-31"
      id="xdx2ixbrl1150"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-06-01to2023-05-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-06-01to2023-05-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-06-01to2023-05-31">2023-05-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-06-01to2023-05-31">--05-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-06-01to2023-05-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-06-01to2023-05-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-06-01to2023-05-31">001-37863</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-06-01to2023-05-31">BIOMERICA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-06-01to2023-05-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-06-01to2023-05-31">95-2645573</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-06-01to2023-05-31">17571 Von Karman Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-06-01to2023-05-31">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-06-01to2023-05-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-06-01to2023-05-31">92614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-06-01to2023-05-31">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-06-01to2023-05-31">645-2111</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-06-01to2023-05-31">Common     Stock, par value $0.08</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-06-01to2023-05-31">BMRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-06-01to2023-05-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-06-01to2023-05-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-06-01to2023-05-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-06-01to2023-05-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-06-01to2023-05-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-06-01to2023-05-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-06-01to2023-05-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-06-01to2023-05-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-06-01to2023-05-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-06-01to2023-05-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-11-30" decimals="0" unitRef="USD">42738451</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-08-25" decimals="INF" unitRef="Shares">16821646</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2022-06-01to2023-05-31">Portions of the registrant&#x2019;s definitive Proxy Statement on Schedule 14A relating to the registrant&#x2019;s
2023 annual meeting of stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal
year covered by this Annual Report on Form 10-K, are incorporated by reference in Part III, Items 10 through 14 of this Annual Report
on Form 10-K. Except for the portions of the Proxy Statement specifically incorporated by reference in this Form 10-K, the Proxy Statement
and related proxy solicitation materials shall not be deemed to be filed as part hereof.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="From2022-06-01to2023-05-31">HASKELL &amp; WHITE LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-06-01to2023-05-31">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">9719000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">5917000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">722000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">774000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">2056000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">2416000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">320000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">12797000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">9427000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">213000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">214000</us-gaap:PropertyPlantAndEquipmentNet>
    <BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">617000</BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">725000</BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1035000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1302000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Investments contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">165000</us-gaap:Investments>
    <us-gaap:Investments contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">165000</us-gaap:Investments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">165000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">170000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">79000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">96000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">14454000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">11374000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">892000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">972000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">696000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">647000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">60000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">51000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">297000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">341000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1945000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">2011000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">785000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1038000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">2730000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">3049000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">571429</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">571429</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-05-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">4428571</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-05-31" decimals="INF" unitRef="Shares">4428571</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-05-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-05-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-31"
      decimals="INF"
      unitRef="USDPShares">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-05-31"
      decimals="INF"
      unitRef="USDPShares">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-05-31" decimals="INF" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">16821646</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">16821646</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-05-31" decimals="INF" unitRef="Shares">12867924</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-05-31" decimals="INF" unitRef="Shares">12867924</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1346000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1029000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">52705000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">42447000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">-110000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">-74000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">-42217000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">-35077000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">11724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">8325000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">14454000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">11374000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">5339000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">18871000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">4893000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">15894000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">446000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">2977000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">6085000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">5699000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1812000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">7669000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">7511000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-7223000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-4534000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">133000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">27000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">134000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">27000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-7089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-4507000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">51000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-7140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-4531000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="USDPShares">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="USDPShares">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="USDPShares">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="USDPShares">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Shares">14154269</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Shares">12673245</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Shares">14154269</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Shares">12673245</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-7140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-4531000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-26000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-7176000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-4557000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12307157</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-05-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-30546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-05-31" decimals="0" unitRef="USD">9228000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">39500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">521267</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">41000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2276000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">2317000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2021-06-012022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-26000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-26000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-06-012022-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4531000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-4531000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12867924</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">42447000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-35077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">8325000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12867924</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">42447000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-05-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-35077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">8325000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">46500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">81000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">573889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">46000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1915000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1961000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <BMRA:StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3333333</BMRA:StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts>
    <BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">267000</BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts>
    <BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts
      contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7081000</BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts>
    <BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">7348000</BMRA:StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2022-06-012023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-06-012023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1185000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1185000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-012023-05-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-7140000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16821646</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">52705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-42217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">11724000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16821646</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">52705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-05-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-42217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">11724000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-7140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-4531000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">84000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">339000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-53000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">342000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-684000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-174000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-772000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1185000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1260000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">267000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">256000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">291000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-1365000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-534000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-1562000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-20000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-50000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-18000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-169000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-80000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">389000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">49000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">258000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">9000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">51000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <BMRA:IncreaseDecreaseInReductionInLeaseLiabilities
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-297000</BMRA:IncreaseDecreaseInReductionInLeaseLiabilities>
    <BMRA:IncreaseDecreaseInReductionInLeaseLiabilities
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-244000</BMRA:IncreaseDecreaseInReductionInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-5474000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-479000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">14000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">113000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">64000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">57000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-78000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-170000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">10014000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">2402000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">705000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">85000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">81000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">77000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">9390000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">2394000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-36000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-26000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">3802000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1719000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">5917000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-05-31" decimals="0" unitRef="USD">4199000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">9719000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">5917000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">51000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">24000</us-gaap:IncomeTaxesPaidNet>
    <BMRA:IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">4000</BMRA:IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment>
    <BMRA:IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">4000</BMRA:IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment>
    <BMRA:WriteOffOfFixedAssetsCost
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">40000</BMRA:WriteOffOfFixedAssetsCost>
    <BMRA:WriteOffOfFixedAssetsCost
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">820000</BMRA:WriteOffOfFixedAssetsCost>
    <BMRA:WriteOffOfFixedAssetsAccumulatedDepreciation
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">40000</BMRA:WriteOffOfFixedAssetsAccumulatedDepreciation>
    <BMRA:WriteOffOfFixedAssetsAccumulatedDepreciation
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">767000</BMRA:WriteOffOfFixedAssetsAccumulatedDepreciation>
    <BMRA:WriteOffOfIntangibleAssetsCost
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">6000</BMRA:WriteOffOfIntangibleAssetsCost>
    <BMRA:WriteOffOfIntangibleAssetsCost
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">247000</BMRA:WriteOffOfIntangibleAssetsCost>
    <BMRA:WriteOffOfIntangibleAssetsAccumulatedAmortization
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">6000</BMRA:WriteOffOfIntangibleAssetsAccumulatedAmortization>
    <BMRA:WriteOffOfIntangibleAssetsAccumulatedAmortization
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">37000</BMRA:WriteOffOfIntangibleAssetsAccumulatedAmortization>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zaNIuuV29Ppj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1: &lt;span id="xdx_82A_zcwwzjYuPkld"&gt;ORGANIZATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Biomerica,
Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is a biomedical technology
company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians&#x2019;
offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. Our diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis
of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens,
or other substances, which may exist in the human body in extremely small concentrations. The Company&#x2019;s products are designed to
enhance the health and well-being of people, while reducing total healthcare costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided
therapy (&#x201c;DGT&#x201d;) products to treat gastrointestinal diseases, such as irritable bowel syndrome (&#x201c;IBS&#x201d;), and other
inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address
very large markets. Our InFoods&#xae; IBS product uses a simple blood sample and is designed to identify patient-specific foods that,
when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, and constipation. Instead of broad and difficult
to manage dietary restrictions, the InFoods&#xae; IBS product works by identifying specific foods that may be causing an abnormally high
immune response in the patient. A food identified as positive, which is causing the abnormal immune response in the patient,
is simply removed from the diet to help alleviate IBS symptoms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our existing medical diagnostic products are sold worldwide primarily in
two markets: 1) clinical laboratories and 2) point-of-care (physicians&#x2019; offices and over-the-counter drugstores like Walmart and
CVS Pharmacy). The diagnostic test kits are used to analyze blood, urine, nasal, or fecal specimens from patients in the diagnosis of
various diseases, food intolerances, and other medical complications, by measuring or detecting the existence and/or level of specific
bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#x2019;s body, stools, or blood, often in extremely
small concentrations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the global COVID-19 pandemic, in March 2020, we began developing COVID-19 products to indicate if a person has been infected by COVID-19
or is currently infected. In fiscal 2022, we generated revenues from the international sale of our COVID-19 antigen tests. However, in
fiscal 2023, due to the decline in severity of COVID-19 and the corresponding lower sales volumes, we no longer sell these products.
Due to the relatively high volume of sales from these products in fiscal 2021 and fiscal 2022, we have seen significant fluctuations
in quarterly revenues over the past twelve quarters.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
other existing products that contributed to our 2023 revenues are primarily focused on gastrointestinal diseases, food intolerances,
and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or
sold for diagnostic use where they are registered by each country&#x2019;s regulatory agency. In addition, some products are cleared for
sale in the United States by the FDA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_z8PkU7pRtSK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2: &lt;span id="xdx_82E_zpHuYaPeoOWk"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z7gFfpvpLaT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zZwFKfOCmSdd"&gt;PRINCIPLES
OF CONSOLIDATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements for the years ended May 31, 2023 and 2022, include the accounts of Biomerica, Inc. (&#x201c;Biomerica&#x201d;)
as well as its wholly-owned German subsidiary (&#x201c;BioEurope GmbH&#x201d;) and Mexican subsidiary (&#x201c;Biomerica de Mexico&#x201d;).
All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zuySZ9CDyIC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zTPMeefF7g3j"&gt;ACCOUNTING
ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful
accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates,
which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of
materials; and lease liabilities and right-of-use assets, which are calculated based on certain assumptions such as the borrowing
rate on the lease commencement date and, the likelihood of lease extensions to occur, asset valuations, among other things; and other items that may be necessary to
estimate using current, historical and judgment based information. Actual results could materially differ from those
estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the global COVID-19 pandemic, the Company&#x2019;s operations have been negatively impacted. The Company has faced disruptions in the
following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#x2019;s
manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping
and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or
sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer
credit risk, and general economic calamities. These pandemic related disruptions can materially negatively impact the Company&#x2019;s
operations and financial performance and may continue to have significant material negative impacts on the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--LiquidityPolicyTextBlock_zW6vUuWhG1Ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjOTo59chAK9"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $&lt;span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn6n6_di_c20230531_zR7wm3w9TnGd" title="Accumulated deficit"&gt;42&lt;/span&gt; million as
of May 31, 2023. Management expects to continue to incur significant costs as it advances its trials and development activities. As of
May 31, 2023, the Company had cash and cash equivalents of approximately $&lt;span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230531_zI7WIQvdh0s9" title="Cash and cash equivalents"&gt;9,719,000&lt;/span&gt; and working capital of approximately $&lt;span id="xdx_908_ecustom--WorkingCapital_iNI_di_c20230531_zS9FSdFRDyN8" title="Working capital"&gt;10,852,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $&lt;span id="xdx_90B_ecustom--ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_iI_c20210122_zNs4j3moD7f9" title="Shelf registration statement maximum authorized common stock issuance value"&gt;15,000,000&lt;/span&gt; in &#x201c;at-the-market&#x201d;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#x201c;ATM Offering&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any shares under the ATM Offering, and may at any time suspend offers
under, or terminate the ATM Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended May 31, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zKcvJRy8jlm4" title="Sale of stock, number of shares issued in transaction"&gt;573,889&lt;/span&gt; shares of its common stock at prices ranging from $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zSjRvtL1zhQ" title="Sale of stock, price per share"&gt;3.15&lt;/span&gt; to $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zdRfY3Ch057a" title="Sale of stock, price per share"&gt;4.26&lt;/span&gt; pursuant to the
ATM Agreement, which resulted in gross proceeds of approximately $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zgSVz1vLMHJ5" title="Sale of stock, consideration received on transaction"&gt;2,014,000&lt;/span&gt; and net proceeds to the Company of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z7YVQm30GfFf" title="Proceeds from issuance of common stock"&gt;1,961,000&lt;/span&gt;, after deducting
commissions for each sale and legal, accounting, and other fees related to offering in the amount of $&lt;span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zFVG7Rapmvy7" title="Sale of stock expenses"&gt;53,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended May 31, 2022, the Company sold &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zk6s2jb3LzFl" title="Sale of stock, number of shares issued in transaction"&gt;521,267&lt;/span&gt; shares of its common stock at prices ranging from $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBGjiqSfbqg2" title="Sale of stock, price per share"&gt;4.02&lt;/span&gt; to $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1tHM7RXW0U2" title="Sale of stock, price per share"&gt;5.63&lt;/span&gt; pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBmMSveBMcal" title="Sale of stock, consideration received on transaction"&gt;2,402,000&lt;/span&gt; and net proceeds to the Company of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zbgeua5vzmrd" title="Proceeds from issuance of common stock"&gt;2,317,000&lt;/span&gt;, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $&lt;span id="xdx_906_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1J6pzOT4cAh" title="Sale of stock expenses"&gt;85,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 7, 2023, the Company sold &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zQQg5I8fRDzb" title="Net proceeds from ATM (in Shares)"&gt;3,333,333&lt;/span&gt; shares of common stock in a firm commitment public offering at a gross sales price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z2pu4lFTRZq" title="Share price"&gt;2.40&lt;/span&gt;
per share, with net total proceeds, after deducting issuance fees and expenses of $&lt;span id="xdx_907_ecustom--SaleOfStockExpenses_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zWIHolrzirAg" title="Sale of stock expenses"&gt;700,000&lt;/span&gt;, of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zqJEv3gsEkG7" title="Proceeds from issuance of common stock"&gt;7,300,000&lt;/span&gt;. Since the closing
of the March 7, 2023 offering, the ATM has been withdrawn and is not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company intends to use the net proceeds from such offerings for general corporate purposes, including, without limitation, sales and
marketing activities, clinical studies, product development, making acquisitions of assets, businesses, companies or securities,
capital expenditures, and for working capital needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has analyzed the cash requirements of the Company&#x2019;s business through at least August 2024. As a result of cash and cash
equivalents on hand on May 31, 2023, largely from the public offering, and the ability to raise additional funds through another new
ATM agreement, management believes the Company has sufficient funds to operate through at least August 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zj7jiqvTvXB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMZUTNqxBcJ4"&gt;FAIR
VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on
a historical basis. The Company&#x2019;s consolidated financial instruments consist of its cash and cash equivalents, accounts receivable,
and accounts payable. The carrying amounts of the Company&#x2019;s financial instruments approximate their fair values. The Company also
maintains an investment in privately held company (see below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zV6dJYlNhv9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z0QxvzjqIh57"&gt;CONCENTRATION
OF CREDIT RISK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time,
the Company has uninsured balances. The Company does not believe it is exposed to any significant credit risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company
performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
net sales were approximately $&lt;span id="xdx_900_eus-gaap--Revenues_c20220601__20230531_zgTugdKjmmsd" title="Revenues"&gt;5,339,000&lt;/span&gt;
for fiscal 2023 compared to $&lt;span id="xdx_903_eus-gaap--Revenues_c20210601__20220531_z5VE0EJrAB24" title="Revenues"&gt;18,871,000&lt;/span&gt;
for fiscal 2022. For the fiscal years ended May 31, 2023 and 2022, the Company had one and two distributors, respectively, which
accounted for a total of &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorOneMember_zCfRW217Lbbh" title="Concentration risk, percentage"&gt;35&lt;/span&gt;%
and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorTwoMember_zGjQu8OVjkr8" title="Concentration risk, percentage"&gt;65&lt;/span&gt;%
of our net sales, respectively. Of this, for the fiscal years ended May 31, 2023 and 2022, the largest of the distributors mentioned
above accounted for &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zBZbRgFVmtve" title="Concentration risk, percentage"&gt;35&lt;/span&gt;%
and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zlgIgVsxXvWd" title="Concentration risk, percentage"&gt;55&lt;/span&gt;%,
respectively, of net sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
gross receivables on May 31, 2023 and 2022 were approximately $&lt;span id="xdx_901_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230531_zeFH384WNPe" title="Other receivables, gross, current"&gt;751,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OtherReceivablesGrossCurrent_iI_c20220531_zW8eMxbbRJU1" title="Other receivables, gross, current"&gt;927,000&lt;/span&gt;, respectively. On May 31, 2023 and 2022, the Company
had one distributor which accounted for a total of &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zaMA0Oy1OT4" title="Concentration risk, percentage"&gt;36&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zeavQLNSShXh" title="Concentration risk, percentage"&gt;50&lt;/span&gt;%, respectively, of gross accounts receivable. Of the &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zLj8Yk8BKDr6" title="Concentration risk, percentage"&gt;36&lt;/span&gt;% as of May 31,
2023, &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorsInAsiaMember_zdwAc3CJuy46" title="Concentration risk, percentage"&gt;100&lt;/span&gt;% was owed by a distributor in Asia.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the fiscal year ended May 31, 2023, the Company did not have any significant concentration of vendor spend for raw materials. For the
fiscal year ended May 31, 2022, the Company had one vendor, which accounted for &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zKxusiWRt50j" title="Concentration risk, percentage"&gt;84&lt;/span&gt;% of our purchases of raw materials largely related
to COVID-19 products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--ConcentrationRiskGeographicPolicyPolicyTextBlock_zas1WR54uYvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zcBx91ToEpJb"&gt;GEOGRAPHIC
CONCENTRATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023 and 2022, approximately $&lt;span id="xdx_907_eus-gaap--InventoryGross_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zSVEX9SVBd11" title="Inventory, gross"&gt;626,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InventoryGross_iI_c20220531__srt--StatementGeographicalAxis__country--MX_zlaRxFv9kbVl" title="Inventory, gross"&gt;621,000&lt;/span&gt;, respectively, of Biomerica&#x2019;s gross inventory was located in Mexicali,
Mexico, respectively. As of May 31, 2023 and 2022, approximately $&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zYBaLgKp5ADf" title="Property, plant and equipment, net"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20220531__srt--StatementGeographicalAxis__country--MX_ziH0FHnFTYf8" title="Property, plant and equipment, net"&gt;17,000&lt;/span&gt;&lt;/span&gt; of Biomerica&#x2019;s property and equipment, net of accumulated
depreciation and amortization, was located in Mexicali, Mexico.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9ZkeOdmCqf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zG3h0TU5Octl"&gt;CASH
AND CASH EQUIVALENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zF4Rf9LewHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zNLY7qix7um5"&gt;ACCOUNTS
RECEIVABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until
they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.
Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in
credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and
adjusts the allowance for doubtful accounts accordingly. Balances over &lt;span id="xdx_902_eus-gaap--ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_dc_c20220601__20230531_zmLrzVXcQFz5" title="Threshold period past due for write-off of trade accounts receivable"&gt;ninety days&lt;/span&gt;
old are usually reserved for unless collection is reasonably assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Occasionally
certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total
gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices
before shipping new sales orders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023 and 2022, the Company has established a reserve of approximately $&lt;span id="xdx_90B_ecustom--AccountsReceivableCreditLossExpenseReversal_c20220601__20230531_zBplFjSnf2wh" title="Accounts receivable, credit loss expense (Reversal)"&gt;29,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--AccountsReceivableCreditLossExpenseReversal_c20210601__20220531_zpZRmWKdXRal" title="Accounts receivable, credit loss expense (Reversal)"&gt;153,000&lt;/span&gt;, respectively, for doubtful accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--PrepaidExpensesAndOtherPolicyTextBlock_zbZ1vAqwJYSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zvMG2dPRgKA9"&gt;PREPAID
EXPENSES AND OTHER&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company occasionally prepays for items such as inventory, insurance, and other items. These items are reported as prepaids, until either
the inventory is physically received or the insurance and other items are utilized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023 and 2022, the prepaids were approximately $&lt;span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20230531_zTc4RwoJUK14" title="Prepaid expense and other assets"&gt;300,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20220531_zmcq7Mv3bvvh" title="Prepaid expense and other assets"&gt;320,000&lt;/span&gt;, respectively, composed of prepayments to insurance and
various other suppliers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_z6EjOOLsoTgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z3XAflCbijqi"&gt;INVENTORIES,
NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out
methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates
quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer
demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision
included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs, and wasted material are recognized as
current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfXAx85nCdEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of approximate net inventories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B1_zbIIOEvcmUOj" style="display: none"&gt;SCHEDULE
OF NET INVENTORIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230531_zxJS0YOBkNe5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220531_zTXs9kF0FWxe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zK9rFPjWIuBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,677,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,717,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zI5pUzxdZvg9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;869,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;763,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z544N6uW1yC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;182,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;782,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_zxuDEwDW0kV3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total gross inventory&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,728,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,262,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zmvW1nT9x7vf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(672,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(846,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_zMrcSIofgNza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,056,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,416,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z2QADNWUiHM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reserves
for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically
reserve for obsolete inventory. As of May 31, 2023 and 2022, inventory reserves were approximately $&lt;span id="xdx_90C_eus-gaap--InventoryValuationReserves_iI_c20230531_zhcqT5mKlPVa" title="Inventory reserves"&gt;672,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20220531_zx6uzyfls493" title="Inventory reserves"&gt;846,000&lt;/span&gt;, respectively.
The Company has fully reserved COVID-19 antibody inventory in fiscal 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk6bOjyUlvKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zksGzV8gHEgh"&gt;PROPERTY
AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are
charged to operations as incurred. When property and equipment are sold, retired, or otherwise disposed of, the related cost and accumulated
depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements, and dispositions are credited
or charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
and amortization are provided over the estimated useful lives of the related assets, ranging from &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MinimumMember_zzBbxxesTGV7" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MaximumMember_zkf43DLyWf04" title="Property, plant and equipment, useful life"&gt;10&lt;/span&gt; years, using the straight-line
method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation
and amortization expense on property and equipment amounted to approximately $&lt;span id="xdx_900_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zdt0SbTs22g2" title="Depreciation, depletion and amortization"&gt;66,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zQRMq8oDZLx8" title="Depreciation, depletion and amortization"&gt;100,000&lt;/span&gt; for the years ended May 31, 2023 and
2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zHpEUEE6lTNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zaJlBQgBPHgf"&gt;INTANGIBLE
ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets include trademarks, product rights, technology rights, and patents, and are accounted for based on Accounting Standards Codification
(&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have
indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in
circumstances indicate that the asset might be impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets are being amortized using the straight-line method over the useful life, not to exceed &lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MarketingAndDistributionRightsMember_zyCruYyiK0ck" title="Finite-lived intangible asset, useful life"&gt;18&lt;/span&gt; years for marketing and distribution
rights, &lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedTechnologyRightsMember_zIk62ly12fKd" title="Finite-lived intangible asset, useful life"&gt;10&lt;/span&gt; years for purchased technology use rights, and &lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zENHs0nm4Poe" title="Finite-lived intangible asset, useful life"&gt;20&lt;/span&gt; years for patents. Amortization amounted to approximately $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20220601__20230531_zMJVurcApaH4" title="Amortization of intangible assets"&gt;18,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210601__20220531_zE1wenKkvlq5" title="Amortization of intangible assets"&gt;239,000&lt;/span&gt;
for the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#x2019;s balance over
its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine
whether there was any impairment. During the year ended May 31, 2023, there was &lt;span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20220601__20230531_zpGA1bc1gRL4" title="Asset impairment charges"&gt;no&lt;/span&gt; impairment of intangible assets. During the year ended May 31, 2022, an impairment
adjustment was made of $&lt;span id="xdx_908_eus-gaap--AssetImpairmentCharges_c20210601__20220531_zUVEsXBiWrDi" title="Asset impairment charges"&gt;210,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--InvestmentPolicyTextBlock_zIjX6nok2s9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_znhP4kr3dE21"&gt;INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has made investments in a privately held Polish
distributor, which is primarily engaged in distributing medical products and devices, including the distribution of the products
sold by the Company. The Company invested approximately $&lt;span id="xdx_90E_eus-gaap--Investments_iI_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zNabs00JsA8b" title="Investments"&gt;165,000&lt;/span&gt;
into the Polish distributor and owns approximately &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zYfiU0qnlX8d" title="Equity method investment, ownership percentage"&gt;6&lt;/span&gt;%
of the investee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence (&#x201c;Cost Method
Holdings&#x201d;) are accounted for at the Company&#x2019;s initial cost, minus any impairment (if any), plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends
received are recorded as other income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an
equity holding may not be recoverable. Management reviewed the underlying net assets of the Company&#x2019;s equity method holding as
of May 31, 2023 and determined that the Company&#x2019;s proportionate economic interest in the entity indicates that the equity holding
was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the
Company&#x2019;s Cost Method Holding during the year ended May 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zi5fht3J56mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zXu5Ufocrqtd"&gt;SHARE-BASED
COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance of ASC 718, Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based
method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments
(options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that uses
assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The
Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based
on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options.
The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the
&#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as
historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under
the straight-line attribution method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expensed approximately $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220601__20230531_z7zUYyTVKW7" title="Share-based payment arrangement, expense"&gt;1,185,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210601__20220531_z3tU1y95IeBa" title="Share-based payment arrangement, expense"&gt;1,260,000&lt;/span&gt; of share-based compensation during the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdEKYnJS0eH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for period ending May 31, 2023 and 2022: &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z9Q59AExJB38" style="display: none"&gt;SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20220601__20230531_zwzgNCPGQTo4" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20210601__20220531_z223yB5oqmTd" title="Dividend yield"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z6diBBXCP6ck" title="Expected volatility minimum"&gt;98.81&lt;/span&gt;
                                            - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zkvWtpzDXNNk" title="Expected volatility maximum"&gt;101.77&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zCLhxdQMqwa7" title="Expected volatility minimum"&gt;102.54&lt;/span&gt;
- &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zo1OdHzsfXwk" title="Expected volatility maximum"&gt;105.48&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zwhwDa4nM9A8" title="Risk free interest rate minimum"&gt;3.12&lt;/span&gt;
                                            - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z29ZDWgpxT77" title="Risk free interest rate maximum"&gt;3.35&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zMhegBQUmCDj" title="Risk free interest rate minimum"&gt;0.97&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zje1Rms6d7fg" title="Risk free interest rate maximum"&gt;2.75&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20220601__20230531_zdmQdYowvAH3" title="Expected term"&gt;6.25&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MinimumMember_zdvX2xmg7cd1" title="Expected term"&gt;5.50&lt;/span&gt;
                                            - &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MaximumMember_zJovgA4h7XD4" title="Expected term"&gt;6.25&lt;/span&gt; years &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zADPwTqKuID8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zTgQf8Mt2FW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zqvIu7A6QYZi"&gt;REVENUE
RECOGNITION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time
the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point
title passes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not typically allow for returns from customers except in the event of defective merchandise and therefore does not establish
an allowance for returns. In addition, the Company has contracts with customers wherein customers receive purchase discounts for achieving
specified sales volumes. The Company evaluated the status of these contracts during the years ended May 31, 2023 and 2022 and does not
believe that any additional discounts will be given through the end of the contract periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Services
for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project
progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories,
medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce
customers as well as to distributors. Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized
below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international
manufacturers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023, the Company had approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromCustomers_c20220601__20230531_zXS0hCVZoOn8" title="Proceeds from customers"&gt;60,000&lt;/span&gt; of advances from certain foreign customers. These advances are prepayments on
orders that are expected to ship during our second fiscal quarter ending November 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaggregation
of revenue:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zanhIyCQdtLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of revenues according to primary markets to which the products are sold:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_zNnuM8NBDbSj" style="display: none"&gt;SCHEDULE OF DISAGGREGATION REVENUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220601__20230531_zP8e8gf5j2q3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210601__20220531_ze3LkGjwz3Gh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zKHvA3J7tN2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical lab&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,310,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,064,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_z9Mve49dOEJd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Over-the-counter&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,169,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,089,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_z9ypGqpq5I81" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contract manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;459,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zkH4ktR4A8Nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Physician&#x2019;s office&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,259,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHpBiDu5C8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,339,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,871,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zvOxIDEPiRA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 8 for additional information regarding geographic revenue concentrations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_zvyO8kcbTwZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zo3bOhAblJwi"&gt;SHIPPING
AND HANDLING FEES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company includes shipping and handling fees billed to customers in net sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoPDGTZ4ZYce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z5WBvU2kFJM2"&gt;RESEARCH
AND DEVELOPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. The Company expensed approximately $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220601__20230531_zxrrWoRg1AA4" title="Research and development expense"&gt;1,584,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210601__20220531_zNsRZitDXup9" title="Research and development expense"&gt;1,812,000&lt;/span&gt; of research and development
costs during the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z7GpIgRB6l2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zHiFcLTqmP0a"&gt;INCOME
TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and
liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the
consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net
operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit
carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent
that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation
allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the
character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance
and income tax expense. As of May 31, 2023 and 2022, in accordance with ASC 740, the Company has a valuation allowance for
substantially all of its net deferred tax assets. During the year ended May 31, 2023, this valuation allowance was increased to
$&lt;span id="xdx_906_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_zd5VCqoAt0z2" title="Deferred tax assets, valuation allowance"&gt;8,940,000&lt;/span&gt;,
which fully covers the net deferred tax asset of $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsGross_iI_c20230531_zdBMfhCgPHW2" title="Deferred tax assets, net"&gt;8,940,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions.
The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more
likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related
appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount
of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized
when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which
is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information
available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an
accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line
and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--AdvertisingCostsPolicyTextBlock_zWTcxet7YGAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z47QZsQ6HMz1"&gt;ADVERTISING
COSTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately
$&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20220601__20230531_z9Fyj00nxcr4" title="Advertising expense"&gt;156,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AdvertisingExpense_c20210601__20220531_zzixh9zoqbUl" title="Advertising expense"&gt;76,000&lt;/span&gt; for the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zKvticJLFUTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zLN0PxTX9iKi"&gt;FOREIGN
CURRENCY TRANSLATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the
U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries
are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates
for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive
loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May
31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z9YTFDd1Gp72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zf9MmdLbU2Oj"&gt;RIGHT-OF-USE
ASSETS AND LEASE LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standard update which requires lessees
to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from
the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value
of fixed lease payments over the lease term. Leases are classified as financing or operating which will drive the expense recognition
pattern. The Company has elected to exclude short-term leases. The Company leases office space and copy machines, all of which are operating
leases. Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options
to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The
leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited
by the expected lease term. For additional information, see Note 9-Commitments and Contingencies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGhUn8gHrkwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zbplaaJ5ElFa"&gt;NET
LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss
per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible
securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation
for the years ended May 31, 2023 and 2022 were &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220601__20230531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z4slMFwctEC9" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)"&gt;2,342,616&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210601__20220531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zob2BtJtsFyf" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)"&gt;2,321,616&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zY7tmLByV8sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zGTwlBY8erm"&gt;SEGMENT
REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about
operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management
and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic
kits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaxSJgIMdnu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zqDWvQiTcYP"&gt;REPORTING
COMPREHENSIVE LOSS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly
as a component of shareholders&#x2019; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments
for the years ended May 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zgusxlyi9MG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zKKValXlvOd7"&gt;RECENT
ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except as follows, recent
ASU&#x2019;s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on
the Company&#x2019;s present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.
This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting
date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective
for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November
2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates, which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered
smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including
interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine
its impact on the Company&#x2019;s consolidated results of operations and financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z7gFfpvpLaT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zZwFKfOCmSdd"&gt;PRINCIPLES
OF CONSOLIDATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements for the years ended May 31, 2023 and 2022, include the accounts of Biomerica, Inc. (&#x201c;Biomerica&#x201d;)
as well as its wholly-owned German subsidiary (&#x201c;BioEurope GmbH&#x201d;) and Mexican subsidiary (&#x201c;Biomerica de Mexico&#x201d;).
All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zuySZ9CDyIC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zTPMeefF7g3j"&gt;ACCOUNTING
ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful
accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates,
which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of
materials; and lease liabilities and right-of-use assets, which are calculated based on certain assumptions such as the borrowing
rate on the lease commencement date and, the likelihood of lease extensions to occur, asset valuations, among other things; and other items that may be necessary to
estimate using current, historical and judgment based information. Actual results could materially differ from those
estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the global COVID-19 pandemic, the Company&#x2019;s operations have been negatively impacted. The Company has faced disruptions in the
following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#x2019;s
manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping
and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or
sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer
credit risk, and general economic calamities. These pandemic related disruptions can materially negatively impact the Company&#x2019;s
operations and financial performance and may continue to have significant material negative impacts on the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <BMRA:LiquidityPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84E_ecustom--LiquidityPolicyTextBlock_zW6vUuWhG1Ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjOTo59chAK9"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $&lt;span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn6n6_di_c20230531_zR7wm3w9TnGd" title="Accumulated deficit"&gt;42&lt;/span&gt; million as
of May 31, 2023. Management expects to continue to incur significant costs as it advances its trials and development activities. As of
May 31, 2023, the Company had cash and cash equivalents of approximately $&lt;span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230531_zI7WIQvdh0s9" title="Cash and cash equivalents"&gt;9,719,000&lt;/span&gt; and working capital of approximately $&lt;span id="xdx_908_ecustom--WorkingCapital_iNI_di_c20230531_zS9FSdFRDyN8" title="Working capital"&gt;10,852,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $&lt;span id="xdx_90B_ecustom--ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_iI_c20210122_zNs4j3moD7f9" title="Shelf registration statement maximum authorized common stock issuance value"&gt;15,000,000&lt;/span&gt; in &#x201c;at-the-market&#x201d;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#x201c;ATM Offering&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any shares under the ATM Offering, and may at any time suspend offers
under, or terminate the ATM Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended May 31, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zKcvJRy8jlm4" title="Sale of stock, number of shares issued in transaction"&gt;573,889&lt;/span&gt; shares of its common stock at prices ranging from $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zSjRvtL1zhQ" title="Sale of stock, price per share"&gt;3.15&lt;/span&gt; to $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zdRfY3Ch057a" title="Sale of stock, price per share"&gt;4.26&lt;/span&gt; pursuant to the
ATM Agreement, which resulted in gross proceeds of approximately $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zgSVz1vLMHJ5" title="Sale of stock, consideration received on transaction"&gt;2,014,000&lt;/span&gt; and net proceeds to the Company of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z7YVQm30GfFf" title="Proceeds from issuance of common stock"&gt;1,961,000&lt;/span&gt;, after deducting
commissions for each sale and legal, accounting, and other fees related to offering in the amount of $&lt;span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zFVG7Rapmvy7" title="Sale of stock expenses"&gt;53,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended May 31, 2022, the Company sold &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zk6s2jb3LzFl" title="Sale of stock, number of shares issued in transaction"&gt;521,267&lt;/span&gt; shares of its common stock at prices ranging from $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBGjiqSfbqg2" title="Sale of stock, price per share"&gt;4.02&lt;/span&gt; to $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1tHM7RXW0U2" title="Sale of stock, price per share"&gt;5.63&lt;/span&gt; pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zBmMSveBMcal" title="Sale of stock, consideration received on transaction"&gt;2,402,000&lt;/span&gt; and net proceeds to the Company of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zbgeua5vzmrd" title="Proceeds from issuance of common stock"&gt;2,317,000&lt;/span&gt;, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $&lt;span id="xdx_906_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z1J6pzOT4cAh" title="Sale of stock expenses"&gt;85,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 7, 2023, the Company sold &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zQQg5I8fRDzb" title="Net proceeds from ATM (in Shares)"&gt;3,333,333&lt;/span&gt; shares of common stock in a firm commitment public offering at a gross sales price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_z2pu4lFTRZq" title="Share price"&gt;2.40&lt;/span&gt;
per share, with net total proceeds, after deducting issuance fees and expenses of $&lt;span id="xdx_907_ecustom--SaleOfStockExpenses_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zWIHolrzirAg" title="Sale of stock expenses"&gt;700,000&lt;/span&gt;, of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMAgreementMember_zqJEv3gsEkG7" title="Proceeds from issuance of common stock"&gt;7,300,000&lt;/span&gt;. Since the closing
of the March 7, 2023 offering, the ATM has been withdrawn and is not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company intends to use the net proceeds from such offerings for general corporate purposes, including, without limitation, sales and
marketing activities, clinical studies, product development, making acquisitions of assets, businesses, companies or securities,
capital expenditures, and for working capital needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has analyzed the cash requirements of the Company&#x2019;s business through at least August 2024. As a result of cash and cash
equivalents on hand on May 31, 2023, largely from the public offering, and the ability to raise additional funds through another new
ATM agreement, management believes the Company has sufficient funds to operate through at least August 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</BMRA:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-05-31" decimals="-6" unitRef="USD">-42000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">9719000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <BMRA:WorkingCapital contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">-10852000</BMRA:WorkingCapital>
    <BMRA:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue contextRef="AsOf2021-01-22" decimals="0" unitRef="USD">15000000</BMRA:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="Shares">573889</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-31_srt_MinimumMember_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-31_srt_MaximumMember_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="USDPShares">4.26</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">2014000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">1961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <BMRA:SaleOfStockExpenses
      contextRef="From2022-06-012023-05-31_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">53000</BMRA:SaleOfStockExpenses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="Shares">521267</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-31_srt_MinimumMember_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="USDPShares">4.02</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-31_srt_MaximumMember_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="USDPShares">5.63</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">2402000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">2317000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <BMRA:SaleOfStockExpenses
      contextRef="From2021-06-012022-05-31_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">85000</BMRA:SaleOfStockExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-072023-03-07_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="Shares">3333333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-03-07_custom_ATMAgreementMember"
      decimals="INF"
      unitRef="USDPShares">2.40</us-gaap:SharePrice>
    <BMRA:SaleOfStockExpenses
      contextRef="From2023-03-072023-03-07_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">700000</BMRA:SaleOfStockExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-03-072023-03-07_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">7300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zj7jiqvTvXB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMZUTNqxBcJ4"&gt;FAIR
VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on
a historical basis. The Company&#x2019;s consolidated financial instruments consist of its cash and cash equivalents, accounts receivable,
and accounts payable. The carrying amounts of the Company&#x2019;s financial instruments approximate their fair values. The Company also
maintains an investment in privately held company (see below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zV6dJYlNhv9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z0QxvzjqIh57"&gt;CONCENTRATION
OF CREDIT RISK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time,
the Company has uninsured balances. The Company does not believe it is exposed to any significant credit risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company
performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
net sales were approximately $&lt;span id="xdx_900_eus-gaap--Revenues_c20220601__20230531_zgTugdKjmmsd" title="Revenues"&gt;5,339,000&lt;/span&gt;
for fiscal 2023 compared to $&lt;span id="xdx_903_eus-gaap--Revenues_c20210601__20220531_z5VE0EJrAB24" title="Revenues"&gt;18,871,000&lt;/span&gt;
for fiscal 2022. For the fiscal years ended May 31, 2023 and 2022, the Company had one and two distributors, respectively, which
accounted for a total of &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorOneMember_zCfRW217Lbbh" title="Concentration risk, percentage"&gt;35&lt;/span&gt;%
and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorTwoMember_zGjQu8OVjkr8" title="Concentration risk, percentage"&gt;65&lt;/span&gt;%
of our net sales, respectively. Of this, for the fiscal years ended May 31, 2023 and 2022, the largest of the distributors mentioned
above accounted for &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zBZbRgFVmtve" title="Concentration risk, percentage"&gt;35&lt;/span&gt;%
and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zlgIgVsxXvWd" title="Concentration risk, percentage"&gt;55&lt;/span&gt;%,
respectively, of net sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
gross receivables on May 31, 2023 and 2022 were approximately $&lt;span id="xdx_901_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230531_zeFH384WNPe" title="Other receivables, gross, current"&gt;751,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OtherReceivablesGrossCurrent_iI_c20220531_zW8eMxbbRJU1" title="Other receivables, gross, current"&gt;927,000&lt;/span&gt;, respectively. On May 31, 2023 and 2022, the Company
had one distributor which accounted for a total of &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zaMA0Oy1OT4" title="Concentration risk, percentage"&gt;36&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zeavQLNSShXh" title="Concentration risk, percentage"&gt;50&lt;/span&gt;%, respectively, of gross accounts receivable. Of the &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zLj8Yk8BKDr6" title="Concentration risk, percentage"&gt;36&lt;/span&gt;% as of May 31,
2023, &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorsInAsiaMember_zdwAc3CJuy46" title="Concentration risk, percentage"&gt;100&lt;/span&gt;% was owed by a distributor in Asia.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the fiscal year ended May 31, 2023, the Company did not have any significant concentration of vendor spend for raw materials. For the
fiscal year ended May 31, 2022, the Company had one vendor, which accounted for &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zKxusiWRt50j" title="Concentration risk, percentage"&gt;84&lt;/span&gt;% of our purchases of raw materials largely related
to COVID-19 products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:Revenues
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">5339000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">18871000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorOneMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorTwoMember"
      decimals="INF"
      unitRef="Pure">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-06-012022-05-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember"
      decimals="INF"
      unitRef="Pure">0.55</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">751000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">927000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember"
      decimals="INF"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-06-012022-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneDistributorMember"
      decimals="INF"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-06-012023-05-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_DistributorsInAsiaMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-06-012022-05-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_OneVendorMember"
      decimals="INF"
      unitRef="Pure">0.84</us-gaap:ConcentrationRiskPercentage1>
    <BMRA:ConcentrationRiskGeographicPolicyPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_841_ecustom--ConcentrationRiskGeographicPolicyPolicyTextBlock_zas1WR54uYvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zcBx91ToEpJb"&gt;GEOGRAPHIC
CONCENTRATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023 and 2022, approximately $&lt;span id="xdx_907_eus-gaap--InventoryGross_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zSVEX9SVBd11" title="Inventory, gross"&gt;626,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InventoryGross_iI_c20220531__srt--StatementGeographicalAxis__country--MX_zlaRxFv9kbVl" title="Inventory, gross"&gt;621,000&lt;/span&gt;, respectively, of Biomerica&#x2019;s gross inventory was located in Mexicali,
Mexico, respectively. As of May 31, 2023 and 2022, approximately $&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230531__srt--StatementGeographicalAxis__country--MX_zYBaLgKp5ADf" title="Property, plant and equipment, net"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20220531__srt--StatementGeographicalAxis__country--MX_ziH0FHnFTYf8" title="Property, plant and equipment, net"&gt;17,000&lt;/span&gt;&lt;/span&gt; of Biomerica&#x2019;s property and equipment, net of accumulated
depreciation and amortization, was located in Mexicali, Mexico.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</BMRA:ConcentrationRiskGeographicPolicyPolicyTextBlock>
    <us-gaap:InventoryGross
      contextRef="AsOf2023-05-31_country_MX"
      decimals="0"
      unitRef="USD">626000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="AsOf2022-05-31_country_MX"
      decimals="0"
      unitRef="USD">621000</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-05-31_country_MX"
      decimals="0"
      unitRef="USD">17000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-05-31_country_MX"
      decimals="0"
      unitRef="USD">17000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9ZkeOdmCqf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zG3h0TU5Octl"&gt;CASH
AND CASH EQUIVALENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zF4Rf9LewHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zNLY7qix7um5"&gt;ACCOUNTS
RECEIVABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until
they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.
Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in
credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and
adjusts the allowance for doubtful accounts accordingly. Balances over &lt;span id="xdx_902_eus-gaap--ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_dc_c20220601__20230531_zmLrzVXcQFz5" title="Threshold period past due for write-off of trade accounts receivable"&gt;ninety days&lt;/span&gt;
old are usually reserved for unless collection is reasonably assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Occasionally
certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total
gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices
before shipping new sales orders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023 and 2022, the Company has established a reserve of approximately $&lt;span id="xdx_90B_ecustom--AccountsReceivableCreditLossExpenseReversal_c20220601__20230531_zBplFjSnf2wh" title="Accounts receivable, credit loss expense (Reversal)"&gt;29,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--AccountsReceivableCreditLossExpenseReversal_c20210601__20220531_zpZRmWKdXRal" title="Accounts receivable, credit loss expense (Reversal)"&gt;153,000&lt;/span&gt;, respectively, for doubtful accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable contextRef="From2022-06-01to2023-05-31">P90D</us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable>
    <BMRA:AccountsReceivableCreditLossExpenseReversal
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">29000</BMRA:AccountsReceivableCreditLossExpenseReversal>
    <BMRA:AccountsReceivableCreditLossExpenseReversal
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">153000</BMRA:AccountsReceivableCreditLossExpenseReversal>
    <BMRA:PrepaidExpensesAndOtherPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84F_ecustom--PrepaidExpensesAndOtherPolicyTextBlock_zbZ1vAqwJYSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zvMG2dPRgKA9"&gt;PREPAID
EXPENSES AND OTHER&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company occasionally prepays for items such as inventory, insurance, and other items. These items are reported as prepaids, until either
the inventory is physically received or the insurance and other items are utilized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023 and 2022, the prepaids were approximately $&lt;span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20230531_zTc4RwoJUK14" title="Prepaid expense and other assets"&gt;300,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20220531_zmcq7Mv3bvvh" title="Prepaid expense and other assets"&gt;320,000&lt;/span&gt;, respectively, composed of prepayments to insurance and
various other suppliers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</BMRA:PrepaidExpensesAndOtherPolicyTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">300000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">320000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_z6EjOOLsoTgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z3XAflCbijqi"&gt;INVENTORIES,
NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out
methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates
quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer
demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision
included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs, and wasted material are recognized as
current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfXAx85nCdEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of approximate net inventories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B1_zbIIOEvcmUOj" style="display: none"&gt;SCHEDULE
OF NET INVENTORIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230531_zxJS0YOBkNe5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220531_zTXs9kF0FWxe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zK9rFPjWIuBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,677,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,717,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zI5pUzxdZvg9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;869,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;763,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z544N6uW1yC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;182,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;782,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_zxuDEwDW0kV3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total gross inventory&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,728,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,262,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zmvW1nT9x7vf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(672,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(846,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_zMrcSIofgNza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,056,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,416,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z2QADNWUiHM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reserves
for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically
reserve for obsolete inventory. As of May 31, 2023 and 2022, inventory reserves were approximately $&lt;span id="xdx_90C_eus-gaap--InventoryValuationReserves_iI_c20230531_zhcqT5mKlPVa" title="Inventory reserves"&gt;672,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20220531_zx6uzyfls493" title="Inventory reserves"&gt;846,000&lt;/span&gt;, respectively.
The Company has fully reserved COVID-19 antibody inventory in fiscal 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfXAx85nCdEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of approximate net inventories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B1_zbIIOEvcmUOj" style="display: none"&gt;SCHEDULE
OF NET INVENTORIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230531_zxJS0YOBkNe5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220531_zTXs9kF0FWxe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zK9rFPjWIuBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,677,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,717,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zI5pUzxdZvg9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;869,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;763,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z544N6uW1yC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;182,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;782,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_zxuDEwDW0kV3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total gross inventory&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,728,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,262,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zmvW1nT9x7vf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(672,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(846,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_zMrcSIofgNza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,056,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,416,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1677000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1717000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">869000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">763000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">182000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">782000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">2728000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">3262000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">672000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">846000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">2056000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">2416000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">672000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">846000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk6bOjyUlvKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zksGzV8gHEgh"&gt;PROPERTY
AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are
charged to operations as incurred. When property and equipment are sold, retired, or otherwise disposed of, the related cost and accumulated
depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements, and dispositions are credited
or charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
and amortization are provided over the estimated useful lives of the related assets, ranging from &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MinimumMember_zzBbxxesTGV7" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MaximumMember_zkf43DLyWf04" title="Property, plant and equipment, useful life"&gt;10&lt;/span&gt; years, using the straight-line
method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation
and amortization expense on property and equipment amounted to approximately $&lt;span id="xdx_900_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zdt0SbTs22g2" title="Depreciation, depletion and amortization"&gt;66,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zQRMq8oDZLx8" title="Depreciation, depletion and amortization"&gt;100,000&lt;/span&gt; for the years ended May 31, 2023 and
2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-05-31_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-05-31_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-06-012023-05-31_us-gaap_PropertyPlantAndEquipmentMember"
      decimals="0"
      unitRef="USD">66000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-06-012022-05-31_us-gaap_PropertyPlantAndEquipmentMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zHpEUEE6lTNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zaJlBQgBPHgf"&gt;INTANGIBLE
ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets include trademarks, product rights, technology rights, and patents, and are accounted for based on Accounting Standards Codification
(&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have
indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in
circumstances indicate that the asset might be impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets are being amortized using the straight-line method over the useful life, not to exceed &lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MarketingAndDistributionRightsMember_zyCruYyiK0ck" title="Finite-lived intangible asset, useful life"&gt;18&lt;/span&gt; years for marketing and distribution
rights, &lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedTechnologyRightsMember_zIk62ly12fKd" title="Finite-lived intangible asset, useful life"&gt;10&lt;/span&gt; years for purchased technology use rights, and &lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zENHs0nm4Poe" title="Finite-lived intangible asset, useful life"&gt;20&lt;/span&gt; years for patents. Amortization amounted to approximately $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20220601__20230531_zMJVurcApaH4" title="Amortization of intangible assets"&gt;18,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210601__20220531_zE1wenKkvlq5" title="Amortization of intangible assets"&gt;239,000&lt;/span&gt;
for the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#x2019;s balance over
its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine
whether there was any impairment. During the year ended May 31, 2023, there was &lt;span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20220601__20230531_zpGA1bc1gRL4" title="Asset impairment charges"&gt;no&lt;/span&gt; impairment of intangible assets. During the year ended May 31, 2022, an impairment
adjustment was made of $&lt;span id="xdx_908_eus-gaap--AssetImpairmentCharges_c20210601__20220531_zUVEsXBiWrDi" title="Asset impairment charges"&gt;210,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-05-31_custom_MarketingAndDistributionRightsMember">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-05-31_custom_PurchasedTechnologyRightsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-05-31_us-gaap_PatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">18000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">239000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">210000</us-gaap:AssetImpairmentCharges>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84E_eus-gaap--InvestmentPolicyTextBlock_zIjX6nok2s9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_znhP4kr3dE21"&gt;INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has made investments in a privately held Polish
distributor, which is primarily engaged in distributing medical products and devices, including the distribution of the products
sold by the Company. The Company invested approximately $&lt;span id="xdx_90E_eus-gaap--Investments_iI_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zNabs00JsA8b" title="Investments"&gt;165,000&lt;/span&gt;
into the Polish distributor and owns approximately &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zYfiU0qnlX8d" title="Equity method investment, ownership percentage"&gt;6&lt;/span&gt;%
of the investee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence (&#x201c;Cost Method
Holdings&#x201d;) are accounted for at the Company&#x2019;s initial cost, minus any impairment (if any), plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends
received are recorded as other income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an
equity holding may not be recoverable. Management reviewed the underlying net assets of the Company&#x2019;s equity method holding as
of May 31, 2023 and determined that the Company&#x2019;s proportionate economic interest in the entity indicates that the equity holding
was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the
Company&#x2019;s Cost Method Holding during the year ended May 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:Investments
      contextRef="AsOf2023-05-31_custom_PolishDistributorMember"
      decimals="0"
      unitRef="USD">165000</us-gaap:Investments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-05-31_custom_PolishDistributorMember"
      decimals="INF"
      unitRef="Pure">0.06</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zi5fht3J56mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zXu5Ufocrqtd"&gt;SHARE-BASED
COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance of ASC 718, Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based
method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments
(options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that uses
assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The
Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based
on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options.
The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the
&#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as
historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under
the straight-line attribution method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expensed approximately $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220601__20230531_z7zUYyTVKW7" title="Share-based payment arrangement, expense"&gt;1,185,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210601__20220531_z3tU1y95IeBa" title="Share-based payment arrangement, expense"&gt;1,260,000&lt;/span&gt; of share-based compensation during the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdEKYnJS0eH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for period ending May 31, 2023 and 2022: &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z9Q59AExJB38" style="display: none"&gt;SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20220601__20230531_zwzgNCPGQTo4" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20210601__20220531_z223yB5oqmTd" title="Dividend yield"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z6diBBXCP6ck" title="Expected volatility minimum"&gt;98.81&lt;/span&gt;
                                            - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zkvWtpzDXNNk" title="Expected volatility maximum"&gt;101.77&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zCLhxdQMqwa7" title="Expected volatility minimum"&gt;102.54&lt;/span&gt;
- &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zo1OdHzsfXwk" title="Expected volatility maximum"&gt;105.48&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zwhwDa4nM9A8" title="Risk free interest rate minimum"&gt;3.12&lt;/span&gt;
                                            - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z29ZDWgpxT77" title="Risk free interest rate maximum"&gt;3.35&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zMhegBQUmCDj" title="Risk free interest rate minimum"&gt;0.97&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zje1Rms6d7fg" title="Risk free interest rate maximum"&gt;2.75&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20220601__20230531_zdmQdYowvAH3" title="Expected term"&gt;6.25&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MinimumMember_zdvX2xmg7cd1" title="Expected term"&gt;5.50&lt;/span&gt;
                                            - &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MaximumMember_zJovgA4h7XD4" title="Expected term"&gt;6.25&lt;/span&gt; years &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zADPwTqKuID8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdEKYnJS0eH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for period ending May 31, 2023 and 2022: &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z9Q59AExJB38" style="display: none"&gt;SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20220601__20230531_zwzgNCPGQTo4" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dp_c20210601__20220531_z223yB5oqmTd" title="Dividend yield"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z6diBBXCP6ck" title="Expected volatility minimum"&gt;98.81&lt;/span&gt;
                                            - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zkvWtpzDXNNk" title="Expected volatility maximum"&gt;101.77&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zCLhxdQMqwa7" title="Expected volatility minimum"&gt;102.54&lt;/span&gt;
- &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zo1OdHzsfXwk" title="Expected volatility maximum"&gt;105.48&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_zwhwDa4nM9A8" title="Risk free interest rate minimum"&gt;3.12&lt;/span&gt;
                                            - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20220601__20230531_z29ZDWgpxT77" title="Risk free interest rate maximum"&gt;3.35&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zMhegBQUmCDj" title="Risk free interest rate minimum"&gt;0.97&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_pid_dp_c20210601__20220531_zje1Rms6d7fg" title="Risk free interest rate maximum"&gt;2.75&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20220601__20230531_zdmQdYowvAH3" title="Expected term"&gt;6.25&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MinimumMember_zdvX2xmg7cd1" title="Expected term"&gt;5.50&lt;/span&gt;
                                            - &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_iP1us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dtY_c20210601__20220531__srt--RangeAxis__srt--MaximumMember_zJovgA4h7XD4" title="Expected term"&gt;6.25&lt;/span&gt; years &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Pure">0.9881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Pure">1.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Pure">1.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Pure">1.0548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Pure">0.0312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Pure">0.0335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Pure">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Pure">0.0275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-06-01to2023-05-31">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-06-012022-05-31_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-06-012022-05-31_srt_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zTgQf8Mt2FW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zqvIu7A6QYZi"&gt;REVENUE
RECOGNITION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time
the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point
title passes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not typically allow for returns from customers except in the event of defective merchandise and therefore does not establish
an allowance for returns. In addition, the Company has contracts with customers wherein customers receive purchase discounts for achieving
specified sales volumes. The Company evaluated the status of these contracts during the years ended May 31, 2023 and 2022 and does not
believe that any additional discounts will be given through the end of the contract periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Services
for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project
progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories,
medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce
customers as well as to distributors. Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized
below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international
manufacturers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023, the Company had approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromCustomers_c20220601__20230531_zXS0hCVZoOn8" title="Proceeds from customers"&gt;60,000&lt;/span&gt; of advances from certain foreign customers. These advances are prepayments on
orders that are expected to ship during our second fiscal quarter ending November 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaggregation
of revenue:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zanhIyCQdtLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of revenues according to primary markets to which the products are sold:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_zNnuM8NBDbSj" style="display: none"&gt;SCHEDULE OF DISAGGREGATION REVENUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220601__20230531_zP8e8gf5j2q3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210601__20220531_ze3LkGjwz3Gh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zKHvA3J7tN2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical lab&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,310,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,064,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_z9Mve49dOEJd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Over-the-counter&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,169,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,089,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_z9ypGqpq5I81" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contract manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;459,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zkH4ktR4A8Nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Physician&#x2019;s office&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,259,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHpBiDu5C8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,339,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,871,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zvOxIDEPiRA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 8 for additional information regarding geographic revenue concentrations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ProceedsFromCustomers
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">60000</us-gaap:ProceedsFromCustomers>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zanhIyCQdtLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of revenues according to primary markets to which the products are sold:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_zNnuM8NBDbSj" style="display: none"&gt;SCHEDULE OF DISAGGREGATION REVENUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220601__20230531_zP8e8gf5j2q3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210601__20220531_ze3LkGjwz3Gh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zKHvA3J7tN2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical lab&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,310,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,064,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_z9Mve49dOEJd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Over-the-counter&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,169,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,089,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_z9ypGqpq5I81" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contract manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;459,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zkH4ktR4A8Nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Physician&#x2019;s office&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,259,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHpBiDu5C8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,339,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,871,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-06-012023-05-31_custom_ClinicalLabMember"
      decimals="0"
      unitRef="USD">3310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-06-012022-05-31_custom_ClinicalLabMember"
      decimals="0"
      unitRef="USD">3064000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-06-012023-05-31_custom_OverTheCounteMember"
      decimals="0"
      unitRef="USD">1169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-06-012022-05-31_custom_OverTheCounteMember"
      decimals="0"
      unitRef="USD">1089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-06-012023-05-31_custom_ContractManufacturingMember"
      decimals="0"
      unitRef="USD">610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-06-012022-05-31_custom_ContractManufacturingMember"
      decimals="0"
      unitRef="USD">459000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-06-012023-05-31_custom_PhysiciansOfficeMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-06-012022-05-31_custom_PhysiciansOfficeMember"
      decimals="0"
      unitRef="USD">14259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">5339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">18871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_zvyO8kcbTwZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zo3bOhAblJwi"&gt;SHIPPING
AND HANDLING FEES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company includes shipping and handling fees billed to customers in net sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoPDGTZ4ZYce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z5WBvU2kFJM2"&gt;RESEARCH
AND DEVELOPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. The Company expensed approximately $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220601__20230531_zxrrWoRg1AA4" title="Research and development expense"&gt;1,584,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210601__20220531_zNsRZitDXup9" title="Research and development expense"&gt;1,812,000&lt;/span&gt; of research and development
costs during the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1812000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z7GpIgRB6l2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zHiFcLTqmP0a"&gt;INCOME
TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and
liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the
consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net
operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit
carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent
that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation
allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the
character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance
and income tax expense. As of May 31, 2023 and 2022, in accordance with ASC 740, the Company has a valuation allowance for
substantially all of its net deferred tax assets. During the year ended May 31, 2023, this valuation allowance was increased to
$&lt;span id="xdx_906_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_zd5VCqoAt0z2" title="Deferred tax assets, valuation allowance"&gt;8,940,000&lt;/span&gt;,
which fully covers the net deferred tax asset of $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsGross_iI_c20230531_zdBMfhCgPHW2" title="Deferred tax assets, net"&gt;8,940,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions.
The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more
likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related
appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount
of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized
when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which
is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information
available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an
accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line
and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">8940000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">8940000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_841_eus-gaap--AdvertisingCostsPolicyTextBlock_zWTcxet7YGAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z47QZsQ6HMz1"&gt;ADVERTISING
COSTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately
$&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20220601__20230531_z9Fyj00nxcr4" title="Advertising expense"&gt;156,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AdvertisingExpense_c20210601__20220531_zzixh9zoqbUl" title="Advertising expense"&gt;76,000&lt;/span&gt; for the years ended May 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">156000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">76000</us-gaap:AdvertisingExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zKvticJLFUTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zLN0PxTX9iKi"&gt;FOREIGN
CURRENCY TRANSLATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the
U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries
are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates
for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive
loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May
31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z9YTFDd1Gp72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zf9MmdLbU2Oj"&gt;RIGHT-OF-USE
ASSETS AND LEASE LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standard update which requires lessees
to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from
the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value
of fixed lease payments over the lease term. Leases are classified as financing or operating which will drive the expense recognition
pattern. The Company has elected to exclude short-term leases. The Company leases office space and copy machines, all of which are operating
leases. Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options
to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The
leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited
by the expected lease term. For additional information, see Note 9-Commitments and Contingencies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGhUn8gHrkwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zbplaaJ5ElFa"&gt;NET
LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss
per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible
securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation
for the years ended May 31, 2023 and 2022 were &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220601__20230531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z4slMFwctEC9" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)"&gt;2,342,616&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210601__20220531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zob2BtJtsFyf" title="Antidilutive securities excluded from computation of earnings per share, amount (in shares)"&gt;2,321,616&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">2342616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">2321616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zY7tmLByV8sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zGTwlBY8erm"&gt;SEGMENT
REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about
operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management
and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic
kits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaxSJgIMdnu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zqDWvQiTcYP"&gt;REPORTING
COMPREHENSIVE LOSS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly
as a component of shareholders&#x2019; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments
for the years ended May 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zgusxlyi9MG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zKKValXlvOd7"&gt;RECENT
ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except as follows, recent
ASU&#x2019;s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on
the Company&#x2019;s present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.
This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting
date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective
for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November
2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates, which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered
smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including
interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine
its impact on the Company&#x2019;s consolidated results of operations and financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2mUAY79V6jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3: &lt;span id="xdx_82A_zzgKt5AWGAT6"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zJRhHLryw4j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of property and equipment, net of accumulated depreciation:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zlMK1GYyzfsi"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230531_zJJG3CVuYsFl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220531_zmEdMEVTHcb9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQNjMA1Nd9d4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,333,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,292,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndFixturesLeaseholdImprovementsMember_z3rFGVi7Fdhe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture, fixtures and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;211,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;227,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zS4848GSRXx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,331,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,305,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zhbLjnLUPcxc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zDflOk4HWhTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zJRhHLryw4j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of property and equipment, net of accumulated depreciation:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zlMK1GYyzfsi"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230531_zJJG3CVuYsFl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220531_zmEdMEVTHcb9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zQNjMA1Nd9d4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,333,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,292,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndFixturesLeaseholdImprovementsMember_z3rFGVi7Fdhe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture, fixtures and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;211,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;227,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zS4848GSRXx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,331,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,305,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_zhbLjnLUPcxc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-05-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1333000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-05-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-05-31_custom_FurnitureAndFixturesLeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">227000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1331000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1305000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">213000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">214000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zHA2uFLvayQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4: &lt;span id="xdx_828_z3a5eCjChvI8"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zG20KfgYEmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of intangible assets, net of accumulated amortization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zzbG1t9TRIFg"&gt;SCHEDULE
OF INTANGIBLE ASSETS, NET&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230531_zjihxqZSSRye" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220531_zrOSrzsA1Dkl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_maIANEGzien_zyNp2gc4Ko4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;196,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;189,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--FiniteLivedPatentsAccumulatedAmortization_iNI_di_msIANEGzien_zpDvvbcHgjWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less accumulated amortization-patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(31,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_mtIANEGzien_zwmRWaZfiCml" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;165,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;170,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AD_zNGOojLeHfjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zzIh9VajLBUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
amortization of intangible assets for the years ending May 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zA8QpIKu38kc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230531_ztK8HuiJZdT5" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzv9t_zi3uv8CnjeCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzv9t_zjjOwufWa3U3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzv9t_z5wWeWCfCUK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzv9t_zOT4Xl021mDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzv9t_zv00voJayX8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzv9t_zpBK3EQeMkqj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzv9t_zpOdlrYPbyM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;165,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zPNbKbPy9ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zG20KfgYEmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of intangible assets, net of accumulated amortization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zzbG1t9TRIFg"&gt;SCHEDULE
OF INTANGIBLE ASSETS, NET&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230531_zjihxqZSSRye" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220531_zrOSrzsA1Dkl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_maIANEGzien_zyNp2gc4Ko4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;196,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;189,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--FiniteLivedPatentsAccumulatedAmortization_iNI_di_msIANEGzien_zpDvvbcHgjWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less accumulated amortization-patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(31,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_mtIANEGzien_zwmRWaZfiCml" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;165,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;170,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">196000</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">189000</us-gaap:FiniteLivedPatentsGross>
    <BMRA:FiniteLivedPatentsAccumulatedAmortization contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">31000</BMRA:FiniteLivedPatentsAccumulatedAmortization>
    <BMRA:FiniteLivedPatentsAccumulatedAmortization contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">19000</BMRA:FiniteLivedPatentsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">165000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">170000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zzIh9VajLBUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
amortization of intangible assets for the years ending May 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zA8QpIKu38kc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230531_ztK8HuiJZdT5" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzv9t_zi3uv8CnjeCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzv9t_zjjOwufWa3U3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzv9t_z5wWeWCfCUK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzv9t_zOT4Xl021mDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzv9t_zv00voJayX8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzv9t_zpBK3EQeMkqj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzv9t_zpOdlrYPbyM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;165,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">165000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zYJXUqkQ19q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5: &lt;span id="xdx_820_zianuoe2c8Gg"&gt;ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zqarcDUnL0Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of accounts payable and accrued expenses balances:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zdgR41Gp4EDf" style="display: none"&gt;SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230531_zpP2PO4IGto" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220531_zOTmbwRahvc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iI_maAPAALzPt0_zBnvfIc1m7A9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;344,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;736,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzPt0_zfot5l9CYtce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;548,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzPt0_ze1uDNAQZb39" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;892,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;972,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zZeUjVO1Soda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zKKTZPhmXCe6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023, the Company had one vendor which accounted for &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zk17hb183dz3" title="Net sales percent"&gt;23&lt;/span&gt;% of accounts payable. As of May 31, 2022, the Company had two vendors
which accounted for &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoVendorMember_ztycs6s3KAi3" title="Net sales percent"&gt;69&lt;/span&gt;% of accounts payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zqarcDUnL0Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is an approximate breakdown of accounts payable and accrued expenses balances:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zdgR41Gp4EDf" style="display: none"&gt;SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230531_zpP2PO4IGto" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220531_zOTmbwRahvc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iI_maAPAALzPt0_zBnvfIc1m7A9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;344,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;736,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzPt0_zfot5l9CYtce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;548,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzPt0_ze1uDNAQZb39" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;892,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;972,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">344000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">736000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">548000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">236000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">892000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">972000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-06-012023-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember"
      decimals="INF"
      unitRef="Pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-06-012022-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoVendorMember"
      decimals="INF"
      unitRef="Pure">0.69</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbhHCfbkUw1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6: &lt;span id="xdx_82E_zlOcBNuB8oA6"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;STOCK
OPTION AND RESTRICTED STOCK PLANS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2014, the Company adopted and shareholders approved a stock option and restricted stock plan (the &#x201c;2014 Plan&#x201d;).
Subsequently, in December 2017, the Company adopted and shareholders approved an stock option and restricted stock plan (the &#x201c;2017
Plan&#x201d;). In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;, and collectively with
the 2014 Plan and 2017 Plan, the &#x201c;Equity Incentive Plans&#x201d;) and on December 11, 2020, the shareholders of the Company approved
the 2020 Plan. The Equity Incentive Plans provide that non-qualified options and incentive stock options and restricted stock may be
granted to directors, affiliates, employees, or consultants of the Company. The Equity Incentive Plans authorize awards representing
up to &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20141231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandFourteenPlanMember_zChdBRNYvq83" title="Equity incentive plan, authorized shares"&gt;850,000&lt;/span&gt;, &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zqUe9ja3kRL3" title="Equity incentive plan, authorized shares"&gt;900,000&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20200229__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zVsCruvCcDuj" title="Equity incentive plan, authorized shares"&gt;900,000&lt;/span&gt; shares of the Company&#x2019;s common stock to be issued under the 2014 Plan, 2017 Plan, and 2020 Plan,
respectively. Awards granted under the Equity Incentive Plans typically vest over &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRMOVxSu8FG1" title="Vesting period"&gt;4&lt;/span&gt; years. Options granted under the Equity Incentive
Plans will be granted at prices not less than &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7k4A8tJCBr6" title="Award purchase price, percent"&gt;80&lt;/span&gt;% of the then fair market value of the common stock and will expire not more than &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXa8VUVJOk9" title="Expiration period"&gt;10&lt;/span&gt;
years after the date of grant. The 2014 Plan expires in December 2024, the 2017 Plan expires in December 2027, and the 2020 Plan expires
in December 2030.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziOpm9lSewRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation expense for the years ended May 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zy1dsdSDCvid"&gt;SCHEDULE
OF STOCK BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220601__20230531_zL85zAK0Uv1k" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210601__20220531_zbkLros4SRt1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4iXckzSV6Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;143,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;159,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zePauF8bdOXi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;971,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3k0YNjrf0F3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_zLfJYM2Dp0G7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,185,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p id="xdx_8A0_zKvAvFoS5Nve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zn7O30hYo6pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Activity
as to aggregate stock options outstanding is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 4.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 4.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z2xMpyNzQEwc"&gt;SCHEDULE
OF ACTIVITY TO AGGREGATE STOCK OPTIONS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; font-weight: bold"&gt;Options Outstanding at May 31, 2021&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210601__20220531_zo2hFF6bHUll" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding, shares"&gt;2,081,366&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210601__20220531_z6xdbLhxFGde" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price"&gt;3.59&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210601__20220531_zpGkCDe79Zmi" style="width: 14%; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value"&gt;2,132,000&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210601__20220531_z3L1j5wDmyRh" style="text-align: right" title="Options granted, shares"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zvtGPLX1ai51" style="text-align: right" title="Options Granted Weighted Average Exercise Price"&gt;4.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210601__20220531_zk0473YWT7ia" style="text-align: right" title="Options exercised, shares"&gt;(39,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210601__20220531_zp0NqWNyUbNc" style="text-align: right" title="Options Exercised Weighted Average Exercise Price"&gt;1.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210601__20220531_zWCGTRMz3gJe" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options canceled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210601__20220531_zcDQAok5oJp5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares"&gt;(64,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zOpdLZXP0zal" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price"&gt;4.41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Options Outstanding at May 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220601__20230531_zdQf3E23Vwq4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding, shares"&gt;2,321,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220601__20230531_zJkrnYufR07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price"&gt;3.72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220601__20230531_z8ybYZsgdPNk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value"&gt;1,838,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220601__20230531_zgwKqTJB8To" style="text-align: right" title="Options granted, shares"&gt;243,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zAu3aZ5yxF2" style="text-align: right" title="Options Granted Weighted Average Exercise Price"&gt;2.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220601__20230531_zLdr29QxUksd" style="text-align: right" title="Options exercised, shares"&gt;(46,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220601__20230531_zOGpuzaXaajf" style="text-align: right" title="Options Exercised Weighted Average Exercise Price"&gt;1.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220601__20230531_zJmB7dY3efQ7" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Options canceled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220601__20230531_z6WB0ibZSw2e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares"&gt;(175,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zrOx3pvwzgu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price"&gt;5.56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Options Outstanding at May 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220601__20230531_zkwTS0lFVOSh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding, shares"&gt;2,342,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220601__20230531_z1hi5b8H75y5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price"&gt;3.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220601__20230531_z2c8DqTMfm2i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value"&gt;146,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Options vested and exercisable at May 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20230531_zFwibW9Xxub3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable, shares"&gt;1,841,933&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230531_zowGPBmgrFF7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Weighted Average Exercise Price"&gt;3.38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230531_zdU5FibUUaFi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Aggregate Intrinsic Value"&gt;146,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_z0TzbMBTVfPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of options granted during 2023 and 2022 were $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQThWfjCcshi" title="Granted, weighted average grant date fair value"&gt;2.19&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210601__20220531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFgq46JWDkr7" title="Granted, weighted average grant date fair value"&gt;4.43&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2023, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPj91oZmGO52" title="Compenation cost related to non-vested stock option"&gt;1,145,000&lt;/span&gt;.
The weighted-average period over which this amount is expected to be recognized is &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnrM0AFHGH8" title="Weighted average period expected term"&gt;2.52&lt;/span&gt; years. The weighted average remaining contractual
term of options that were exercisable on May 31, 2023 was &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWDaNsXJNQCi" title="Exercisable weighted average remaining contractual term"&gt;4.97&lt;/span&gt; years. The weighted average remaining contractual term of options that
were vested, exercisable, or expected to vest on May 31, 2023 was &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLLC6H5J3e8l" title="Vested, exercisable or expected to vest weighted average remaining contractual term"&gt;5.67&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;COMMON
STOCK ACTIVITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 22, 2021, the Company filed a prospectus supplement to the base prospectus included in a registration statement filed with the
SEC on July 21, 2020, and declared effective by the SEC on September 30, 2020, for purposes of selling up to $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210122__20210122__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--ATMAgreementMember_zaJqgr6E1nuh" title="Consideration received on transaction"&gt;15,000,000&lt;/span&gt; in &#x201c;at-the-market&#x201d;
offerings, as defined in Rule 415 promulgated under the Securities Act (the &#x201c;ATM Offering&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 21, 2021, in conjunction with the Company&#x2019;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#x2019;s
annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210521__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z3u5hlzBj3nj" title="Share-based payment award, number of shares authorized"&gt;900,000&lt;/span&gt; shares of the Company&#x2019;s
common stock that could be issued under this Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the ATM Offering, the sales agent uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the shares requested
to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between
the agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend
offers under, or terminate the ATM Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended May 31, 2023, the Company sold &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zQWvxiQtBZP1" title="Sale of stock shares issued"&gt;573,889&lt;/span&gt; shares of its common stock at prices ranging from $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z7bSyUzPSDE3" title="Sale of stock, price per share"&gt;3.15&lt;/span&gt; to $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zs7aCSP9Mkf5" title="Sale of stock, price per share"&gt;4.26&lt;/span&gt; pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $&lt;span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zug3rQXYpOpi" title="Sale of stock gross proceeds"&gt;2,014,000&lt;/span&gt; and net proceeds to the Company of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20230531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zeQS9XUkloCe" title="Sale of stock, net proceeds"&gt;1,961,000&lt;/span&gt;, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $&lt;span id="xdx_907_ecustom--SaleOfStockExpenses_c20220601__20230531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z0HVVTT6Sz1k" title="Sale of stock, offering expenses"&gt;53,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended May 31, 2022, the Company sold &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zZK2meEqkbw4" title="Sale of stock shares issued"&gt;521,267&lt;/span&gt; shares of its common stock at prices ranging from $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MinimumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zfhtqETBlY09" title="Sale of stock, price per share"&gt;4.02&lt;/span&gt; to $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20220531__srt--RangeAxis__srt--MaximumMember__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zAouvBLmCJo9" title="Sale of stock, price per share"&gt;5.63&lt;/span&gt; pursuant to the
ATM Offering, which resulted in gross proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zufG6d53VyK6" title="Sale of stock gross proceeds"&gt;2,402,000&lt;/span&gt; and net proceeds to the Company of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210601__20220531__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z3kOxhiIOwIl" title="Sale of stock, net proceeds"&gt;2,317,000&lt;/span&gt;, after deducting
commissions for each sale and legal, accounting, and other fees related to the offering in the amount of $&lt;span id="xdx_90C_ecustom--SaleOfStockExpenses_c20210601__20220531__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zREuYEjknI2a" title="Sale of stock expenses"&gt;85,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 7, 2023, the Company closed on an underwritten sale of &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230307__20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_zcEtYtDvhBNh" title="Sale of stock shares issued"&gt;3,333,333&lt;/span&gt; shares of our registered common stock through an investment banking
firm, which shares were issued under our shelf registration. In this offering, the Company sold the registered shares at a gross sales
price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_zUSLHMp2TIyf" title="Sale of stock, price per share"&gt;2.40&lt;/span&gt; per share, with net proceeds, after deducting issuance fees and expenses of $&lt;span id="xdx_908_ecustom--SaleOfStockExpenses_c20230307__20230307_zmNdRyFO5XUg" title="Sale of stock expenses"&gt;700,000&lt;/span&gt;, of approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230307__20230307__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--CommonStockMember_z4HF9uWKXtN8" title="Sale of stock, net proceeds"&gt;7,300,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PREFERRED
STOCK ACTIVITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with
Palm Global Small Cap Master Fund LP (&#x201c;Palm&#x201d;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed
to purchase from the Company, &lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z5NxG1RtzGei" title="Preferred stock, shares issued"&gt;571,429&lt;/span&gt; shares of the Company&#x2019;s Series A 5% Convertible Preferred Stock, $&lt;span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zSGCnxnJ5xvj" title="Preferred stock, par value"&gt;0.08&lt;/span&gt; par value per share
for a purchase price of approximately $&lt;span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20200224__20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_znG0WIEMDBI6" title="Preferred stock, purchase price"&gt;2&lt;/span&gt; million, or $&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zUIZ8j3Gkh51" title="Sale of stock, price per share"&gt;3.50&lt;/span&gt; per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase
Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#x2019;s
common stock, subject to certain adjustments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $&lt;span id="xdx_90B_eus-gaap--DividendsPayableAmountPerShare_iI_c20200224__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zy6Z1y2Tbnm4" title="Dividends payable, amount per share"&gt;0.175&lt;/span&gt; per Series A 5% Convertible Preferred
Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay
such accruing dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 24, 2020, Palm converted &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20200304__20200324__us-gaap--EquityInterestIssuedOrIssuableByTypeAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxLKRzngjOw7" title="Conversion of stock, shares converted"&gt;250,000&lt;/span&gt; shares of Convertible Preferred Stock into &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20200304__20200324__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zasmcDMqdl4h" title="Conversion of stock, shares issued"&gt;250,000&lt;/span&gt; shares of unregistered common stock. On July
21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered &lt;span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20200721__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuedvy7FJcI5" title="Conversion of stock, shares issued upon conversion"&gt;571,429&lt;/span&gt; common shares
issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. On September 30, 2020, the Company
received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares. On January 21, 2021,
Palm Converted their remaining &lt;span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20210121__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGvFdWY8eRi3" title="Conversion of stock, shares issued upon conversion"&gt;321,429&lt;/span&gt; Convertible Preferred Shares into registered common shares. On May 30, 2021, the Company had no
shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative dividends were
paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past
cumulative dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandFourteenPlanMember"
      decimals="INF"
      unitRef="Shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-02-29_us-gaap_EmployeeStockOptionMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      unitRef="Shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187"
      decimals="INF"
      unitRef="Pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziOpm9lSewRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation expense for the years ended May 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zy1dsdSDCvid"&gt;SCHEDULE
OF STOCK BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220601__20230531_zL85zAK0Uv1k" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210601__20220531_zbkLros4SRt1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4iXckzSV6Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;143,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;159,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zePauF8bdOXi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;971,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3k0YNjrf0F3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_zLfJYM2Dp0G7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,185,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-06-012023-05-31_us-gaap_CostOfSalesMember"
      decimals="0"
      unitRef="USD">143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-06-012022-05-31_us-gaap_CostOfSalesMember"
      decimals="0"
      unitRef="USD">159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-06-012023-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-06-012022-05-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">1021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-06-012023-05-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">71000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-06-012022-05-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">80000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zn7O30hYo6pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Activity
as to aggregate stock options outstanding is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 4.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 4.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z2xMpyNzQEwc"&gt;SCHEDULE
OF ACTIVITY TO AGGREGATE STOCK OPTIONS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; font-weight: bold"&gt;Options Outstanding at May 31, 2021&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210601__20220531_zo2hFF6bHUll" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding, shares"&gt;2,081,366&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210601__20220531_z6xdbLhxFGde" style="width: 14%; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price"&gt;3.59&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210601__20220531_zpGkCDe79Zmi" style="width: 14%; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value"&gt;2,132,000&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210601__20220531_z3L1j5wDmyRh" style="text-align: right" title="Options granted, shares"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zvtGPLX1ai51" style="text-align: right" title="Options Granted Weighted Average Exercise Price"&gt;4.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210601__20220531_zk0473YWT7ia" style="text-align: right" title="Options exercised, shares"&gt;(39,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210601__20220531_zp0NqWNyUbNc" style="text-align: right" title="Options Exercised Weighted Average Exercise Price"&gt;1.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210601__20220531_zWCGTRMz3gJe" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options canceled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210601__20220531_zcDQAok5oJp5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares"&gt;(64,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210601__20220531_zOpdLZXP0zal" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price"&gt;4.41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Options Outstanding at May 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220601__20230531_zdQf3E23Vwq4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding, shares"&gt;2,321,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220601__20230531_zJkrnYufR07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price"&gt;3.72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220601__20230531_z8ybYZsgdPNk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value"&gt;1,838,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220601__20230531_zgwKqTJB8To" style="text-align: right" title="Options granted, shares"&gt;243,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zAu3aZ5yxF2" style="text-align: right" title="Options Granted Weighted Average Exercise Price"&gt;2.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220601__20230531_zLdr29QxUksd" style="text-align: right" title="Options exercised, shares"&gt;(46,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220601__20230531_zOGpuzaXaajf" style="text-align: right" title="Options Exercised Weighted Average Exercise Price"&gt;1.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220601__20230531_zJmB7dY3efQ7" style="text-align: right" title="Options exercised, Aggregate IntrinsicValue"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Options canceled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220601__20230531_z6WB0ibZSw2e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled or expired, shares"&gt;(175,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220601__20230531_zrOx3pvwzgu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled or expired Weighted Average Exercise Price"&gt;5.56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Options Outstanding at May 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220601__20230531_zkwTS0lFVOSh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding, shares"&gt;2,342,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220601__20230531_z1hi5b8H75y5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options Outstanding Weighted Average Exercise Price"&gt;3.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220601__20230531_z2c8DqTMfm2i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options outstanding, Aggregate Intrinsic Value"&gt;146,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Options vested and exercisable at May 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20230531_zFwibW9Xxub3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable, shares"&gt;1,841,933&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230531_zowGPBmgrFF7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Weighted Average Exercise Price"&gt;3.38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230531_zdU5FibUUaFi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Options vested and exercisable Aggregate Intrinsic Value"&gt;146,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-05-31" decimals="INF" unitRef="Shares">2081366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-05-31"
      decimals="INF"
      unitRef="USDPShares">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-05-31" decimals="0" unitRef="USD">2132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Shares">344000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="USDPShares">4.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Shares">39500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="USDPShares">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Shares">64250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="USDPShares">4.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-05-31" decimals="INF" unitRef="Shares">2321616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-05-31"
      decimals="INF"
      unitRef="USDPShares">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1838000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Shares">243000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="USDPShares">2.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Shares">46500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="USDPShares">1.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Shares">175500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="USDPShares">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">2342616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-05-31"
      decimals="INF"
      unitRef="USDPShares">3.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2023-05-31" decimals="INF" unitRef="Shares">1841933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-05-31"
      decimals="INF"
      unitRef="USDPShares">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187"
      decimals="INF"
      unitRef="USDPShares">2.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-06-012022-05-31_us-gaap_EmployeeStockOptionMember58847203"
      decimals="INF"
      unitRef="USDPShares">4.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1145000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187">P2Y6M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187">P4Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-06-012023-05-31_us-gaap_EmployeeStockOptionMember58847187">P5Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2021-01-222021-01-22_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMAgreementMember"
      decimals="0"
      unitRef="USD">15000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-05-21_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="INF"
      unitRef="Shares">573889</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="INF"
      unitRef="USDPShares">4.26</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="0"
      unitRef="USD">2014000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-012023-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="0"
      unitRef="USD">1961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <BMRA:SaleOfStockExpenses
      contextRef="From2022-06-012023-05-31_custom_ATMOfferingMember"
      decimals="0"
      unitRef="USD">53000</BMRA:SaleOfStockExpenses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="INF"
      unitRef="Shares">521267</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-31_srt_MinimumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="INF"
      unitRef="USDPShares">4.02</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-31_srt_MaximumMember_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="INF"
      unitRef="USDPShares">5.63</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="0"
      unitRef="USD">2402000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-06-012022-05-31_us-gaap_CommonStockMember_custom_ATMOfferingMember"
      decimals="0"
      unitRef="USD">2317000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <BMRA:SaleOfStockExpenses
      contextRef="From2021-06-012022-05-31_custom_ATMOfferingMember"
      decimals="0"
      unitRef="USD">85000</BMRA:SaleOfStockExpenses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-03-072023-03-07_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3333333</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-03-07_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">2.40</us-gaap:SaleOfStockPricePerShare>
    <BMRA:SaleOfStockExpenses
      contextRef="From2023-03-072023-03-07"
      decimals="0"
      unitRef="USD">700000</BMRA:SaleOfStockExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-03-072023-03-07_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">571429</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2020-02-242020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember"
      decimals="-6"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">3.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="AsOf2020-02-24_us-gaap_ConvertiblePreferredStockMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">0.175</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2020-03-042020-03-24_us-gaap_ConvertiblePreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2020-03-042020-03-24_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2020-07-21_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">571429</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2021-01-21_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">321429</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zY4kAUNlBHb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7: &lt;span id="xdx_82E_zjBXGgx5oqyd"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zN1RjOEMDHg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision
for income taxes for the years ended May 31 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zEdv7rDKFfD3"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220601__20230531_zC8A2hrtPn6b" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210601__20220531_zW6c9qy468jl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzN4S_zVPkhJ98LI4f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzN4S_zhSeGrRiyTv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign Taxes
    Subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzN4S_zs6t4Al7tRaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    and local&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzN4S_maITEBz44d_zJSwJaeEK7N5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    current&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(51,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzeSN_z5EJuxrkvNvd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzeSN_z3rrGLRSjih" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzeSN_maITEBz44d_zaouIu8VrYq5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBz44d_zx5zSBw96vN" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(51,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zkqKzrzEHToe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision
for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220601__20230531_z0NJJDom9wf8" title="Federal income tax rate"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210601__20220531_zlvPESmUANb9" title="Federal income tax rate"&gt;21&lt;/span&gt;&lt;/span&gt;% for 2023
and 2022) to pretax income as a result of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwSclUVi4pBk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zY3eUHn24cJf"&gt;&#160;SCHEDULE
OF EFFECTIVE INCOME TAX RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220601__20230531_zdJI70dx3xVl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210601__20220531_zPT0Hx4RkPBh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maCITEBzLRi_zFnJYfux1Ws2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computed &#x201c;expected&#x201d;
    tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,490,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;947,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase (reduction) in income taxes resulting
    from:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maCITEBzLRi_zZD9Sq7KH1Hb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,973,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,022,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maCITEBzLRi_zouQNNB7pZS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;583,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msCITEBzLRi_zW0GZGjlV8ge" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maCITEBzLRi_zBLkiluNOQa8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent tax differences and other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(197,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maCITEBzLRi_z0MsKHPsszE8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock based compensation benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maCITEBzLRi_zMZuhGRMn09j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign taxes of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(129,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(113,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzLRi_zCbHblsos8G3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(51,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zQk8aWH9yqGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z6t9YwLvlCnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effect of significant temporary differences is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zKa0cnEl6IC"&gt;&#160;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230531_zcdSpE1advel" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220531_zz4jubQPL1s5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzl2T_zoJPLcS3oaN3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable,
    principally due to allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzl2T_zyTgsXHyl9uh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory valuation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;237,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_maDTAGzl2T_zk8LFjL4wJbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensated absences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;118,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzl2T_zR4790kv4XPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,817,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,349,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzl2T_zK6tOU68FhUk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,239,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,096,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_iI_maDTAGzl2T_zDZQkHcikds4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred rent expense/Capitalized leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DefferedTaxAssetsStockOptions_iI_maDTAGzl2T_zmkKMKaREBJ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,296,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,035,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsCapitalizedCosts_iI_maDTAGzl2T_z6LtUkQbqmsa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sec 174 capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_iI_maDTAGzl2T_zUFMFuKsa3c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Losses of foreign subsidiaries &amp;amp; other,
    net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAccumulatedDepreciationAndAmortization_iI_maDTAGzl2T_zUO37fP95gvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzl2T_maDTANzFA8_zzMFePDOqVx3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,940,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,967,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFA8_zrhlaIp5jY1h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,940,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,967,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFA8_zJYyCrD9RqUg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zWmyURdUshQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has provided a valuation allowance of approximately $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_ze734Z4lUAEk" title="Deferred tax assets, valuation allowance"&gt;8,940,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20220531_zcDoET38PTkh" title="Deferred tax assets, valuation allowance"&gt;6,967,000&lt;/span&gt; as of May 31, 2023 and 2022, respectively. The
net change in the valuation allowance for the years ended May 31, 2023 and 2022 was an increase of $&lt;span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220601__20230531_zQdExubQabfl" title="Increase in valuation allowance"&gt;1,973,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210601__20220531_zHRYO3gq8yYk" title="Increase in valuation allowance"&gt;1,063,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2023, the Company has Federal income tax net operating loss carryforwards of approximately $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zPqi3ES2hLfj" title="Operating loss carryforwards"&gt;21,958,000&lt;/span&gt;. On May 31, 2023, the
Company has California state income tax net operating loss carryforwards of approximately $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zOpAhQ8VXQF7" title="Operating loss carryforwards"&gt;17,269,000&lt;/span&gt;. For tax reporting purposes, operating
loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in 2024 and
2038 for federal and state purposes, respectively. Federal net operating losses beginning in 2018 have no expiration date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2023, the Company has Federal research and development tax credit carryforward of approximately $&lt;span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zQqy3RFzC9Gl" title="Tax credit carryforward"&gt;817,000&lt;/span&gt;. The Federal credits
begin to expire in 2028. The Company also had similar credit carryforwards for state purposes of $&lt;span id="xdx_904_eus-gaap--TaxCreditCarryforwardAmount_iI_c20230531__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zvcL5mkbI1N9" title="Tax credit carryforward"&gt;533,000&lt;/span&gt; on May 31, 2023, which do not
expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company&#x2019;s net operating loss (&#x201c;NOL&#x201d;)
and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections
382 and 383 of the IRC, the annual use of the Company&#x2019;s NOLs and credit carryforwards would be limited if there is a cumulative
change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period). Management has
not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended May 31, 2023, the Company performed an analysis and has not identified any uncertain tax positions as
defined under ASC 740. Should such position be identified in the future, and should the Company owe interest and penalties as a result
of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The
Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal 2018.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zN1RjOEMDHg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision
for income taxes for the years ended May 31 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zEdv7rDKFfD3"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220601__20230531_zC8A2hrtPn6b" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210601__20220531_zW6c9qy468jl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzN4S_zVPkhJ98LI4f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzN4S_zhSeGrRiyTv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign Taxes
    Subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzN4S_zs6t4Al7tRaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    and local&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzN4S_maITEBz44d_zJSwJaeEK7N5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    current&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(51,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzeSN_z5EJuxrkvNvd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzeSN_z3rrGLRSjih" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzeSN_maITEBz44d_zaouIu8VrYq5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBz44d_zx5zSBw96vN" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(51,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-50000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-23000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-51000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-24000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">51000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-06-012022-05-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwSclUVi4pBk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zY3eUHn24cJf"&gt;&#160;SCHEDULE
OF EFFECTIVE INCOME TAX RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220601__20230531_zdJI70dx3xVl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210601__20220531_zPT0Hx4RkPBh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maCITEBzLRi_zFnJYfux1Ws2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computed &#x201c;expected&#x201d;
    tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,490,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;947,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase (reduction) in income taxes resulting
    from:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maCITEBzLRi_zZD9Sq7KH1Hb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,973,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,022,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maCITEBzLRi_zouQNNB7pZS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;583,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msCITEBzLRi_zW0GZGjlV8ge" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maCITEBzLRi_zBLkiluNOQa8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent tax differences and other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(197,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maCITEBzLRi_z0MsKHPsszE8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock based compensation benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maCITEBzLRi_zMZuhGRMn09j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign taxes of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(129,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(113,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzLRi_zCbHblsos8G3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(51,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1490000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">947000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-1973000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-1022000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">583000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">300000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">50000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-17000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-197000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-5000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">11000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-129000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-113000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">-51000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">-24000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z6t9YwLvlCnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effect of significant temporary differences is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zKa0cnEl6IC"&gt;&#160;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230531_zcdSpE1advel" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220531_zz4jubQPL1s5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;May
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzl2T_zoJPLcS3oaN3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable,
    principally due to allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzl2T_zyTgsXHyl9uh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory valuation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;237,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_maDTAGzl2T_zk8LFjL4wJbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensated absences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;118,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzl2T_zR4790kv4XPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,817,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,349,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzl2T_zK6tOU68FhUk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,239,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,096,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_iI_maDTAGzl2T_zDZQkHcikds4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred rent expense/Capitalized leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DefferedTaxAssetsStockOptions_iI_maDTAGzl2T_zmkKMKaREBJ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,296,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,035,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsCapitalizedCosts_iI_maDTAGzl2T_z6LtUkQbqmsa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sec 174 capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_iI_maDTAGzl2T_zUFMFuKsa3c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Losses of foreign subsidiaries &amp;amp; other,
    net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAccumulatedDepreciationAndAmortization_iI_maDTAGzl2T_zUO37fP95gvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzl2T_maDTANzFA8_zzMFePDOqVx3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,940,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,967,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFA8_zrhlaIp5jY1h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,940,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,967,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFA8_zJYyCrD9RqUg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">8000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">43000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsInventory contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">188000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">237000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">118000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">120000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">5817000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">4349000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1239000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1096000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">11000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">20000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <BMRA:DefferedTaxAssetsStockOptions contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1296000</BMRA:DefferedTaxAssetsStockOptions>
    <BMRA:DefferedTaxAssetsStockOptions contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">1035000</BMRA:DefferedTaxAssetsStockOptions>
    <BMRA:DeferredTaxAssetsCapitalizedCosts contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">284000</BMRA:DeferredTaxAssetsCapitalizedCosts>
    <BMRA:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">41000</BMRA:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet>
    <BMRA:DeferredTaxAssetsAccumulatedDepreciationAndAmortization contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">-21000</BMRA:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
    <BMRA:DeferredTaxAssetsAccumulatedDepreciationAndAmortization contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">26000</BMRA:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">8940000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">6967000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">8940000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">6967000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">8940000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-05-31" decimals="0" unitRef="USD">6967000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">1973000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">1063000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-05-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">21958000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">17269000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2023-05-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember"
      decimals="0"
      unitRef="USD">817000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2023-05-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember"
      decimals="0"
      unitRef="USD">533000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zcp8WCGGJ4z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8: &lt;span id="xdx_820_z9pn3jfZJG11"&gt;GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as &lt;span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20220601__20230531_z6J7Ksl9YdH9" title="Number of operating segments"&gt;one&lt;/span&gt; segment. Geographic information regarding net sales is approximately as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zGGLNwuVGY9k" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z7cG5U7SlX8b"&gt;SCHEDULE
OF GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220601__20230531_zJfyALI3Y6F9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210601__20220531_zAIUzto5L65e" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues from sales to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--AsiaMember_zQWtR9KMXSg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--EuropeMember_z3ylp06Qme38" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,798,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,339,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--NorthAmericaMember_zbpKxULpKhTh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,470,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;997,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zZIzZe0FWy96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Middle East&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--SouthAmericaMember_zT16pDj3POM3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;South America&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_zVsIXdCQwpva" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;5,339,000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;18,871,000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zaI9zcEDAC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2022-06-01to2023-05-31"
      decimals="INF"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_89B_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zGGLNwuVGY9k" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z7cG5U7SlX8b"&gt;SCHEDULE
OF GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220601__20230531_zJfyALI3Y6F9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210601__20220531_zAIUzto5L65e" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues from sales to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--AsiaMember_zQWtR9KMXSg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--EuropeMember_z3ylp06Qme38" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,798,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,339,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--NorthAmericaMember_zbpKxULpKhTh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,470,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;997,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zZIzZe0FWy96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Middle East&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__srt--SouthAmericaMember_zT16pDj3POM3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;South America&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_zVsIXdCQwpva" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;5,339,000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;18,871,000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2022-06-012023-05-31_srt_AsiaMember"
      decimals="0"
      unitRef="USD">2021000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31_srt_AsiaMember"
      decimals="0"
      unitRef="USD">13375000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-06-012023-05-31_srt_EuropeMember"
      decimals="0"
      unitRef="USD">1798000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31_srt_EuropeMember"
      decimals="0"
      unitRef="USD">4339000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-06-012023-05-31_srt_NorthAmericaMember"
      decimals="0"
      unitRef="USD">1470000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31_srt_NorthAmericaMember"
      decimals="0"
      unitRef="USD">997000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-06-012023-05-31_us-gaap_MiddleEastMember"
      decimals="0"
      unitRef="USD">39000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31_us-gaap_MiddleEastMember"
      decimals="0"
      unitRef="USD">70000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-06-012023-05-31_srt_SouthAmericaMember"
      decimals="0"
      unitRef="USD">11000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31_srt_SouthAmericaMember"
      decimals="0"
      unitRef="USD">90000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">5339000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">18871000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zYX2kOwmmqc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9: &lt;span id="xdx_82A_zvcFWIup17c9"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OPERATING
LEASES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases facilities in Irvine, California and Mexicali, Mexico.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 31, 2023, &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20230531__20230531_zdyr3kDXFQ31" title="Operating lease description"&gt;the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue
in Irvine, California. The lease for its headquarters expires in August 2026. The Company has the option to extend the lease for an additional
five-year term&lt;/span&gt;. The Company made a security deposit of approximately $&lt;span id="xdx_900_eus-gaap--SecurityDeposit_iI_c20230331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--BuildingInIrvineCaliforniaMember_zxo40vLrPuui" title="Security deposit"&gt;22,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2016, the Company&#x2019;s Mexican subsidiary, Biomerica de Mexico, entered into a &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20161130_zPHTP8zOzvEh" title="Operating lease term"&gt;10&lt;/span&gt;-year lease for approximately &lt;span id="xdx_906_eus-gaap--AreaOfLand_iI_uSqft_c20230531_zsw5BBM5JbTa" title="Lease area"&gt;8,100&lt;/span&gt; square
feet of manufacturing space. The Company has one &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20161130_zhJ22IGPxyX7" title="Operating lease renewal term"&gt;10&lt;/span&gt;-year option to renew at the end of the initial lease period. Biomerica de Mexico
also leases a smaller unit on a month-to-month basis for use in the Company&#x2019;s manufacturing process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany
subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of
the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising.
The Company&#x2019;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included
in the measurement of the right-of-use asset and related lease liabilities. Additionally, under these lease arrangements, the Company
may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable
and therefore not included in the measurement of the right-of-use asset and related lease liabilities but are instead recognized as variable
lease expense in the consolidated statements of operations and comprehensive loss when they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zJccOLgSar7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information on our operating leases for the years ended May 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z9hcafgkEkTd"&gt;SCHEDULE
OF OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220601__20230531_zSzDegJAzyT6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210601__20220531_zQ6uvSHpEBVh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseCost_maLCzsjE_zN9b0A329Qqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;353,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;352,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maLCzsjE_zTPhJXEV48ua" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LeaseCost_mtLCzsjE_zKSdFz0elaw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;357,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A1_zxC4EHaOxkXi" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMFnK54RcJih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
future minimum lease payments of the Company&#x2019;s operating lease liabilities by fiscal year are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zACTi91hd6Ai"&gt;SCHEDULE
OF FUTURE MINIMUM LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year Ending May 31:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230531_zuR7SXjplLs8"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzfjE_zjXCJmEkQTEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzfjE_zAz6xE532JNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzfjE_zWZRjsXHwgS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;376,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzfjE_z0aV6G8x0Yj5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzfjE_zaZRFkGJqlt6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1150"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzfjE_mtOLLzK2p_zUh9Z1G7RAq8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,199,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_maOLLzK2p_zxa9kfLeFwn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_maOLLzK2p_zyNHw99PWPk1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,082,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zHgbJopHfgO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfSupplementalLeaseInformationTableTextBlock_z3mnnqSft9jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s other supplemental lease information for the years ended May 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zG6Y8pfXecUh"&gt;SCHEDULE
OF OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220601__20230531_zwIB7iGhv1g8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210601__20220531_zfkQ1bB7XCih" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeasePayments_zqcuHF6ogFGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;347,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230531_zG20xRD4gK87" title="Weighted average remaining lease term (years)"&gt;3.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220531_zJZ4ZwmrD4f7" title="Weighted average remaining lease term (years)"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230531_zQnLWfU6akt8" title="Weighted-average discount rate"&gt;6.50&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220531_z1eVUJIjyLqg" title="Weighted-average discount rate"&gt;6.50&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_zxi278JrRhUf" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also has various insignificant leases for office equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;RETIREMENT
SAVINGS PLAN&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute
to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404.
The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each
year. No contributions by the Company have been made since the plan&#x2019;s inception.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LITIGATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is, from time to time, involved in legal proceedings, claims, and litigation arising in the ordinary course of business. While
the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that
exist. Therefore, it is possible the outcome of such legal proceedings, claims, and litigation could have a material effect on quarterly
or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes
such matters will not have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations or
cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no legal proceedings pending as of May 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CONTRACTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contracts
and Licensing Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products.
Royalty expense of approximately $&lt;span id="xdx_902_eus-gaap--RoyaltyExpense_c20220601__20230531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_zSkPdbkblpJl" title="Royalty expense"&gt;13,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--RoyaltyExpense_c20210601__20220531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_z4csWzkUuQe7" title="Royalty expense"&gt;19,000&lt;/span&gt; is included in cost of sales for the agreement for each of the years ended May 31,
2023 and 2022, respectively. Sales of products manufactured under these agreements comprise approximately &lt;span id="xdx_904_ecustom--RoyaltyExpensePercentageOfSales_dp_c20220601__20230531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_zDb8N2abyE39" title="Royalty expense percentage of sales"&gt;2.1&lt;/span&gt;% and &lt;span id="xdx_906_ecustom--RoyaltyExpensePercentageOfSales_dp_c20210601__20220531__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementsMember_ziVgqX5EL2Q5" title="Royalty expense percentage of sales"&gt;1.5&lt;/span&gt;% of total sales
for the years ended May 31, 2023 and 2022, respectively. The Company may license other products or technology in the future as it deems
necessary for conducting business. The Company has other royalty agreements however they are not considered material.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
Trial Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing
clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.
The initial budget was estimated to be approximately $&lt;span id="xdx_90F_ecustom--ClinicalTrialAgreementMaximumBudgetedCosts_iI_c20170930__dei--LegalEntityAxis__custom--UniversityOFSouthernCaliforniaMember_z901oPW5eYb7" title="Clinical trial agreement maximum budgeted costs"&gt;82,000&lt;/span&gt;. The work started in October 2017 with charges for work performed being
invoiced and paid monthly. This study ended in February 2020. Approximately $&lt;span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_c20220531__dei--LegalEntityAxis__custom--UniversityOFSouthernCaliforniaMember_zamhDWJ9hjQa" title="Accrued liabilities"&gt;17,000&lt;/span&gt; in fees has been accrued for unbilled charges as
of May 31, 2022. There are no unbilled charges as of May 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into a Clinical Trial Agreement with a research institute for the purpose of conducting a clinical trial of the Biomerica
InFoods&#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly
for work performed in the previous month. The maximum budgeted costs will be approximately $&lt;span id="xdx_901_ecustom--ClinicalTrialAgreementMaximumBudgetedCosts_iI_c20220531__dei--LegalEntityAxis__custom--BiomericaInFoodsMember_zGozQprfkaK7"&gt;107,000&lt;/span&gt;. This study ended in March 2022.
Approximately $&lt;span id="xdx_900_eus-gaap--AccruedLiabilitiesCurrent_iI_c20220531__dei--LegalEntityAxis__custom--BiomericaInFoodsMember_zLOalagqTprc" title="Accrued liabilities"&gt;28,000&lt;/span&gt; in fees has been accrued for unbilled charges as of May 31, 2022. There are no unbilled charges as of May 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2023-05-312023-05-31">the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue
in Irvine, California. The lease for its headquarters expires in August 2026. The Company has the option to extend the lease for an additional
five-year term</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-03-31_custom_BuildingInIrvineCaliforniaMember"
      decimals="0"
      unitRef="USD">22000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2016-11-30">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AreaOfLand contextRef="AsOf2023-05-31" decimals="INF" unitRef="Sqft">8100</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2016-11-30">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zJccOLgSar7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information on our operating leases for the years ended May 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z9hcafgkEkTd"&gt;SCHEDULE
OF OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220601__20230531_zSzDegJAzyT6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210601__20220531_zQ6uvSHpEBVh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseCost_maLCzsjE_zN9b0A329Qqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;353,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;352,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maLCzsjE_zTPhJXEV48ua" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LeaseCost_mtLCzsjE_zKSdFz0elaw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;357,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">353000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">352000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">5000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">5000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">358000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">357000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMFnK54RcJih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
future minimum lease payments of the Company&#x2019;s operating lease liabilities by fiscal year are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zACTi91hd6Ai"&gt;SCHEDULE
OF FUTURE MINIMUM LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year Ending May 31:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230531_zuR7SXjplLs8"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzfjE_zjXCJmEkQTEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzfjE_zAz6xE532JNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzfjE_zWZRjsXHwgS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;376,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzfjE_z0aV6G8x0Yj5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzfjE_zaZRFkGJqlt6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1150"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzfjE_mtOLLzK2p_zUh9Z1G7RAq8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,199,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_maOLLzK2p_zxa9kfLeFwn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_maOLLzK2p_zyNHw99PWPk1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,082,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">356000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">376000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">101000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1199000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">117000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-05-31" decimals="0" unitRef="USD">1082000</us-gaap:OperatingLeaseLiability>
    <BMRA:ScheduleOfSupplementalLeaseInformationTableTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_898_ecustom--ScheduleOfSupplementalLeaseInformationTableTextBlock_z3mnnqSft9jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s other supplemental lease information for the years ended May 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zG6Y8pfXecUh"&gt;SCHEDULE
OF OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220601__20230531_zwIB7iGhv1g8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210601__20220531_zfkQ1bB7XCih" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended May 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeasePayments_zqcuHF6ogFGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;347,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230531_zG20xRD4gK87" title="Weighted average remaining lease term (years)"&gt;3.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220531_zJZ4ZwmrD4f7" title="Weighted average remaining lease term (years)"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230531_zQnLWfU6akt8" title="Weighted-average discount rate"&gt;6.50&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220531_z1eVUJIjyLqg" title="Weighted-average discount rate"&gt;6.50&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</BMRA:ScheduleOfSupplementalLeaseInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-06-01to2023-05-31"
      decimals="0"
      unitRef="USD">347000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-06-012022-05-31"
      decimals="0"
      unitRef="USD">338000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-05-31">P3Y3M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-05-31">P4Y3M10D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-05-31" decimals="INF" unitRef="Pure">0.0650</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-05-31" decimals="INF" unitRef="Pure">0.0650</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-06-012023-05-31_us-gaap_RoyaltyAgreementsMember"
      decimals="0"
      unitRef="USD">13000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-06-012022-05-31_us-gaap_RoyaltyAgreementsMember"
      decimals="0"
      unitRef="USD">19000</us-gaap:RoyaltyExpense>
    <BMRA:RoyaltyExpensePercentageOfSales
      contextRef="From2022-06-012023-05-31_us-gaap_RoyaltyAgreementsMember"
      decimals="INF"
      unitRef="Pure">0.021</BMRA:RoyaltyExpensePercentageOfSales>
    <BMRA:RoyaltyExpensePercentageOfSales
      contextRef="From2021-06-012022-05-31_us-gaap_RoyaltyAgreementsMember"
      decimals="INF"
      unitRef="Pure">0.015</BMRA:RoyaltyExpensePercentageOfSales>
    <BMRA:ClinicalTrialAgreementMaximumBudgetedCosts
      contextRef="AsOf2017-09-30_custom_UniversityOFSouthernCaliforniaMember"
      decimals="0"
      unitRef="USD">82000</BMRA:ClinicalTrialAgreementMaximumBudgetedCosts>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-05-31_custom_UniversityOFSouthernCaliforniaMember"
      decimals="0"
      unitRef="USD">17000</us-gaap:AccruedLiabilitiesCurrent>
    <BMRA:ClinicalTrialAgreementMaximumBudgetedCosts
      contextRef="AsOf2022-05-31_custom_BiomericaInFoodsMember"
      decimals="0"
      unitRef="USD">107000</BMRA:ClinicalTrialAgreementMaximumBudgetedCosts>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-05-31_custom_BiomericaInFoodsMember"
      decimals="0"
      unitRef="USD">28000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-06-01to2023-05-31">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zZAureC8xYdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10: &lt;span id="xdx_82A_zqBIax2NwMch"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 3, 2023, &lt;span id="xdx_908_eus-gaap--SubsequentEventDescription_c20230803__20230803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrEmnUmfwd14" title="Subsequent event, description"&gt;the Company announced it had entered into a sales agreement with CVS Pharmacy wherein the Company&#x2019;s EZ Detect&#x2122;
colorectal disease screening test will be offered at approximately 7,000 CVS Pharmacy retail stores&lt;/span&gt;. Biomerica has shipped the EZ Detect
product to CVS Health distribution centers in the United States, and the product is projected to be on store shelves in September.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventDescription contextRef="From2023-08-032023-08-03_us-gaap_SubsequentEventMember">the Company announced it had entered into a sales agreement with CVS Pharmacy wherein the Company&#x2019;s EZ Detect&#x2122;
colorectal disease screening test will be offered at approximately 7,000 CVS Pharmacy retail stores</us-gaap:SubsequentEventDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M5(+K^*\0;6W/*0-WOV_4[[/"0V&FF!./1M_#0"RN6N<M%) 93B/Q3%\_DZ)
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M/ #VSR@5FPUY@NV[0M?_ U!+ P04    "  ,B!E7<Q]"8D4&  !]'   &
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M81JQX>TYV^&</9)2(,O:/+A4VDI: WT9MP&(6@(!99MR4[C&F0LHY4SRAIG
MG)>J-O*;^P&+;=;?!33L1X:9#6_G=!=8Z@W,<?6I6IYNM&CSCT:U'X2]=A+3
M9 QW=Q&>)&S:G&A[;;_AN^NV=X^ALO5:.*8N'K \I/UG'(33?B(0NS!@@YF@
M04=_P:.EK4TYU"';U0<WCA%\C]L=XMNC9_H(/L.K6PFM\=@GA89!CPP#L4N&
M*YYV#$R]I#?_TW8B3ZVWRP\:-T)$B%DZW#MI1YK4SYI-2UH,PPO[>8FB:80@
M1"QIZ.$@VK$EC8Z2,1\DOY&%-,!&J):A7M9]JIAY+F^'07?,2_W4N],(:_[
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M>2$TEF7M&CM7VU[V\S@,IT$0S,;[PP3Z=G0R2>FAX1%<W,+%7KB%U,8N[$'
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MVEJ*DH(?AI$8TK0XK^?5HDZ5E;$ E"")5CHIW=+&Y/9B#3(2U47!:^#T9I6
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MRX.-\H@3ZAX<107VG'7!&Q:,%]8PT.4JV6Q0E$F#\B7TSMKJSW.9/YLB(^$
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M0AOZ,\)X,%N8WD/FIKT-.#OD$V0CT;76+-(5I90:SC7,,HX#%JQRH%0,N N
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M$\6]%:5,<V<*SV'BIBZV>IL ID/J#+G 3,KY+,B@7+O30>O?A5^3B;;6A0?
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M_$NX7 $S5RM(_;* _OQH2$%U=&2HV-"'X&KHKBG3\!@DJ-[M#5QHT%( Q0K
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MH"8)J$EV3OZ^Z6M(>FF:]N(X]C+[R)P<7+9:"MMJ[,%"/#G!>*85THB7JBI
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MQ)S^0*B= 9VOE+)[Q04X_-.&_P-02P,$%     @ #(@95XMT#M72 @  3P8
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M)7W-498$\'YAC*]O:(/F/Q\N_P-02P,$%     @ #(@95]=OAI"@ @  F 4
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M-N,A2X] D"_N8"E1J<6PK)*8172_7>4B*M9J"9)?L(XZV%&D$:%+NZBV8@S
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M)%<L..1$6>S=_"H[,V IV(DA4PR,POY4#D OC\DM#"+?8P(SG10U%6X9]T0
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M.=)*()),.J PI%"NBU;ST_/RO;WOR?_,U'0\&L/JWGT:A^IV_-"X@ZVD6I-
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M,_@$@[L*P((&SR:.]H6Z6X!0$C=L]H&!+ANPK6=H 6-.(MA(ZM,:O"&PW4
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M8<%I%(&Z7-2WQ9,P&"TA#7%\NCC#N98LCLR<\3#5.<"A4TTCLI1B8.N$QF[
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MC._OWKFL^RY+L)K:NI8(UYD<8L*E22MB]HJFO,HR-%/H'BRD6TA*4I@$T0L
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M@Y\;\M9I+5L]!Z#V-<Z>TOK]"/XF<6#0U'72^;D VM$1U:'&S60V_/!A.O[
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M\.8,=AYH">D4ZP/E"FZ^MZC-(K@FG'Y[$P[VQ'RZF\W4_7C*A2:-JO\'&G"
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M*QF60Z81V2I5$MR.5R/JMS7EBN2P$!RU]YYOT8AG1UYG9]"WO;!&]P^(W>G
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MN@GFX<WT^U4XCSY^Z#MV[PN$?SW<+G["IP59YE1\'G8D.E+JG;@&O:Q G7=
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MVIXJCG9"LJ02*X*$I.4W>J_6X4A@.V<$L!+ SPJ<2N 404NR(M8(210&G.6
MZVKEI@?%VA1JE8:D^E=<2J[N$J63X7)X/QX]_QJ#QPF8C9_ =/8RGCT]+J;C
M);@888D(%9?@"CPO1^#BZV5@2M542\VH:G!7-H!G&CR@#^#8WP&TH-.B'GY:
M#4_5I@I:IX5U6EC8.6?L;J.([5))T@V8,THB@@7X?;L2DJO'Z4];N-*OU^ZG
MM]B-R%"$!X;:0P+S/3;";U]LU_K9EO4_F9U$=^KH3I=[N$"Y>FXDY@11T9:T
ME/<+N=[[^]!V/<^RK,#<'X=HJ?/LD[H3OE[-U^OD>U6['9 49)QM5/I6Q-+!
M/6KMNS^:A,TRSW7. O9KP'XGX(2D1.VS6!/&NTBV$O8;K6T?-@F;9=YIV0FA
M6Q.ZG81/3"(*-IP)H59RCU/)^$<;I=MH#SWH-S&;=0YTSW-Z-:?7R3D]L('J
M,6]C]!J]KURO92E;ZOR>>Y;1KQG]3L:9.D [U]!O; -H]=TF7TM=SV[A,X_>
MX?K\?$!\0U(!*%XKI77M*0M>GDGE1+*L>*VOF%2'1#'<JF,<<UV@[J\9DX>)
M/BGJ/P;A/U!+ P04    "  ,B!E7VSZ+ZM #  #U#P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6S5EUEOVS@0Q[\*H06*72"-+I]9VX!\!"FV;@PK
M2;$H]H&VQC81271)^OKV2U**?)36QEV_],4F*<Y?OQEQ2$YK0]DK7P (M$WB
ME+>MA1#+.]OFTP4DF-_2):3RR8RR! O997.;+QG@2!LEL>TY3LU.,$FM3DN/
MC5BG15<B)BF,&.*K),%LUX68;MJ6:[T-C,E\(=2 W6DM\1Q"$,_+$9,]NU")
M2 (I)S1%#&9M*W#O>FY5&>@9+P0V_*"-E"L32E]5YU/4MAQ%!#%,A9+ \F\-
M/8ACI20YON>B5O%.97C8?E._U\Y+9R:80X_&7TDD%FVK8:$(9G@5BS'=/$#N
MD :<TICK7[3)YSH6FJZXH$EN+ D2DF;_>)L'XL# K9\Q\'(#[[T&?F[@:T<S
M,NU6'PO<:3&Z04S-EFJJH6.CK:4W)%6?,11,/B723G3"WL.@__QY@![O4?@0
MC <?NT$XZ*-1\/=P\.4)!5^#<?\&A4^/O;_0X^CIT^.7\ :]!)^? ]5&01@^
M#[-A]'L?!"8Q_Z-E"XFF7F!/<XQNAN&=P7 ]-*2I6' T2".(C@5LZ5/AF/?F
M6-<K51SB'?+=&^0YGF_@Z;W;VBN!\8LH^UK./Q?E!6;PL2N76X1Z-)$YR+%>
MQ0%C.)V#S N!)CMT.&^$=WHXV& 6W:![3!AZP?$*4,!ETBV5/4<XC= 0Q()&
M-*;S'?H63+A@,CG^,7V$C+)BIE0[QAU?XBFT+;DE<&!KL#H??G-KSI^F"%Y)
M["B@E2*@E3+U3I^L2032]QV!.#*YFMDWM+W:R]8=IV6O#_G+9AQ!50NH:BG4
M8+N4FY/\=&L:R\\;$[%3*4N256(BS,2:A^^_;38:[@GFC]/<6\>K5LRLM8*U
M=CDKWIYCK9D@W'K]A-4XK5IIF%GK!6N]E'5,^"N:,0!$4@%R,0G$L("RV-8-
ML75\USOA-4YSFG4S;Z/@;?P<[_GX-HR\?O6$USC-JU?-O,V"M_F^M2!AC73E
MYC6T \PX\E&BMW#37E&J\)-[A>OLSSBGE'"8+13T;0C)!)AQ:RR7N'1OO);:
ML<,'A[K[2YPW.>:U@GHEM>.@>ON@>O\O3<KM+_:VG*::9UW-F'7'+NZO*6[I
MH2VO/=O_3I2K7B*NI7;L\/X:X59^C40IO>Y<'-0KJ1T'=7\-<M]Y#SJ;**7V
M%WM;3E-^/&4NV@<%5 )LKNM*CJ9TE8JLY"A&B]HUT!7;R7A7U;2Z,-O+9 7Q
M$+,YD>LBAIF4=&[KDIIE-6;6$72IR[0)%;+HT\V%K,N!J0GR^8Q2\=91+R@J
M_<Z_4$L#!!0    (  R(&5>-@ '[?P,  .4/   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;*U7T6Z;,!3]%8M-TR9M!4.@29<@M4G616K:J&FWAVD/
M#G&"-<"9[23MW\\&2J EUEKY!6QS[_$]]L&^M[^G[ ^/,1;@(4TR/K!B(39G
MMLVC&*>(G] -SN27%64I$K++UC;?,(R6N5.:V*[C!':*2&:%_7QLQL(^W8J$
M9'C& -^F*6*/%SBA^X$%K:>!6[*.A1JPP_X&K?$<B_O-C,F>7:$L28HS3F@&
M&%X-K'-X-H2!<L@M?A"\Y[4V4%06E/Y1G<ER8#DJ(IS@2"@()%\[/,1)HI!D
M'']+4*N:4SG6VT_HWW+RDLP"<3RDR4^R%/' ZEI@B5=HFXA;NO^.2T*^PHMH
MPO,GV!>VOF^!:,L%34MG&4%*LN*-'LJ%J#E(HNT.;NG@/G?PCCAXI8.7$RTB
MRVF-D$!AG]$]8,I:HJE&OC:YMV1#,K6-<\'D5R+]1#@??A^/[J_&X.8;&$WF
MYY>7M^/+\[O)S36X'?\87]^/P<<1%H@D_!/X N[G(_#Q_:>^+>3<"L&.RGDN
MBGG<(_- %TQI)F(.QMD2+YL M@RZBMQ]BOS"U2).T2/PX&?@.J[7$L_PO[U=
M33!>M8Q>#N<=@9LQNMQ& DRRXL]2"OUU)8W 1."4_VY;L *QTXZH?M\SOD$1
M'ECR_^28[; 5?G@' ^=K&UM#8 WRG8I\1X<>WE&!DC:&A9N?NZGS9!?ZGM=S
M'*=O[^K!O[2#W>XIK!LV O.KP'QM8$,Y0"*4@"NT +^F.%U@UKH56IC7;H4A
ML ;CH&(<&-=A8)*\(; &^=.*_.G;=%BX!35]>9Y2UW,=MM@Y0>>H#+M57%UM
M7#<[S,!=C,&0;C.!M4K4(KUV,PR!-4CW*M(]XTKLF21O"*Q!'CJ':]5YFQ9+
MO[K(( Q:#L4V0Z?;.ZI&6+ORH?Y8E!<QD_D3F*)LNY*-+2/96BM+/>)KM\84
M6I._>^#O&I=F"6EJ 0RA-1?@D*Q ;3J@$:?W0G-!VT'98M?Q-=(\9!)0GTK,
MXD=.(H(R#FY6*Q+I#TL]V*LWQ1!:D_HA5X&^>54:35Q,H347X)"Z0&URH%%E
M\"(_=/TV5;ZT@QVW39=VK6!*,5OG=20'D;J?BPJD&JUJU?.\0GLV?J%JV+P0
M.\ 4!? 4L361,D[P2D(Z)Z<R+%;4E$5'T$U>EBVHD$5>WHQE'8Z9,I#?5Y2*
MIXZ:H*KLPW]02P,$%     @ #(@95Z$*L7YJ#@  >(4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&ULM9W_;]LV&L;_%<)W.'1 %EN4]26])$!JL5L.
M2Q,T[7:'P_V@RK0M5)8\26Z:87_\D;)BFA9-1]F3_; F#OF(?E[I%3\D19T_
M%.77:L%Y3;XOL[RZ&"SJ>O5V.*R2!5_&U6FQXKGXRZPHEW$M?BWGPVI5\GC:
M5%IF0SH:^<-EG.:#R_/FL[OR\KQ8UUF:\[N25.OE,BX?W_&L>+@8.(.G#SZF
M\T4M/QA>GJ_B.;_G]>?572E^&VY5INF2YU5:Y*3DLXO!E?.6A:&LT)3X->4/
MU<[/1'Z5+T7Q5?YR/;T8C&2+>,:36DK$XI]O?,*S3"J)=OS>B@ZVQY05=W]^
M4G_??'GQ9;[$%9\4V6_IM%Y<#,(!F?)9O,[JC\7#S[S]0I[42XJL:OY/'MJR
MHP%)UE5=+-O*H@7+--_\&W]OC=BIX(P/5*!M!;I?P3]0P6TKN/L5W ,5QFV%
M\7.;Y+45FJ\^W'SWQK@HKN/+\[)X(*4L+=3D#XW[36WA5YK+$^6^+L5?4U&O
MOKS_?'-S]?$_Y/8]N;_^Z</U^^O)U8=/Y&HRN?W\X=/UAY_(W>TOUY-K=D_>
M1+R.TZPB'^*RC&5\?R _DL_W$7GS]Q_.A[5HC=0<)NV1)YLCTP-'=BBY*?)Z
M41&63_E4%QB*K[']+O3IN[RC5L6;N#PEH^"$T!%U30TZ5OV1N,[!VM&S:U-#
M;6:O_:\X/R64-M4=BQ7N-JQNH^<>T+LKB^DZJ<EUOLDE\IK\[R^B$+FN^;+Z
MGZ&%[S:*8[.B3%AOJU6<\(N!R$@5+[_QP>4__N;XHW^:K$:*14@Q!A+3PC+>
MAF5L4[^\2I+U<IW%-9_*;)8F:6V*A%6D;R0V8EXC)F\;WR['E#K!:#0Z'W[;
M=;E;T/5&0;<@ S5/<]#;.NA9'9S$U8+$^90D\@?^^SK]%F<\KRN3CU:IOCYN
MQ/P=>\X"YZQK8[><=V:PFX$:I[GH;UWTK2[^)F[>:3X7)J[2.LY,WED%^GKG
M=SQQ1J%'N^8AC\I 8IK#P=;AP.KP_8)G,]&3FJ=576[R;U6+ZU[TL6IY_TZ7
MZR6)U_6B*-,_1#9(BN6R*5,D7TE:5>LX3S@1Y_::FZ)C/7C?Z"#%(J08"SHI
MR?%&S7_;\T:+3KB-3FB-CK@])IQ/*S(KBZ6RNYAI<3 9;]7M:WQHN"Q&SKA[
M670+TO&H>_DP4.LT3\^VGI[9SWB1AZ6#FU.8?Q<H4W%C6C[K1#708[IQQWJX
MOJ<E4HR!Q#2;G9'JL8^L1G_DWWB^-EMKK]KW_&S5M'N9ZQKN>8:"3A@&3O<,
M1350]VZ'=ARK=[?U@I<B+2=<]!N^9+PZ(?.RJ,0_R;HL16XVFFK5[&VJT_$J
M\+I.189R9]30CT"U3G>4*D>IU='K7)R-=5$^MDX:#;1*]#:0=K-A0$.#@]V"
M+O4-:1/5/MU"Q6J.E3GDW6C%RUHXN,IBT3V0W5O9LUW)SL()R;GYK(3R6JNV
MFY2IXQH\=;OF&^Y8#-4ZW5+%68X=M#XMA.JBR*9$.)L6XI^XJLETS8G@8?)0
MIC7_L9C-Y/U*=,^FG,1)4JP%1NSD!J/I4#0[\B7.1F0:/YJNJ C:#H92TX.E
MD,ZQ,]U5UWN1CTL^36N2B93RU)D@;^2MKZSBS#3<],Y^E-ZQ\;H7A.G.U\4]
MQ^M>-PS5.-UBQ7N.'?CN2KZ*T^G629EBBN9>&%<5-].S7;*WGUT&= V]OLA4
MCG;+,53K=$,5WCEVOMO>]DBK;K80RFFMVJXU?F" :$.Y<.P;+ 2U3K=0,9AC
MA["("]DD;>#XA$SY*N.;N0-Q;L;+HJS3/YJ_&8V%<IC3Y:O00&&&8J;>,$,U
M3O=5<9AC![&K'>_D#2[-ZSB?IR*KVBYV)"!-6C6=!PR&=HM1HZ&O 5Q4 1>U
M ]>5=(VD2Y%!RV;\)EG$Y=Q\Q=NE^OI(NURU[Z&A"'4,^1+5,-U#!5[4#EXR
M7U;U\M!(K;UV;]NZZ.3X7O?\>V8YAFJ=[IU"+&I'K'MQNO$?Y72H[,<^-J>@
MG(++YWQ#".U=W6@L%+UHEZ@<)S0Y:RA(?=-I^1KH115ZT:/HM3,0N)EO%3U,
MHY-0WJ)=CC+8$T$/RE!JNMD*RJB=9SX*S;A,-O,W4]&5SXH&<:WG+Q2X6C6]
MMVZZU9L*AHYAZ #5/MU2A4[4CDX1G_%2D!*IX^_MW?VDF378W/WC+"L>Y-"V
MT5HH+]$N"(5G8],IW2WHG_F&@2U4^W1K%3)1.S(9K3TP%F.7ZFUE%X$.6-DM
M>,#*UX EJF")VF'I:BJPO4XK.>5HN]:AM$1-DT=="HH,Y0(#+*$:IUNH8(G:
M86G3!WC7] 'NVC[ U6X?X':U6>1QPY=?>&E<X&$_1&]_D6H15(VAU/1@*0*C
M&R!!KKZA4 "#JD50-892TQ=&*9ISC]!<7J?3-%O+!6RDXLFZ3.N4RT'&)%M/
MQ>6UZ0H6R]6ZWC*TZ+?D(GM5<CB95/):/)%C%&MQ%;Y)\\TGE7%4TMZ:WLNJ
M#+3GCJGO^'M9S5B0.IV"#-4^/1J*"UT[%]X565HM2"272:1?UG516E.87:VW
MFTBU"*K&4&IZ7!1SNA2>PEPH:T+5(J@:0ZGIP=E9W&FGUB.#*?;:O>/0G1DT
M#J9 C\I0:KK#"E5=.ZJRW]=I_4B6O%X44Y)N_3XAQ4/.RVJ1KN2M(!$?Q7-C
M9]9^@-Y!V*B%NP.!IZ-.TH?."J+4]! HM'7M:'L3EU]Y+9%!#A=L;Q R$36/
M,U3V&P44;J%J$52-H=3T,"E,=GW\C0**RU"U"*K&4&IZ<!1XNW;P?I_F<J5#
M)KJZT\X\T E95WRVSDB6SLPI#,KC1YKJA.11]+*-JQV@#6$H-3TFBN3=(VM/
MUV6R:#C^$T\6>9$5\\=G930HO4/5(J@:0ZGI 5+T[N+IW872.U0M@JHQE)K^
M_(RB][&=WO]:1K.+]WZRQMY49W0XHT$;PE!J>DP4PX^/,'Q<2Q2Q9B^[1&_G
MH> .56,H-3T8"MS'>' ?0\$=JA9!U1A*30^. O>Q'=S_8O:"<OV1IE);]H*B
M/DI-C\G.(YEVU%>KK^^VJZ_9T^IK>TZ#(CY4+8*J,92:'B(U%##V\#D-.@
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M3V%VP=ZAH:84MK]>V%AJ/X.A&J8[J?#>M^,])H/M9*]*7#'DJDIC>QJ#CA%
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M%-'+K9SSP%2"/%]3*IX#-4J:+X?_%U!+ P04    "  ,B!E7WM9K<=H"  #
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M0@1X"?R0#[6M$+LK7>?NE@28=^B.A/+)FK( "SED&YWO&,&K."GP==,P'#W
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M=S=$8,_G[\%'\#2_ >]^?3_0A202P>EN.NEU,JE9,RDTP3T-Q9:#:;@BJS*
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M%""?KRD5IT$T0?;Z9/0O4$L#!!0    (  R(&5<ITN'$U!   +X2 0 9
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MFHMJ'JKYJ!:@6HAJ$:K%J):@FD U26GZ:-!$TNRWRJ39:"@-U5Q4\U#-1[4
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MS44U#]5\5 M0+42U"-5B5$M03:":I#1]2&@R>T['.\@M'_+)?;I2F\E_ZUB
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M\4\,.]ZX1LJ56TI_J,%5.#4LQ0@2"(2"(/)G"S-($H4D>?PL08UJ3V78O'Y
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MCK"0HV_OY6IT)2#EW[N4*Z 'W= J=T_YF@0P-61R<F!;,/S?7V'7^K/+[9[
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M?+[%2'9]T4VTJ%TM'H0VE>V&A?F5@+0!9C\30I\F]H#AYQ3_!5!+ P04
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M=V]R:W-H965T<R]S:&5E=#0W+GAM;,6;76_;-A2&[_LK"&\86J"+)?DS66+
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MO7(6#A.,W8M@SF)BIK'[- VY@IB8:VS3KO%G=+)0PT4E2SVL6:2-$Z<=Y$1
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M9]UOSNDG4$L! A0#%     @ #(@95P=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  ,B!E7$X50+.\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ #(@95U.+' !- P
M*PT  !@              ("!:Q<  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    (  R(&5>K*NGB' 4  *@5   8              " @>X:
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  ,B!E76VYI
MEP<&  "6)@  &               @(% (   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ #(@95^>0SOV#!P  [2,  !@
M ("!?28  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  R(
M&5<9@_G*,P@   L3   8              " @38N  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  ,B!E78\T*W$LD   ]8@  &
M        @(&?-@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    (  R(&5<DG7M J <  "X2   9              "
M@5MM  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ #(@9
M5[0CI;?* @  %08  !D              ("!.G4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  ,B!E7HG(1>I<*  "(&   &0
M        @($[>   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   (  R(&5?7;X:0H (  )@%   9              " @0F#  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ #(@95XAKZBY>)@  67$
M !D              ("!X(4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  ,B!E7\HB3G,P$  #'"@  &0              @(%UK
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  R(&5=Z,*H9
MV (  $D&   9              " @7BQ  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ #(@95^0 7I0I P  EP<  !D
M ("!A[0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  ,
MB!E7KNG8Z:H"  #N!0  &0              @('GMP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  R(&5>^8D3@$00  *8)   9
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M970R-BYX;6Q02P$"% ,4    "  ,B!E7VSZ+ZM #  #U#P  &0
M    @('LS@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M  R(&5>-@ '[?P,  .4/   9              " @?/2  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ #(@95Z$*L7YJ#@  >(4  !D
M             ("!J=8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  ,B!E7Z&$6710#  !?"P  &0              @(%*Y0  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  R(&5?#,@=VA@(
M &<&   9              " @97H  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ #(@95]S6 V6$ @  S 8  !D              ("!
M4NL  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  ,B!E7
MU6IIA'<"  !%!@  &0              @($-[@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    (  R(&5?>UFMQV@(  , )   9
M      " @;OP  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ #(@95Q#' ](! P  R D  !D              ("!S/,  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  ,B!E746()>#($  !*$0
M&0              @($$]P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    (  R(&5<ITN'$U!   +X2 0 9              " @6W[  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ #(@95]"M,9PA
M P  &PL  !D              ("!> P! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  ,B!E7XZOI5Z(#  #*"@  &0
M@('0#P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  R(
M&5=HM4= %P0  .T-   9              " @:D3 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ #(@95_]W@^CX P  Z!(  !D
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M=#0U+GAM;%!+ 0(4 Q0    (  R(&5>JTL3Y] (  (X'   9
M  " @6DH 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M#(@95W2KY4Z6!@  SS,  !D              ("!E"L! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  ,B!E7IXNAI(H"  "H!0  &0
M            @(%A,@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    (  R(&5>+88>F, ,  .X2   -              "  2(U 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ #(@95Y>*NQS     $P(   L
M     ( !?3@! %]R96QS+RYR96QS4$L! A0#%     @ #(@95R-8*_-S!
M5"    \              ( !9CD! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   (  R(&5>2+*"6N $  .<<   :              "  08^ 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  R(&5>,3^J/N@$  .X<
M   3              "  ?8_ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   X #@ /P\  .%! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>308</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/StatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/Organization</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/IntangibleAssetsNet</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ShareholdersEquity</Role>
      <ShortName>SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/GeographicInformation</Role>
      <ShortName>GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/IntangibleAssetsNet</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SHAREHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ShareholdersEquityTables</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/ShareholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/GeographicInformationTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/GeographicInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biomerica.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SCHEDULE OF NET INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfNetInventoriesDetails</Role>
      <ShortName>SCHEDULE OF NET INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails</Role>
      <ShortName>SCHEDULE OF DISAGGREGATION REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails</Role>
      <ShortName>SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SHAREHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biomerica.com/role/ShareholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails</Role>
      <ShortName>SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure -  SCHEDULE OF DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biomerica.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SCHEDULE OF GEOGRAPHIC INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfGeographicInformationDetails</Role>
      <ShortName>SCHEDULE OF GEOGRAPHIC INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - GEOGRAPHIC INFORMATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/GeographicInformationDetailsNarrative</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biomerica.com/role/GeographicInformationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails</Role>
      <ShortName>SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biomerica.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biomerica.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>bmra-20230531.xsd</File>
    <File>bmra-20230531_cal.xml</File>
    <File>bmra-20230531_def.xml</File>
    <File>bmra-20230531_lab.xml</File>
    <File>bmra-20230531_pre.xml</File>
    <File>ex10-1.htm</File>
    <File>ex10-5.htm</File>
    <File>ex10-6.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex3-1.htm</File>
    <File>ex3-2.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="600">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 600,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "contextCount": 128,
   "dts": {
    "calculationLink": {
     "local": [
      "bmra-20230531_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bmra-20230531_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bmra-20230531_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmra-20230531_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bmra-20230531.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 488,
   "entityCount": 1,
   "hidden": {
    "http://biomerica.com/20230531": 7,
    "http://fasb.org/us-gaap/2023": 47,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 58
   },
   "keyCustom": 26,
   "keyStandard": 282,
   "memberCustom": 24,
   "memberStandard": 32,
   "nsprefix": "BMRA",
   "nsuri": "http://biomerica.com/20230531",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://biomerica.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - INTANGIBLE ASSETS, NET",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://biomerica.com/role/IntangibleAssetsNet",
     "shortName": "INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://biomerica.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - SHAREHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://biomerica.com/role/ShareholdersEquity",
     "shortName": "SHAREHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://biomerica.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - GEOGRAPHIC INFORMATION",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://biomerica.com/role/GeographicInformation",
     "shortName": "GEOGRAPHIC INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://biomerica.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://biomerica.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://biomerica.com/role/PropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://biomerica.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - INTANGIBLE ASSETS, NET (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://biomerica.com/role/IntangibleAssetsNetTables",
     "shortName": "INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://biomerica.com/role/ShareholdersEquityTables",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://biomerica.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - GEOGRAPHIC INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://biomerica.com/role/GeographicInformationTables",
     "shortName": "GEOGRAPHIC INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://biomerica.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - SCHEDULE OF NET INVENTORIES (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://biomerica.com/role/ScheduleOfNetInventoriesDetails",
     "shortName": "SCHEDULE OF NET INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "shortName": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails",
     "shortName": "SCHEDULE OF DISAGGREGATION REVENUE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "BMRA:LiquidityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "lang": null,
      "name": "BMRA:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://biomerica.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "BMRA:OperatingLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedPatentsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedPatentsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-012023-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-012023-05-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
     "shortName": "SCHEDULE OF STOCK BASED COMPENSATION EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-012023-05-31_us-gaap_CostOfSalesMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-05-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails",
     "shortName": "SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-05-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details Narrative)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-03-042020-03-24_us-gaap_CommonStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails",
     "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure -  SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - INCOME TAXES (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://biomerica.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - SCHEDULE OF GEOGRAPHIC INFORMATION (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://biomerica.com/role/ScheduleOfGeographicInformationDetails",
     "shortName": "SCHEDULE OF GEOGRAPHIC INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-012023-05-31_srt_AsiaMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - GEOGRAPHIC INFORMATION (Details Narrative)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://biomerica.com/role/GeographicInformationDetailsNarrative",
     "shortName": "GEOGRAPHIC INFORMATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - SCHEDULE OF OPERATING LEASES (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://biomerica.com/role/ScheduleOfOperatingLeasesDetails",
     "shortName": "SCHEDULE OF OPERATING LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails",
     "shortName": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMRA:ScheduleOfSupplementalLeaseInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails",
     "shortName": "SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMRA:ScheduleOfSupplementalLeaseInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2023-05-312023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2023-05-312023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2023-08-032023-08-03_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://biomerica.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2023-08-032023-08-03_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://biomerica.com/role/StatementsOfShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://biomerica.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-06-012022-05-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - ORGANIZATION",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://biomerica.com/role/Organization",
     "shortName": "ORGANIZATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://biomerica.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://biomerica.com/role/PropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-06-01to2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "BMRA_ATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Agreement [Member]",
        "label": "ATM Agreement [Member]"
       }
      }
     },
     "localname": "ATMAgreementMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_ATMOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering [Member]",
        "label": "ATM Offering [Member]"
       }
      }
     },
     "localname": "ATMOfferingMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_AccountsReceivableCreditLossExpenseReversal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable credit loss expense reversal.",
        "label": "Accounts receivable, credit loss expense (Reversal)"
       }
      }
     },
     "localname": "AccountsReceivableCreditLossExpenseReversal",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_BiomericaInFoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biomerica in Foods [Member]",
        "label": "Biomerica in Foods [Member]"
       }
      }
     },
     "localname": "BiomericaInFoodsMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_BuildingInIrvineCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building in Irvine California [Member]",
        "label": "Building in Irvine California [Member]"
       }
      }
     },
     "localname": "BuildingInIrvineCaliforniaMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_CashPaidDuringYearForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During Year For [Abstract]",
        "label": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringYearForAbstract",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "BMRA_ClinicalLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Lab [Member]",
        "label": "Clinical Lab [Member]"
       }
      }
     },
     "localname": "ClinicalLabMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_ClinicalTrialAgreementMaximumBudgetedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial agreement maximum budgeted costs.",
        "label": "Clinical trial agreement maximum budgeted costs"
       }
      }
     },
     "localname": "ClinicalTrialAgreementMaximumBudgetedCosts",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk Geographic Policy [Policy Text Block]",
        "label": "GEOGRAPHIC CONCENTRATION"
       }
      }
     },
     "localname": "ConcentrationRiskGeographicPolicyPolicyTextBlock",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "BMRA_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Manufacturing [Member]",
        "label": "Contract Manufacturing [Member]"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Accumulated Depreciation and Amortization.",
        "label": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccumulatedDepreciationAndAmortization",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_DeferredTaxAssetsCapitalizedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized costs.",
        "label": "Sec 174 capitalized costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedCosts",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets losses of foreign subsidiaries other net.",
        "label": "Losses of foreign subsidiaries &amp; other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_DefferedTaxAssetsStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deffered tax assets stock options.",
        "label": "Stock Options"
       }
      }
     },
     "localname": "DefferedTaxAssetsStockOptions",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor One [Member]",
        "label": "Distributor One [Member]"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor Two [Member]",
        "label": "Distributor Two [Member]"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_DistributorsInAsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributors In Asia [Member]",
        "label": "Distributors In Asia [Member]"
       }
      }
     },
     "localname": "DistributorsInAsiaMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_FiniteLivedPatentsAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived patents accumulated amortization.",
        "label": "FiniteLivedPatentsAccumulatedAmortization",
        "negatedLabel": "Less accumulated amortization-patents"
       }
      }
     },
     "localname": "FiniteLivedPatentsAccumulatedAmortization",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_FurnitureAndFixturesLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and Fixtures Leasehold Improvements [Member]",
        "label": "Furniture and Fixtures Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesLeaseholdImprovementsMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_IncreaseDecreaseInReductionInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in reduction in lease liabilities.",
        "label": "Reduction in lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInReductionInLeaseLiabilities",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in lease liability due to lease extension or establishment.",
        "label": "Increase in lease liability due to lease extension or establishment"
       }
      }
     },
     "localname": "IncreaseInLeaseLiabilityDueToLeaseExtensionOrEstablishment",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in right of use asset due to lease extension or establishment",
        "label": "Increase in right-of-use asset due to lease extension or establishment"
       }
      }
     },
     "localname": "IncreaseInRightofuseAssetDueToLeaseExtensionOrEstablishment",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity [Policy Text Block]",
        "label": "LIQUIDITY"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "BMRA_MarketingAndDistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing and Distribution Rights [Member]",
        "label": "Marketing and Distribution Rights [Member]"
       }
      }
     },
     "localname": "MarketingAndDistributionRightsMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_OneDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Distributor [Member]",
        "label": "One Distributor [Member]"
       }
      }
     },
     "localname": "OneDistributorMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_OneVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Vendor [Member]",
        "label": "One Vendor [Member]"
       }
      }
     },
     "localname": "OneVendorMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loease right of use asset accumulated amortization.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_OverTheCounteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over The Counte [Member]",
        "label": "Over The Counte [Member]"
       }
      }
     },
     "localname": "OverTheCounteMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_PhysiciansOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physicians Office [Member]",
        "label": "Physicians Office [Member]"
       }
      }
     },
     "localname": "PhysiciansOfficeMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_PolishDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Polish Distributor [Member]",
        "label": "Polish Distributor [Member]"
       }
      }
     },
     "localname": "PolishDistributorMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_PrepaidExpensesAndOtherPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other [Policy Text Block]",
        "label": "PREPAID EXPENSES AND OTHER"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherPolicyTextBlock",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "BMRA_PurchasedTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased Technology Rights [Member]",
        "label": "Purchased Technology Rights [Member]"
       }
      }
     },
     "localname": "PurchasedTechnologyRightsMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_RoyaltyExpensePercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty expense percentage of sales.",
        "label": "Royalty expense percentage of sales"
       }
      }
     },
     "localname": "RoyaltyExpensePercentageOfSales",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "BMRA_SaleOfStockExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock expenses.",
        "label": "Sale of stock expenses"
       }
      }
     },
     "localname": "SaleOfStockExpenses",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Supplemental Lease Information [Table Text Block]",
        "label": "SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseInformationTableTextBlock",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf registration statement maximum authorized common stock issuance value.",
        "label": "Shelf registration statement maximum authorized common stock issuance value"
       }
      }
     },
     "localname": "ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares issued in connection with public offering net of offering costs.",
        "label": "Shares issued in connection with public offering, net of offering costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "BMRA_StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value shares issued in connection with public offering net of offering costs.",
        "label": "Shares issued in connection with public offering, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOfferingNetOfOfferingCosts",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_TwoThousandFourteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2014 Plan [Member]",
        "label": "2014 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFourteenPlanMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_TwoThousandSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Plan [Member]",
        "label": "2017 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSeventeenPlanMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_TwoThousandTwentyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Plan [Member]",
        "label": "2020 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyPlanMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_TwoThousandTwentyStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan [Member]",
        "label": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_TwoVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Vendor [Member]",
        "label": "Two Vendor [Member]"
       }
      }
     },
     "localname": "TwoVendorMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_UniversityOFSouthernCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Of Southern California [Member]",
        "label": "University Of Southern California [Member]"
       }
      }
     },
     "localname": "UniversityOFSouthernCaliforniaMember",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BMRA_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "WorkingCapital",
        "negatedLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_WriteOffOfFixedAssetsAccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of fixed assets accumulated depreciation.",
        "label": "Write off of fixed assets, accumulated depreciation"
       }
      }
     },
     "localname": "WriteOffOfFixedAssetsAccumulatedDepreciation",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_WriteOffOfFixedAssetsCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of fixed assets cost.",
        "label": "Write off of fixed assets, cost"
       }
      }
     },
     "localname": "WriteOffOfFixedAssetsCost",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_WriteOffOfIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of intangible assets accumulated amortization.",
        "label": "Write off of intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "WriteOffOfIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BMRA_WriteOffOfIntangibleAssetsCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of intangible assets cost.",
        "label": "Write off of intangible assets, cost"
       }
      }
     },
     "localname": "WriteOffOfIntangibleAssetsCost",
     "nsuri": "http://biomerica.com/20230531",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r629",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r629",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r629",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r629",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r629",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_AsiaMember": {
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]"
       }
      }
     },
     "localname": "AsiaMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r245"
     ],
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r298",
      "r415",
      "r460",
      "r496",
      "r497",
      "r551",
      "r555",
      "r557",
      "r558",
      "r560",
      "r580",
      "r581",
      "r595",
      "r596",
      "r599",
      "r606",
      "r672",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r298",
      "r415",
      "r460",
      "r496",
      "r497",
      "r551",
      "r555",
      "r557",
      "r558",
      "r560",
      "r580",
      "r581",
      "r595",
      "r596",
      "r599",
      "r606",
      "r672",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r233",
      "r418",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r583",
      "r597",
      "r605",
      "r642",
      "r668",
      "r669",
      "r674",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r233",
      "r418",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r583",
      "r597",
      "r605",
      "r642",
      "r668",
      "r669",
      "r674",
      "r724"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r296",
      "r298",
      "r326",
      "r327",
      "r328",
      "r414",
      "r415",
      "r460",
      "r496",
      "r497",
      "r551",
      "r555",
      "r557",
      "r558",
      "r560",
      "r580",
      "r581",
      "r595",
      "r596",
      "r599",
      "r606",
      "r609",
      "r666",
      "r672",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r296",
      "r298",
      "r326",
      "r327",
      "r328",
      "r414",
      "r415",
      "r460",
      "r496",
      "r497",
      "r551",
      "r555",
      "r557",
      "r558",
      "r560",
      "r580",
      "r581",
      "r595",
      "r596",
      "r599",
      "r606",
      "r609",
      "r666",
      "r672",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r493",
      "r494",
      "r495",
      "r552",
      "r556",
      "r559",
      "r561",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r584",
      "r598",
      "r609",
      "r674",
      "r724"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SouthAmericaMember": {
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "South America [Member]"
       }
      }
     },
     "localname": "SouthAmericaMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r493",
      "r494",
      "r495",
      "r552",
      "r556",
      "r559",
      "r561",
      "r568",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r584",
      "r598",
      "r609",
      "r674",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r20",
      "r604"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://biomerica.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r150",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r29",
      "r88",
      "r157",
      "r442",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r2",
      "r10",
      "r29",
      "r375",
      "r378",
      "r408",
      "r461",
      "r462",
      "r652",
      "r653",
      "r654",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r80",
      "r604",
      "r726"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r481",
      "r660",
      "r661",
      "r662",
      "r708",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r62",
      "r63",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "ADVERTISING COSTS"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r330",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based payment arrangement, expense",
        "verboseLabel": "Total stock option expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r6",
      "r51",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Lease area"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r6",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r121",
      "r152",
      "r178",
      "r210",
      "r224",
      "r229",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r370",
      "r372",
      "r384",
      "r438",
      "r518",
      "r604",
      "r617",
      "r670",
      "r671",
      "r715"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r145",
      "r160",
      "r178",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r370",
      "r372",
      "r384",
      "r604",
      "r670",
      "r671",
      "r715"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33",
      "r148",
      "r585"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r33",
      "r99",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r99"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r142",
      "r153",
      "r154",
      "r155",
      "r178",
      "r195",
      "r196",
      "r198",
      "r200",
      "r204",
      "r205",
      "r246",
      "r266",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r276",
      "r277",
      "r279",
      "r282",
      "r289",
      "r384",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r506",
      "r527",
      "r545",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r638",
      "r657",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/BalanceSheetsParenthetical",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r74",
      "r439",
      "r505"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r260",
      "r261",
      "r570",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r660",
      "r661",
      "r708",
      "r725",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r79",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r79",
      "r506",
      "r524",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r79",
      "r441",
      "r604"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.08 par value, 25,000,000 shares authorized, 16,821,646 and 12,867,924 issued and outstanding at May 31, 2023 and 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r30",
      "r162",
      "r164",
      "r170",
      "r433",
      "r450"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "REPORTING COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r41",
      "r43",
      "r71",
      "r72",
      "r237",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r41",
      "r43",
      "r71",
      "r72",
      "r237",
      "r467",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r41",
      "r43",
      "r71",
      "r72",
      "r237",
      "r569",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r75",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "CONCENTRATION OF CREDIT RISK"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r41",
      "r43",
      "r71",
      "r72",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk, percentage",
        "verboseLabel": "Net sales percent"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r41",
      "r43",
      "r71",
      "r72",
      "r237",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "PRINCIPLES OF CONSOLIDATION"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r291",
      "r292",
      "r295"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Advance from customers"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of stock, shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of stock, shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r279",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r18",
      "r58",
      "r78",
      "r111",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Conversion of stock, shares issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Cost of Goods and Service, Product and Service Benchmark [Member]"
       }
      }
     },
     "localname": "CostOfGoodsProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r93",
      "r178",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r384",
      "r670"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "SHIPPING AND HANDLING FEES"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r643",
      "r659",
      "r707"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "U.S. Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r643",
      "r659"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign Taxes Subsidiaries"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r358",
      "r364",
      "r659"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails",
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r643",
      "r659",
      "r707"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r42",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r659",
      "r706",
      "r707"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r6",
      "r117",
      "r140",
      "r363",
      "r364",
      "r659"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r659",
      "r706",
      "r707"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred tax assets, net",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r66",
      "r705"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Inventory valuation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r704"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r66",
      "r705"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r65",
      "r66",
      "r705"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "auth_ref": [
      "r66",
      "r705"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).",
        "label": "Compensated absences"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r66",
      "r705"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Accounts receivable, principally due to allowance for doubtful accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r66",
      "r705"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred rent expense/Capitalized leases"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred tax assets, valuation allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative",
      "http://biomerica.com/role/ScheduleOfDeferredTaxAssetsDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r6",
      "r213"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization",
        "verboseLabel": "Depreciation, depletion and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "SCHEDULE OF DISAGGREGATION REVENUE"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends payable, amount per share"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r171",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r193",
      "r195",
      "r198",
      "r199",
      "r200",
      "r202",
      "r382",
      "r383",
      "r434",
      "r451",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r171",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r195",
      "r198",
      "r199",
      "r200",
      "r202",
      "r382",
      "r383",
      "r434",
      "r451",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes in cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r179",
      "r348",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r639",
      "r703"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Stock based compensation benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period expected term"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r701"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Compenation cost related to non-vested stock option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r11",
      "r143",
      "r166",
      "r167",
      "r168",
      "r180",
      "r181",
      "r182",
      "r184",
      "r190",
      "r192",
      "r203",
      "r247",
      "r248",
      "r290",
      "r332",
      "r333",
      "r334",
      "r359",
      "r360",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r408",
      "r461",
      "r462",
      "r463",
      "r481",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination."
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2028"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r52",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r105",
      "r419"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfExpectedAmortizationOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.",
        "label": "Patents"
       }
      }
     },
     "localname": "FiniteLivedPatentsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "FOREIGN CURRENCY TRANSLATION"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r92",
      "r178",
      "r210",
      "r223",
      "r228",
      "r231",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r384",
      "r593",
      "r670"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r90",
      "r123",
      "r210",
      "r223",
      "r228",
      "r231",
      "r435",
      "r448",
      "r593"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r259",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r344",
      "r349",
      "r350",
      "r356",
      "r361",
      "r366",
      "r367",
      "r368",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r141",
      "r191",
      "r192",
      "r214",
      "r347",
      "r362",
      "r453"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "negatedTotalLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r345",
      "r346",
      "r350",
      "r351",
      "r355",
      "r357",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Foreign taxes of subsidiaries"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Computed \u201cexpected\u201d tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Permanent tax differences and other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r416",
      "r655"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Advance from customers"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r50",
      "r53"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net of accumulated amortization",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, gross",
        "totalLabel": "Total gross inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r159",
      "r586",
      "r604"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories, net",
        "totalLabel": "Net inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r147",
      "r158",
      "r250",
      "r251",
      "r252",
      "r417",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "INVENTORIES, NET"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r48",
      "r650"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory reserves",
        "negatedLabel": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfNetInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Dividend and interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r452",
      "r470",
      "r471",
      "r472",
      "r473",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r401",
      "r603"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "SCHEDULE OF OPERATING LEASES"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Operating lease description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r178",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r371",
      "r372",
      "r373",
      "r384",
      "r504",
      "r592",
      "r617",
      "r670",
      "r715",
      "r716"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r84",
      "r122",
      "r444",
      "r604",
      "r658",
      "r665",
      "r709"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r146",
      "r178",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r371",
      "r372",
      "r373",
      "r384",
      "r604",
      "r670",
      "r715",
      "r716"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MiddleEastMember": {
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Middle East.",
        "label": "Middle East [Member]"
       }
      }
     },
     "localname": "MiddleEastMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r91",
      "r101",
      "r124",
      "r144",
      "r161",
      "r163",
      "r168",
      "r178",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r197",
      "r210",
      "r223",
      "r228",
      "r231",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r383",
      "r384",
      "r449",
      "r526",
      "r543",
      "r544",
      "r593",
      "r615",
      "r670"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows",
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/GeographicInformationDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expense"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r210",
      "r223",
      "r228",
      "r231",
      "r593"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r402",
      "r603"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r398",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use assets, net of accumulated amortization of $617,000 and $725,000 as of May 31, 2023 and 2022, respectively"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
        "label": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r406",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r405",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r120",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "ORGANIZATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r3",
      "r88",
      "r386",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other receivables, gross, current"
       }
      }
     },
     "localname": "OtherReceivablesGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Costs from sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Expenditure related to intangibles"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r78",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r78",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r78",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r78",
      "r506",
      "r524",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r78",
      "r440",
      "r604"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid expense and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r651"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCustomers": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.",
        "label": "Proceeds from customers"
       }
      }
     },
     "localname": "ProceedsFromCustomers",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Gross proceeds from sale of common stock",
        "terseLabel": "Sale of stock, net proceeds",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/StatementsOfCashFlows",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r15"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r135",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r108",
      "r149",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Furniture, fixtures and leasehold improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r436",
      "r447",
      "r604"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net of accumulated depreciation and amortization",
        "terseLabel": "Net property and equipment",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r135",
      "r138",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease."
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r172",
      "r249"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for allowance on accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r297",
      "r409",
      "r410",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r523",
      "r525",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r297",
      "r409",
      "r410",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r523",
      "r525",
      "r550",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r76",
      "r342",
      "r723"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r81",
      "r112",
      "r443",
      "r464",
      "r466",
      "r479",
      "r507",
      "r604"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r143",
      "r180",
      "r181",
      "r182",
      "r184",
      "r190",
      "r192",
      "r247",
      "r248",
      "r332",
      "r333",
      "r334",
      "r359",
      "r360",
      "r374",
      "r376",
      "r377",
      "r379",
      "r381",
      "r461",
      "r463",
      "r481",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r211",
      "r212",
      "r222",
      "r226",
      "r227",
      "r233",
      "r235",
      "r237",
      "r293",
      "r294",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "SCHEDULE OF GEOGRAPHIC INFORMATION"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/GeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r528",
      "r582",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r169",
      "r178",
      "r211",
      "r212",
      "r222",
      "r226",
      "r227",
      "r233",
      "r235",
      "r237",
      "r246",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r384",
      "r435",
      "r670"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Net sales",
        "terseLabel": "Total",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails",
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "auth_ref": [
      "r67",
      "r343",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Agreements [Member]"
       }
      }
     },
     "localname": "RoyaltyAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of stock, consideration received on transaction",
        "verboseLabel": "Preferred stock, purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of stock, number of shares issued in transaction",
        "verboseLabel": "Sale of stock shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r237",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "SCHEDULE OF PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF DEFERRED TAX ASSETS"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "SCHEDULE OF EFFECTIVE INCOME TAX RECONCILIATION"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "SCHEDULE OF STOCK BASED COMPENSATION EXPENSE"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r52",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "SCHEDULE OF INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r19",
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "SCHEDULE OF NET INVENTORIES"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://biomerica.com/role/ScheduleOfDisaggregationRevenueDetails",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r47",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r13",
      "r14",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF ACTIVITY TO AGGREGATE STOCK OPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "SCHEDULE OF EXPECTED AMORTIZATION OF INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r645"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r215",
      "r225",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "GEOGRAPHIC INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/GeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r235",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "SEGMENT REPORTING"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r646",
      "r647",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/BalanceSheetsParenthetical",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://biomerica.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based payment award, number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Options exercised, Aggregate IntrinsicValue"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options cancelled or expired, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Options canceled or expired Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Granted, weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Options outstanding, Aggregate Intrinsic Value",
        "periodStartLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding, shares",
        "periodStartLabel": "Options Outstanding, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options Outstanding Weighted Average Exercise Price",
        "periodStartLabel": "Options Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and exercisable Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and exercisable, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and exercisable Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Options Exercised Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Options Granted Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r299",
      "r304",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested, exercisable or expected to vest weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Award purchase price, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r403",
      "r603"
     ],
     "calculation": {
      "http://biomerica.com/role/ScheduleOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r102",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r142",
      "r153",
      "r154",
      "r155",
      "r178",
      "r195",
      "r196",
      "r198",
      "r200",
      "r204",
      "r205",
      "r246",
      "r266",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r276",
      "r277",
      "r279",
      "r282",
      "r289",
      "r384",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r506",
      "r527",
      "r545",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r638",
      "r657",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/BalanceSheetsParenthetical",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r11",
      "r27",
      "r143",
      "r166",
      "r167",
      "r168",
      "r180",
      "r181",
      "r182",
      "r184",
      "r190",
      "r192",
      "r203",
      "r247",
      "r248",
      "r290",
      "r332",
      "r333",
      "r334",
      "r359",
      "r360",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r408",
      "r461",
      "r462",
      "r463",
      "r481",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r203",
      "r418",
      "r470",
      "r492",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r506",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/BalanceSheetsParenthetical",
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r203",
      "r418",
      "r470",
      "r492",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r506",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/BalanceSheetsParenthetical",
      "http://biomerica.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r112",
      "r475",
      "r545",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Net proceeds from ATM, shares",
        "verboseLabel": "Net proceeds from ATM (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r112",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options, shares",
        "negatedLabel": "Options exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ScheduleOfActivityToAggregateStockOptionsDetails",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r112",
      "r481",
      "r545",
      "r563",
      "r616"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Net proceeds from ATM"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r27",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r103",
      "r508",
      "r524",
      "r546",
      "r547",
      "r604",
      "r617",
      "r658",
      "r665",
      "r709",
      "r727"
     ],
     "calculation": {
      "http://biomerica.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets",
      "http://biomerica.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r177",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r290",
      "r380",
      "r548",
      "r549",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent event, description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [
      "r395",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r395",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r395",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r395",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r395",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative",
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosure of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period past due for trade accounts receivable to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Threshold period past due for write-off of trade accounts receivable"
       }
      }
     },
     "localname": "ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "ACCOUNTS RECEIVABLE, NET"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://biomerica.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r132",
      "r133",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "ACCOUNTING ESTIMATES"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r194",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common and"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r193",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biomerica.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org//280/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org//330/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-30/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org//830/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "47",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r619": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r627": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r632": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r633": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r634": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r635": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r636": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r637": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org//705/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001493152-23-030254-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-030254-xbrl.zip
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MDP4VAT8*S-?R8*:[^*<2==+@)X%?%_G+ODL?<O1Q5R6%UAMYM'C+BFBZP:@
M(X,MD$>^B=%&T.R52"'R$[?[P*ERJ1\R#'\8YITZTG]7+=T8-3-?I!WA:H78
M!K8MLO# #;"1%ZBV34,O .=]#$O:)CA1%SE:*;3>'J(UF0Z'JOE9,?K*1+\;
MZ7V]JXXL1>UVC>G(TD=WRM@8Z%U=FS18%F Y9A1.^6 #!@4_$]9\!QKA( *O
MJ%(*K7>':(U-8ZR9UF=%'?44[;]3?3S41M:/RDBS&G@*X-%!2&]!9BY6?1_,
M["TT>14RL%R<'\*BCRQU=*??#C1%G4PT:](@4H9(O'F!.[5!?/8]!TI8B!WM
M<0VF<;+O'2>30NOB$*UX;YLH8_6S*C #98)"<ZJ!4OTVUD:39K<K/KF*;/'3
M[.^+R\R)]$$UM0_&H*>9DW_\_>WEQ4\_BZW.^MQ@4KC%P4]LH<=$==(%4BA<
M9;>TKC'4%$O]K=&%PGF_PW3!T'I);/Z(@:U2AG1^E106KPZQN-.,.U,=?]"[
M $O?,(>-;5T>OUZM2"#\0!'C$68R]G8&=1F!%$*O#Q$"71GJ%K?%)N(TZ1K"
M=M9&C>%<Z@3-?/PU!%FU>PY&XNX<E$I!\B;KV-Q.X-@ 2!3M(P>F@>%)ON@I
M/FDEW_0B$TF0]TV5'Y*NFJCYTV"VN*E=">280PKB)X0?E!^BCAJ *\8ATHB6
MDTA!6"4FT6!V0G BC5=QM0Q6EY*!B@:F)T<LTJ#)$DM!>%KTHD&T>AAC[^0K
MJI7"K$)(HP&J0FQC?V<\+):"IC3.T8!Q4L C#4L9@11 DL&/!JHG1$'2@!TG
MDX*M6D2D0>_H\60OL1.ZV)B#R:=[/!!"&6#2PP$B;G)*'2&20BX;..E^T'I3
M,"S )^/&H3[BX1/#%+C%33? '0=.V!!M?B_; 4N0:YCZ@)@S":C]Q5B+.V'\
M&KJ0"ZS[<!65%2#\Q-:DED(V )-:"L*&:=^J$S SP?3DFJVHGU2S]Z,RL8SN
MKXHQYALS>!0?U<$TVJ3!QY@.H^)FZ518.@ "6BP87HB1FQ@T.\0%"Z.45@KV
M;% F!7M/GZAW=Z9V%R%J\ECJ5&O0?*9P6SR-(\3X-=%[7"7PEN&50CL3OZD2
M@HN[5+9]-O@?U^:"H%N!/A^AEL'X*A/W26MT:;RN46MI6'-B<P60EE!*P9F)
M :7A+ KI-4A*(\GC<G: '75%61!??LVB5@!N-68IO+/QHQ3>/,37M< (4X>&
M:<7W;',70K,&*JR!HT'; OBE^:20SX2GTLA+1GX;T)\:S,\WRJJS24&>"7A5
M@[DQQ2KYY-Q=ON5.-'\3"U 3$L0 %GG>,CQ24&>"9'O^M7"B(_^Z:PPYS-'6
M'D/>*':EW1PT@C^UH6KL&^-TI*1P+Y?BDL*Z-*RF=BW](W_Z8QE*XEUK^V&4
M!NX3'N$5>-/'Z:0@S8;'2A[K-=OS:9[R/>$I1OJ4I1[P%7O*9=12F);&OL!3
M_JA/^![<-\R#)X6-=LJ[5_,YYCLKWH)D8IMZ-G&)D*7(L9)DD\(Y$_7:]ZGZ
M?8UOR5H*9,74NL:HJP_T^(%C@[A\_!K/,6/8 <Q*?>=".AE,7V6B7/N!:ZVO
MF2884QS+QB&N?MLB_S M(Y!"+1/,RMU7FW.SBK[EWKHHT+E26BD$2\-31=<U
M&LT[Y6I-O@[*D4IAF0DX'<&OT<LJ>AEG?_$6 XR*0X@%5%+X9:)':5WDSWE4
M\01OH*E-;+ :=OTP@!D=0O^K<"60B>]=%,%XG$$*T=(@47]J34U-&>HC?3@=
M1K FMS$:>"NI9K#$;!*NUU%J/N0*Q(X?G])\4F"71HD,ZX-F*I/I>#S0.,#J
M( :\.5B?Z2)D_O%:A4$*Y4S@Z,CER.:L/?D5TJ+[-$>HI&#,>7GMX!73_WOH
M^'_X'443SQ61P?::ITV]:?F$YQ!NQ65+AN<WK=F*H7:2U/0/$/OL<>4F)+R'
MD@RV OO#F8H[3II S,ZTDLFP"XV(ZS:@VYUD\$D# 0DX^SC5C<+[@3.A\XR2
MNVA657)@P>X+BCS@[;^$K+! J\IZL*9?2.+NKI>7D!NTJZK<^PKY0F+WMIUD
MI7[?V4\F#'\?)AQ^#X)3%BA>)G5Q6=+I*%WV@-JBJ1(6_E<[X6OSHO;%9?OJ
MXNS1=W8CK3*(W314&T3"=\(@"E)?Y_7O%Y'S'V(QR79:D$*[M--<G@YV S\I
M.7D(Z83;3QB#:*;2((YG\2X:SC%.\;=_TB(0UTC8ILI"2+,D?YR&QBY5NAP0
M"7T$ L^>?FJW)ZR";.>%2R!.L1[E;!Z:ZA^J-507#(O2(5[->$IS/L";5FX-
M<5U^J^>F%;"0[Y(\A?XU[)Z$.I;8Y)V0Q>E]HDU_FS+^VJ$K1#P]P"M.";*!
MM0G[:\BI[Q@-US>MJ#D")&5#!N,R8&06!I09'MX?=$%=S89M/=#"8:?KZC!L
MF,;4Z/:'75!7AV&GQN7KGNH35#CCA_5U&#[,;/1)D,R$'Q378;!#Q+Y@[OVK
MGK.=5VC$)(MEX.]+($E;!['&(;.7_$*;A>VE1UVZV.1)=)RL%L)0E_C+0DTN
MKJ[#X+M@6/)<_^!P[0\[KZ(. S;N,;.6N,M-D(,3*K^J#H/F(3R&[&"(O' .
M_P\9J.G!?)>2U$&(\7+C$YL@SS?F<V(?3'YA;1V&W@\9.)DAXW>F^^21__)%
MV)Q?RM-7X*;>1VG;]V6JSE8'8<',R3O@LL4U&:RUI*&/8(9IR *,O;&+O,S0
M2XEJ)LB$OP)[5))\JIJ)8CU S:94CAR26@HA+E+KG@V_R3V6$*F$H0X"@A,)
M.RW.GB1Y%748L)C/Q*0K\(R/T-1!C-N0N/S[AKJGLWOBX2[_BAJ%@^+ #9*@
MJX,X4X^([S<&&Z,_H2%_N.P5B21)6P>Q;I,G=;K7I]0Y.-@+:^LP]/W;.,+A
M,>93/WJ/4[7M<,6?$^R_[[DU@4_C/2IV% ,/DJI9]-FPFY;-L$."9#*BRA7U
M<(#8YKFV#-WW0^STA$$\%F,2'\\4+U7X4:7N@?GL\<O:U/M$@N4XG+G$3G;!
M$89)2/[H4I_G^4UM-R_3?H655(LY?<'I_/-F,CUE?M3KTR<,3 #&M:F'H__K
MGHF=4$B@>T+/!@3-B$L"D9PXFHJJ3*<O%P?/7G"U\&]8C1&)\?R,$>M3ID)C
MW%?=^J[E1"C^E0AW,J(!;_X9$=6CV!B=A_$.V0NQ104ZVF/ OY%'/8-IL/7-
M> R'-W*([VE-U!7MG51[2W1SRKR<T$)M]\Q/#"A@7S+F??((IZ=X583O3XG8
M903?EU0I(Z&'UPS;9,_ J,CS'<A^F"@C']8"JN]0OB,6Y"F,M9V% ?D:$NA@
M(S)6;2S\&-RZ8*,DPI;4/\$3"))FGB=RS ,045<F\;_L7KV(QEP@V0E\-9%X
MS/ :;(DDIX7J.>+&<X&<TM0UD2Z5U:'D"K=(3IJ1]43>FDC^B;(OW*I':Q+P
M;UO'V\UA:6U=T25VYR9>\.=X8K:VWWH=HD?^PH4:!DO*R#>1I6/%ZV-GB ]/
M>)1;')^EJ=I.%-KF+-E]32\6/+>JKL9PDF['Q#8F]WR(73%S_*/9\?!YLDOF
M[U9S-9:Z"M[G-S+!=+_GF5X#\19"N<U0A:&NR[:'>=@A]29X.O'*]FK+$:*3
MA7M90#-ON<?;;;3#I (X,H3?BXQ<Y[ /?@IEF"P\_@8&F'J(IZ<6)H+X"FN!
MV'*\W\M,%+AG/']8CC*?SE[3^1A@$ /O1\:W<8GM&Y(A5N<!9E'P*MP^*3B5
MN:[;G$DWR TV\6$TQHQ["6C!CV7D[D[JXV1/L"K747//>'O)8@2YN\>%D15U
M&SH+'!SL<)4X:KJ@4\?M@-B1WR-]0!_GJ.O2M1YH^FIIYNE];N6?^T#O?2>Z
M5@X__P=02P,$%     @ #(@95_?2H-;!%0  %Q\! !4   !B;7)A+3(P,C,P
M-3,Q7V-A;"YX;6SM7>MSXS:2_WY5]S_PO%5;V:KUV![/))E)YK9HB?*P3@^?
M)$\R]V6+)B$)%8I4^/!C__H#0%+F$P^*)."JS8<DHP&:W?UK=#=>C5__\;QW
MM4<0A-#WOIQ=O;L\TX!G^P[TME_.[E?G^FIDFF=:&%F>8[F^![Z<>?[9/_[[
M/_]#0__\^E_GY]H$ M?YK(U]^]ST-OXOVMS:@\_:+?! 8$5^\(OVS7)C_(L_
M@2X(M)&_/[@@ N@OD@]_UCZ^N_ID:^?G''2_ <_Q@_NE>:2[BZ)#^/GBXNGI
MZ9WG/UI/?O!'^,[V]WP$5Y$5Q>&1VN7S9?I/TOU7%WI_?,;_>K!"H"%]>>'G
MYQ!^.</?33_[=/W.#[87[R\OKRY^GTU7]@[LK7/H8;W9X"SKA:G4];OZ].G3
M!?G;K&FEY?-#X&;?N+[(V#E21G\+*>USG(3P<TC8F_JV%1'8F9_1&EO@/YUG
MS<[Q3^=7[\^OK]X]A\Y9IGRBP<!WP1)L-/Q?A-[QJP_0WX, VA9&[ +_[<7(
M1Q:)6"7]=@'8?#E[V <6(O_^^O)C0OPOA4;1RP%99@BQ89UI%VT_?&.Y6$NK
M'0!1R&*@MG$?C-Q9 ?"B'8A0$U>(J]J>';&(APW8(_+A8K,XX*&.;"G4/0</
M[P#L@!?"1S#U0Z8BQ2GU(,)JAW2U\UT'N23CSQA&+R)L-_?N@=61%>XFKO\D
MI-A*IXX86P1;RX/_(IBQ^*EKVY5^XOW>"EX0$G#KP0WZ.R_2;=N/O0B%LCO?
MA38$;(4)4>F(];O 1T8?O2"#QZ9SP(#-0<3BE=&M(^9,#\6-+7QP@1Z&R*-P
M,$;ITA%3*23(O;U8^#.>@WX)8N 8SP?D+-@X<Q/HRCK%G4O?#L5$6=X>K*UG
MMK9JFG;$Q"WPMX%UV$$;)V3!GLN+4#MUQ!B*/'L8$==)XA 9_R@QYO A'%T[
M\WD/(?@S1E\R'O'GV-ZMOOV@+KA;5]R32^;[^!K[CHX$*=+J-[+P\<W5N;\H
MP\<DL^-0$8>/74$RO44?3LME].L^$O&"WM"ASZC$QQI'U_XC%!^KW 2ZLD)[
M!YS8!8L-&J2FAR.0'Z"/C4%D09=MC'S=.V>6#()SO+KAH%&+U:4_68&SBGS[
MC\6!S%3QPA$!&OF@>)_\)BQ5-]_I7/PQ#*WM-@!;\N$E0'J/@;!P/%0&#=WI
MM^=6@%<;'D$W0;R):N>H-,1F85SXZ'3.?DW4%F:=3:-SMG&0MB/@Z'L_B-)E
MC"HCPI*T(MNY<,S41%@N48I#I6JB8[\UP>YC$0X&-SA$X)51]&UB*RD;XA%'
M@%H/YH8TA3-*7T\# \B'NA;&)D*OM\1:.*YP4^@CACQ"O/LV\8-<1MTFAG#0
MZ=X9;S8 8PZ.WUP"VT?IJPN)'8N[83&"W6=:8 ." #CHPRT#"8M"]_,U47/G
MZ-JY7FNG9,*ZY:'2Y_135--"1#K7>;J+YVVGP&J3.M#[=\[N)([B ,R@!_?Q
MGGPRG8*)<\Y-JGN=1SL0K.(#HH>_9[GDZZ?8O"C%_E<V1$=!"U(]K<V+3SCY
M^M/8M2W7CEV"U!3]N= #/$? <X"3T<%,<Q_)B&"$6Z?'9*ZT<WRF)L9J1O^;
MMNR/E?IS%P66WB,^CIO?A"<O1'-T!_WB:&E_+260\IEQZOIV@3L7GY+Q2Z=1
MLA-'Y"S,Q@H?R(&8.#S?6M;A @-Y =PHS'XAT!)8TQ_^F<3G41S@\QD9;==Z
M "[YXC_3=J5F%U)XQ2<'\.A!_\$IZJ/EDO$4C9 MOJ#Q1,Y--<O V;TL6\YB
M],#6_ "ER%_.KK+O6(%=L)/JR:2TQ46(EVXPF7.(["'KOPG\/4W5J5K]-J+D
M(4%<G&E/ &YW$>%>#H39%!9EM "QC6:Q<Q"QK8_:BP^P]U(!XY%;)9RR=>V7
MW)F)*B[%5GPX7$O%H4XNE?1^%X"#!;,%'33$2>K#Z:2Y.O.A]$$J2@):4 F\
MA$%6$%4EPC1Y*M6UG&T5W+EXZZ/^S%G=V*#U4B.$-(X&ML J 52<,R\Q-XO-
M?9AL'S0CQ.BF1G1I@(A+9)4PPG$P3.:C]/!^;*1&W*"$]9(X:FF[LD5H/-MN
MC"^WW/J^\P1=EP8#3V\^?#[*PH=? 2H!E\L[YKYGLQ*PAN9\T/PHR7711%0)
MBRFT'J +(PC8F7!=6[D3WLJ>K8@X0D1D9Y?-@C7,B054HY(]&ON#Z[\ L 0N
M7LT3P9.CJ^R,E!M%;C6HA!U>@ \L._H-1KM1'$9X:3?C_*49-T8WV2DJ-V9<
MXJN$5S&_/K+*'&BL?K*36F[$^!2@$F0YT;CBM%*!JP&%M^'<&FR%*X%E=U4H
M,(F-%;6S6W)&K/::716ENK;2EJN3DSZ$)<;^6VUCV8.^6>_5->DF456R(WS0
MP/=XX*BVE#VTN;%H$E(E('3'@5ADR[VSH&-Z(^L (XNRS-/8079:R0T+0V2E
MT+'M>!^3&0M9 "D4>$@.!^(R#W,0+39KZYDZ-1<C)#OEY$>SG8I40GF)SRIY
MP#&LP$/Y0)@3:0PVT(:45(BGK^PU5VXL^16A$GRY5$_W')$,B=U3=M[!*UOS
M#$1%Q#A*#M0G(HV=9.<D+7'BKKW PDWB&I*(O)2&5#%_O2A+.45_'N;$9GU-
MJL+QS6O^XYO:#P5Z?^OSX&F+.E4%L3[0Q'HEKOD;[96\9GF.5OB 1KX@Q='<
M!NC3=X&_H87P0B-9&0BY84SQ?J\M9(>D&IU6THBB-&J%GA EHBF'M&!3:"8[
MO+!U7BM7C>+/Y:\WEFM64=877YM*6FX#KHO/'I#2H"[>>G3VT(-AE%QJ2-FC
M+,%Q]I<]IANQ*<=O(7VH-.Z7( 2($WP<?HP&B>N3HW%, !G=9/L%7MRXI%<)
MKJ-@KRL('.XBWUB9(565H 1.G7,_(>D?P-J8(C7;I4H1:>Y[?E$DIC^@=)%]
M0C-AQ_0B$*!?\$B'C]!!$X9F:;@ZRQY(3)0:#WDR-:*4Q\.+IU59*5ZOJ8-L
M-R$*&$-RE4!Z=7P3)'6R7A,CCE^GOS=@XP<@5S? >$;)$=(Y]*S@Q41Z(^<G
M\<D:G^12F7G21FF/'Y4]N@?0:%-LJHEB2H;=X57$'L$*C4E27H^=))::R;;[
M6JXKD:Q_X!4"\BA&:FPW:)9)7;AK["![Q/*#VRBM4HERS9XN>\N;VDGV\..0
MJ.P3:S%5:/@T[;Y/D(> 6R\YB6B_K /+"RV;:-ISR)\2O=]:T,.RZ0$,D:<8
MQP&N% D"Z#MLL ?YN.QA+6XT V*BU 8:YU,CA=VFC_R[37F2?[4.?OB+5MZP
M[U>FZN,D!5%^Y!<%4](24K*R)\P"*8J'E''S<A\"Q_2.27):IY"Z,R]"X]\Y
MHE :(8C-6XM98X \HYW5*\2/K"4N,%]:MADNOMZRH\;)*(HH225PL^"U\%96
MOG@S*5!PK$Y V9?G["_[+,S) (LI2JF90;Z8ZMB/'Z)-[&87-IN1I?>2??3U
M9#QYE*+20#U6.YJ:DP7>*@P>09)DCE"BM:6L0;-[RC[[>C*8O,I1"5"2'U<J
M95..*32TEUV1X&3PZ(I0"3)J:9A\I&=N48I3XH/Y)W5A;JL\E0P )>H!YGX,
MDO^:7K48('4IE*,W'] _JPNTB)*4RI.JC.>>!!*!M="-#\]/;PG/&K4H#F1:
MA3 K9E];C5 $83YZG&L3EV\)>Q%-*FX4A.-770@;07U_3M 57I$2TY3B(/-4
M)FH3LNGT.(U X06MTS2I=M+67.=(Q!)H5#CQ5WB]JXW6U$:]9:$H84*<V"N\
M-M92=QW"7WV[XF:VU&M 70(G)GNRIE<H$5,_EC$101J<:*JX.-9"6O7&<8/X
MR0'BT_8^:VE(6J)/W_-9^[K]9PSQ<;%BE57*.CV[JZ)[I!0,RXOUO.I1*AFM
M<-U8_5L 70H-13=13X"9J3"E\&Z0?P(]R[-/<U6U-*3M)MH ..2XJQF&,;XW
MO]CDRCA1MQ19715U510,J_N*?.I1*<AF R]]OS7C&]]7YH@\];T4]48"2'(H
M12G_DS>]_#NUQC,(;!@"RB4SCJZ*GN!H-S*IZE%I9&*12T^#+5$T#2!^W#M]
M.JSX0ZYEL@5>G0*DU?J-9WN'LBBP1-/YY*':9@,9F@_9<4".WJM' T6G?DI>
MCE)9F;3L5,FJ3BHKD^:,%7*JB6B+35[<A7>28H\J',/PX(>6>QOX\8%<9P[M
MY%(8<%[OA#4[6A5XDWVX3PD35P$(GJ$S\*V11;"UO/*!YL+%BI_PT[U((-</
MXP"@/RR6M_K<_#]];2[FO5[^P-85O*!\'6X]N$%_YT7IIA6^D>.[L%"SK\#T
MSV6F5_>SF;[\KBTFVLJ\G9L3<Z3/UYH^&BWNYVMS?JO=+:;FR#16?8J4+8 T
M/157D.%368:[Y>+.6*Z_:_I\K!G_>V_>S8SY^N_:W%CWR73-"U&U#%]=EADV
MYVM]?FO>3 U-7ZV,]:IW7ALW-2M%40J<7Y4Y3^UBI=WIWW7"/U(Y^G%Y;R#5
M_WYGS%?]6@KG#:ZK]Q5#_ZHOC:^+Z=A8KO[ZEY_?7_WT"[&5]?=^;>1X';J>
MS^NJ;8P6,T-;Z[_WJ\A;X&\#Z["#=NY1^GH>/Y1YO#46MTO][JLY0NQ.%LM9
M[SZ/ISAI@>>/99Z15F?F&CN&%3':T8*X-V/>MV\KOT9?S^^/5<=\LT+VB?C5
MC&^8:_DAA1I:KBKQD#^T:#]DI/NM0<HEY1H[R 893PB?V@\)X5XE;(BC-)%$
MHND@,M2$50K_[SF#ZR"L,Z,L39!VL780N:I!ER:(0.@=R*".,9C&-C42#\)H
M;4BFL<P9F =AGA*A:2*(Q>EAK-W> 2?&EQ_)G>7C&? Q?I' ;9"C&K]'7XWQ
M/1JU*#1@_V/.<11?+(D4*:F_R;EG?[Q&1JH]THZ$%=M)OA&XM)YF5H3 LEQ2
MZ#T^'%S&64963]G+[_5(--WZ8RA I:7'(\^_^<$?^#2];P,N4RNUE[VD+P90
MK;!*PC+!E9*1F\,O6?/ 4FHO>W- #)9:896$);>$1 &#M%+&=>67O1H ***D
MHN+QFVQ$Z/16-<^8J.FCC+OB *519,9ACZ'+-QVS,3(+.7_ -ZC3,ROZDQ4X
M^3,.1YG0U#'>)[]1T[;JHD4N;2/SEO,;?87F6V@.AG-23?]-7X[_KJW6B]'_
M:(L[G%ZC">8W?7J?I-IHRGD_2W[.I7F#9*M(#FN[#< V194\OT"5OKJ<D9-^
M;*[TV]NE<9L(ML2K4/?&0$)QK=2DG,RM("GY7R]D98%#9,TF_81V_,9 6#8L
MY-#0O*ZLA.31I*[J#&NG-0L\5+DJ"R-YN9I6>V3/L"HB&L_IIBC.0IZ@2WE6
MDZ^WG(B)<ZD(3-%(0$XXPK-]QB2RL8/\!(8?HU(,92BA_PM"509RSR,R"I9A
M @+]Y:<TXC )BJAVVH/7CNT2SU4G2O6@U179G ?%*\FC-4IQ]-EBN4[/+]2Z
M5ME>-0<I9>^=ZH)J^TGWI&6N:LK$S)$!K9^ ^PAFOA?M^!QN*[JR_3(?RLT>
M^01EJC0U%9/H.[""]9/?E54<R<GV_@,80TEU;]P&T)<II9E:$Y2]X#>4'>35
M][8M8>+'09>&D-"3?61V(#O(*^^-FT%N7:03,R#T9%?2',H,\HM*;]8,]$T$
M@JYMH414=G7. 0RB5HU*G5E_G3,R#R)1IXN5DS#YZ2+GJ22Y,T6>&D[)@Q>4
M::,0$3F.H,2BJ$B-W \]YVN!5VDLTS6ADO-N9XF\=C?T!*T3Y!CM5?*QO)Z5
MOBEU73FY)^96!]^/(INLE>+5J<S48%(YX%?8827;J,D.ZV@QPU(FRX^IQ$-O
M3:7W.5_6OI[NI(+\]C)54.H)0'VT-K_A Z_KA9;MJAK%7>2!9*T<Y>4SV.I&
M.>50K\1=T^-C![E3OU38J'O@=\O%-W.%#7*R6)8.!,O-<%(?*?Q.(:N?I/(/
M"5<3@,S2<L7%:>XH.[/APZD4$CG5H5)6D[&</";7 L'&CK(SG),09*A#003)
MDW HK9FBC[08B:SNLA>23T&33S4J89J5+Q<.$\R.<N5)/6-KL5C]94<-3MPJ
MC[.):$=%.RV,L-;H\E&1'5=.PUA$4RHA/?3#VGV>'VL10CI!:O@C6&TL]"11
MY9VV(N5PCH\C(_:7P/8]&[K9HY>4N63EJ''QH-5D8N!E ",WD=26QF@Q'YE3
M,[VI^>]990^^I@AA Y=Z-M_"KC7&-R1>^R-?R^&ANOF,;+_6*D/N1=5*QJVB
M@"-2,\OT,J>'&B0;B*\W45S7?\(%584-2(BV[!C1I=6T4.H;,)7ZC(WQ%HL8
MH3<YN6ZIKC> ./IAA,P7DMIY +&Z$\:ZCH3L,UA=HMRL(J5*3C=P/_=QDHF?
M&7EP ?,Q5"$BLD]8=0DR34TJ#>.:W!_YH));JGW%UWC&-_Y1ARS!V>--XF93
MZ/Y+L@]@M;*7OA2NDE$UC(ET9Z @^!@B?6 M0HMZ.[ E0=E/*W?I4GC5I^@J
M0R6SI2TK?*A<["W>TS8FQG)IC,ER@AH7M2KB,>Z(-K67NQA]Y ;]3^D=V*QD
M0G;\!Q?DR:8DR#3'?OP0;6(W.RPD('D'WY*]@$!'OV&UL'MEJQ0$*E(>JW (
MF$:NC^S9_FD05X17&JJJ0>83$624:0 +CS\#1W\( ;+.TP:^R&=DS_R['O/B
M*E;:AHY/F4R15D96$+QL_  7KQ&Q$!H1V6L"I^'/5H_2Z!X7,=HBVT1 ]B+
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M9JQ<Z$;/:%7 4-(.IW#L7FE=<C-(/<TNKUYK9]A=$9>3:QFX]KRZ_;MW%FA
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M4-I!*3?$LU.7A*9FW@R==</N0!L0B:P<I@<9>',4-@[K4/E9C1.VESD&6P'
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MDQ:'^2C+FV2GXF.^J@,OFZ'*Y*'.2358Q0<IZ&^0N=9J3$.2A%OH^>KRK%.
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M$SCK9\&T2'>^"ANWS.P[;A>UOXU:'T>/>]26JP @CN *,0R(@T M%+QS:.%
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MJ&5$6J917MNN]VQ0T%A'(3=/9:A]%%<?0,_L"]ZG6HN 7P9FT.YWFT=,JJ2
M.2L(EA.Z]72P:KDSR(33=>81SG66G /TO9/^!- "P8-R$<H9>X52;H;_@1OB
M'*:\CE-4'&Q!HO(#B4-</P-K+J>>N">*2D$KZ-B1A4@]&4 #S;9,!6TITSC-
M(/&)KDOR.,*DNK(58I8O?S:L;[2QX8EY]NXIZ&@V )&CUJ@-Q W;=NB\H#2$
M,NON\;(;7B'&4<Y6U_7<AB<XK2<\BFTOO9+C*W[/F#QF.=8M2NTA2W;#N"9B
M!7>8GM'J;<_;+K6,.;"QRB_;WT)5B[E;9JA!'I8-HHSW)F\ IFW5"%?"GMIM
MLQC!T?6.L"=P>=KZ<B9WCU_X3](]:SM->"UX(&[9!=YMIRF/EG?HUW2.6EKX
MC?_Y!,/!YT6ZP\U*P/DI=0>8<*K,?_7>H)60I%><R@FEM^U@OJDM;:'U;_#:
MH(!,B%2I!+PWIC&K@K3:?F'Q,[2W8'\(GK JJ$2OXK+!V8!O$T8G#Z916H#L
MLZFC@@C5N6+KOTK+.\=FQ1J3<EW #MYSG@"F>MI;40AZ%9<<LP'?YIA.'@S'
M+$#V.<95JD49U[DJT_3095NIYSNCBFU2)+>#A:X6%,"4N6NJ$O>W I:G/E"D
MLM')PQNQK="JDSILFZ0.N%:\0BD^^53VY+YW2>WDZRRIGNMZ"/+B>H=O,O(#
MB0N<K5:SU9($$:[?Y#MT"HJ".L6@RW[[=,?;9#[>&IC>YF07A"B1VB";:U"+
M:$M-HFB'T2HCZ(59?4?-LJV @AE&066Y-8I<:#M(]&%,<!07M[3[K'8OV R<
MY/*0AD'JSK:/CG"JV58:H.N=L$<"EL3(]-E&YRK<"$I8?L%J9PK]NC;D?VOC
M@>!M$$>5@W08XK.N\KT4Y<"E4W$;$VH&WYT@J.6]DW  2'%6P%4:?K%90<9G
MSP%7\SU1/C47), )M!JD,1&D_RT8Y=3S<XY7N^0V7JGF8E::(/*_B:Y8+14.
M:F X9X]UX&IAQ_510@UXZB&N\9:.E>5;=/3?">9W@M*H_72]K/IL]."M^ :A
M%A+]M)2O4%2K\SH-6@:\=RXLS7:!;]E!^C0MJ LQ>W&=C4/&WL5.U67W,L29
M-D%M],!T, / RG*JTT57PL,FXD:YG'=8]S!.>-EN9>QQV(ZCJKFN2<DE%^T<
M:+-0KP&&?U8PA<562XDM^/OD\S_+XO"G&SHS)VR\':\#\J3,WZX2=DHP+> .
ML:22< BE@R<0B0FCN)%&82GNG3]LGE?LRZR<;!&1%PS>["7%)%_'V\,AG:(4
M!NB[9-E@M]K$LU8&P\6AB(5K[%P?;;@!GNB^M'"%LMH&I)/74<+MXDB>F*/:
MU5"U6TMEIYWB((<ZG:25)ABB#H(KSTS,<S>@;95Q.#CD=KBJMZ:\\[,=;=J\
MC:M>>,MD'6]OJ.&J G\;03#<TJ'31_6&M;2W:+ <4_$U7:9?XV><9'SO1-/J
MM0KP]B3LX(K!9*46WWV(#GI@FKGP]GNS7\NZN1<6)Z[<I+'0=-D%#'"ENT5F
M5 /3/=AC%7?%2DU4!*_5NN^*W\\LUX5!K0Z/D+HGWU3"7FFGC':22\(EE^XU
M."F?($35C"+:F1=Q'J=/ACFT1-#I?%D)M#,W%J3 \$4)3=@X. B"&?=&:1%'
M<;(KXF>\P"%[Q#S&>9F(!4=EHI;-=E=4>VUU(I#ZNN=HPP(85 5S'MM.R7C.
MXNCP]QR&X5#^C-X(K:1E&^6-<=IB2NO5-/]@GVWFXNH+ASO%5^R0BWZ%WPO*
M@=P+4I[,Z@9WDQ*(TW/E8*_7 ,-H*YC"8=:.LJ[8,;*MXE?VC_)AI 0'.>9A
MA_%F2[)GOJ7A?W^XD[W)?+*L+!)5IW V\TY[_#,72J?3/Y-M*)FA+N17OUG=
MXCQGD;BM_&&'CWP)5PN^<_MJ+B8G7"SX3E%)U25<KMB-$_+>S[7"$QXH?U+]
MVEDI[2EL1 99$2G2%@4SDNKQ"9NWI<B%@NQ%+*VN2Q8S5ODR5-E9@/U@AYKP
M>FM-*(/-4:B-0TD[\NW=UDR^"[;Y?MP*[5&;!*B?LBQZB9-$U@'8Z,%[F'T
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ME8)BC7+DDPEU9FR'X8PZ/$WQ=+M^#'UY>$AE02C"* <\A6AG!OFH']7P%HI
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M5LE_COO#*=;V,Q,MVLGF^(#]I[(2TDL5@+1!1D.R=H/8*Z6>T.*[$J=!9\-
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MY8\R\]R0R'>9N4U=17'H)51KFTVH!E9L[:72H\^)NY=X)L0EWA.?(G3TR&M
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MEA@+9\VT3#:.-\^ZQR8DL9RGSKBJ:5E5"ST=9)UI60\#.E?[E9U?1&665!X
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MP.L#PI.($^I?]2-/W)2%>(D_X)9K(64Y$5,3:K:*7:]9_XM&$^NAW1=BK?P
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M&!_-UAW@\UVK,@KGL7F.-VLU%F#1;TI3;#1S<4KR)6#W-*K!.$'HXX1[8O@
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M"6KB)L]L]*&(E3Q^O#A<IHM\[R93T=XLC6"1L4KD/5Q@=O<*(S!/Z]HZY"T
MUK9N^/^K8*WAV>HVS7J^^^/+>79\LCS\Y!Q?]BB___%)C]([O_+149#L:R2Z
M+R@)_+?]Q^F'!WW,___Y9/9E#V]+4U^6IKYN>OGPX;S3'PR[[4L015:Z7[3M
ME7I",E'\30<?&[*Y8<4>6<D*VM!]@UW)=BD7B1@+VN'Q;PM(;\CF3E0Z@Y_&
M88OJH+;O\"O<W/^&XX]AMH07F(6)VM!-TN>/Z2.EXP6YA\SGCS=TNW\@5?*'
MU\9%H@_%1:CS;>;D[\Z<7*L\QC]-##X_Z9V]1_#Y_.WP\N+X_P%02P,$%
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M B)5R87VH0-;9\/FB5<Q1XS+HOXYC4!:\&N*6:REP\8300RM(;6(+S3P\Z*
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MLGX8(.2BO@NPBX'HFK!;76,:- 5A?+!F?5E_E6Y%-.HDGSO5R3VCVQR4"]_
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MX4PIP$E\B1<557S:949OZ2.G1 ,\8F* \DJA#$J5I 3(#!Z:E;=Z%W?9X2&
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M OKR1(3#PG@,M@2!FL5G&S1;CSDS&1PWQKBGAN+Q0;7B A3*P!G* * G=0Q
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M4.R).%;I[HMJH+V1T(HT!57-BU$I(-CQ+V_7O/I'+X^0\-=R6HRECG@8<R.
M>+5()N=H@4[DE*K!YYC6B-0$78(4(8"64 RE/F#.^M<.95YQ7JVD!$PO5J"(
M^>U7'S*(UO%L%?#W:7%'R!A2L$SYM'1=(.EB;@ASUI&AX"RKD>N<XVHQ0629
M[(/)N)06$E]:.:L2[;!HLJZQ7"KMV6QDF4\F8@WH1I2@*G!;D\-EMK<[QHU*
M]3%G9<;NA6C\&1E[):4^!XT_&6/70\!9)"8"9I?(T3>;??YN!L \6\2G>*7
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MCZGPNZ,G'E,*?S<$2!N*GA]2K>? Q83[6-69<SCEE.X?\C_J2IZ?K9V4;^7
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M2C#U%+:5D(BU(MS"@_9C0F_.@P92DH;CA=DPBC2(22 0AEU\N_9AM@V.(G$
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M0:)^]&&YF%USO9'&0G)7CO6V^*=H'?QI/-H,_BF^$0 5W81_&H_N!( Z_20
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M,@-BI*V #D$8@L70F2%DOP1QCD>\WV3P 7+@F:2FFC1EQ1@.MR)ED'268N!
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M"Y)BV&D7/DO4 @1G$(3A>JF7KD47\1XX6#YQQ;M+[0J># P5A'E7BR8<(N:
M+9*/;6/R\ZJ1;X!4N@._SU"ZG>-#FP;3/7K(:+H/&C0?H0N&T9TQ*NBJP,R1
M289)5V(_F4QYJYQ !M/T9&V:ODN8'BHM&:-ZH)4FER U3GD\E1!S0:->S51=
M%3BX9]&!.N1#C&W0B:)&;!R*:\:%B[,C%B'*Q C6#S?"\;9:]GA$AE(X2WXR
MG4K>7I<#J9;^.&0OF7F+=I>EB 42(#94@5+?I87#-MC<< 3A%8<M*<J!Q/D=
M#;  JAY#D?P3(#A"9DP.7=G9!IJO:D1)<#Z;@L//XXZ#?/6:>$@.6E->E$]>
M6$9)?,;*'CJD%/G4RP9FCRDI*?:(:@!SDBB[ LAD8>)PH,R4S>V<EV(\ZO1_
M8\_WF97N&>EG3!=C@XXY,Y*1W+!TJ)!+NB!$)L]:?=2YS3LRU[J6,M'.I[ZR
MRI"-.N06K!%0N4;,E)/*DJW()D@B*UN;, 4('FF96JP9F BK)+E=X5"PT%7U
M!F3SF=@QD0W=Y;'B@;&EC#J6_E".X@ZAHZG!2$G)*0;?F-PF&6K5]7['0:_[
M\[.ET\50I#8^E9)94T2*M0IU$EE/J PC"/8I)5"]1@;><'X5WPRKD 93"DHB
ML:+]IT+C\46#Z@3BLQ::PEKE(%4N=1EC7-I<8(0^1BT'CYND2).+"8<P4]UK
MA8RVF@"3=*8=B(;320OJCFD\Q$[F2QA%&$>+TZ/,2 (EF^-,E>2-@<' '(^B
MW]H#;*?%*:*M'5^.DMBUJ8N*G+6\/$'J6QXN@[/MIMA@XU7;D9F/^JY[$HS,
M;<..G_;UT**_[Z%%&X46_7T/+=I#BW;QZOU9JDD(+\=07D*QVQH2,4EW:K$@
M&U$0N/3:L6S)=^I$V9(!WV3C2MN\$]/N51='Z(HEW%$Q'X_<#8JO_0[7OTF]
MJ)K@.P*OTNL$6HW2IG1YXS*M*B^M'<N2-CB>4[GS!35!R/Y1='Y5>((O1TH,
MS9+["](<_Z<IRF;>-HX0 .54V4E3H;6_XJCJU4T2ZIO#J9<(@2G182!%0-%\
MV1&+!;1.EE*7]83R5TA_[%Z83D&S'UIUUY6KS<P@>$I!W'N;U FV&M"B81*#
M#"VV"".^:69XET=M3CM8?%"1*Y<4V@IA[LJ//%)4) FV-30X S3\@:-Q&^C)
M(=SE1ZT7KF',UE>FM A(UK8?D:70"-'B_T7=YS6F5+16C]MQ2>0OF2[?[!NM
MVO3JY?'[\[/7;T['H[-_HI5S:^=IMW&+IV@+9VWU)._7/GX5#O1(Y!$;,C>$
M+6XU[5E1Z3RX!M@(95]0K1@ALH9()?^$QMO?4!M&N"A"^TI):P7#*%F0 +7Z
MEVXA)Z]#NDDQ(Z\3DJ+7,[AZ)<PFN+KAI]-WV!GUO^JUF)HP>DHEWW+4XET&
MX#@ZKE#60A7=CIA@!NUC-^ZJM<BQ+:&-0^300U;/74@BW+BFIOE@##':/18X
M>;1LY@W*1V09X488V* 7?('*,YQ%*[=AXVY18VN^)%.Y[!C'W7'F+,X\LW)%
MC#@XN2<)VA0K1B@N=JF#! @U+T0\=/+H_E;?TND^%A9"B'%'L&1]0ABG92R.
M3I O+#7; IN\-IEDP)&X")1K)74W870Q96#&#C0DOO\T,+?ILB.+3II:C'A>
MMO$)^2,+C+$CHK2)\ 020;;QHG2F?:YTX:<HESY0%"_G#%6S]C@%/?S),<ER
M<+HJ#7.@>L9%*+AO.-S1I4J QRRMDU!6R]9]X-/CZF[(-*;HXFJ5JB;7UPOR
M>'A^/:MM!2NS/W1;.MTG<.C^R+F2AP,4D_6JIZ<-L6M2@:E*P%"4?5!AL"L-
MU,YVS34]QB,L#"+U/>AXA-XV-HYS;,@R<ODR>XIOU1:@[':)IP _M,T8AQ,7
M55>ZLB:-!:$"JYZ.SYD\!5\N^48I!H"U?@-7/ZV1J*;%E:!Y'-RGV[]D*JW:
MUZWWL%^L<TXI@6GA97S"T>SH^-85P+ZGFG=\,[TBES1%KO[#[@#>4BQXQ\Y[
M0>G*-6__VE_(VZ*V.#5[KV5_XU,\:3A\#OC-7N'>3EYD%>Y!!0IUT%Y,YJJ$
MRC92T[O1+;Z7?F91VCF5G9SJ[-B<%JAJ%N@8]VO6.<,V*J1R.0\E]AJ:!XW#
MTX'3AE-EMM>L&)K17% Q'&8\ZE]J*XP,"^Z.9(PL"V0,TG#]G-SXU5X*WN;I
MHNIYTKJBU*0B-W)!<8,=:&I+J >B1KT^?8<2%^JCIK+F))U263]W^%*--*KJ
M%>Z/UGV$_V($9Y[PD:%(2R;_WAC:(1Q%I\H96LK>*;*'AHO%<1@E_V)/UL!Q
M@D,T,W-;GGW]X=KQPR'8CV_/<;XSV_9$;DQG9_7/""F1&/:;+JW%20ZAA#JW
M*MO@%?8OM,_D&JU-%$%3BAF6U>9.EY@@.BW*2J_5D&.RTR!R1-!<<+'KY&.%
M16-KN0K%/CS)),BR\JZX5%-JM)ZG- '5GJHE]'5+6T("8\\I\@7_J&(.7*;6
MBC+D%2O96L'U!IUEJB1! ABL%-UP1@)7;W8\"MA)-+17G))?W,04G1U-BN)C
M)2C=CVC8MM8MFVQ?L8&"91G81*K?QG'W=JOG18[38I@>CH3$# SP0QFI?7=P
MVS',H<4.]VTFW3F46LJ.=$?AP1!PB3U/!N\U]S^UO@5<N=3X(EE/J.IV+=(.
M1VE0C9^:#I&^GID)T,2,<PLB3?&R<EU:'B87^?#AD ,")5H+; TAEC!]3\/0
M%P(!<;+BK&A*GXRE5+.]&$E*ZUI87 Y :-_-&8.8)W]Z$0%4W+IP8(DU9$;A
M!!-87D=,4V7J&=#1>-3>GM".MV!RC1K?;U05EC"&^TD+%FAYBD/B;N]2IEL8
M3N[^&MXQ&;4[T34HTY_W*-.-HDQ_WJ-,OV&4Z9XU?>GI_B"2]1"6(;:X1R+6
MMDX):-B&!$#1@-U[3OF>#NO?WOUN[TW"!XC)T_>$1'TH9BA2!1+&\/7K7>;.
M<$3E!?87[99.]ZE0<PLLLL(S>RMO8RX<>LEBA#@>J"CYK4NGR]5A>!WIB7Z,
M'25)1[&\K^R D"W:SO,!NB9GGE#TU*4):&.*&#7;RJHB%+OY6W?H!27<09V4
M, 4\"GR8DTKJ@34"EVUW;4)S++SAC63=H031NRL4N\,8ZEV=\;>6\>JJ*',7
M(BTB?;1>HE^Q&)\JNN\-:#O'4'[L78\! O!V]^-MKT</N?<)UV,(IMQ?CWMJ
M'@R:/\O;*')D^:V_Q.26'KFZK"M3M-X'*6\)MD1B=%V<2VH;@X<M?X;;$714
MR6C18GH=DX6%?$!,-M68UZ$.Z#WTJ7@0U=):N0+HK8WN3[U:VE[-X38U_]Q"
M<2L"&^Y/P98@#%ILS-E]@1GL )+BBTS1J]K-$)D/**%N]93OUZY^57Q,FW=N
M*GF,6GUD;9"*38=,JD7BT0SI4/!:J5O]1EY86@0!QUW0S_0BUF821&:;M$DR
M/O/M0R(6)WV2L%ST;[B\*^M*S8=R6' '.D5C+Y=M^W1/*:P')'P?R>V[)3-U
M)=G.IS;52(>(UQV'N4K179TM;24A=A .?&+3;)7Z JD8>Y?C)IAFZQSV5&V;
MLYU?::CD>BO]P;LN'Z1[,VVRI8#<! #=257DJ>PKBG!R_DNW)E&2Z9*2-GK/
MN/J9 _50L%50COT'KF(L&=".T9R>:9=\1O*UX"$OV?'K1I/X1[H<8#$"RL,M
M8C !3IB! ZFSI"S4TL:2DX,4T]7*0HL3V);<)/D4:")7<PW,\4-G\[FRVDV;
MZ^C!EJOL M8Y/PQJ@K92IT+'^H7">.ZND]K+81!1IIH>X\+XLX\"5%(IN[M5
M%I5-IFTX.&(!K,\\"(3#!#:IH1C"E8P5UN/5$DX&Y[ '=E_FEH>;JFIT>V*L
MY>Y"DD^SMWG-Q< :$J<L776^]MQX2Z=[CAPP(([VH#EKI,OAUL/TJ4ZD*U=U
M6'9L-*2$#IB5EA86Z+P=7#<X'_+02/XWK0+FZ6>5"& E'SA^!?-NB74SFJJ$
MLOQB2%Q^@<4J.(5>21R30#*EYK Z3G;K,;XPE5V7[;(.7L]4WF-$:&NH*Q<%
MZP!'[H26:[ZFY0@_ITD3E*GQSJ\7AAQN2.P;V@9V(/8\3=#7P+I+8$UO16RH
MGEW4:L6JGN5L?W%I-:VI G.L4%E 7M>B%+[O6FSG2>]--*;\(UM*ROB=WI@\
MH%P"PV_+% ]L)[%-C$&J[53XB27?H-J4(S?$IW'^3I)@3,<F@S4QD8?W>Q=\
M$=T9DBZ$^MMQSKH>(/+HX1XALE&$R*.'>XC(-PP1V0LZGQ4Z<9:+]XH\T5TF
MS_(XAI2;7/?=Y92N/F.FWGJ1J4S!4!APSZ4LEGB5_EDT9<[Q2+ZBB<43K]'\
M4;5Y= L7,*QMMEU4CQ#?#3WT<O12._XX!2@<*%_D'2";4>IR\1-:M"[-I+$R
M"]RC1>U_P^'#O1Z"4&,),0YK/E)P/\@V6 ,+)@:GU&9XU]?\W"T5B3M=6+1U
MS)"0!!H0>L)M]9^.-<E<DY=2I9>8 30F(8L #"DL8"S1RRPCX"6-U@),UD*2
MUX\/X1ET .N/^P)/'CV$[Y8H=TSY+4WM.#^,6_3<9GVQ#=%GE"PY=-+PL'?\
MQO\ZTX69W&;"#S<[X;/I>)07/M5Q:NIKG3[;H678L:OEG*V([9Y/*0Z%;Q)D
MU'>_1U;>(FWJ*;[ DDQXI(U+ !Z:"Z]:1CG,FE)$<S%>^[BPB2>D?Z!1@4<5
M)25E:)]?*0PTB5=V%ZWLC:-V@NX(.6;3R7/ICCTSW-+IWNU0V+HLDKI#KOX;
MB=VGOH#*!+>7%HNZ8D+T,HJ4&@VQ?!ZP3L&>!K=TNL<@UPK%.4-X*)-/[5V]
M":Z,X61+*_$%<KY+F46?/_>\+K/B"N/RXE8E">19Z#.'Z7;/$0'LV@YLPWM"
MWM+I8DCPVR*P8 XY]]?YP<2X">H165"=9N8UJ;"N$!\!,J&BP14K3M98-!C4
MPV*)(:=4[Z'(4%J0#(W0#1!TVKBT&Z0>N3+-]@'6KI26[*M$R=/:^AY=B61!
M/@=^4#]@T8*;6RQXS$GJ*!82S:NP#_.<:]B)_97*848'J/CAN$4BNL*3CNU>
MHIG1X>1Y87TLQ&39LR(?QN-1:X?FS-\N!-O[!,WH6&"CBW[H)4-W09@[0]@[
M=HY_Z'J275)7/WELZ.<GR]'@SUZ25?]WYUB2I&W8C1 6.;R3 %<VQ$?(;:'*
MT-=$A5X"QQ/C9?&M^9YBMW2Z-LB(@!9QY$+LV^B@(?B%NQHDN*0%^DQ"K$]5
M*RQUX++W4JP0UBO%G$<6ZP_O:)*A3D!POU+([&TB1+G+2OZCN@W"3$Z<GW#0
MYJ&PME];U%N2/&*5R(CK$[(N<=?%L,H-GY6XZ_#E0P?"YP4E W!Y8Q?:Q0"9
MG'/%]F78F&,E\B( # :%'\0PBVU)._009Q&WN1UL-8,A*:+=39<%P]L]=FFC
MMC=84&O/&[8$G>MAR_?@\F]\BO9T V/]H%6VU7.]7]OY%6%=SG>X B7EE1PR
MC#ROK]#EF.,VE":)$E,FA.RQ%75\%YH44D*8YN"M1ZAQ-+_A-<&@%Q\-'EM8
M.6-,*6%2JZWF-EX6?\4JT3 (J6CO2#="RCV2>O8[L[6? J-YM(?1;!9&\V@/
MH]G#:.[G_?+%1;^][/>-3_%XKO,4_0;[9-M;)AN0V,=Q(FN= 5["0975V@ED
MEC#8&K  \8JE-/1!2;/#$2H4%(].+4FK+2D[.W$%830@%XX.S#\8O.7JU:RI
M1H///1^>5YP&;>IM)"4/H^ORZRZ+&/G)-^**1DQH0M=+"^M3>=Y(M>NPGO?*
MW#J>2W$\XI&+O4=6?XZ9>C"NP=;YG&AL3X83]PN#&\^;@I%6!058)=[>MGX;
M G0X\1I_ SF#U\-'"]ZIY,\53,_E!^(.9'56ESO?FX*VD;>VE2[_][XPV!VX
M0[[(%'\Q58(% /^M5;G5$_VK]_+HJ0-C.MPE/MNX #"E'96:<ZND -T&T68*
M+DN"4$VCW]@O31D(L(&_B&-_C;7:%1:]Y]#?^!1_0>%PJV=XOS;QJ^5]L7M+
M8*[C],\FM=GHT=EMJ@7FV,15.8JD]F&7ETND4.6'!8G+F!-[26.8Q!\5O9Q%
M_"GV&DMK3<D(Q=<SC)HIEX'?/?+<[EA(AG!8C#C!L@;3MHWH5DV@$;GJ:$"P
MX*6I8.ZDA7(-/_$9E-%4IU3B*:$^LB*A&@ZH=(INT^OC,/1/5*BS<#K!)&LJ
M-WW\WV?1@3KDD"C8IDM>'%:H".C6IC6-)F71H!-]?26,@PDWIQS S6M"514J
MQ/A7E&3*4/58M )3 #$&J)NT =VIQ*0AJ'5=2;$)/Z-;[*=Z8R"!#0X?NNS[
M2#I7BJ=]]+>R0A=*%0(+HH/$GTQW0?JS41?*Y%4_L*Z3D^Z.,["58A=-636*
M(!@%J:Z5UA^%WG4.FYGX6 <R8,QUNN0Z'G'/0D']G/SZ^DV\<C76Y3*BU?#S
M<D0'5FS":/=8D"A+:]D@TXJD0T'C!%%Q#YQR"(N>WH6"X+!\D46_*"Z!6;3!
M\&13P80F:CI5IJRBM$CJTN2<S^! '_*I'1PTP4[@\T6IZYA!TK'=,2G9X@==
M7@(73L7HT-FTLOW'D"'';MQXM#8+U1?:. P\1&>JPEPR?.Q %,>*+@P=0ML2
MI0_F%!)<>@1+F\ @I)!ZIPH(,#Q'BS-U28> [%.P#S[+C'"S9)M2N#5T7E'#
M"U5R,E5TT5)&H%1/839PB"HNN]Z:N\A8M<1#ELQ4Q=8A!]I2"2*VK,D(RY.8
MO)&M+:ZXKK.SNIG<PQ,&>66&\AOU$_4(^-A+U)RW3^6^X_<H2K1#$*;R<QX]
MLCF/;+JC_]U;H+9TNH]%GA)Q@>6J#U8&^L)"E!52.(H:<X/0Z75,ZH_<(,V2
MJ$(/C^<PC43=7E*).C%,%KY? !-7"" .K@;*>X[F;V'(]@[EFE8U)^>Q9<*.
M.4[[T<]/GA#W$XZW20[!M\,M6,2M4GE]*H<0_A.RB,=[%G$G*,GC/91DLU"2
MQWLHR1Y*\I??V-]MH57I]>G[\[-?SEX?GY^]>SL>O?LE>O7O-\?_^G!?[$P[
M8$K[(E-\]\M63V\'=O#5V;O?3M_#R8S'H[.WKX^V>K+;OI]J/'+F74]NW\[)
MWCNM>J/IB^ X'F>9SJ-7JIP8>"NV">,9@W0&RF'D96^=1J],P:ILC%:V(P0S
M.6+PC6X'J(H)@-\+/Q'57##\AY(&X0STQ3DGS@YKJU".92J)PI'BK,VU :VV
M3(M+IJ#J6B4S^%AL?3@LS-[:<#.D/NL:A[IP3@N'GQNL.\W)/U%/EM=M3K#.
M4.Y5$/>VG("O+J5Z';;:DZ\M=;6I.P\J4*96*EW?D;KCJ5:W[> [JR>U.M:=
MQ_:4=-N-$= )FM"?\;#^K_]_<?3XX>,GCK) [>N-W8YHHP/J4/10OW=>LQ^^
M]!!)(_[Z1/&5UGWCO7S^_ZZECYL,7#RNOWZ!/X=JGD==>PY/]_.HZ4MM.]G9
M-G*F-YJ1"J4K'HD5L8:W1TQ=VV/'NL&L_.1Y]&Y!U3&>16\0C[BW+6_ MOSD
M4VW+6V15[4JJW[]Z=_)O/%C?_^/\MS<O_S]02P,$%     @ #(@95TXTWB#_
M!P  ZC    H   !E>#,Q+3$N:'1M[5MK;]LZ$OUNP/^!&V O6D!^)9O%(O$-
MX(>R,38;![%ZT>XW6J)L;B11%26[WE^_9RC)=FPG36_=M Y2H'$DD<-YG)DY
MI)7VE?/OZXMJI7UE=_KX9/2O[0R<:_NBW<@_\;11/&YWA_U/;.1\NK9_/_)5
ME)ZQ5C-.F2-#H=F-F+,[%?+(RF]8;"02Z1]A(J;>EO-2\26M\4!.HC/FBB@5
MR3D+>3*142U5\1EK+B_'*DU5B#M'%[]%8QV?MQNW&\*>JT0I$\(P=/G_G*UK
MD\C)-#VZ:%\.;YSU!6H^#V6P./O:$F:LEO\3N4:0U+VP/UX-N@.G6CEIU5OM
M1A=N)?$7WV]*X:TXW?87W=MV\Y^V;.7^/:G^9!2^4]G=8>C9=\[@<M#K.(/A
M3;4RO&2]JX%]R>R/=N^#,_C#9L-+/+;O]AJBE[?S]L/=Z$/G!GASA@=N2NL?
MU<J'^JC>J[.1W:.XL=;):=,Z<+,ZHVJETQ_>.G:?E=%B!Q^L(D(H<\UCI!)S
MKFPVZMQU.S?VJ#;\>&U_8IV>0T^.F\WC ZV#.TQ_R<+XWTRGTE_L4_V!5:W\
MA[OW/%FP49T-$AY)"VY*:"&63GEZ]A:G7R!.K7JU,F!3/A,L$3,IYL)#=*1F
MG2C*>,#N1*R2E*F(7:HDQ*3:OYCR65>J$!)=;K%!Y-8/U_X##]\QPM?E&D%#
MA,(%NX_4/!#>1%AY%),\?)Z"U$BES(4 +B/&HP7+HC3)!-,I3T6(O*"X<MB!
M!)&(O,]=W$J8"F7*4I6/VQH0"5=HC2RO5C FY/<""Z\)U;CG01NL&1 )ID5H
M@"L3-PLQ+,)\J.*)A,VGTITRG=&/U?RY2$0AA"P(I0X$]V0T87.93F&ACH5K
M-(3<:B6&<LJ#H3/,\]AXL>Z(PPWT@>/TY"F<"N;+"$ @4*T";P&D&(['R=IS
M&?FH0SR5D",C-\@\R 2XUH)L 9DR"18L!C8(UX3W(%@"MUHI,*,W%T=V>))$
M6P2K+ #Z %<%2)D%M='(Y7K*_$#-=8GE1$RD3M'A4L;I9JXY],SEYXC4I3HK
M?4F1-U3^1/7_!E0Z#P+X6Z(_9^I<%[@K^ H5&^7[$I<FM /&$V$J#T AQX&@
M8#,![(X#J:<TG(:%J+14;>G:D]H-E,XPCVIPHH(<37&B7.'A-M#P#NCQ!."8
M0\3^XDYY-!&L@_)VEP4PK77":ZW3=^*]F=LZ]?*K_%(2M8ER&-,"C$K@&KIS
ML)$R3RQ4K3Q8R7^PDH^5R-)-T&,$,8C],;I?#,=F=8D>158TZ\>G,LJ%?+--
M/]P2_KY:\82&>,36M-*O(\^B-N_R3#]_"K7;L6#+E?(&KK($ E#O9E)3%36<
M0$1&$%'^%7=8+^.)"+B!9=["UY!E%26>'DH48RBC52 ]GAI-QUIZDB>2+) Y
MT3"-)2))F:;>;](8J454P51=I04T2E'E:5;,D1!N%G!J%S#,:+$LV90;.2=9
MYU+X;2QH(.HYY@OO<.O?CRC?A=*;V?*#+1EOP?[9U7 +_<^OH[N2H%K9S (:
MALR928^PS;6*.+4,KI$71'\)\#SQ2NPA'20?RT"F"R(8N]:E7#0P-0C,L^C!
MT!6+JE9,:_I2F!1G28P4T(83N:Y*/*.!8=(3$8'H!,@$/!$QY1@-P38A1SMR
M4<;H#6]X__EX=X%W,>-!9DHA84'X/BBMG"&(>@<S71*;9]3V_'*#K);EC]"-
MB2C+!&[@BX]5ECZNPG/:#U^.%D3Y_?4:O'LCQ\;E9L*D;.$**'0.A2+O#:$_
M':$>5>0\]ML@HN.'@G.:)SN1^@UUF+B%<MTL(:2L]?%MJ=5*J'2*!W02"&':
MA:3/&7@ 9+][1!,?H$>!+(<5*F,C*,R9"1VGF,.R7*/WN3Y3KI=\AVJJ20[A
MF7:3[_V*5K!@@;P7^# '*!L3K._VSCE[2XB?IO[IG]YAFB/990)9JX)'!7@=
MPZO:9PXKLF0W-$ $=G&?+<Z]U(^#=Z<JT4NV86Y 9AC*-!7BB1XS5N S]-R3
M4-((>4<GB62Q.:'3=)B"3]H$E+DJ/F<2IIBTS"+7'+B\?[5;R@.JY+2EI/,S
M8KD2$*4M/YT>N%( 3@5?6.[LYH+?4__/.:9A (8?FZ/D\B2-L/'\\I[OP;#5
M>J1H<@\SM5C6S$<17;!J3 $LP7VMG(5H&*^S$(Z&U<::HDWM/'9\8QB_""YI
MST=$PD]0F2R@1)B*"IR9[PD*0%IY-Y;13 4S02TYXI/B^XZB)#$1QH%:"#R=
M3U5>>?D#N .>3S"5:N796*Z_X>8%U'],6Z?3O;99S[Z^ONWT^X.;?_Y^U#PR
MUZ/;3J^\+I8;HT"(I.:J(."QAA_*W[[EZ&\NO71*0YM_I;?5VLY=*7Y&C1_D
ML[0Y5?%#)P3"3X_,FW-MI[^A5/G]=C?@[CUKU4^AB3D96ZYX2@ON\46,P45#
M-TB9S2_UVXW!ZHT+I[^I<,P].ME8:FQTW8N66T'&XOAQ]SUNWJ/'MOVTY:-7
M:GEO*H7/["_"S>@P@ US7OM*';!+EU=DWH[X]M%9SU@GFZ!*L^-3BQTWCT]>
MR/R&*>$OTWM>JL>]MG5^+.6  7^IU=BE%(%WQF[!Y<XAX'.&O0A-/&?#V&P=
MS]@U!SYKM>+E\W9_\$>IU<9;8G^GCO2US@K#]D4?UDC!KE;[S2F^UFX?\(W2
M?V7^E-G3;L 7I5O6G-D@;^8>VR-,#A%Y[>[2>=OODS;H;Q7R/UZ@OW'X/U!+
M P04    "  ,B!E7)SH R-4'  #4,   "@   &5X,S$M,BYH=&WM6VUOXD@2
M_H[$?^B+=*L9R01(+J=3PD;B+1MKN1"!Y[3SL;';T!?;[7';,-ROOZ?:-A @
M&78F2I911IH0V]W5]?+44]6-T[IU_CVXKE9:M_UV#Y^,_K4<VQGTKUOU_!-/
MZ\7C5F?8^\S&SN=!_]<37T7I)6LVXI0Y,A2:W8D%&ZF01U9^PV)CD4C_!!,Q
M];Z<EXJO:8T'<AI=,E=$J4BN6,B3J8QJJ8HO66-U.5%IJD+<.;G^)9KH^*I5
MO]\2=J@2I4P(P]#5_RNVJ4TBI[/TY+IU,[QS-A>H^3R4P?+R6TN8L5K^3^0:
M05+GNO_'K=VQG6KEO'EZUJIWX%82?_WCIA3>BM-=?]&]73=_MV5K][^0ZL]&
MX0>5W1^&;G_DV#=VM^W8P[MJ97C#NK=V_X;=V'?MNZ[='K#A#1[W1R\:HM>W
M\_[3:/RI?0>\.<,C-Z7YKVKET^GXM'O*QOTNQ8TUSR\:UI&;U1Y7*^W>\-[I
M]U@9+7;TP2HB!)IKG"&5F'/;9^/VJ-.^ZX]KPS\&_<^LW77HR5FC<:P\N,?T
MUR3&_V8ZE?[R)=6WK6KE-YXLV2"SX)V$Y+-TQM/+HS7IR"/2/*U6;#;C<\$2
M,9=B(3P$1&K6CJ*,!VPD8I6D3$7L1B4A)M5^9\IG':E"2'2YQ>S(/3U>^X\\
M?&<(7X=K! T1"I?L(5*+0'A38>513/+P>0I2(Y4R%P*XC!B/EBR+TB033*<\
M%2&8BN+*80<H2R+R/G=Q*V$JE"E+53YN9T D7*$U4KI:P9B0/P@LO"%4XYX'
M;;!F0.TN+4(#7)FX68AA$>9#%4\D;#&3[HSIC'ZLYR]$(@HA9$$H=2"X)Z,I
M6\AT!@MU+%RC(>16*S&44QX,G6.>QR;+34<<;Z"/'*?GS^%4,%]&  *!:AUX
M"R#%<#Q.-I[+R </\51"CHS<(/,@$^#:"+(%9,HD6+(8V"!<$]Z#8 7<:J7
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M9NQ">NF,AC;^3J]_M9Q1*7Y.M1C]8&ESJN+'3@B$GYZ85]%:3F]+J?*+_4[
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M1:M]>JO[X8'"=WFU$J2<TT"RE,,MDPN0"PHVYTL2PY1FJ9"01M!E:8(Z F*
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M C'FV,+4&=24G"K&BQPB7\MK4I:?58EAM.742KS( TRW)IQIV'0]MLP2;7E
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MMH;_VUYO[*[=9=Q=:]SF0$0^_/_T('1[W[IN*,5=AFI:0^W'7D8C!=)SPU,
M7>P?P'?RV\&?=QAS>^O;'_M_?$,&45^#8;^OPM=W>'_K QS^_K?Z-\41>7'P
MU5W&:'QK]]U$R&^-;W0!\""2OKO+./NXEE,UUOK8DGYN\-UOIUDBOFW8HPSA
MF[L!JRUZ>&K?UO2GN[S>_-;^NYM^V_D&3%%M _Y6(W1B?^3(=!2*_[SH F&_
M<>IKP]0Y#P:PSV-QZ9S% S>J\1<UF"4)NL1"_.!"O^<'<ABZHS=.%$>"?@RN
MWB O$ DR&?HK\'T1$<O!/^'!XXP(E[G)57J&?/\@B0?,*K=6UNIIC 2YLK9)
M;#."K<%4(G@SD<Q>O,_I[-WKPA2SF;5 A"_>$Q7>RT132?3%^X,_9SACX/_G
M!2!((T#,7%O;V"CL-O.#-$X.@F1PZ+]X#W?J-3,?)*Z'8H)Z7]VK;_;BP2!(
M<2NR&?EXAX <"?)D(.2+PBJ;\J0[?67U^LX+)XL"?A8($BX[^28*0KB D@SP
M3:],+^,>EM:8MK3=F2_M%&0<D23";Z>Q]_UW-\S$==#ZIM[[AI0I9+/X^I$8
M=$0RMNS&QJ,MN_$SR]Y\;&B/+6EC_;$A.;ZDQSO<:5#::CPY*&W-_N!.TKY(
MCN,H'HK$189R"+KSH+0LQ9'KS)&G+Q DT9DOD$!U*&4F_/TL@07RY4+ H]].
MAOB6;%V)Q ND\&^W=$/+30]NKBQT4^$3+(#+#A/1%Y$,+@0#8S)E-W;J<[?9
M,U"20%OV6VX2P>ARVLYFC_K7[0PD-OI%/MS1S?X*O(\-WO*X=F=/==/@>1 G
M(NA%>QEPL<@;G:/%A0< D83^"LGX\A'6_3F6LID$$E9N0^18I"?=<_?JCK!
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M(0/IU=UPD"51 -*8 "@=!%?X27X6KA3]./0/!\,DOJ#4@P6)<+D58M ]<D?
M/!-^46'-HF#-0]1 OCF)_=0=_531B>>9 CL1>C?CTD\N9MZRUI]2[NL<*8TS
M)='SR[@BT8I$IY%H"3TJ+7V"[%7?6*DW;A7(9Q'=>3_.I LR2)PEJ1 12BZ+
M08+-2S?Q)RAQ/QZ?=R=)$.!8"G>^%MJ/)^!IM+E/M:"^_1.HV<:2E!5N/A1N
M3@#W(R+G]OTC9V-M9:VQTMC](>0\OX2MC2K,? C,+,/Z$95BA3*/I!1//8W-
MG9V-[?K.=H6%E<KV0RD>A$"-M?4*@2J%XCDEJ#UQ='GXSJS8!#W_-*$-8EZJ
M<#"((X)044A:G*YD#]L@D1-G#^%0$B'30RDSX9\D^"_:AR::;LI',-L%60::
MDA/C\=NPE?DH(NO=^&CII7OAHW6DV49]JOI 1W=(=K?@0BRL,C%9GI^V^4?D
ML>J\'DFZOXZCGG2[8OY#0)\LJ[M%W\GB"52*QYUJ,#XC''_8_MT5)3U5D?JF
M,I;/G"2>D1Q=D<0M$Q<6!N'GYN2?N%AQBWX)B\X[*ZZVV*;6J=5OGA&.5R+S
MTZ:D!TY F%K_YYF31"4R/S^2N"ES<V$0?FY._HF+%0IA0"R'_]O./TWGG?..
M,0_"O.X1A]0!W5GMLE^Z+VMNA3E/#'.*IAH;!>[EWAEC(X]VY(M,:!Q4N&$1
M6G0ADA1KJY\F BZ[1/@3A%WZ2A?;7Y"0BY\AS6N!-N/0")C^I-M,$A31<9N6
MA'+=L3PBNU!(=J_L0LU1H72%T@\C.Y60^G8LO?32O<C?:W1M;.A/=Z $T^47
MIA>R.>F9BA+NE1),-TWJ95)00<TCTP_GL>D!T>[.]+#^F/2P8%J%01]&<VPM
M$$?PIWQBJL031YQ<-M[&$,H*79Z.YJG.Y%Z= !R>6YW[4SIW=28/'!R28X!,
MX3)V0[$@18,.(R\>"(,'GV./:B^4S[^TZRI$Y*XA(A7:/#;:/%DWR71NTQ9A
M&$2]CR(2B1LV([_I#X((6]:YF*[0NAK"N3PKE+H31"HN=3<N5:';_*+;''*W
M,R&%FWA];.(L+D084[%"!=-GA&2W@$/%R>[&R2K4F@_4>GI<:TKQ@7V M4P#
MCSK1)*-%0J%S]ZJ9I?TX"731._W[Q$T_;K#!@W=.)P(#\D'Z"G_)DD#Z@;<X
MM2=N0H$;MO_,D&$B08Q=.L\#,WZ0.=QE"3#Y7B+\(-USDV34C1/,Z)]\P3U+
M=+R!.)\I8OXTRZI0=);:'B90-&7@SC?R8>Z#D;4_BKB7N,,^]CO-4R/R35;:
MVNU[:U>H\9RUK6NY1BO#AA8+CQSV-BO.<7O.4:%'Q3VNX1['<9+VFP,8V%O\
M"V9\LQ4GN3TGJ5"EXBIW\%L=!;X?BI8KYSPGX 9DT?IK>;L59[F;+ZI"EXJ[
MW%)F:<?9\[F(QC=;<9;;RRP5JE1<95*F-,Z1?YKS3&D;8$^ (.V2!'GUDP]9
M (@8]0ZCP^0BB,2>&P;=.(GFW:YIVN*HMK+MK/.7\-+S^"1I7KA!B&ER!W%R
M C^Z*>R?&LA:^9HWP>5Q/2'K]]UT;&NE7E]97YLS"K2:7ZD-/+"[R/@LXY$;
MIB.3Y[L@4:=3$IR-KW#RKBO!Z([A?Q7R/!'D>7JBDND)N;8+W$U?XE^BX$(D
M$K9Y<D#2IDBB1;G(?1&\^2QZ;MBB]5I7]&UV_7C7M#ZC^[RFRZ7L*CQX>GCP
MH/4^M5 ?Q*QN'D8'<>S/^04R_>0G[W-1SSI7DW=  \@_Y1%U64>*OS-8?0O[
MT,[WJ=O5+*U-C1<VF;CK1Q4;U+G<6>:T7_IYL2&+ L:;+^W],208@+J;)>)]
M(..-1GW[#3RC!],_%:? T::,W^Z[B9!3IU! H(=^> Y8W^F4>?S@ K!O'+;X
M[G$V0/T^GA @>0<8E-<X:51KTGT1Q8,@NFG:F^%2GG?2P/KW A1N =!3F.:&
M(QO"QQ]'"B:KJ5-P42Q^Z,<G^;L[?88L3=Y(>."6H[]['5R]@:.(L\03$K^B
M;_K"]8EOO'L-((9_\?^]&SHR'87 (;M >6^<^MHP=<Z!=TGG6%PZ9_' C6K\
M1<W!0D?=M\[ 37I!M)+&PS<./&Z^Z,0I7-G%[T+1A5'7WCI(U2L@RO2B-PYV
M>4-V_N[U\/VC+^+__K>^M?;6+.5_5E:<@T"$_AOG+ O%RJG;$\[*ROMW #.]
MREO-?1GX:1_WLO;O%X6W.W$"Y\!O?PA=[[NS =N5<1CX;QT$P(H,_A'P)HZB
M'M8C\_/UU4W]1KY^/%/U7VL/KPN;>'1@/XD3?R>';F3/O])U!T$X>G/3"NS#
M@=E@I(X!?P?VAN,NT!9WU!:_'!^>M_:7E]KGS?-6>Z&WVF[M?3D[/#]LM9>7
MFL?[3NN/O4_-XX\M9^_DZ.BPW3X\.5[(_3?4_K\VVY\.CS^>GQS7EI?V5_=6
MG<;:YL;N0NZ9*%B3[X+M3>/SP<G9$>R'AD0QX\J_^K:[UO@F0!-=6=F/O6R@
M-)%O'BI]:UMK]6_?4(9?VP0E_)_D0/SW]ZO&:;2V!>.!$!'%$<F,@><H4?U,
M=,MNA#2V/)].Y*("AJJO/=^+]_6UE5]),,G'S)'LX?#M>>)7C@R[)61H1E'F
MAF=B&"?I9*00O=:7C8OO.ZV@\\-(T8V3@9O^YT5PE;[IQ'$HW"A-,C$)6^P%
M(4!WMS>VWDY#G%E>[7 %T-0.S^V HB$S6*>3QO :I;(Y]74G3ISZYDO_E1-W
MG?.^P)^R)$@#F*YUY?711^ TO11_KN^N;U2X_<1YIS[^@SA97L(#/0BD!UCP
MIW 3IQ7YPG?*-+11HJ%3,FVTV/ QF8CV?JT?'C2.=EO)QDR(R,? '7BO[[NC
M$:Q41)-HJ;"P<5ZPI_:QER4P0,H;QWU?NY5LZ^]V+_C]]U_^NS[SK12W,6U=
M+]X?N2,'K943N4)M[,#V2@>6CW@ W\@I?"_^*#:ZY]]_#\4,+\/2U"_(@C;U
M7ISXM8,\)4XJKO(P-^:8^)2XD0SP.KCNUCRY^J7E_?%/-OIK<Y:W9M<-Y<1K
ML[PJ=75NW/_5N;SDY)//^O*L4/QI7YSFUK10@&\=!S';^4;_<\YC]:DZT:=^
MHB *8=WA0*(W:WGI( B% [RC(Y(W8_=J7;%&]F_BH_SD9);X3VOS+!H>C<3V
MCRL2.>,KSXG.O?K*^O;.UO3KM!+%GS3^:3-&83":S1=>G%"AM3=.!C)Y$@;1
M!(&V4<#',]&CDI%1>@Q8,QDGC]-.1\KF;[_4@YGA9''>%^\_')X<M<X.]YJU
MY:7#X[W5J>CYX%CZL)SE9>O*]=+E)80*WO")@9/C2D<.A8=^>-\)X$A3Z8 X
MD, *7BTF,":3<(K1W3!;&,+W7A#U_O-B[07]/71]7_]]Y_U;SBGC8_+B,'2'
M$A:D/[%#\EV:W'T":M ">HV&%T!:NS??I?X/+WB3G&F+<>"&KXW;$9AM8(&E
M9*C8'&7FJ!I?>[$_317?_OWPOU__VW2_;L]"R5B1PL.@CU0,D_@"V5I1'[_%
M.E^\WQ>A>^FB _YVES#AR&(<\4N"!F\)-)T8 _J<OZQ26,#UWG42YS5YY1<3
M!@7L4*#H C1Z;A3\0U_:#/W=Z]2O^,1-?*)5X!/G[M6A"EKCVK/7R=S9X7XS
M^NWP]]:'WLSDFRD+>/%^=W.EL;6QN;E]:PE\@1#_Y>'JV6I[E??4&@S#> 34
MK\F]"##G.%X=(P/X#X?KD!!0DG5X+["-L0B62F1X3JQ@O\ *FKZ?"%!?^)_/
MH!/5)[.!=I;\U0O]S4_2GQD;F##YB_?U[<WM^O+2[X#CO[H@6$1.\T)$V31I
M8-Q4?S!I@WL8(I^<QY?1Y.VMMWM'YX=M>?%;=];;RZ>&NXT2*F^]E>:DK9"(
M<)*<@H 51-X4N2[=__#U8//[E^,_9N&'OV[^%^_WFM.8M9%4%IAI*Z@80668
M %2"H1LZXDIX&7:;@*^!;PM9R2UW958[DPC@- 8-(_QO,)RNUNR?#';#YB^]
M_N?9"2V39@>)I;%5WWC.^ ^0X TA/*:))!ACK(621]GX7YD$X6E4F5!O>:K7
M" YXGS43X4ZGOLW&;R=;?QUD61K.@/KL^8#>,+AP(K6]&H];T_<G590^[<?1
MM=Z%^"#[^/FWCY^]I#&#99?G?/$>%)N51KT^+>A@@<VVN3W[__YWIU'??@O7
M92I",43P.!'!I^; O1EFJ&\X+APW@+S(3Q8(((O,.G*'_/(2V^=%(GSVN>2.
M_,;+#KGPT[XH^.W?+"90GJ.M_J9,E/%Q^%$&WYVVNM[X]WV?X'F0AL((^<+U
M^HZ'#=[-F4X2Y\>7]-911VO@0A Q.\&-3 9+CD239GI 8#?6[A_8B8LPXEVV
M1X-.'#Y#0&]LW#N@T9%:1&JAF3%PZ<M^ -_D3-P^@ERP?PJFNWM63*<$K:BK
M;E1O=(@]3!8K__R\^??E3M,_.Y]%T$IYSA?ON<>WHA7L]%T#U$^<"S?,A/.O
MM=6UG9O"!6P\OQ;YG^J!:-5$\0WF&)-/X\OW/_;DUX.-H3N+<(W"A%R98>&!
MO5W"?BV^30^1":.+KR?MO6#KP\[,G,S(I\;]RY/6A%Q.^N[?4PY&&2_<89"Z
MH7/D)M]%.IG1/:X%8Y&UD'NPSAQ&/KK*X';KC!RO+^"6AA5\=P+6.:S(H4 Z
MKG,)0O?*]RB^A-F%*T$M]>$'F:%>ZDK'%]T@XL BS(]V-M8VM?9B!2"#_K*@
MT/P3M3D5#C[FI5@O&&F_ B1_14"V%1P/"8R3.8/\\.M6EOQRLCWR9F:GG;(
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MK]4<)/Q7;YQ_75^\\I2DEX,P=M-OP2&SFWI]?>W;/[_]UFUGC?#/@[W<OGI
MKEZ8M<PCK&%>%%A04_??Y';I!;8390,_3GWA!0,W?.&H#Y)\-]AVC :@YGP;
MC=KV^DYM8].D1>N5:.ZSJ/?&0K.=\SXPG3A+24U&C.<D;Z)<IA3XI,A73DQ:
MTN3<S'JP/*>Q27B_3MSB^D!4)A^B'NZ;>)*O REA&/A$#>MK.XW-;__\\L]O
M6Q_.KO[[Z]_^S=1PW=@3R8-Z6S8V;TD>A\<'%H'HKH_UK1KPJMK6QM94&G$6
M&IL6>G/[)WM?CEK'YVVJ[7MR=GIRUCQO[3L?_G3.6@>ML];Q7FN\<':SU%-
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M9B&V1T)\ >[5!?7<Z-3A"'AB$@\4 >D(+"+Q&_:[ZAP.T%" 3F*U,H853P0
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MVZDTAJT \JU0X7"\&Y.LAZG$\#O9:;^ZX0#K4N'#\+F7"" QY3FT]D*"R/=
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M#;5O%D9FD\;*S>4YBJ-B>@DH8E*[!0'S-BKN.H>;0X6"D,K44 <*PD9,,((
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M,,H!!%9RXCM8_T5;E(P<C\G(.CY#&\8M)'Y60L6B;,Y4:D.L#*CEAJ3J<WU
M&V5$)-9U"#(]QKSLP5J E408,L)F#M T05&B$C>%[.V:ZNPA:K9Q@R-8^.L)
M2%1;7IK@K@(Y&4M$#)#TE7+!+OI4FM3V(E&IQ#:J#)%7H\NW6'R:Z_QP_3OK
M5:KL1Q7S8-,U4SO/=IA950\\938:'QKWC.GE@SBAQ'UM#<O#I.Q%&F48<_IZ
MJ-0)ZH.*\W(5OMI803Z3"9\7$M!.!'U96$%ZEB\@'%5D.X>;:YIX":J,9;KF
M@+*:I18N86:H4935;7$I.C)(N3_XY>5J1S^\"FC*X7#4A92;?.)-IU^@II*)
M+AI0ZL1 *0JDF'/[1S3R)'?I2PEZ?(C)?W#989VM$!MZ4QP)7L'7]>;\C;D4
MO, _2]-8$]MPKOP&/$NUK%&_.^;G'7R_U I3E2((0]WP(PC)3W.)AK7OXBY-
M29>7M(.PW=HSOD&R54TY%*#D1!#YPF @-I"'3,9X$&@B=D%$<CN4'X!""E[*
MW.?TDKMOXKH&*ML75IX!FY8<XS/0KC)8B3%Z$:>QET)E252HC5HR25X6RA1P
MF+#<%U[,#/,-M[; 45Z\1]R2PEOMQ1=55_'YW1S6HS\[V?^RAZW<JI+)\[DY
M]&B1-199S=1@9ZLHJ_%P*:F(-1GR+W/UA4!,D0IU\<FRV,1:H423!_ D](2I
M+F&6K&0J.TQXO^"@7UMG^9!*W[@%U[MJF^R,;W;H>M_=7EG<4T$?;FIFK]C4
M'&[NE*5;NG3AZ,?<7-063G7[0G$I4^W*432/(Q0.\JAWQ@\5^$XI7>P-$7XI
M,+U&=08X3,U%^X''2@%YR-0 J 4I05Q/12)X[%Q@.^U:"2WA)A;X-)&+RA0B
MNXN(>F@.A-6 5D9$HGJ,<=4$GRHILPZ?)5HAB20G (Q8V]=OCOFV(Y6'1T4K
M27R@4&2/Q *.#O9+,41*I:OB\^=T<Q0D,DUGYIH7.:=700Q9:'>>1+SXB)$9
M1X513EDT526SC=5)D-9N14-'QJJXO*01TXI*Y9*O7,BQ:,S+HZ#U:QQ3E0ZS
M-+>/E2=!-8$>5K7W[;DN,?9J>:D7<W$T*L:MJ$C=>GF='(O:5+G_W**A7')*
MVZ!2;7LM#/_CHB2'!0*R"YL1J$ #B7SLO<G?Y<K#83N/EK7)CF[4@)04AHC@
MM5Y&4YD9IA)G">@64J@ <=T#4$6Z$4B)U5V(R ?0L_=4!;#S^E$KT77G),QH
MSAH-(!ZJ1'CBB7MI#:Y5#IT-P%6SO"RQABT,1FY<P&:5(+Z\Y,>D7N)**H8S
MAYL#1>*LU6XUS_8^+2\UC_>=_=;OK<\GI]CUN=(KYG-S'ZCC*8OR7*H^CB;E
M==TFQIXSH)!UZZ! MRS,G]GNLWUK&LTISZ@P['Y>*Q38M.(IJJ4T5M/S[>JD
M-V6>L?UIJN-.HK>/ DV2 "NEP=U8  8Q62Z>H6-_4W0,CGM5N'ZH4,5;31%?
MQ0A=&70"+;P5<\.*(=GY#:BCH(S[BFIHL)--I8Z3?\WRJ_D"TV+5=6O\4%9:
M1E \7LL3I&"I.E?8WBX=*1[KBJ%F,FL@XW)SE*>.2BF/)9^0/0Q;8CCD*1N&
M:%$W;8S) 9@'&HF\O,@ ZWQ=@N)9#BXKY,&O%C',7B"Y=:7(NV9KB[]DD[^Z
MY[#1 27QH6"? ]NJ659;7LH%J]HX.G")5K2VJ6/X.PL4C/*=F[=0!0#8&:_(
MJH,EAV.N$^Q/1UN]';0>D[Q"4EUN-]8W\+0 WSR^UW%[/>P9KDL %Z*)_U6O
M;>YLU-;6UCB&"?[>J3?X;SLL&(2,IK3]-/$%BP%4TI)0M=#RPJ+?\B$:JK92
M"K^+43D$FILYY 54: [RU*)43 &'I=(+-\*2Y!N[L&['4L%2'3V=#3VL,]W3
M$?J5]C2/F]/9S1QL6*JK.I[7B^R8$G-31 VE>P\3U2TCOWLXU=E4>B8RS!E]
M7FM59?U:N;[+2^?]"9<*#E"\WJB2>5ZU6QG[B[7VV\!?@$-'!6>OJYR/ ,'\
M:95/H\)*5*L62H73U4MM_ZOQ)] ^2VU/=!%=%2%B8C EWD)T.["BIT-3\6_<
M7A%ZVHY"*;-*?52]DTRY?Y.:'(R5G539Z;JPV,2T9')VVRSHIAQEC,8Q]A7T
M W-D&^<'J(KD7!K95/MF'N,A/%3^HHL1K9RZ'!5RP9\5_[@^EG.SBN6<:2SG
M9A7+6<5R/M,;WF386P&/#@B#?V=V+)]JE&:"++D>#E9NQP"":]/+\QC$FJIN
M4KP/B>%;M;K)4753;["78K6WBFKS]YH#^X;_PA5(G@J9]=P$-!%8X'>XQ'7"
MB9I[<C.Q<AT?:BZ&\K'=70RC//+.-T$RUOW%4B_'RR4&(>?E"&XK00(.AK"H
M:I^ACVH4QB\IHR%^GU& $UL=IH*WH,;GT9ZQRGJ96OI07E>ZLURT:15MW]SL
MB*VI>B?%V@Q<?T7*3&=M4  I18,I$<3J2P*@E,)333?04,LQ.<6LOE.:AYX_
M3UR?BK\L+YVH#"UE#?G2/CW/+<<HDJ@UV$G;F'&L5VV58O!"-Q@HH09;DE"E
M$90Z;F/* 6GTU :$JN2: T%GB%$.9,"%)IH8ZPKT#*+F+^X0*?17 )";A]WA
M9MMP%"Z@-P E#X%2Z]<^*_9@Y&ACTOIO5>DA#^=EW)Q:T@ZC  FKS2Z,7$G[
MS1/\33L9S&*W\9TJ>Q;T4E60LE3=DRTY.O?V%AS%&89NREELW,Z.C19OG(,L
M\G3<V/X(F,=0(L#WDK@?662N*G=^R4OH[G$)W9INEH')6W"E44Q6-\RN\OJ[
MNG=&Z\S8X> ,58U8[%C@NUX?.>^^H$ OC!1E]^0)",LQ*%%]="&HV&O5>H$/
MF'5J8HRFWJB:][6JIZM 1WF(>*S8.DF_ "=&F(4?FED/BY&"BE97K<-X#LR@
M0]W&8C376S!+S,4*U5=-,=D,-,9*?+/[9R7 +\KFWG7>'S7/?FV=M]F9<=0Z
M_W2RWW9.#IS]P_;YV>&'+U7 U/QNS@J+ITCL@E5S9\WX>'58.O/R(.\)AW)'
M!VL5 XW7.%>$6J87!MI8H^L"52/82*'F5PT6PHD],#S;T0LEP72:=L<-R2A0
M+*N@7S)-K9T\V:-4;;-F7/3&P&GWY<I_EM3V$>W70ZRV['K4C-LN-(O2)4::
MYY4W:]287F!$/VYI:A-NOMPQFYH,N2*'ZZK=TFVA46ZA-T>9<90315<V-FB.
MR50ZJ389DI+*;B"9#ZV1V""*7 /8\B4HI*?PS?Y1)"A5KSIMS(%V5;//QIIR
M85 E,^W&RBLLE8JB%7O.AT%7<*J99R?%>2"@2RZVC"4#[/(+!=^3ZOWNP5/(
M!GAE6).!>T^3G(W^%SLH1+,,:[$UG>AMUVZ4WT'>D?F^:TXKZF%@)1P!$B-^
M.,! ^SZ3UBEZ,GJ90*F.C*AYQAAQDMQ%2!'<6-_55V;3"759Q@K_\MY,X@J^
M "]3)2%D(OU@J)0+],2P7[,'KU->BXHDU9DM+1<KI43+2_J+SQAWHX\?(TTC
MD"!KA@&."^:7PI1&I#+\?56W,6^FIOHO6RDWOJ]+PQ>J+AH'I%4]AB)9U//J
M2VK=RB]T,PR?S0?"P^J,0)*LI+PYW-Q7:BK.B99N%S-!W%37?(BL+XHWM^N3
M=5&JMFKZ F65 &NS_ 4:143>8G'5#SJZ7D>J?L;N#+*FV"3FK%$"BE*2[) V
M9IZ4E,I%0=AO60I[-C3ZU30\X#K<IHJI?..\=*^KQOVR4RK'S5Y]W.!X76[G
MQK+<#DL'KYX23:@O@P@M;&^<K9W5!LGY%:'<I7JBJIQ(TASPVWC )622;,@X
MCOT[\@A2]71>ILQ43<1?X0J)J7"P2UUAOGPG"X+B_.@4Q $[(KVDFD$8<JUJ
M:E$MNS[<59,OB4+1PKPP2A[\FIN (@QLX%3- ![W*!_MW+*>X6W7!5'8)_'<
M;-/*T5=51O.*-&Y"UE==G0??QDPM-B7UT:X:]73=00HF&6FQ.I^@QLFF0=3E
M&[;FA"!7D!U2AX1(G<%A1&FL-1136*M>4Q[@J[XI T4%LY#LKMI3L":1CPF3
M76"("U[R0[HI272B.C^ZND"^;*OU7FYPQ6 -M):/AG@X4P2B))#?&;#&:&BJ
MK)GCP 0]SFRGZFR"9*146N%#"">*4\H K0$=63M".YRI/Z#<N&K,&@]@[QZ_
ML"! "S9'CX;I/"3*2ESV0% -4MH'GSZ7RPQS0@%H ?EQW8%S;IJCR.$23??\
M3CPD2QPK;*&^?<ST;&;4\4B81#F.PC?A/_G/*74[X,(,E%^JV@@0TA9$*>J3
M;;>6U[.;N=7,.B#.')=BAK[0071H\M9%R^Q=$3$HT0JT ?(I4C SV9,!7+,N
MGHB%U.ERI7")4E#39FU]?1>#F%CBLZJ&VK5,_U7?J>ULUR<\UWA*]UYUQ=VZ
MCW6BXGVNKWUIA<:EA9O"IY 22U3DZ^DR+HF/Q7J9RFYDE^S$%ALIM90'1K:^
MR04[M[A@)W]O\+<49N><<,VVO&# W39# 7)<Y8 NW(*^A%P=J!7EXPYZ XME
M1O4Z-S?_7=XBC&867)'&'&[N')&.>DWC14W=$S :@OC]1&R:R%:W-YE94J#H
M;F-[0IBHTZ3+^V9R0[/M.+U-H"5G716\W5R;A)>\)?6&O3=%2H+?'UM5C>)$
MEI?0_42^IPX;OO*UH$U#!FZ%[W.XN7>=]Q^:>[]^/OE8^7?F<W,GT?+2%"Z2
M6P61A;C8/N@[J#-(X1F9,C$4B"+06',I,K&MS<V<B6UO;DQB8B=%KEA3O5UT
MK+AO.7*HB@I-A1%!SYZ!7!_^N56%?\XT_'.K"O^LPC^OO04U'!;V$L2DU>97
MN"N:YZVSP^;G]@+O=:$O_',J6I\$D1<,QY+35:9D*0=.W<=VLTZOC_8XSO,3
M238@_1K;-:3*HIL7\]!Y@*"SA)083Q7%*)AL>:F4&U\H",:&7Y51H[)7:]JQ
MB8]B%CR;S-",F@U5E39T-X4ZAYY<ZVP\IB@YS*0WQMQ5YQ/H)# !2!Y^WD1'
MERJ/LD&'\YC,&_0'UA6W$AU)I&$;(_>NH1Q4ZE.=MP]-N4(DQN!=NB..JF,+
M'R>SFNQ^:B$:&2=1@"ZD+.120&2G4,:_CHX%1D]R$8PZ J=8U$(E]PC)-='1
M(9Q1RU+]&L[<09>Q)P1>/5@2"*WK**D=C%M))G8[L0T]?N";0@7J8/+J1(7Z
M,8195&6!TXAI!X4]K2XOW6H)4VQ-//A$&Y*SD_=HTA4AZ)B+,"6##T+$= 6*
MG;&N,L]*!%V4S9&=.X@ 15195F)VA=;$Y) II#<[>6GFR4V"<4=D=NS$5_C/
M!,;I4K<(9IJ&\U*E541AJP:91D^K2%F> 6VW'->3R-3M\8)5IET57#N?FR/<
MI(M,QVBQX4U%)!59%)D2)WFYK'95TQS-J\[7/I;-',3&J"T+GB>5 P1WJZ=<
MPEA1(KS 9L !I>QD$27H(F.\Q-N%RB:DA37JRYVO/-5#-E^GON$P)$((53 >
M"8!II1]?JB8W]":_9M?OTOFBE?U\7C<'6L;A\<'G9A4Q/K^;F] _E ) =23V
M]% .'2:%"H*)Z,"Z )0@0I7&%(O@2($1U10@OF1W5]#<ADIZ))PX9/*L\H9V
MXV6Y5(?*O,29JD.(L2,Q5Y0A)JDG==-4#(9*&.0H#M*<U+2*Y^8QMJ!U>7G3
MK\O(BL8@8'$X+9V6U.60S?5.'?:N#\A94(1Z)N:5O9.CT];Y8<7ZYG=S)E7:
M:C5@BIODQ*[M TC?K?\Z^YR'Z\5A')GL06I>A@(_\X;F)1H\/B34V*TMPJ[3
MNG(')E?35;UTQY/S +B4GF<GI9:[VQ263 )405''E@T!12]1TT76+>P ']T%
MKRM4^23]3EP5]9G+S9':81TB*I8CN)^$BTG<6 >8:H1ARC>G9H%&PE&H5(&M
M(P,_<'4Z,RJJ*U:]ZT(8^+0,*FVIP0#K 9(+V5]4.JN5KD#EV<ADA--B73$V
MQ-%:L8/1@.,5Z+U+3")CV]*4$E:UHLVL$,&NPLY-DDR%V7.X.6W]'KC)J,#:
M\,PIG9";TBAU63<$GY!%0(C/93 XM=$N8V'5ES9%':WPT1J+@MCBA\O5Z2AH
MC5J.U:<3:VBHMCF6.SQ228^J32DE:9O%E.M:\QTRI>AUC8/YY% (OV!I4OTW
M:_PT)YX/8ZG:,/,0@3%,J"$'Z$+N!WG12W+:TX;H@L X JJKD%"+D!Q <GFI
MDREC,9IMM1$^3TKSW*$R'>1V^[RTA*4)N&05Q@5-2JK+AZGI.ANZTIW>2YZ8
MY<4F'-BJC)=8C$HEMQ434N$.[ =D=,'D*-4#31?7*\U%2R3]!?B,*%09QBRR
M(.'*_C'%("/OQ.Y-V/0VH11 KA%*^D+A&<^%%0(9Z3I_Q*83H6N=63J*B[+%
M)+1AAH?U/,F/0PO-"WR8;)I"=VYE:[)B@5E)XVU$!45MKQ^(+G6)X9J%#I?M
M(#L]Y3:J^J?4Q@:TH\O",FY;3M74E(GB2R J-IVQJ$(^&N?S_KE540[E(*[[
MO/?YL(GJ7\7HYW!SH%!]//F]=7:,5967E\Y:'[^P60D+$YQ\.7/V#YL?CT_:
MYX=[SH<O[</C5KMR:<_IYDA<U9>ZR9.Q'3FY!:90^Q1XHLH]@0N$6LQ17\\N
M=>1T9;EFOS82701I$MLR0;FV/Q5Q==4%6M/N:MT)U=1$=7]T MLYI/)A,-DX
MPR1G-1F(P]A4WECBK'+YNO80"<_8,LUCK0VCSS-@Q>A!RM.3,"]'92=KQ1%=
M5AYG*^<E@*G(?RNZ"))8OW?*Y9*HA'\3WX$;]T#XY,^G8DU6A[":<^)YV=!5
MV4YMMRM4F<M/7$BY66JI2+4U]_/6!5@XJ9>0KQQ=9GGII_VFJ;[#%QH6!L9]
M.JI5BI[,7HSE8#/%/C_F*5L: ER:QZ[9K(L>%9I$:+^<?DW7R4)'G4[6QC*A
M>3LA5G^*O4GP5./0UZ=@GR@?%PT98"\4JPXU"B#7H-3RDHU[)3Q3Z8<=E%*Y
MXF;>G5>J)@U*J%&!G3J$PO9>VMU<R(DZ81+5=%-$Y6D2[*GFJY4DU+9.#9,7
MN]87/?S;"<5 6Y(ID7" 1MIG9H:X/CATNPH.G6EPZ'85'%H%ASY3R8O,*:B"
MU9Q]+&= 72?@(I4#@7=,TZ-[N;Z[ON.\1 :N+N6#_;UFN9&/&!>W)E8<1/-R
MB/VYNR-EI1E0%S%4$E5"-S8.I6?P<1?3[)6Y1(4D8.2$N3RUG07KF&!\',J0
M>=\CF<LAIETQ2I>KSAY.X!SFHAME8%/[)/U5UV1:31N&NK%9W4Q1*"1/IV\T
M4IT<K9J<6>X#GL8)N3 +VBJ!]V A4GW9ZD(9?E^UFE67<[$!E'.6PT)+3;^U
MS_(NK;DH=*0.:)]G/C/7L7[O:/\L+W6HE\&KX.O8ZG^-5<&#A#O-KCIM]'=H
MF(Z)Q=1/ 'VM>4E6ZW4\T--$K!QQV8_CF.KYJ,A"JVX\R.5JA@G'YOS4J3&Z
MY*=F%4U4T:'Y 2XOZ1.T,\J-/%5#(UNZPE8B..SD0@1A:++.5456A"19G2CL
M+#^BL<,NXX^N34)5YB6']E@][C"LL8C9!M5+4-.?297*U:A!1J9#C%(25LE^
M4,_B)*_-@DAC=4\;9HG,*&6>LGN&<)AJ_]Q?"]N!6+W(J+CN5,K\J-=2F[)R
M;5J$(;&RU8J$)7,P;4U_,528#8?%97U#='Q1-KZ&BC%!<LX2\R2-=H@AW%28
M@AU2;-EU(4*[2":,R[*YZG:3J=#<0O'68NDE,_=)63'(+<.J#YH^Q-A\'".K
M9R43+\KF3FU*0=*QV6@>#\/<@6P-UW27-1V\J;.E'#-(%.P,JA*<U'4SQA3(
MR\+SQ1K RAS!#=,Y!1"9<X16DCA+L2 N^S*HT4>ICR!OTVKW1V5JE?&!0^GA
MP@)29;:M(&+W/+)":<OM/DGO=%7HCQ][V4 U)F4^)+TDZ) ;(HK0XE[2=;GL
MAG4EH^L<?:?ZLB[Y$U6Q*-90[>8]QH2PZAQP#1QCRE'[&>M,RC=J&0<*2R0L
M,;HWS@DW=,%R, 5DN@=)$-$%Q=T]\G8LU-S,3?OL\!5LW0BBOS(NE!6&HL?K
M-0%+<,E(\D^DNO1WJ:[PQ,96Z&#6VOW #;NJ:+-EOPN#[X(9+%54HOL>@8_>
M&,%5SEUN J^6B5%AL,Z1$W25I<(,RQ&T%,OE94G!":?A0G8\+GG*GG 3VEI&
M6@QB2T0H,&("T=."OB7W+"B76F@6?(C(;!Q>5BOP$7J9;&IE-Y[=$[PD01\5
M^/)G^"K29>Y#_H,=5U00+Y)=D&M0!B&^E6$G\PZR!Q CT,X(R,<MDED^T)5Y
MK8&(X3A9E 8A2,D7@M*;ZKN4.;.!T[+P.HG_DN$TWX?%0I#O"A)XM,B*HKRB
MZK(D7VIL4%#M5DM]88VG;Y(Z4+Y5R(8X1;N@FJ>NUW=T6;2\7I9F+H%4MM7#
MO  G_LXNT^#">#X+O9\LC:GU10G6U&N1YE9,2M^E&AE4'UR\<=!"HWP!%-Z)
MU3^_E,KHVQP?%O<[V7'W<SMN$:,D_*16;+7-_7W?5*!W=G=>;^^^;NTQ/RJ]
M;*F"C;7Z]NOMC<U)NEW>6K&PNO:)4U_?V-E\ ^]NZ;&7E_3@6NT\(N\U*6ZZ
M!?$*S&R=%PH!9_E9@LP#*E$EL,[EYIHI^N:$I.@JW:Y1T]*7FO99C#=49RJF
M;B"Z+]D%!Y61#4#3,@E%])&P$MLJ*_&(JG_F@1ELAF"FD@BU))=IV\H\P?KC
M>64]XXHA,=)4%<W]B,4.V9=%>K4<;[B;T+W4KA\T.!3IO"!IX!S!!&:(\@Q:
M>/(X\ EMM[D^U:4I)SAI5UI6UOK"@,JM4MZ,T[I"Y9<Y+\;+WX;]:G>-):JK
M9#J2@RO*G</-D7&7-1I26:Z+DS16G>G6JUJA%G0QM'+,1SC6*1'$=BS['8,6
MX8XF.C2MV\Y<=B5UMNA+S;'7L@9/LSE35C&YC):7\'K:M[RF9ZX?4*USG$JY
MJQ6'TZ(3.7HMMW%)I74*(@,)4%95;16AG5O%R!B4V];8:,1F,LNHQNF">MQ"
MQ#?+')9>3+('YD4G?I&1'+#[G"IC:HGR8QS[1=%U>>D42ZU2SR7OX]'IJX*
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MUSV&$XU%;#A^K.*'KC. Y[$3, 9UW$Q1KO;Y6SW#A*"BENZR:=DO+>?!N._
M=G*@:*-D /?"#4)RL6)X$ H*?V5)('UET%]4[(3+4B/HPEZ.L,?3YGGK^%Q)
M!(?'!R<G^VWGO+7WZ?CD\\G'1;8#+C3[,1:8+N@-H!Z 0H71!V302TPL'G(
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M+ )9U5LE'*V +CGR^I30A1VY<[6QYAR>.QW74.$@!KDS3C3E:@(K<AG@]WO
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MTG*AWEYR>4D[7HE38LDP^7*:E]7<!/A&>_"BX-SAI(3E,?+,],9CVJZ7\8Q
M'A)M^8$:-@+?ZO:3:4B,U<VB[6@^:R6#QP= @E5<RLZTH T^&O^MI;;QL3^
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M%O$560"=.-^ =G'LD;>\A-]YF/,@R=]7CR+%;>BZVN\[0)(EN#7<EKMY7;E
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M.PS8EHMRX#.IM.* +R:ACN52S@J/NJPGPLL'[+S>(7H )=&I:',:K 'L1.[
MP!)L/IX=%%^!V0RO=\1B']21N@4J^+2'"GY:J.#3'BK80P4?C,=D\_#--@)A
M_$B=<;4<)=-^E91I,:^"7 V\( 5K21%^=V+_NJ.#6I#"W]X:)VG&N2>D\)
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M=TZ:D0IV/@$VX+;4FYWQ> C!"D;VFGRT0QJ_K#I3'&03T*!2J-2@SB9+!E4
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MP],WDPSB,TVI*-H40R(F ;5<'V)Y()HI* $@6ZZH],*UX%\@Z"OQFMCU%+"
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M9NVX<8AZIGV:I=*$";4F&1L#+G?B [5TM4G5PRVB"4OZ:I[E6HX%J+%DU17
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M=7RQT0QR#T%/7TABVLP2C8QP#OFV!*YDJ\?DI2$)S":/HIAAI2C9'.PB[6X
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MURYR$X^]PJRWSBD.#I@F@_K;YOY>[;SDG&YVN<P HV,;%IV3('G%[4'C"G\
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M>J)Z)#C_,.EU!R;]TP?<-<^/OA03)^EB(I5*N>D<[@*_S-F?<+DQ$Q*XG,5
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MW#FY7#?HE$CEXM^X8ZURCW''A?OR>YLAS+D1)V[,K_$HZ[V>PAI"XF1R>!U
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M2A)O1]Z=3MWO6]&H&W1_9;KUM\2@9LSHY,"'\%B1M3O?OW7U_F6M[<W+8U\
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ML/KVHX(<#]:)_\T9SQYA_.^U4SQ[%%^^U7[G>/R/Q__XH7UO2IS'__@)X">
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M^!WOLI#[*U0  5IF=;ISWIKY*]IK.==U#I>V:7=M[MO&MY*WT(B.%].NA;F
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M6U5#]_%:$=N*JEB#135-KVK*O?+@YZ_A*A<I<0F'>EJ'J175W06V&JYR=@)
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M6@8#!1#$EHH>85 .A)[<[0&5]/N62F_* $8F-NOE.PF&*Y<4;"29YB2"-#9
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MY?>WPC#1-0IOM^FCT#7W<7"1Q.*CNQ3JL@WNCG5?5-OD)5H^R>BPR(B3NN)
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MI9!?V/V5U09BQW!?/:#&&^R"EJ3;  4E!+Q118["Y+ G1-BT#(OWQZ0EA+3
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MV&I&.-8%#$8/!8<+2I#XLJD@\1@X%W"1_I4L?01[91!U1JQLO!M?OJHRF"M
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M+FL3X[H:@)GW"6W6X^]@(Y$A]I&/\/B,S?2]/HJI5BQ&.(0YA*B5>)J8^Y4
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M1N+XD-=G,>-\0:N* ^)S[XK=G-4VTKB;!3ZC<D,.?@U+QL]M/DH%L<&#AO#
MO[NN$X_#!/[,_0[P )L/@D+K!"C70+!\]$5\,@UW#_[EG$25'90XF,^Q)/W#
MF_B\Y,WFY+G1?B=F^N4VUSME;W.\.4FF?_PR?ES=/4QB7[[F;IX*M4:I3M-
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MK!)9?3U-94Z%R!E78X!VIR<31+M9P"4'$0KA[.;BY<$?99@-UXPF+4 H\ 3
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ME]DUM549BP(Q;/0MLMN4+ ]GS3/.FM^1LNK_[(!+/3=B\\2H]![M2:)(X.'
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MFUL=1I3/>!9_7H)^6\?P5\RZ!\&DV]Z=BD=2^0. B%@%3>$X>7,O.!'[9M#
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MD'5VR#H?=:,CL7SF<%AG.6S19ML"]A4-HAC3^OKR]WW_6I#ZHIXZ>/_:*>K
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MWW1:O$,1.C2$*>>7:8C)PP-HV#,%QO*"28)<)+X 19:9,=#TEAT#EC7!43-
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MH/LFQE..ZI]<RA&\-@*:UAG(PM-[EJR#?.>BL>3DDY,-]AW%$LF_=+_<G57
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M%ESTG_\/4$L! A0#%     @ #(@95R;_QR)M#@  &X\  !$
M ( !     &)M<F$M,C R,S U,S$N>'-D4$L! A0#%     @ #(@95_?2H-;!
M%0  %Q\! !4              ( !G X  &)M<F$M,C R,S U,S%?8V%L+GAM
M;%!+ 0(4 Q0    (  R(&5=IYJ6?9RL  'Z3 @ 5              "  9 D
M  !B;7)A+3(P,C,P-3,Q7V1E9BYX;6Q02P$"% ,4    "  ,B!E7@X!,C>1C
M  "YF04 %0              @ $J4   8FUR82TR,#(S,#4S,5]L86(N>&UL
M4$L! A0#%     @ #(@95RU!R=Q<10  86 $ !4              ( !0;0
M &)M<F$M,C R,S U,S%?<')E+GAM;%!+ 0(4 Q0    (  R(&5='F@0[DP$
M %T$   *              "  =#Y  !E>#$P+3$N:'1M4$L! A0#%     @
M#(@95[.A>O9G'@  CL$   H              ( !B_L  &5X,3 M-2YH=&U0
M2P$"% ,4    "  ,B!E7,R-DV@DD  ",!0$ "@              @ $:&@$
M97@Q,"TV+FAT;5!+ 0(4 Q0    (  R(&5?:++J=E (  !<2   *
M      "  4L^ 0!E>#(Q+3$N:'1M4$L! A0#%     @ #(@95X0_]*&@ P
MM!    H              ( !!T$! &5X,C,M,2YH=&U02P$"% ,4    "  ,
MB!E79O_=_U<-   O;0  "0              @ '/1 $ 97@S+3$N:'1M4$L!
M A0#%     @ #(@95X+=$3<&/0  ><8!  D              ( !35(! &5X
M,RTR+FAT;5!+ 0(4 Q0    (  R(&5=.--X@_P<  .HP   *
M  "  7J/ 0!E>#,Q+3$N:'1M4$L! A0#%     @ #(@95R<Z ,C5!P  U#
M  H              ( !H9<! &5X,S$M,BYH=&U02P$"% ,4    "  ,B!E7
MD)B]IFT$   D&   "@              @ &>GP$ 97@S,BTQ+FAT;5!+ 0(4
M Q0    (  R(&5=S A&V;P0  #08   *              "  3.D 0!E>#,R
M+3(N:'1M4$L! A0#%     @ #(@95_3ZEOIM$P  86<   D
M ( !RJ@! &5X-"TR+FAT;5!+ 0(4 Q0    (  R(&5?_[$&@:.P! %3A$@ ,
M              "  5Z\ 0!F;W)M,3 M:RYH=&U02P4&     !( $@ B!
&\*@#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
